{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: \uc2 KaloBios \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Pricing Model\b0\par\par\uc2 1,078 \uc2 words\par \uc2 11 April 2016\par 08:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 KaloBios\b \highlight22\uc2 Announces \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Product\b0 \highlight\uc2  Pricing Model \par \par \uc2 \f2 \par    -- Model applies to all product candidates \par  \par    -- Focus on affordability, transparency and reasonable return \par  \par    -- Company will not engage in aggressive pricing or "price-gouging" \f28 \par \par \uc2 BRISBANE, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- \uc2 KaloBios Pharmaceuticals, Inc\uc2 . (OTC:KBIOQ) today announced the adoption of a new pricing model that will guide the company's strategy and operations. This framework applies to all products in the company's current and future pipeline, including benznidazole in the potential treatment of Chagas disease.\par \par \uc2 "Our new pricing model is a commitment to define and develop transparent, responsible pricing for the products we hope to bring to patients in the future," said \uc2 Cameron Durrant, MD\uc2 , MBA, \uc2 KaloBios\uc2 ' Chairman and Chief Executive Officer. "Drug pricing is a big concern for all stakeholders in healthcare. We believe that our approach balances the needs of key stakeholders, including patients, clinicians, payers, NGOs, investors, policy makers and advocacy groups."\par \par \uc2 KaloBios\uc2 ' Responsible Pricing Model: \par \par \uc2 \f2 \par    -- Responsible Pricing = affordable for patients and payers, transparent for \par       stakeholders and delivers a reasonable return for the company taking the \par       risk of bringing products to patients. \par  \par    -- We plan to price our products at overall cost, plus a reasonable and \par       transparent profit margin, if and when we commercialize them. \par  \par    -- In the case of benznidazole, for instance, the price will be cost plus a \par       modest profit margin. We are not conducting original research on \par       benznidazole and therefore do not plan to incorporate an "R&D premium" \par       into the price. \par  \par    -- We will publicly share the key elements that make up the pricing of our \par       products. \par  \par    -- We will seek input from key stakeholders on what would constitute a \par       reasonable return. \par  \par    -- We will not take arbitrary price increases on our products and will limit \par       any increase to no more than the rate of inflation or Consumer Price \par       Index and to no more than once a year, if at all. \par  \par    -- We will not engage in aggressive or predatory pricing policies or \par       "price-gouging." \par  \par    -- We plan to ensure patients, irrespective of their ability to pay, will \par       have access to benznidazole, if and when \f28 \uc2 \f2 KaloBios\f28 \uc2 \f2  commercializes the \par       product for Chagas disease in the United States. \par  \par    -- In developing countries, we plan to make benznidazole available at, or \par       near cost and plan to work with partners on creating access programs to \par       ensure patients in need receive the medication. \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 KaloBios\f28 \uc2 \f2  anticipates sharing additional information related to how it will implement this model over the coming months and years.\f28 \par \par \uc2 \f2 About Benznidazole\f28 \par \par \uc2 \f2 Benznidazole is an oral anti-parasitic medication used in the treatment of Chagas disease. An estimated 300,000 people in the United States are infected with Chagas disease, which, if left untreated, can lead to serious and potentially life-threatening cardiovascular, gastro-intestinal and neurological complications. Chagas disease can be transmitted via insect vectors, from mother-to-fetus and via blood transfusions or organ transplantation. Benznidazole is the standard of care for Chagas disease but is not currently approved by the \f28 \uc2 \f2 U.S. Food and Drug Administration (FDA) \f28 \uc2 \f2 and is available in the United States only from the \f28 \uc2 \f2 Centers for Disease Control and Prevention\f28 \uc2 \f2  (CDC) under investigational protocols.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 KaloBios Pharmaceuticals, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 KaloBios Pharmaceuticals, Inc\f28 \uc2 \f2 . (OTC:KBIOQ) is a developmental stage, biopharmaceutical company focused on advancing treatments for neglected diseases. On Dec. 29, 2015, \f28 \uc2 \f2 KaloBios\f28 \uc2 \f2  filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code, and currently manages and operates its business and assets as a "debtor-in-possession." \f28 \uc2 \f2 KaloBios\f28 \uc2 \f2  is working to emerge from bankruptcy.\f28 \par \par \uc2 \f2 Forward-Looking Statements\f28 \par \par \uc2 \f2 This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, Bankruptcy Court approval for the Company to continue its operations; the Company's ability to manage expenses and fund its working capital needs during the Chapter 11 process; the Company's ability to manage its relationships with its creditors, vendors, and customers during the Chapter 11 process; the Company's ability to emerge from bankruptcy successfully; the Company's access to limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the Company has initiated or plans to initiate; the potential timing and outcomes of clinical studies of benznidazole, lenzilumab, KB004 or any other products undertaken now or in the future; the Company's ability to consummate the acquisition of rights to benznidazole; the commercial viability of the Company's proposed drug pricing program; the ability of the Company to timely source adequate supply of its development products from third party manufacturers on whom the Company depends; the potential, if any, for future development of any of its present or future products; the Company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the Company's ability to protect the Company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in the Company's most recent quarterly report on Form 10-Q filed with the \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2  on August 10, 2015, the Annual Report on Form 10-K filed on March 16, 2015, and the Company's other filings with the \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. \f28 \par \par \uc2 \f2 \par Media Contact: \par  \par Lisa Guiterman \par (202) 330-3431 \par media@kalobios.com \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 April 11, 2016 08:00 ET (12:00 GMT)\f28 \par \par \uc2 Document DJDN000020160411ec4b001l1\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; \uc2 Amneal Pharmaceuticals \highlight22\uc2 Announces the Launch \highlight\uc2  of Diclofenac Sodium Topical Gel 1%\b0\par\par\uc2 342 \uc2 words\par \uc2 8 April 2016\par \uc2 Drug Week\par \uc2 DRGW\par 119\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016, Drug Week via NewsRx.com   \par \par \uc2 2016 APR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- \uc2 Amneal Pharmaceuticals LLC\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of its first-to-market generic equivalent of Voltaren(R) Gel (diclofenac sodium topical gel) 1% in the United States. Amneal recently received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for the product.\par \par \uc2 Amneal's diclofenac sodium topical gel 1% is available in a 100g tube and is now shipping through wholesalers, distributors and directly to the trade.\par \par \uc2 "We are very pleased to be the first generic supplier of diclofenac sodium topical gel," said Chirag Patel, Co-Chairman and Co-CEO. "This significant milestone continues to demonstrate our ability to bring complex dosage forms to our customers and patients, and generate savings to the healthcare system."\par \par \uc2 According to \uc2 IMS Health\uc2 , the U.S. sales of diclofenac sodium topical gel were approximately $413 million, for the 12 months ending January 2016.\par \par \uc2 Click here for full prescribing information. About \uc2 Amneal Pharmaceuticals LLC\uc2 Amneal Pharmaceuticals LLC\uc2  is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities-all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.amneal.com"}}{\fldrslt{\cf2 \uc2 www.amneal.com}}}\uc2 .\par \par \uc2 All trademarks are property of their respective owners. View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160324005826/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20160324005826/en/}}}\par \par \uc2 Keywords for this news article include: \uc2 Amneal Pharmaceuticals LLC\uc2 , Pharmaceutical Companies, Drugs, NSAID, Therapy, Diclofenac, Phenylacetates, Topical Agents, Ophthalmic Preparations, Cyclooxygenase Inhibitors, Ophthalmic Antiinflammatory Agents.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document DRGW000020160408ec4800008\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw112\pich40\picscaley100\picscalex100\picwgoal1680\pichgoal600
47
494638396170002800E60000004A8E5989B62B66A19BB8D300146DE3ECF3ABC2DA326BA4F5FAFCB8CFE16487B5DAE9F11C5B9A739BC13B73A9A5BAD5D7E3EEFA
FEFE26619EB3C7DD4677AB135193D3DCE9004D900041896792BC013A855475A996A9C9CCDBE9EDF5F9015294002B7B175B99215C9A7AA3C6134D91899CC13658
98193B85E9F0F68BABCB7794BD0B448B17468C83ABCB456CA4F1F6F9BFD3E4E4F4F818539599B0CE386DA600448A013481233A8500478C718CB80D4C9009498E
001F74EDFAFC002F7EE5EFF5CED4E521478D37609C8BB0CE2B5E9C8398BF90A1C544599980A0C54B639E82A5C8CCDFEC07478C1A5998172779234D91C8CFE12B
51931F609CC5DAE80026785B7FAF556AA2093A85C2C6DC3167A26C78AB3B66A1C0D7E7013E8704418920509305448B0D35820B2E7D364D91CAD8E71758973040
890F1D7010559688A5C82D70A7222C7B004088396FA70005625181B191B2D00D40891B5697EEF2F70924772757974B7EAFC9E6F0E8F8FBDFEFF59FC0D903448A
E1E6F0403C84366FA7FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D6536323166353162393836332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A42434235393642363343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A42434235393642353343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222073745265
663A646F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000700028000007FF80026521650C522188884D87898452528388858C9265520C918E94848B8D8E0C8D6522908993A196A0A58F99658B
A9928FA18684026817353A5965350017381812123800C41872073A3817B74C82C3BE35120238CA00181559C9BD354C590CBCC4350C124CBDD6150715BCBECDDF
CBD622593BD5B85915CAB7350222CF00354D02983CC3A0E3009A616842D4D87140C43A006C24C81B664D461B19EBB86511D6EB978403F32E9CA3212723930302
6A54C3C000D9CA0A6D9AACC3D18CA32F0C22DAE800878B64C63D02048059D9C4A54882341C12235450049B8E110F300187C1620536CBB81D9080A163341A606A
2CBBE60063D69302BA8A6423C2CF0EB1E7FF1CC8E9D2114C16017BA0E6DC9955871F3918B2DA15E0852832B117083A1041576488261B9FFA8AE867EA51AB586F
813940C44B470C52A43E05D08544D92EC3306C16D0A5711711A2C75638BDCDCB5D2F544538D08141250EBF7224D7F022200B866A6C9AF8E10B51C7E2C6D44230
403393F2D45E55DB54089C588784153CA880C0C0A48C8E3D357C80A062034D05F5EB41A03960833D081F521C84E1E1838A0F190EB0C0C3051FD440451D6AD4D7
1F154DEC660308F5D9E0871436F850CC0E6558465A133A21C686732268E095250A41254165DC5D43830CDC71F3110523B4E0021568BCF1461732B4D0C01B030C
E05C0B1928F0801220D091010C2AACC0C0FF0E4264D0420E41348106116F5CA0811719D861431D01B450C4163ABC27460606CCD0461C1A48F106001A1C800411
1A88D4851C0E90C0DD878B89F8010E6C04D5440826B6C1448A30B178961F1A54F187056420A042176FF450C70913F0F1071F09301000141144B004123C341081
012FC0B01F177F60814002E0C1F1030B6EB8F0470604CC906A01085441800D03FC31010A2F3CC1430605A0C186037F703060170DDA39168874EDD9C547E501EA
118AB25DA4163734084040117F1CE186AA363880C016E1A9F0C706037A4107107C884185097F94E0461A7F5841C012069C4141040AB831C0025EF8E007020D10
F0EB155F2C3105011BFC91030F24F03101FF010AA0E0000651FC31030FCCD69919063BB4C15847D31E101622D69C38E85824B401D836274950030FE08E410012
7380E1800744D8D00505EB125083061AC00004153C2421B11B22E8B105151D4CD04518733CE0C6100550A8C30F09CFF0830EC32E00420E7F4CCD430E23D04101
0A6D50D1B11104349BD9427E9C3C19B56211B207DFB2AD080E4D5B754585BA148010C00F4C383087411A58F1870220E8A383011660A041184B2CE1030F1A6060
43070910E0C41F46B8D102024410408207093FF08318048C000115689B00C2075D6860430305784180191194E083C8DB30C4805A7C0A20155C8F496459628532
DF0D57CAACFD870B0A7BE0C3BF5568C043FFC4555021800420180081066CB0F1EF046280DC85051D68318301715031F00A04C8E04106549840019E6082511100
0E08F802847800820B200105346081152200071CD8297907F8C6678A139665E0403A22B845B630420C1CEC200B2238CE3278A0803F00010805A0000FDEF0822D
80000411DBC00EF0E2830958C0062DA1C2113C00812080A00C309803145E900210306102106042FF5090021BA4E1050BC81A0B343080089CE00A70484300E240
0104A0800F28F803122A87410DFA022859408F0775008A7E5C435B1D69865244723425A0AE0A4D0041171A300722A827620D500D0E6C30810E9040003B10DF13
16000111F8A003067042107EF0002AA4A0FF00FC23C10F52C083194060031E78830D6AD0803F9C200C5D5CC219EC80020A3CA1854518D02D94373838CA313165
D807A02E834776A07026C0F082BAC6003A1DA021031EC8827A2497032A28C30706E0431976E08530E0800092D355D58A340120F04009A02400111040AB0740C0
0964E8407F94108127F827010B70421582C7832CA08E0A89511EF37C0997AAD0A0028320268B68B611649E487B4200013A86F6822C88076D1B682000B0C907DF
1D20014250670432C0034CD2E10A4AE3C11020F03901BC2076F11A41015840801678F10A1A30000AF45900484601011CA002C9F236D0E2A8102232F0833A5856
95B208E77A79B9890468B0039CFDC1041AFFF0830C7C40432280000019F84315BECA062F58C0021AF081ACECB585C911C0027AF0010B16000502B492086E686B
000820BB0A0801756E68A10278C00328C87203B5A4C218924500BFA4B02340494B35E6E480ED000011D991C1DD362301CF4895062BC0010F8C90363904C70601
F08000481087882940A80CA840070A80341BE821024800420F9E40800EFCE10130F0000508F0D305E4000231E0ED042210073A4C610954A003AA8A6080080C37
033F68020FE8A5ACE74056227B982C9DAEB20C4260E62C28290C34A63A950FD8600B0FB0C35B1223801450000D2010821EB20082B65C210023C00006BAC08007
E0810B51A082064690001818C0053ED843FF17DA00831E4CC09E714082127AE70738D401471C88C102D8C5820CA4C14A3248411544E014007C0000BEC4C18B29
7B958E14421023EB820088102D6B30200B2BE0450D7A538632F4AE2BD70811352054949D54A8062450431C40D71F26A88104E1518F0624A0062A10C07754708E
0E40308CF570D906A0437305A4FCD50F68800A2190401754326011E08518BE2B03052AD0050F7E30046F814A05C04305F6EC410415608F9B41A7063430B04220
78447F6C00001B5CE1033EA046A1652080377B990756C672A1A9A0E303C487003C98CDF2E043EA82B917D55210C0E77CF0010C44387417500F153CD3E737FBC0
0B158803627021011184E01935B001051EFF908614A4400157685C03D240011FD861002920020FA29086090C40013B28D7001AA08127E861008913808EA44001
0DB7000E0D38000682A08404E8C1052B38800FA230002E0C40085F68C280DF900225C0E10133B043170230EE3AD000092978830F4800070334200E2C1881B30D
900209F8E00A2A98000C7220C802AD800612904308B2328F3744E00F308F00192AF00504FC960043F8031E6E208629C0FC0F08D840EDFED083281CE1E53D5883
A2681B809FC3FC085480C1CF3DA0021E08C1E63F7700997D0004A7FF61003630C01FA67006B42D4A7130EF8119CC807598BF810E62FF39127CA00126A0BC0609
255C1C84E0013566E0057F38C009E6803AFF1EE8E10F0B10430B110681450DEB0F1138C209F20073131C00011040FB0BE0908211680F010A20830B55FA8704BC
A1F170A03B1BEC30044B8D720B61FF83010860F60234A1953A37C30D62E02B1534400644F8C3FF52407413F0C00F36FB334DEE62F5BE1FC1060BF8831D4E5080
3FA440030FF803046C00AE39ACC1050998810FC21A831BDC80F27F68801D5EF0C3A67B807BFD81C31F0AE0840D24800339FD3A0B21308238D0650757D02B5C00
026ED030B2B7362F870202807B79700263607301E00685D6740DB80677600026F005C9770184703D3500025BD0772E200269E40771507D1FD3028827065A0073
45400727E503AD547EBB077309F077ED07FF74426720EAE23162400796D62BB3420074B003B7506C62907D53501F02E05B0680807F30076F9073C2570726D077
00F46B4D277B61400057A0065270548F713EBC00827D47492F9006364002D5473739B700611005BC372AC2B202B6428331800073300703800016E0034D17017C
C0077BF505D1277BF6C4553F370361604D41E1055720766480067B000613207B181301C0024508D0296330797FF00316300015C00252B72842100765400D22F1
41527010BD905F7DF7022FF03F54200384E786F3E70754B00196327F5BB0607F40833D600170300780D7013610567F00780DC00336A000D5377F86440245F072
7F400641F048831289DA97053C80527FA0FF075695008D87020FF0023B5783088000301007205007BE0573002416D4800687D00F54E00236B762D517004D9046
BA380734C00304100409007350F07834E88707308F64A00348207C0A100415606C3C700209F90730200257E00644D0785F4702228203DEB80455B5025297001A
002E157729F4D403E6C77B03B022FEC00362602BDAF7043E708402000A75C1066F607349D05BB2F70596622F2A58442BE000271040DA875A7F90072C402F1E40
027117454D170363E0062BA006592078E9337F0CF0050E40079CF3071D700236700B6120765370337120755CA078113002616501ADB48EBC472B3C500321E007
4F60031C00731B4005D19005D522552440FF043FF00749C0034BF00770307880A5820BA00185C90567002E10C0064D870042C002BC770355F0721D807631607C
632676B2A42816000097C801F7F2074B100471A2012420751D205A5790907A407B11D0007EF0072D40033A677E94B757FD11567960037D60983CC03788E01171
73043637032960732A7006A8020169107D30400025007329207A164005618500BA87077F60062BF0982C159A133001091006E5F90745909040000287370501E0
5B7A10061A500315C00009B90452C4023E37013CA02E29200008F0067FB5736CA7963D92056DF5024850983F100571E0071D4408C040553CE002D8087330C002
FB984631F706041007F3287C42B7973740FF3C57A50193C907E3E7755640051B297CBAB20584077335E403C9910594A2965DD04FD1573AEA020375F00314D056
1EF0044EE374231006419A7ED1305F1CD804EC55033520036FD00070A0021B802638000214900270A0045EA50138B0051910A733B202671A002BB0020110004A
950519F0066CC0004AA0040A90011910023CF0052D30004AE00236800120D0064300A975E00304A6131A40010D40014C20014DE0A914B0256274050E80066590
030D40032410008A9AA801C00461A0000330042EB00352C01B1E640912C0AB6E466B6F062100B003120006FEA11E362001FA91AC54B00375C21F2FC6033BB403
EAE10350A603FD711F6C400232A00137E4FF0324F3ABE2711F1AC021242016E22306C8D705CA8A03DB64038B74343E8006C6724385E64C9586AF5EB0ABC3B603
75840FDDAA55742A127B701760206035C016BB41671AE0174DC006BC8003D38217F6382754851AA4B10213D21ABC0006C5C1046CD01B18C02196951827A13747
E33C1D8454CB411710611B2DB6275BE21629C269C6860F18601A02E7158F881CBAA10399F11B7ED0B393C1B288610CCBF1AF26A31630561CE1B50C6C305EDBB2
037923197C0238155159C2C159510B632E43282B3208E10013C1610E3810144371147BC11DBF7100320159503B6C724003CCD1134E510D38200D6BEB0F72A01D
CCD314CC130DCFC347327050D65338D5F0843785EB0F8502986800006F1BB1682B05C7AAB7C7C0AB22B143462BB9D2F04B38800D3BD11127F45825C40001410F
E870B20010AA8FC547F1A021A16B0F6E9BB652A012AD0819D3F3B6248406821002ABE00952D00491300897C00AC12B09E340BCAA400ACA0B099900BCCC9B08C9
8B088610BDD21BBDD56B09D09B08AE80BCA4104C8100003B}}
\par\par \b \uc2 Five things to know today, and Trump campaign opens office in region\b0\par\par\uc2 Paul J. Gough \par \uc2 248 \uc2 words\par \uc2 7 April 2016\par \uc2 Pittsburgh Business Times Online\par \uc2 PITBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved. \par \par \uc2 Here are five things to know in Pittsburgh-region business Thursday: Property sale in Hempfield canceled\par \par \uc2 The Westmoreland County Blind Association's purchase of a former Shop 'n Save in Hempfield for vocational training has fallen through after environmental issues were discovered, {\field{\*\fldinst{HYPERLINK "http://triblive.com/news/westmoreland/10263489-74/association-asbestos-building"}}{\fldrslt{\cf2 \uc2  the Pittsburgh Tribune-Review reported}}}\uc2 . Mylan \b \highlight22\uc2 launches new product\b0 \highlight\par \par \uc2 Mylan NV, which is run from Southpointe, {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/mylan-launches-generic-epivir-tablets-300247142.html"}}{\fldrslt{\cf2 \uc2  launched a generic version of the ViiV Healthcare Epivir Tablets}}}\uc2 , medication that treats HIV. The drug had sales of $27.1 million in 2015, according to \uc2 IMS Health\uc2 . CMU professor wins NSF award\par \par \uc2 CMU Assistant Professor Wolfgang Gatterbauer has received a prestigious award from the \uc2 National Science Foundation\uc2  for his work to draw conclusions from uncertain data sources, {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/gatterbauer-receives-nsf-early-career-award-300247102.html"}}{\fldrslt{\cf2 \uc2  the university said}}}\uc2 . The five-year, $550,000 award is from the Faculty Early \uc2 Career Development\uc2  program. Bruster's Real Ice Cream opens in South Korea\par \par \uc2 A little bit of Pittsburgh is now in South Korea: Bruster's Real Ice Cream {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160406005405/en/South-Korea-Welcomes-Bruster%E2%80%99s-Real-Ice-Cream"}}{\fldrslt{\cf2 \uc2  opened its first franchise}}}\uc2  in South Korea in Seoul, the first of 10 shops in the country. Trump campaign opens office in Pittsburgh region\par \par \uc2 An office for the Donald Trump presidential campaign will be opening Friday on William Penn Highway in Monroeville, {\field{\*\fldinst{HYPERLINK "http://triblive.com/politics/politicalheadlines/10264620-74/campaign-trump-pennsylvania"}}{\fldrslt{\cf2 \uc2  according to the Pittsburgh Tribune-Review}}}\uc2 .\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=pittsburgh&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Pittsburgh Business Times for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PITBJO0020160407ec4700005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Epivir tablets in U.S.\b0\par\par\uc2 106 \uc2 words\par \uc2 6 April 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Lamivudine Tablets USP, 150 mg and 300 mg, which is the generic version of \uc2 ViiV Healthcare\uc2 's Epivir Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product. Lamivudine Tablets is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Lamivudine Tablets USP, 150 mg and 300 mg, had U.S. sales of approximately $27.1M for the 12 months ending Dec. 31, 2015, according to \uc2 IMS Health\uc2 . \par \par \uc2 Document FLYWAL0020160406ec460060p\par }\page {\par\fs20\b \uc2 Interventional Spine, Inc\uc2 .  \highlight22\uc2 announces New \highlight\uc2  Line of Opticage\u174\'00\'AE Lumbar Interbody Fusion Implants\b0\par\par\uc2 Interventional Spine, Inc.; PR Newswire\par \uc2 434 \uc2 words\par \uc2 5 April 2016\par 11:37\par \uc2 PR Newswire Asia\par \uc2 PRNASI\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 IRVINE, Calif., April 5, 2016 /PRNewswire/ -- \uc2 Interventional Spine, Inc\uc2 . today \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of a new line of products that will be showcased at this year's International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting in Las Vegas, NV. The \b \highlight22\uc2 new products\b0 \highlight\uc2 , available at exhibit booth #229, include recent size additions to the Opticage\u174\'00\'AE Lumbar Fusion line of spine products, as well as lordotic versions of the interbody device.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20100419/LA88318LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20100419/LA88318LOGO}}}\par \par \uc2 "We are proud to introduce this year's line-up of new minimally invasive spine products at ISASS and provide an opportunity for surgeons to see a demonstration of the new products," said \uc2 Joseph Darling\uc2 , Interventional Spine's Chief Operating Officer. "These new and innovative devices, which build upon our existing line of products, are designed to assist surgeons in delivering superior patient outcomes in an affordable manner for Lumbar Fusion Surgery. Important to note is that this latest generation of the Opticage is derived from, and uses the same basic mechanism, as the original Opticage expandable which has been used in over 2,500 clinical cases. We look forward to showcasing their benefits at the ISASS meeting."\par \par \uc2 The new product features include the following:\par \par \uc2 Opticage G3\par \par \uc2 *Superior Expansion Strength (1600N)\par \par \uc2 *Support for Multiple Surgical Approaches including PLIF, TLIF and Lateral\par \par \uc2 *Intraoperative Flexibility\par \par \uc2 *Significant Graft Window Size\par \par \uc2 *Lateral and TLIF designs for parallel and lordotic applications\par \par \uc2 OptiGraft Inserter\par \par \uc2 *Offers opportunity to fill the Opticage with additional flowable graft material post expansion in situ.\par \par \uc2 In addition, during the Scientific Sessions on Wednesday, April 6 at 5:30PM, Dr. Rudolf Morgenstern, longtime collaborator to \uc2 Interventional Spine, Inc\uc2 . will be presenting his experience with the Opticage, in an oral poster titled: "Percutaneous Transforaminal Lumbar Interbody Fusion (pTLIF) with a Posterolateral Transforaminal Approach."\par \par \uc2 Interventional Spine, Inc\uc2 . is a privately held company based in Irvine, California, that designs, develops, and markets patented implantable devices for the spine that can be deployed via both surgical and minimally invasive techniques. Supported by the Company's unique product introduction systems, Interventional Spine's products provide benefits to patients, surgeons, and healthcare facilities alike.\par \par \uc2 For more information on the Company and its products, please refer to our website at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.i-spineinc.com/"}}{\fldrslt{\cf2 \uc2 www.i-spineinc.com}}}\par \par \uc2 FOR FURTHER INFORMATION CONTACT:\par \par \uc2 Walter A. Cuevas, Chief Executive Officer\par \par \uc2 (949) 472-0006\par \par {\field{\*\fldinst{HYPERLINK "http://rt.prnewswire.com/rt.gif?NewsItemId=AE63508&Transmission_Id=201604051137PR_NEWS_ASPR_____AE63508&DateId=20160405"}}{\fldrslt{\cf2 \uc2 http://rt.prnewswire.com/rt.gif?NewsItemId=AE63508&Transmission_Id=201604051137PR_NEWS_ASPR_____AE63508&DateId=20160405}}}\par \par \uc2 http://photos.prnewswire.com/prnh/20100419/LA88318LOGO\par \par \uc2 Document PRNASI0020160405ec450015p\par }\page {\par\fs20\b \uc2 MilliporeSigma\b0\par\par\uc2 263 \uc2 words\par \uc2 1 April 2016\par \uc2 BioPharm International\par \uc2 BPI\par \uc2 English\par \uc2 BioPharm International is a copyrighted publicaton of Advanstar Communications Inc. All Rights Reserved.   \par \par \uc2 The life-science business of \uc2 Merck KGaA\uc2 , Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, offers a broad range of products that span from research and development to production. We partner closely with pharmaceutical manufacturers to simplify the complexities of advancing your molecules to market. Our decades of industry expertise and regulatory know-how help you get to clinical faster, allowing you to focus on what matters most\u8212\'20\'14delivering safe, effective therapies sooner to the patients that need them most.\par \par \uc2 Driven by innovation and fueled by a passion for science, we are proud to \b \highlight22\uc2 launch\b0 \highlight\uc2  the following \b \highlight22\uc2 new products\b0 \highlight\uc2  at INTERPHEX 2016:\par \par \uc2 * Lynx\u174\'00\'AE CDR connectors, a fail-safe alternative to time-consuming and costly configurations typically used in upstream and downstream processing\par \par \uc2 * Mobius\u174\'00\'AE 1000L single-use bioreactor, offering homogeneous and fast mixing and the industry's first pull-out, bottom-loading drawer and self-deploying bag for greater flexibility and convenience\par \par \uc2 * Mobius\u174\'00\'AE Power MIX single-use system, which overcomes the challenges associated with difficult-to-mix buffers, media, and biopharmaceutical ingredients\par \par \uc2 * Mobius\u174\'00\'AE single-use 3D large liquid transportation system for safe and convenient road transport for aseptic and non-aseptic substances and final bulk drug products\par \par \uc2 * Expanded portfolio of off-the-shelf cell culture media, available in a variety of formulations, for superior growth and productivity\par \par \uc2 Visit us at booth #2841 to learn more about these innovations and how they will help you improve productivity and lower costs.\par \par \uc2 MilliporeSigma\par \par \uc2 290 Concord Road,\par \par \uc2 Billerica, MA 01821\par \par \uc2 Phone: 781.533.6000\par \par {\field{\*\fldinst{HYPERLINK "http://www.emdmillipore.com/"}}{\fldrslt{\cf2 \uc2 www.emdmillipore.com/}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.merckmillipore.com/"}}{\fldrslt{\cf2 \uc2 www.merckmillipore.com/}}}\par \par \uc2 INTERPHEX Booth # 2841\par \par \uc2 Document BPI0000020160413ec410000j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Before the Move: Intercept rising ahead of April 7 \uc2 FDA\uc2  panel\b0\par\par\uc2 261 \uc2 words\par \uc2 1 April 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Intercept Pharmaceuticals\uc2  (ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has a scheduled FDA Advisory Committee meeting on April 7 for its Primary Biliary Cholangitis, or PBC, program. The program also has a PDUFA date of May 29 with a planned U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  in June if the \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application, or NDA, is approved. ANALYST VIEW: On March 23, Leerink analyst Joseph Schwartz and team reiterated a Market Perform rating and $144 price target on Intercept, saying that while they believe the company is likely to get a positive panel vote on April 7 and secure approval of the revised May 29 PDUFA date, they believe "Street estimates ...\par \par \uc2  still look overly aggressive despite their ongoing decline." Schwartz noted that M&A is a wild card, but added that "suitors can wait for a slow PBC launch which should keep the stock otherwise range bound." On March 30, Goldman initiated Intercept with a Neutral and a $114 price target, saying "expectations for a positive outcome appear high" for Intercept's lead PBC drug obeticholic acid ahead of the \uc2 FDA\uc2  panel on April 7, and the firm expects an approval on May 29. However, Goldman said it saw a "dearth of catalysts" following April 7. PRICE ACTION: Over the last month, shares of Intercept are higher by just over 5%. The shares have seen some volatility due to renewed takeover rumors that resurfaced in mid-March.\par \par \uc2 Document FLYWAL0020160401ec410070t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Medical Device Company CardiacAssist(R) Announces Rebranding As TandemLife(R) With  \highlight22\uc2 Launch \highlight\uc2  Of  \highlight22\uc2 New Product \highlight\uc2  Lines\b0\par\par\uc2 620 \uc2 words\par \uc2 31 March 2016\par 09:15\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Newly formed TandemLife will offer several innovative product lines to help medical professionals improve the quality of care for patients in need of advanced cardiac and respiratory support \par  \f28 \par \par \uc2 \f2 PITTSBURGH, March 31, 2016 /PRNewswire/ --\f28 \par \par \uc2 CardiacAssist, Inc\uc2 . today announced a rebranding of the privately-held company and will begin to do business as TandemLife as it rolls out several new product lines to hospitals worldwide. Following the \uc2 FDA\uc2  clearance of its TandemLung(R) oxygenator, the new TandemLife company is focused on making advanced cardiac and respiratory support technology available to more patients by providing medical devices that deliver on its mission of Life Support Simplified(TM).\par \par \uc2 "Twenty years ago, Cardiac Assist Technologies began the journey to create a circulatory support system unlike anything the world had seen before," said John Marous, President and CEO of TandemLife. "With the commercial launch of the TandemHeart(R) system in 2001, we delivered on our commitment and the result was a product that is still widely recognized as a robust, reliable treatment option for patients requiring cardiac support. While we're incredibly proud of what we created in the early years, it's now time to enter a new phase in our company's history where we have the ability to help more patients than ever before as TandemLife." In addition to its recently-announced TandemLung oxygenator, the company has developed and commercialized six new products since September 2013, including the ProtekSolo(TM) cannula line, the ProtekDuo(TM) veno-venous extracorporeal life support (ECLS) system, and the VoyagerVest(TM) mobility platform.\par \par \uc2 In North America, less than 2% of patients who experience a cardiac or respiratory emergency currently receive care with advanced cardiopulmonary support, in part because the complexity of such therapy has restricted its use to only the largest, most advanced hospitals. With TandemLife, hospitals can deploy a single pump and controller platform upon which all of the company's products operate, eliminating the need to train and certify hospital staff on multiple different systems. For cardiac support, a physician may choose the classic TandemHeart procedure, the ProtekDuo procedure available since late 2014, or the new TandemLife procedure, depending on each patient's individual needs. Likewise, for patients experiencing respiratory dysfunction, either the TandemLife or TandemLung procedures may be appropriate. By offering multiple circulatory support options on a single platform, hospitals can turn to TandemLife as a premier, single-source provider of a comprehensive system to control healthcare costs without sacrificing the quality of care.\par \par \uc2 "Our transition from CardiacAssist to TandemLife is the end result of years of collaboration between our employees and top tier physicians, patient caregivers and hospital administrators," said Mr. Marous. "We will remain focused on improving patient outcomes and reducing the cost of healthcare by continuing to develop simple, reliable life support solutions. We expect 2016 to be another banner year for our company with more exciting products still to come."\par \par \uc2 TandemLife products can be found in approximately 200 centers across North America. For more information about the company or its products, please visit our website at TandemLife.com.\par \par \uc2 About TandemLife\par \par \uc2 TandemLife is a growing, privately-held medical device company headquartered in Pittsburgh, Pennsylvania, that developed the world's first FDA-cleared and CE-marked short-term extracorporeal circulatory support platform. TandemLife products have provided critical cardiopulmonary support to thousands of patients in the top hospitals worldwide.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160330/349799LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160330/349799LOGO}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/medical-device-company-cardiacassist-announces-rebranding-as-tandemlife-with-launch-of-new-product-lines-300243905.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/medical-device-company-cardiacassist-announces-rebranding-as-tandemlife-with-launch-of-new-product-lines-300243905.html}}}\par \par \uc2 SOURCE TandemLife\par \par \uc2 /\par \par \uc2 Document PRN0000020160331ec3v000ap\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Anacor Pharmaceuticals Files 8K - Other Events >ANAC\b0\par\par\uc2 249 \uc2 words\par \uc2 30 March 2016\par 16:40\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Anacor Pharmaceuticals Inc\uc2 . (ANAC) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on March 30, 2016.\par \par \uc2 On March 30, 2016, \uc2 Anacor Pharmaceuticals, Inc\uc2 . (the "Company") announced a proposed offering of $250 million aggregate principal amount of Convertible Senior Notes due 2023 (the "Convertible Notes") in a private offering to qualified institutional buyers that is exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance upon Rule 144A under the Securities Act. In connection with the pricing of the Convertible Notes, the Company expects to enter into capped call transactions with one or more financial institutions. The Company's press release announcing the launch of the offering of the Convertible Notes is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1411158/000110465916108714/a16-7555_28k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1411158/000110465916108714/a16-7555_28k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1411158/000110465916108714/0001104659-16-108714-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1411158/000110465916108714/0001104659-16-108714-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 30, 2016 16:40 ET (20:40 GMT)\par \par \uc2 Document DJDN000020160330ec3u003wt\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E60000CA4A54F9ECEBE0969BF4DADBBA1121AC0000F2D3D4CC515AEDC2C5BE212DB3000BB60518C22D39CE5961D67379F6E2E3B80D1ED4
6C73CA494DD1626CFDF9F8BB1424C8454AB10004BC1B24B7071ADB858BBE1E2CBF2431C12935EAB9BBE8B1B4C63D44E7AEB1BE2230D87B81FCF5F6B9131CDF92
96C53941E6A9ADFFFDFDDC8A8EC3313AB60417D05D66B80A1CF8E5E6BC1928E3A1A4C4353EBD1C2AFBF1F1C02633C43541F0CBCDD2676DA50000B50215BA1420
C9464CC3303DE4A4A9C12C36E29B9FB60914FEFDFBC73F46DE8D93F1CFD1ECBDC0DA8085C53946C84248C02832FDF8F6B40010E9B5B8C63C43C63D49B7091BEF
C8C9B90F1FC73F4BF3D6D7C8414DC4383FCD6162B80E1ABC1629EEC5C7B50510BF262EFCF5F2FCF3F2F6E0DFFAF0EEC23439F5DDDFB70D16C4343CF3D8D7D060
64BF2533BD1A2BC23037C73D47BB1224FAEEEFC3333CC74147F8E9E8C4353BBB1626C12C329C0000FCF3F4DE908FECC1C0B8061BBA1720C12838B4090FBE1F2F
FEFBFBBA1423BA1323FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A38626361373663392D363138342D343661342D396436382D3831633536376638656232332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A38363837393630353343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A38363837393630343343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A38626361373663392D363138342D343661342D396436382D383163353637663865623233222073745265
663A646F63756D656E7449443D22786D702E6469643A38626361373663392D363138342D343661342D396436382D383163353637663865623233222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF8079301D331B1B0971221D6886883535851B7B71351C8686591D099733681D977B683384867B301B8B8D89A98771
1CAC938F917B5995971B999B869D9FA5A2A492A7AC095909C3597E361C4E1B1004150B33163052047D2C1C1615D5042C3F20DCDD324ECE7E5219562B2E047E10
50203FEB7E2E10431CEB7D190416CDCF193049A8595B90608839762C948023C090C50A10CE089C4B27CF9D9B3450D8D173A3045F460B09D655F8E7A643071810
FC409B210106143FD73848A8E0C28F9F053F9210484960818C2110A498CB704246451743306A9462A1C3CB7C152488C8A072010C09339EB248C083A6CD843A79
3A7413D40F810C328CB23B37A44DC67610FF4A52F5F3924702AAD0AE1A122174A5843819FA5C1321E16C053F2C3A2481E0A24F3732493240E8236581152B0BAC
314E92868535175278286101334305000958F419C912C682C30425F481D207B1121E521A775B61811E65CB273248E903214312199EFBD06B4A7A2401BBAA47C6
C1BAA0D233161B5A9A8E29C18FE96E3FC8F2F40942F8502B6DF4B573C15181F075166AB058C044C7F4D419EA6FC0CDC405142622F04080029E2DD0811B0B7CC7
C40A49D0630E14974121140471A5F799144974B0406915D8B5C06A565157C1191C5480DD5FA62156436181F5C4C06293F564851BC25196811332E8A39C0B49AC
C0041468287081053F3051C0060C289086FF7C1760908702706CB0CE022E70C0831E05307046015CF0E082024154A04341504C56D9650B0C575C126D24079A05
A3A9149804A98178956B151070C619D1A0580177044091274E408D27437942E5768285F360F8430123D071C3004760C1840226D0F0C6124E14A040046C905006
80625051C40B5A6CC144145EB01182120520F1C704059C40850D4C9C97233B9BADE02686F271C8C3062C5430D29DAFB523021A8441E5870E4A482085A0DDA4E1
866F52B070020869DAE8C40A99ED98C40F2C1410C20330A0F0471B398CF047034E88F1400135FC7184137F0870410F1AFCE10003052040821407FC61420E00FC
11C216073C508502D3E2A8A30B2EF0E0ABFF35128AD69C6912106B6C8878E63383964EC090E202B705EA58060C147A1E0812AEF76DB8A065485A014D0CA0C018
603890C300761819C61F222041811C39D4F1C1053998F1C71647BE5BC005265050000F7F74B102145F3C8C0E19EA2DD719C6FB049BCF741EB3D6D26B31C55743
6E87E9D081048CE5E9D010657AEB44B78C0D01EE853C74409A1FE6BE50400114449083185A5C70C10A7FD810C71F57E4A003141904518717155CF083BF09402A
4401007CF1020E17BCF0C4054EB441B30B1630A003C64C71401A5422F6D127607F6253D80622B08358071630E6D80269C09CD239279C90663BEFFCAD1C04CC95
76811D2F9C21C00D505CC0870F0530D1C6FF1F382800C41F0084AF090E5EC0708108FE5E50800A564710850046042106125C80FD19043CE80C4C32C203F9AC26
03682B965F7807A80C5807313FC08D6E16B08221602B032070DE849032369A00304EF9F003067CF0872818EC024AA0010AC2C7803F8C407EE773C016DC508016
2C210E0550C31F0E70380D2C6107232802081EC0832844000399699404C885313F486543F9B8CA0C4C038DECF0CE368579098920C883BA9DA50DCAB31108F6B6
41BF658626A1119C9C9C7801140CA0005060C30AC5F081A9C98A87467240FC0A80031A2C000B056B80FCDC05C83728200A3EB083203F533106DC2E63B63BE074
66F09A05A688052B52999E6CF783E24D70FF054E9090B7AC601EC680800167840F07A088C08E15C0036F2C00158C90833784A0000468C00E2FE00223994A7E38
60031C66708677C9CF04A36B8017F8F88732F480096894801A43E8213B69A777D971162671432D17886003BC315E4FC05823B65821397D73E43320B9B10E11EB
9545B8C018A2A0851CBC007C1C185A071AA0050C6C410586ACA1103A95801D16600B315842011A100005C8E00F7F60407FA4B0C4DB714C041B936260AAE8272C
4E2B4F0E64400D644000DDA0E504319BD61076358FB8FC4047045CA59CD0B6A1027CE001419841BE72703EA409E00F17C01A0F7280002AC8CF011480001398F0
060F5CA004A8CA410B680002057820A217FF080D084D33AC0FF9C564C6620161BC73186F7073650FE1C0194073BC719473014338A76620302ECF54202312B0DD
4C3BF621C211A1991428C30E8E1400120CE00F2D28C00EB4400131FCA10A0528411DD8E09D0B80206B34A0011772A04B06E4408F6750803475B046BE5A133082
D98A802ED9812EBAC06E69C0DB1E38B016B490524D50684B1237A2A1013EA74ED2E10125C30A83031C20020DD8C2051820872D3840002B28401AC2A0001C00E1
513668C306A6D00E296040061A384209780900005009034F80019C36769F4AF609AC8391CD253B294E0A3A811ED6390708D23035C7B1C0022790DF16D6A0000C
9C250EE5E25248B020BF194C014B41C8C2FF0514A0063CE4E0C20518C310B2A0801CCC21074A58CC163C9C032EA8C105415000017480013C38EE7005C003832B
B08602E4E0043D385C10A4B08504608909258D0317269C05A86D00009D73DCE3003086A961010A6DB0604A48740E19A4010D00E00100F8870116D8A0013DD081
1922C080CE95A00144E06106F690657B20E1005C50800D8E203B2D4F010011D8C0058270DC0670810910B800127010012B5C600DC461010F7030850440A10018
18810618B0E73820C1014E50C0131AB0072820170900E080620F90E50E30A1070D38402F7B90E52A382F0EE525400740E0203D4DE50456284004200AD1076000
677F40C0169AF0070314400460E0F51172FF50B03F9802A20228800166A5000AF03A0533B8C00D788D020514A05F10FDC20698302D2E38ED5D52E5F51F805080
38F061560538AC094AF000751321085580280A724042074CEDAA7FF8C2020AD0EC0960A046813AC31E2E93015DFF41084678C1BA73F0816217E0A7C63EDF0D2A
CE0705C8CAD9F0FBC30B1260046A5BFB014588C2A7FE108010A4E0B104D0F761D99D812160A003109DC205BCF08722D801A2707E370EE2FD87185CA0087F1880
09FFD0033FF47A0C21706101825006882E41D409436C5689E3823630C024A071381D0AA0C726E420EAB48C41B099306DC53D20004A6801444510F23F0CE1A713
B880B52B273F127A80E28F6DE11F727085FFA25FA02DB582A8152C0051FE9260DD586003F964692FA20F1DE83107BA0A5C988382528006E8431844917001E2E4
D60A7B10013E9819801CF4CB07392879DA8B8D0104885C0439284102E44EB40D28FBA70DC00244719083819F2FF4423AB7090E07050B9081050A3801D0B30E30
891FE1028F4FACC43540740760FF5D9977E111385F3023945C71BCAFC2058AB3526CD0761EDFFE031FA8F0072A6C000BB69FFD1716CA6B07608174100503F512
004210055735025CB0047F007AFEC67BF902691DA00510650078800136E019D1A778C514510A007A1AA00074E02F25F0057FC07D87F501389073314702246000
15E76F75F0072A60027F4004640751EA67FF1CCFB7492D85019BC76B376068EA82003CD57346026E06C36C10E50409630724C4804C1082101503FFE78045103A
1B506F104543307101E313519FF3074EC0051E0882257874324879BCD604B1526C6A976CD1B67907E0348D936F7F800405701C9EA1276B453D5B2077347001EE
720305A02E6C486C54307073C0032FF70710F07181F30746D06C88A50042F00747D420173007F30451B472617F657825A500BAC4748267066340821A7001A097
5887F54212F701D356392948050EA80267B7434EF34676880409F037667106CDC0038FB26B0150437FC0060AA0764650006A77035830011A30061C00516D9007
10250AF5870587456DEFE66F05C0021340FF045C80078FE700049066E6D2732C303B256005D6888D7F002B6FE04296886EF4070425E05838D02F1EE071C99800
D3868994D7884BC0041F27480A602C1492071CE006A8E4706C800734F80217703E5FB00543A800F467060500511DF0857417701AE989D526830AB0010A406C46
A000D3D600F9960217A04745E01EFC30011095077B005100B00310A502781000F62879CB87741380354BA000D5C80717F053E4A3777F60071547348287031090
00D3E20727D0013F701784B36B7F4001EFF6019F0551D65682AFB480F5F8003B908244033F5D3006A598776709511C50308D0551360001BDF678DC770233B06D
7F802E6920717C70964347422970963650FF00FCA853E85301618901E7D600BED77105A08000009910754BD4F3097B50137D500013200445C0065F000458B005
72A001A047012A20641B4042F567064100006F206E5920045AA00071600014B0990630006210003480044160028F470311C004BB4782EBF68E33A0003F770300
900663F0032694026F70040A50602170896C30742ED00429A001185072E828062F90065B607B5560037F800217C002C4D60243F00006E0584470016EB04AD621
1D6E40004C401F31060078500052900741700132102405800630B0035C70160BA0030E2107B962290AB00227A0033A401F0AB05FB8C4A079185D5B9007836505
359019F4C00472B00777202404D00661C0FF4B68802532700050F30C4CB00110511F67F1033F7007AB59A043900040E6074B65013E321F0AE00279451A247236
1DD31FBDD41AA6C10217800716C03B52D0A54EB006CE401F0F311F94A1033FE016190005ED48060CA00F5C1A0481532CDD13046E005C4C300649305C6282052B
E00E87910122E023A475131C0036520001172A032BA00352000D4C700269D01F15E00E5B79392E703943102C7C1818C2E555BBB31D62C52271F30374F35A3D41
06432019DE92231BE406D223211525277D40275EC502C5D565BD930033C15A9EE4182C105B65B20DDA42466274313451313F405AB3B10F18651352B02C71D055
83CA125744A8161028369101F4551367F1FF1031535256C0528BBA5F9ED10E04204D83F35AD0511B1930039B592C74E1AB2301AFC4931B660105B14521FB6A05
4E601EE70A8C41C103B2631335C10318551B2E10070C200243B001AFB113D20056259500DBFA1225453C8C61162EC00088E2B164200399C1101040A97B281143
102712510111FB213BA15E78B2131BA0132DE20221D6B125D53265E2B1E3F03C3B811E252B1110491A12E107F6B021143B041D800471300335B02722D0038410
B56730B535B001568BB57BB0B53DC0012260B567D00322A0562452033DB0077B42221DC0005A2BB50CC000502BB5548B065E9BB55EAB705E0BB6624BB6617BB6
69BBB6AFD003737BB5716BB7743B033D100108003B}}
\par\par \b \uc2 Organs-on-chip maker triples investment to date with $29M round\b0\par\par\uc2 Don Seiffert \par \uc2 404 \uc2 words\par \uc2 28 March 2016\par \uc2 Boston Business Journal Online\par \uc2 BOSBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved. \par \par \uc2 The Wyss Institute spinout that aims to develop and sell organs-on-chips for testing drugs, Emulate, has received a $28.75 million investment from its existing investors, more than tripling the amount it\u8217\'20\'19s gotten to date.\par \par \uc2 Emulate \b \highlight22\uc2 launched\b0 \highlight\uc2  two years ago, and now has about 40 employees. Last month {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/boston/blog/bioflash/2016/02/south-boston-s-newest-life-sciences-firm-wants-to.html"}}{\fldrslt{\cf2 \uc2  it moved to a 20,000 square foot headquarters}}}\uc2  in Boston\u8217\'20\'19s Innovation District. The company says the new investment being announced today will help speed up the commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  of its chips designed to simulate how human organs like the lungs, liver, intestine and skin work. The company is betting that it can help make pre-clinical testing of \b \highlight22\uc2 new drugs\b0 \highlight\uc2  \u8212\'20\'14 as well as cosmetics and products for agriculture \u8212\'20\'14 easier and cheaper than relying solely on animal models. It\u8217\'20\'19s focus is on creating two-inch plastic chips that contain living cells.\par \par \uc2 The Series B round of financing comes from existing backers Hansj\u246\'00\'F6rg Wyss, NanoDimension and \uc2 Cedars-Sinai Medical Center\uc2 . It adds to the $12 million it got from those same investors in July 2014.\par \par \uc2 In an interview last month, President and Chief Scientific Officer Geraldine Hamilton said the company\u8217\'20\'19s technology is already being used by \uc2 Johnson & Johnson\uc2  (NYSE: JNJ) and \uc2 Merck & Co\uc2 . (NYSE: MRK) as well as several undisclosed companies \u8212\'20\'14 including those in cosmetics and agriculture \u8212\'20\'14 and the company will be announcing more clients in coming months.\par \par \uc2 The money will be used to expand its offerings to chips for organs like the kidney, heart, and brain, and to accelerate the applications of its chips to mimic various disease states. But a big part of the financing will go toward the launch of the company\u8217\'20\'19s Human Emulation System, which will include not only the organ-chips, but hardware and software to allow users to easily conduct experiments without any specialized expertise.\par \par \uc2 \u8220\'20\'1CIn addition to evolving with greater accessibility as a plug-and-play system to be used by any researcher, our system is growing in functionality to include eight different Organ-Chips as well as disease-state applications in core areas of Emulate\u8217\'20\'19s research focus \u8212\'20\'14 including neurodegenerative diseases, oncology and the microbiome,\u8221\'20\'1D said Hamilton in a statement today.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=boston&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Boston Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document BOSBJO0020160328ec3s0002u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Foundation Medicine\uc2  Files 8K - Other Events >FMI\b0\par\par\uc2 401 \uc2 words\par \uc2 28 March 2016\par 07:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Foundation Medicine Inc\uc2 . (FMI) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on March 28, 2016.\par \par \uc2 Foundation Medicine, Inc\uc2 . (the "Company") has announced that the commercial launch of its liquid biopsy assay to evaluate circulating tumor DNA, FoundationACT, is now expected to take place during the second quarter of 2016. The Company launched the assay for research use in December 2015, and anticipated making the assay available for patient testing in the clinical market by the end of March. However, to complete the full optimization of its laboratory operations for this new assay, the Company has shifted the target launch date and currently expects to launch FoundationACT in the second quarter.\par \par \uc2 Cautionary Statement Regarding Forward-Looking Statements\par \par \uc2 Statements in this document may contain, in addition to historical information, certain statements that are "forward-looking statements." \uc2 Foundation Medicine\uc2  has identified some of these forward-looking statements with words like "expect," "believe," "may," "could," "would," "might," "possible," "will," "should," "intend," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or the use of future dates, including its target commercial launch date for FoundationACT. These statements are subject to risks and uncertainties, including risks that could prevent \uc2 Foundation Medicine\uc2  from launching FoundationACT during the second quarter of 2016 or other risks detailed in \uc2 Foundation Medicine\uc2 's most recent Annual Report on Form 10-K on file with the \uc2 Securities and Exchange Commission\uc2 , that could cause actual results and events to differ materially from those anticipated. \uc2 Foundation Medicine\uc2  undertakes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. All forward-looking statements in this document are qualified in their entirety by this cautionary statement.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1488613/000119312516518606/d155968d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1488613/000119312516518606/d155968d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1488613/000119312516518606/0001193125-16-518606-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1488613/000119312516518606/0001193125-16-518606-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 28, 2016 07:01 ET (11:01 GMT)\par \par \uc2 Document DJDN000020160328ec3s000jb\par }\page {\par\fs20\uc2 Business\par \b \uc2 Life Spine\uc2  in Huntley sees sales increase 45 percent in past 6 months\b0\par\par\uc2 sdibenedetto@shawmedia.com \par \uc2 316 \uc2 words\par \uc2 22 March 2016\par \uc2 The Northwest Herald\par \uc2 NWHRLD\par \uc2 English\par \uc2 Copyright 2016 Northwest Herald, The (Crystal Lake, IL). All Rights Reserved. Distributed by NewsBank, inc. \par \par \uc2 HUNTLEY - A midsized medical device maker in Huntley recently announced a 45 percent increase in sales over the past six months, creating momentum for future growth as it prepares to \b \highlight22\uc2 launch new products\b0 \highlight\uc2 .\par \par \uc2 Employing 50 people from a 58,400-square-foot facility near the Route 47-Interstate 90 interchange, \uc2 Life Spine\uc2  reorganized its sales team and focused on exclusive distributorships to help boost sales, Joe Loy, executive vice president of sales, said in a statement.\par \par \uc2 Life Spine\uc2  designs, manufacturers and markets health care products used by surgeons to treat spinal disorders.\par \par \uc2 "It is truly an exciting time to be a part of this company as it continues to revolutionize the industry," Loy said. "Our market share continues to grow, as well as our commitment to the spine surgical community."\par \par \uc2 Life Spine\uc2  is set to release other new products later this year, setting the stage for additional sales growth, he said.\par \par \uc2 Since relocating from Hoffman Estates to Huntley in fall 2014, \uc2 Life Spine\uc2  representatives have voiced a desire to grow the business. The company more than quadrupled its space upon moving to the Huntley Corporate Park at 13951 S. Quality Drive, providing additional room for administrative and manufacturing operations.\par \par \uc2 CEO Michael Butler told the Northwest Herald at the time that the new headquarters in Huntley could accommodate as many as 200 employees. Butler estimated \uc2 Life Spine\uc2 's sales roughly totaled $28 million in 2013.\par \par \uc2 He also said the expanded I-90 interchange that opened Huntley to interstate access from both Chicago and Rockford also motivated \uc2 Life Spine\uc2  to relocate to the village.\par \par \uc2 Earlier this month, the medical device maker announced it would release "Prolift," a titanium system that restores disc height in the spines of patients, later this year after gaining approval from the \uc2 U.S. Food and Drug Administration\uc2 .\par \par \uc2 Document NWHRLD0020160323ec3m0000h\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Lilly Wins Approval for Psoriasis Shot\b0\par\par\uc2 291 \uc2 words\par \uc2 22 March 2016\par 18:45\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Eli Lilly & Co\uc2 . said Tuesday that it had won regulatory approval for its injection to treat plaque psoriasis, one of several \b \highlight22\uc2 new drugs\b0 \highlight\uc2  the company is hoping to \b \highlight22\uc2 launch\b0 \highlight\uc2  this year.\par \par \uc2 The \uc2 U.S. Food & Drug Administration\uc2  said it cleared Taltz, or ixekizumab, to treat adults with moderate-to-severe plaque psoriasis. The autoimmune disorder and skin condition causes cells to build up rapidly, resulting in itchy, red patches.\par \par \uc2 Plaque psoriasis is the condition's most common form and is characterized by silvery scales on top of lesions. The \uc2 American Academy of Dermatology\uc2  counts roughly 7.5 million people in the U.S. who are afflicted with psoriasis, with 80% to 90% of them suffering from plague psoriasis.\par \par \uc2 Lilly said in August 2014 that the injection had met late-stage study objectives and that it was statistically superior to the psoriasis medication etanercept. The company said at the time that up to 41% of those treated with Taltz were able to achieve clear skin at week 12, with one injection per dose.\par \par \uc2 Taltz is poised to challenge etanercept, made by \uc2 Pfizer\uc2  and marketed as Enbrel. The drug, sold outside the U.S., brought in $3.33 billion in \uc2 Pfizer\uc2 's fourth quarter, down 13% from a year earlier and representing 7.5% of total sales.\par \par \uc2 For Lilly, Taltz represents one in a string of launches the drugmaker is counting on this year. The company in January filed a new drug application with the \uc2 FDA\uc2  for its oral rheumatoid-arthritis treatment baricitinib, and its has a diabetes drug under regulatory review.\par \par \uc2 Write to Lisa Beilfuss at lisa.beilfuss@wsj.com\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 22, 2016 18:45 ET (22:45 GMT)\par \par \uc2 Document DJDN000020160322ec3m004a5\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Life Science Leader MilliporeSigma  \highlight22\uc2 Launches \highlight\uc2  New Innovations at Pittcon 2016\b0\par\par\uc2 323 \uc2 words\par \uc2 21 March 2016\par \uc2 Pharma Business Week\par \uc2 PHBW\par 84\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Pharma Business Week via NewsRx.com   \par \par \uc2 2016 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- The life science business of \uc2 Merck KGaA\uc2 , Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, is launching a range of \b \highlight22\uc2 new products\b0 \highlight\uc2  for separation and analysis at the Pittcon Conference and Expo 2016 in Atlanta, Georgia, March 6 - 10, the world's largest conference for laboratory science. The innovations include high performance liquid chromatography (HPLC) and capillary gas chromatography (GC) columns, and tools for effective analysis of water and easier sample preparation.\par \par {\field{\*\fldinst{HYPERLINK "https://photos.prnewswire.com/prnvar/20160305/340775"}}{\fldrslt{\cf2 \uc2 https://photos.prnewswire.com/prnvar/20160305/340775}}}\par \par \uc2 "We are committed to providing innovations that help our customers solve their toughest problems, advance science and accelerate access to health care around the world," said \uc2 Udit Batra\uc2 , CEO of MilliporeSigma. "Our customers are benefitting from our expanded global footprint, industry-leading capabilities and broadened product portfolio."\par \par \uc2 Merck KGaA\uc2 , Darmstadt, Germany bought \uc2 Sigma-Aldrich\uc2  for $17 billion at the end of 2015, making it one of the leading players in the life science industry. Pittcon 2016 marks the first major conference at which the combined businesses will exhibit together with a unified presence.\par \par \uc2 Among the new life science products are new categories of Cerilliant((R)) Certified Reference Materials, including bile acids, antiretrovirals and fatty acids. These compounds allow clinical researchers to accurately quantitate therapeutic drugs and endogeneous biomarkers.\par \par \uc2 "We rely on MilliporeSigma'sCerilliant Certified Reference Materials to provide accuracy in longitudinal testing of patients and as well as between-lab studies," said Brian Rappold, scientific director at Essential Testing, LLC, a Collinsville, Illinois-based clinical medical laboratory provider. "MilliporeSigma's Certified Reference Materials are fundamental tools in providing quality results to providers and patients."\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Merck KGaA\uc2 , MilliporeSigma.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document PHBW000020160321ec3l0006a\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Teligent, Inc\uc2 .  \highlight22\uc2 Announces  \highlight \highlight22\uc2 Launch \highlight\uc2  Of Cefotan(R) (Cefotetan For Injection)\b0\par\par\uc2 464 \uc2 words\par \uc2 21 March 2016\par 08:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 BUENA, N.J., March 21, 2016 /PRNewswire/ -- \uc2 Teligent, Inc\uc2 . (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Cefotan(R) (cefotetan for injection). This is the Company's first product \b \highlight22\uc2 launched\b0 \highlight\uc2  from the portfolio of discontinued and withdrawn \b \highlight22\uc2 new drug\b0 \highlight\uc2  applications (NDAs) and abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  applications (ANDAs), which the Company purchased from \uc2 AstraZeneca\uc2  on September 25, 2014.\par \par \uc2 "With the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Cefotan(R), we are now marketing four injectable products in the US, and nineteen in Canada," commented \uc2 Jason Grenfell-Gardner\uc2 , President and CEO of the Company. "This is our first product \b \highlight22\uc2 launch\b0 \highlight\uc2  that will start to address the drug shortage concerns in the United States."\par \par \uc2 About \uc2 Teligent, Inc\uc2 .\par \par \uc2 Teligent\uc2  is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website {\field{\*\fldinst{HYPERLINK "http://www.teligent.com"}}{\fldrslt{\cf2 \uc2 www.teligent.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain \uc2 FDA\uc2  approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in \uc2 IGI Laboratories, Inc\uc2 .'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the \uc2 Securities and Exchange Commission\uc2 . \uc2 IGI Laboratories, Inc\uc2 . does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.\par \par \uc2 \f2 \par  \par Contact:   \f28 \uc2 \f2 Jenniffer Collins\f28 \uc2 \f2 \f28 \uc2 \f2 Teligent, Inc\f28 \uc2 \f2 . \par            (856) 697-4379 \par            \f28 {\field{\*\fldinst{HYPERLINK "http://www.teligent.com"}}{\fldrslt{\cf2 \uc2 www.teligent.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 Logo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20151113/287129LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20151113/287129LOGO}}}\uc2 \f2 \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/teligent-inc-announces-launch-of-cefotan-cefotetan-for-injection-300238579.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/teligent-inc-announces-launch-of-cefotan-cefotetan-for-injection-300238579.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Teligent, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.teligent.com"}}{\fldrslt{\cf2 \uc2 http://www.teligent.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160321ec3l00048\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Valeant says guidance does not include forecast for any new  \highlight22\uc2 launches \highlight\b0\par\par\uc2 28 \uc2 words\par \uc2 15 March 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Valeant says if approval and \b \highlight22\uc2 launches\b0 \highlight\uc2  of \b \highlight22\uc2 new products\b0 \highlight\uc2  come with guidance period they could present upside.\par \par \uc2 Document FLYWAL0020160315ec3f002uv\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Acura Pharmaceuticals Files 8K - Other Events >ACUR\b0\par\par\uc2 182 \uc2 words\par \uc2 14 March 2016\par 16:21\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Acura Pharmaceuticals Inc\uc2 . (ACUR) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on March 14, 2016.\par \par \uc2 On March 14, 2016 we issued a press release announcing that on March 10, 2016, the Indiana General Assembly passed legislation to require state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, and the legislation is awaiting the Governor's\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/786947/000114420416087834/v434233_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/786947/000114420416087834/v434233_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/786947/000114420416087834/0001144204-16-087834-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/786947/000114420416087834/0001144204-16-087834-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 14, 2016 16:21 ET (20:21 GMT)\par \par \uc2 Document DJDN000020160314ec3e003fo\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw171\pich40\picscaley100\picscalex100\picwgoal2565\pichgoal600
47
4946383961AB002800F7FF00DACBCB9624288F6B6BBDA3A4C2999AD3C4C4CCBBBBF1F1F1BA151BA78687712023C11E24EEEDEDD1B9BAE5DEDEA71E22A43E42C4
ABABFCFCFCDDDBDBCDC4C4ECE9E9F1EDEDCBB3B4FAFAFAC4A4A5B81E24E9E6E6BD1E24BE9293AB0C12B37A7CAE8081CAAAABE5E1E1A62C30AB1419E1D4D5BCB7
B7B16769E2DDDDC6B3B3B59293B91A20B3898BB28485EAE8E8A30C12BA181EB91C229C0D12E0D9D9F4F2F2A26163BA2026BC9B9BAA696CBE1C22B62025DDD5D5
9D8B8BF6F6F6A13135981E22BD1920B10D14BD2026D2C9C9A35A5DB720269A5254BA8B8DA97375F8F7F7E6E5E5B6161CF4F4F4B5181EA44144D4D1D184191CA1
9FA0C6C3C3AB242ABB1E249C595AB2141AAD9A9BA25255A56C6DA05F61982B2FAA7B7CCCCBCBADACACA3292DAB595CA31419DAD1D19A313596080D885B5CD5CD
CDD7C4C5B21016E2E1E1A34649A21016A27476B5141AF0EAEAB51218DED1D29A14199D4A4DA74D50AB1016AC2126F8F6F69B4143A27C7DAC4A4E96393CDAD6D6
A3050A9B4E51B38E8FB9818296151AB12025C7AFAF8437399B1016A23438F6F4F4B87B7EA45558AD5D6093191EFBFCFC9C3B3FB012188C0204AC181E9C353899
5F61A4393CAC6163EAE3E3B47779B31F24954A4DA4252AE7DDDDB46D70B2161CAA34397D4749AA6E70F4F7F69C191EA34B4EAB292DAB5356A84549F8FAFAAC56
59DCCFCFA84246B05256BA8688ECE6E6B27274955052D5C8C9B01D23A4191EEDECEBA93135B15F62AD6668963134A12125AA3B3FBA1F25B41F24B61C22882528
B61A20FCFAFAF2F4F4B11A20B12E33AB7678B996979B4649B81F25943639F9F9F99C5658F6F8F8BA1017E6E3E3935B5CD9D3D4961217933F42BC2127C2BABAB6
8688ECE3E3E8E3E4B92025A67778BA1D23B81D23A56668B71F25BB2025FEFEFEB61F25FFFFFFFEFFFFFDFEFEB61F24B71E24FCFCFBF8F9F9B71F26B61E24FBFB
FBFDFDFDBFA8A9900D12E3D9D9B99FA0D8CFCFE5DFDFD0BFBFDFCDCDB23C3FC09F9FE3E3E3D2C7C78E474AD8C7C8EFEFEFDFD3D3F5F8F7B87577DDD8D8D9C9C9
D2CDCCE7E7E7D8CCCCFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A31453036373638353530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3145
303637363836353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3145303637363833353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3145303637363834353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AB00280040
08FF00FF091CF8CF98190A43120E993744998481C64420543884C21E0C04336ADCC8B1A3C78F2039764BC26FA2427E6652326BB7A1021373C642CA14D88DC981
0349CC6DFBB7CD5CC61E82C2F0A296AD68B6222B7E05A3F40F052318C48C0A91D16111C124FAB8DC193125D0AB5796024DF161045D8F810ED86CF1C1966D002E
18FFB5AB62ABAD8F11BB0074FB87CCCF962F76035489F5EF80811A92BED4F90A36509D2F7754F43B37904686472B8A18CDC641571F754C6E84E1B0391B104E82
28FC0D9CE58040667D02D8F5114005E19915882CD150DA282E0ECE3A895A609418902D3BFE9500B4C286D122401EB190D08D800CD29B81485AF92306AEA24510
70FF72652EDE03189A8DC6B0F2A1C73D4039A216CD218A4D825FD6E44387754360BC30C9AC00C3800890E1CE3F15C801036F9B5111C8187214620915C454488C
3540C81001466EB0F04A66D9D8B0C2303C1462CD77D93CD3860F62EC359340EE3493C366391452C625F1F576D47A2D5850C1218D3008DE0A3EF851403DFB00A0
E49200D4730F133D6440470CE9091188020A08A14D3642FC00C503B8E0A28D220A80B200374569B0422D0E0CF44D3F6C00B20407159656042E40D0D1870B025D
4008719B69E3C12C1BFCA38C136838075E0C6B444083403DA880597ABDE510C7052F12C484261E0861D4356DD460C13F1638B36069362C818918DBE8430B1AF2
15FF25C40B7F9CE502048D785A9488A0F8F3D03E889CDA9B354BF461813273B4A123528F7091C43F06E481C066B8BCD00132FFD873C7261CA0998D3656F8A00C
13F9745A1A073284B04D1282D4B104A5DA2C61CB0CFFE8A3461BF269F0C60752A882869045C0F08501996E644E165680980D37DA34B18532026D734633F915C5
0D0C234450F0C61C773C10325A58416569DC94ECADC5452CC0C707B7792C1049C618F384175E48214546EAFCB00215BDE1B2421C25F8A28A072866434D109AB4
F38F39C2AC01C333DEE2A2C117A14858F4B71E7C70402677AC608D51408491814029C88200A51AC0A0871BFF6C7087B09CE910090FB6E46083B736E882892910
04FF5274111A34E209612528B2C2D5365851483BDB1C5089B946D9E0C121E318A24713280A3ACB4BC1909083B7542C714705993241C00BB8C47A940ED45E7D21
210D20580B0C571F458C151EFC4B6951D512F00900841CBE2B1A9A3CD1422E0A17454C0C8F0CE0C714331A9543AF9FFCD18835BB17C1C1123260E38E123B6564
4F0744AB7E271008E4F01D31D4BCA2C8250380EFE60E982CA12837B9500A1D2803849FA9187378437A8841851784001F0D9041C54A133A3D58A01B21B88EEA80
000A4108A400F048C60236C8415094E01F22388415AE41296A50232AC4C88124AEC0057C29AF34D668421F68D08D76C4230438CCA13BD28002157C411744314A
0CFFB160811D90E26CA541800F0AF08F45742E079422D6305C738E7DC027884278C00FB8112B217840137CCAD4396E000B20B02E1B3E0B409BFE41830808457F
3078851F9EF50F1718C1030B700EE872A0BE92154108C95843300A3590120420479B418A1CCFE28E42C0A0373A80C10332E0A21E08830C0B784611D0C40D5CF0
F16EDC28820D16108400B8A31BDEF04318A2571C3A7C8001200C4013147594254C4110F6F840A74A468D1510C21DE670C311E8A0812EBEA01231F1580F52B086
202CC10A56D8C41B3C60844F0CC402C508421BA0690504F0C11371719938C7A91143A0230CCEE4A63AB9D90812B87304443000B6C6D90D1A4881014C8882148C
E1FF85286884125BC0DC66A8D1840718E0592E18663177158459A0802312308405DC40510BF4C07F19D9864637BA0D170D84A31BCD284835EA8D8C60800613AD
A8211EA2916E644296B58B4A201EC18BDA99C61604E309483532D29046CC1CDDE8C639CC618EA166A4023568420C7AD684628CEA021204DB1698281076E0009D
4010820D8AC0D5AE5243080B40800CB8004B386021071CB0C1339EB100121CE11B4BFBC30BF2B856B006401D4DDC471C72F00CB53E0301F04881AB5EF0861C68
B5AB5E7D861010E0814B40EC1F86C0C26E1229C90158C54FAC2C0A0248B10711FC20AB7545C32C46150B53A041AB6BE5000C6A00CB173121036B18999D624082
01FF40C314D3320ABA32E00D090883042B082297AC3006D2D5E3B3A5014221F451812D08EF2830C084C67A80083A08E164D7580211A691840ED06181C6518300
18A10D9E1585037420826B869007012AEF1A7438023EE331A5DDE580044858C439063002F4D0081000F84726B4A08BA572A9A169B880289610440E580112D3C0
A84CDEA1083AE9281BC4E8D20F2C81226268000D7FD8801BA221B2122EE10B2938C01EB090A8CD10E30D89E84726E2F05C6AA0211528A88024ACB0A5E7D03603
13384410FE86864350E00F6D902D1A37510803942216997043055CB00A2AAF02A8FB9091EA94A70D0E68A34E5A84042D042102CAFCA30717780083D1A8034540
21FF1CBA0ACFC04A5A303180E10D9BC922141421842D1B256DB57860024F94489FB5E1D0884E74814EF18D06C43688B8E0C53178F0054213A36468D40626CAE0
0C446643037488866B62710C0F0061ABBDB1410E1AA108166CC0CCFF70C51C729B9D11E0011D59A8430CE4D3492028E21EFE8B0524AC705D1D718010F1B0CAC6
98A08A17E8EAD36DC847173A703D3F8B280EF5F00600C60004D579511367C1C0055AD0817297FB082D6086396271844690B028DAD022982AA48D41282017A923
C657B858945E364AD904C18032E2B1053A2C40B8426C82162CFA07C81965013220C0363050B635F36E058080C34ECC718135049777B59BD511C6B13108EEB538
39FF50C40797E31D3B25850507B0C7213C404BA3DDD80CFFF8860ACA18C525B0F61FF7C0C1647B538418D0E102410E829F43242F769C6303F9088297B5D1E564
CC821DFF48420B7EA13066A9401C0D20446643F445D25560D8CF66963046358F2D745B568118C4203850341BA7C2150593802BDA1B447F0BE22C1508C62694CC
192BC8E1510C68F8B3D1D8045280C01385B88679B9F18C2580C21DE1ABC0538414B926D86207E768C011752484464060033B8916AD31CC0B527021186AD0C5D7
C0038329AC23090540451B76970D188C610FFFE80536AC30FBF35A81083DB0472282F08C34E5600B28F0C50782442364D37926FD200209741088EEBFE211AD89
D8FF3D14F10BEE775F07242804E807328E21D4401681C805A6B3018E72E42210C040440AECA19153284217DD178081C00D24D007AEF10FFBF003BC2080DD5704
6B400B4C4010DE2002D52009756009E5500E9C647F96300592E0093BA06CB180056B607E01080ECDD000DBC004E7F40B02A8039BE00452500D0F0080DDF70BB0
A0026761011DB0066111803AB0066010461D730E33D00792800A4AA8848CE00724271034000292E0044B880A63C0058F424E5A484EE2B00372908455880AA430
86A1300A603009ACC002EBA0042C454FFD000D4FA00452003E287033196107C2F00A40F00C54870B0B203A07286087A425DAE087614000D7B7858AC83134B075
7BFF487590088961D2651C90038CA507EC20611D23017B600E12600226200F5E000DE5340C9B605EBBE2796240194910026BB04045F0067970208B588B1B6301
8CB004A8E81B7C840BE4602708E004B4284EE6200FE68001B1C00F5DD00F139011E7E00FA0304B8994146BF70F3380036D100E52E10195108802710E867000EC
10012C0002E6A80229800234904C02B16E28E000ED108FED8002B1E02212500128208FF188023DB0172B388FFA8802CA904CC64003B1300F03508EE6E807E860
0607006B02810167108D3527355F1009913002BA503B40800917D00322008FF2986366660E2E908F01B90174841B47005CBC1743C7C03670A0089E9603841002
1EFF85027E00018FD0086DB0042B109441B9046FD0085F500DA4A31C4610046FC04DDE9405CA7601E9900CDCD406C9900EFB2010B1904DDB044DC9F04D58810D
B2D0936D000342199430D0068D000B7D3004CA6608205062CFB102CD821105000840501A30700B0630043280065DE94D73C07FE7E007644095D06495E9500010
1912B1A00730B08B17F70394700EA75334E4800073E00F02B101D8B00608A049DCA003BDF4061F071EDA0004E99002E7F00E72E035D2B30604B01769600A41D0
639FB6025BC01407C0028D60604C370A2690058DB08725439A2B8006B4931EDCA06A6490013E5101B5F05CBB72628C790E1DE06C89840689500116105028E245
B3FFF090293002481422BE6400002713E7500084D072A5E16FEE80029A002B462128AA800C13B8056D506C46B3020FA00213A0020F307608A0064AC00090B033
E001040FA031DBD002AB74469F060372B00ADD9065EA233D9C200091400DD8F19FA2200CCCB00E9C00157F66059EE002DB1076F0292B8D100A8FB20760D06252
F10219B00D6E20074D307B9A630FB1400AA78526D40003B0707B05E3022DE06E4B1743D59000B79097CA9303CDC04434300C4B507C9C41024480110D2023C9A5
7E1BE05C0C121E9C7001E6C00C9260A345710D56800334E0027D800042126955800753400545930361E007702508B7800052A301B8600D389A04ABF00123541A
39FFF008D5C000FA800824B078B8F00658D00FFF400948C0759A61036D900814E009E0307BD0410220D09832210DDCC679D4220450000575F06CE1B004888002
E610011EA73F4B200AAC390E1FA09D9BB159138002868322B1880A33600CD8D008DDE2638DD001F61002C05A1430900757D0024A45236170AADD200C50E00390
10AE3EB005838057D210006FD71BBA6005494614B8005662850461440303F00A4DD0A9DAB00B0A10AB51C10D3940079E500A1B730E506561CA933AC5610996C0
6F185640048001ABA01B5ABA3C7580087F3009A2B06B2E5664F6500234862236D05013E00E0B8670CB430282000DD2422D06A404959064FA830B9BB005C2200F
1DFF610E1164B02EB64968820B45000A0A5006CCC08E4B330FB6603F68940B0F0026E1E90193E08D2FA20C42162BB860094B6B53BE610D2AA71C346953D4B056
7D6542626B0353D1008B70068FB62B6D400B26100A31C033C480B0045407095003BC809BC470A065760164706A27D36F0B8006E9800DA7B092023103AC609F9B
61039630029CF008D7804561450620108103B10163C063C5513436800660A0341C730A63F04852610B0AB00B0B80B5D9905D88400396F9020B6514D4900B7520
0A533005A290BBBA2B0A75500C0E700EAE285BB8500E83D00913824681600B7510265DA200017026BC832E0DF010DFA00F97E0341C8070CA430540B00646A00F
66FFE60AE86A27B2380FE6B00788424BD4C028117016FFE00D33B0054B809B8C0A08C35830E7100F32B07830300A57100C43179FB4150176E00F6040A78B8B06
A6800218B00D434554107C8CE7B00D164000F5252B0FB06742F01D0B00050AF00A6162038AA008AF1067EBE109FC47109F90027AF00259D51B9487006B3000C6
6099FB5B1AB352093D700E3B700B6C2A9F71B101C5A08B17C619C886AA3221029CA2281EE6011DD00F21F05D7EA60D2BF0034A530FF0A13A0BB0064740192250
0C8EF0023230C632F0028E2008F7180DEE961E553B80F4560702B00C350572545BC5EAD00D138701C75854DBE00BEE5003C1430DBB630DBC70A11B700241A0BD
14FF644118A00275E05FBC030301300D02C100C790A59A410C45A0037F3B2B87E00B1C73065F00C9C4802E67F00DF5F09E3615034D500307600ED97935E1D164
FF700EE8609E94E233B5403A33E0096D700D2E261FD9C50A52F0078AEB728FA0024980012D10C62FF0CC2FC007BB90028551039B9059D6B00938600EA7600B52
FA1C6F3007F4D203586005219A0D31B00928DC36D3E7B318860B1E6C039C2BB2037B046B0028B9A9074CF152D4D96F05250849A00C9A1004BB232827004BE680
0D7410A2484102C2C07F7030094B00CC3DB3028A8002FD30096FE0670C630577C07FEC90086F906F713B397C920459B009C557044B50074E763AE7CC252F7004
49FF700E70F0056DA0BE05650018D05DCE86423900013C8004015C046D800A399529CA000641A02845D70847403A8650056DA0A55CB209635028F4890608372B
20400376B00E530003C2650D56D0078620105C033773F908376008A7902C3A420DBBCAD3FF207AAB870B1E7004078001EE600BD2B8300E867CFD609B35970D39
00084C640C7E3029F7F960F6E00DF1F027CA63A80DD00FC6CC798B9C7765739ED7560F7055012AE092CF715FE054CB828049A882830F80399A11C361C002962B
60B590AECFC1019B2007AE11011040BAE74202DB5C55CB577336C0DA9B80B00BE345A1C000DB300098F0CD46F1068860B3347007443C24BFD002E36000DE8C26
45FF670548C000B91424B1B2C5D180C41E9104D3B7001CD0DE967807AD650CEEB00640C0DEED1D56BC4A471240017AE0016D6058856821BF61891EF0052DF050
045102A0000468D5DEF79D0C5F60060F5102B680000EEEE00B900C92B003FEA3045520036F00041CB0C102DE6540F0062FC008291013E370027874E139B0001E
4000355D0F618000F6CD01190E0C05600019C4DE7C84007AC0270CD00141C04718EE0127908533910678D00A5A10E55A5005651188151009C720E55A500397C0
06293C1012600F82A00590F005C070E6C0300290500503100B6D481033D00A44A0E5517E0CC730003EF10F3BB00C594EE744D00A112061DE900414C006CEF005
A23E80E6A23002C3C0051490042EB20D1BC0069750037EBE0C6D720011D00AC760E9525E052020057860049E5E03461009334019CB440F74CEE55C4084321110
003B}}
\par\par \b \uc2 Bioventus LLC\uc2 ; \uc2 Bioventus \highlight22\uc2 Introduces New Products \highlight\uc2  for Spine Surgery, Osteoarthritis at AAOS\b0\par\par\uc2 1,307 \uc2 words\par \uc2 11 March 2016\par \uc2 Chemicals & Chemistry\par \uc2 CHEMEC\par 329\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Chemicals & Chemistry via NewsRx.com   \par \par \uc2 2016 MAR 18 (VerticalNews) -- By a News Reporter-Staff News Editor at Chemicals & Chemistry -- \uc2 Bioventus\uc2 , a leader in orthobiologic solutions, announced it will \b \highlight22\uc2 introduce\b0 \highlight\uc2  several \b \highlight22\uc2 new products\b0 \highlight\uc2  in booth #1851 at the Annual Meeting of the \uc2 American Academy of Orthopaedic Surgeons\uc2  (AAOS) March 1-5 in the Orange County Convention Center. These include GELSYN-3(TM), a three-injection, hyaluronic acid (HA) based product for pain relief associated with osteoarthritis (OA) of the knee. HA is a naturally occurring molecule that provides for lubrication and cushioning in a normal joint.\par \par \uc2 This week \uc2 Bioventus\uc2  will also \b \highlight22\uc2 introduce\b0 \highlight\uc2  CellXtract(TM), a novel cell and bone marrow extraction tool; and SIGNAFUSE(TM) Bioactive Bonegraft Putty, which is comprised of a bi-phasic mineral composite combined with a patented bioactive glass and resorbable polymer carrier providing surgeons with exceptional handling properties.\par \par \uc2 "\uc2 Bioventus\uc2  is very pleased to introduce a full portfolio of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals this week at AAOS," said \uc2 Tony Bihl\uc2 , CEO, \uc2 Bioventus\uc2 . "We are also excited to speak with attendees about GELSYN-3, our newest HA as well as the rest of our active healing therapies product portfolio. It's our goal to provide customers with leading orthobiologic products that heal patients quickly and safely while helping them resume and enjoy active lives."\par \par \uc2 Also on display in the \uc2 Bioventus\uc2  booth will be EXOGEN(R) Ultrasound Bone Healing System - indicated for the treatment of established non-unions and indicated fresh fractures; SUPARTZ FX(R) - a five-injection HA for treatment of pain in the knee due to OA; DUROLANE(R) - a single-injection stabilized HA based upon a natural, safe and proven technology called NASHA(R), and indicated for the treatment of mild to moderate OA pain in a variety of joints; OsteoAMP(R) Allogeneic Morphogenetic Proteins - a uniquely processed allograft bone graft substitute and a suite of additional synthetic and allograft bone graft solutions added with the recent BioStructures acquisition. About Bioventus Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. \uc2 Bioventus\uc2  has two product portfolios for orthobiologics, \uc2 Bioventus\uc2  Active Healing Therapies and Bioventus Surgical, that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, \uc2 Bioventus\uc2  is a trusted partner for physicians worldwide.\par \par \uc2 For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.BioventusGlobal.com"}}{\fldrslt{\cf2 \uc2 www.BioventusGlobal.com}}}\uc2  and follow the company on \uc2 Twitter\uc2  @Bioventusglobal.\par \par \uc2 Bioventus\uc2 , the \uc2 Bioventus\uc2  logo, EXOGEN and OsteoAMP are registered trademarks and GELSYN-3, CellXtract and SIGNAFUSE are trademarks of \uc2 Bioventus LLC\uc2 . SUPARTZ FX is a registered trademark of \uc2 Seikagaku Corp\uc2 . DUROLANE and NASHA are registered trademarks of \uc2 Galderma S.A\uc2 . Summary of Indications for Use The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at {\field{\*\fldinst{HYPERLINK "http://www.exogen.com"}}{\fldrslt{\cf2 \uc2 www.exogen.com}}}\uc2  or by calling customer service at 1-800-836-4080. A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.\par \par \uc2 SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.\par \par \uc2 You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to avian (bird) products (feathers and eggs). SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found at {\field{\*\fldinst{HYPERLINK "http://www.SupartzFX.com"}}{\fldrslt{\cf2 \uc2 www.SupartzFX.com}}}\uc2  or by contacting customer service at 800-836-4080.\par \par \uc2 DUROLANE (3ml)-Europe: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes. DUROLANE SJ (1ml)-Europe: Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to 6 months but results may vary depending on various patient factors. DUROLANE is not approved for sale in the United States. Indications presented are those approved in the \uc2 European Union\uc2 ; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest.\par \par \uc2 OsteoAMP may be used in situations where an autograft is appropriate, such as spinal fusion procedures. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects. Please see OsteoAMP instructions for use for complete list of contraindications, warnings, and precautions. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080. It is available in the US only.\par \par \uc2 SIGNAFUSE is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. SIGNAFUSE is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). SIGNAFUSE can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process. Full prescribing information can be found in product labeling by contacting customer service at 1-949-553-1717. It is available in the US only.\par \par \uc2 CellXtract is intended for use for aspiration of bone marrow or autologous blood using a standard piston syringe. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080.\par \par \uc2 GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). GELSYN-3 is not to be administered to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations and should not be injected into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site. View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160302005120/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20160302005120/en/}}}\par \par \uc2 Keywords for this news article include: Surgery, Analgesics, Pediatrics, Bone Marrow, Orthopedics, \uc2 Bioventus LLC\uc2 , Bone Research, Immune System, Pain Medicine.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document CHEMEC0020160311ec3b0003k\par }\page {\par\fs20\b \uc2 Life Science Leader Merck  \highlight22\uc2 Launches \highlight\uc2  New Innovations at Pittcon 2016; - Wide range of products for separation and analysis; - Increased accuracy, quality, convenience for laboratory customers; - New HPLC and capillary GC columns, tools for water analysis and easier sample preparation\b0\par\par\uc2 Merck; PR Newswire\par \uc2 687 \uc2 words\par \uc2 7 March 2016\par 08:00\par \uc2 PR Newswire Asia\par \uc2 PRNASI\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 DARMSTADT, Germany, March 7, 2016 /PRNewswire/ --\u160\'00\'A0{\field{\*\fldinst{HYPERLINK "http://www.merckgroup.com/en/index.html"}}{\fldrslt{\cf2 \uc2 Merck}}}\uc2 , a leading science and technology company is launching a range of \b \highlight22\uc2 new products\b0 \highlight\uc2  for separation and analysis at the {\field{\*\fldinst{HYPERLINK "http://pittcon.org/"}}{\fldrslt{\cf2 \uc2 Pittcon Conference and Expo 2016}}}\uc2  in Atlanta, Georgia, March 6\u160\'00\'A0- 10, the world's largest conference for laboratory science. The innovations include high performance liquid chromatography (HPLC) and capillary gas chromatography (GC) columns, and tools for effective analysis of water and easier sample preparation.\par \par \uc2 "We are committed to providing innovations that help our customers solve their toughest problems, advance science and accelerate access to health care around the world," said \uc2 Udit Batra\uc2 , CEO of {\field{\*\fldinst{HYPERLINK "http://www.emdgroup.com/emd/products/life_science/life_science.html"}}{\fldrslt{\cf2 \uc2 Merck's life science business}}}\uc2 . "Our customers are benefitting from our expanded global footprint, industry-leading capabilities and broadened product portfolio."\par \par \uc2 Merck bought {\field{\*\fldinst{HYPERLINK "http://www.sigmaaldrich.com/united-states.html"}}{\fldrslt{\cf2 \uc2 Sigma-Aldrich}}}\uc2  for $17 billion at the end of 2015, making it one of the leading players in the life science industry. Pittcon 2016 marks the first major conference at which the combined businesses will exhibit together with a unified presence.\par \par \uc2 Among the new life science products are new categories of Cerilliant\u174\'00\'AE\u160\'00\'A0Certified Reference Materials, including bile acids, antiretrovirals and fatty acids. These compounds allow clinical researchers to accurately quantitate therapeutic drugs and endogeneous biomarkers.\par \par \uc2 "We rely on\u160\'00\'A0Merck's\u160\'00\'A0Cerilliant Certified Reference Materials\u160\'00\'A0to provide accuracy in longitudinal testing of patients and as well as between-lab studies," said Brian Rappold, scientific director at Essential Testing, LLC, a Collinsville, Illinois-based clinical medical laboratory provider.\u160\'00\'A0"Merck's\u160\'00\'A0Certified Reference Materials are fundamental tools in providing quality results to providers and patients."\par \par \uc2 Merck is also launching the following new products:\par \par \uc2 *Spectroquant\u174\'00\'AE Prove Spectrophotometers\u160\'00\'A0-- A new class of spectrophotometers for simplified, durable and secure analysis of waste water, drinking water, beverages and process water.\par \par \uc2 *WatercolTM chromatography column\u160\'00\'A0-- New capillary GC columns that contain innovative stationary phases that produce a sharp peak shape for water, allowing convenient measurement of water.\par \par \uc2 *Ascentis\u174\'00\'AE Express Biphenyl chromatography column\u160\'00\'A0-- A new U/HPLC column that offers alternative selectivity for pharmaceutical analytes and drug metabolites that are not well retained or difficult to resolve on traditional alkyl (C18) and phenyl bonded phases.\par \par \uc2 *SLB\u174\'00\'AE IL (i-series) chromatography column -- New capillary GC columns that provide both selectivity and inertness toward polar analytes, resulting in better accuracy and sensitivity.\par \par \uc2 *SupelTM QuE Verde sorbent\u160\'00\'A0-- A new QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) sorbent for the analysis of challenging compounds in green matrices, exhibiting improved recovery of problematic planar analytes when compared with traditional sorbents.\par \par \uc2 Pittcon 2016 attendees are encouraged to visit booth #3157 to learn more about Merck's products and speak with company experts. Follow us on \uc2 twitter{\field{\*\fldinst{HYPERLINK "https://twitter.com/merckgroup"}}{\fldrslt{\cf2 \uc2 @merckgroup}}}\uc2 .\par \par \uc2 About Merck\par \par \uc2 Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life\u160\'00\'A0-- from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of EUR11.3 billion in 66 countries.\par \par \uc2 Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as \uc2 EMD Serono\uc2 , MilliporeSigma and EMD Performance Materials.\par \par \uc2 All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to {\field{\*\fldinst{HYPERLINK "http://www.merckgroup.com/subscribe"}}{\fldrslt{\cf2 \uc2 www.merckgroup.com/subscribe}}}\uc2 \u160\'00\'A0to register online, change your selection or discontinue this service.\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160305/340777"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160305/340777}}}\par \par {\field{\*\fldinst{HYPERLINK "http://rt.prnewswire.com/rt.gif?NewsItemId=AE39873&Transmission_Id=201603070800PR_NEWS_ASPR_____AE39873&DateId=20160307"}}{\fldrslt{\cf2 \uc2 http://rt.prnewswire.com/rt.gif?NewsItemId=AE39873&Transmission_Id=201603070800PR_NEWS_ASPR_____AE39873&DateId=20160307}}}\par \par \uc2 https://photos.prnewswire.com/prnh/20160305/340777\par \par \uc2 Document PRNASI0020160307ec37001md\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Life Science Leader MilliporeSigma  \highlight22\uc2 Launches \highlight\uc2  New Innovations at Pittcon 2016\b0\par\par\uc2 804 \uc2 words\par \uc2 7 March 2016\par 08:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par - Wide range of products for separation and analysis \par  \f28 \par \par \uc2 \f2 BILLERICA, Mass., March 7, 2016 /PRNewswire/ -- The life science business of \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, is launching a range of \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  for separation and analysis at the Pittcon Conference and Expo 2016 in Atlanta, Georgia, March 6 -- 10, the world's largest conference for laboratory science. The innovations include high performance liquid chromatography (HPLC) and capillary gas chromatography (GC) columns, and tools for effective analysis of water and easier sample preparation.\f28 \par \par \uc2 "We are committed to providing innovations that help our customers solve their toughest problems, advance science and accelerate access to health care around the world," said \uc2 Udit Batra\uc2 , CEO of MilliporeSigma. "Our customers are benefitting from our expanded global footprint, industry-leading capabilities and broadened product portfolio."\par \par \uc2 Merck KGaA\uc2 , Darmstadt, Germany bought \uc2 Sigma-Aldrich\uc2  for $17 billion at the end of 2015, making it one of the leading players in the life science industry. Pittcon 2016 marks the first major conference at which the combined businesses will exhibit together with a unified presence.\par \par \uc2 Among the new life science products are new categories of Cerilliant(R) Certified Reference Materials, including bile acids, antiretrovirals and fatty acids. These compounds allow clinical researchers to accurately quantitate therapeutic drugs and endogeneous biomarkers.\par \par \uc2 "We rely on MilliporeSigma's Cerilliant Certified Reference Materials to provide accuracy in longitudinal testing of patients and as well as between-lab studies," said Brian Rappold, scientific director at Essential Testing, LLC, a Collinsville, Illinois-based clinical medical laboratory provider. "MilliporeSigma's Certified Reference Materials are fundamental tools in providing quality results to providers and patients."\par \par \uc2 MilliporeSigma is also launching the following new products:\par \par \uc2 \f2 \par    -- Spectroquant(R) Prove Spectrophotometers -- A new class of \par       spectrophotometers for simplified, durable and secure analysis of waste \par       water, drinking water, beverages and process water. \par  \par    -- Watercol(TM) chromatography column -- New capillary GC columns that \par       contain innovative stationary phases that produce a sharp peak shape for \par       water, allowing convenient measurement of water. \par  \par    -- Ascentis(R) Express Biphenyl chromatography column -- A new U/HPLC column \par       that offers alternative selectivity for pharmaceutical analytes and drug \par       metabolites that are not well retained or difficult to resolve on \par       traditional alkyl (C18) and phenyl bonded phases. \par  \par    -- SLB(R) IL (i-series) chromatography column -- New capillary GC columns \par       that provide both selectivity and inertness toward polar analytes, \par       resulting in better accuracy and sensitivity. \par  \par    -- Supel(TM) QuE Verde sorbent -- A new QuEChERS (Quick, Easy, Cheap, \par       Effective, Rugged and Safe) sorbent for the analysis of challenging \par       compounds in green matrices, exhibiting improved recovery of problematic \par       planar analytes when compared with traditional sorbents. \f28 \par \par \uc2 \f2 Pittcon 2016 attendees are encouraged to visit booth #3157 to learn more about MilliporeSigma's products and speak with company experts. Follow us on \f28 \uc2 \f2 twitter\f28 \uc2 \f2  @MilliporeSigma.\f28 \par \par \uc2 \f2 About the Life Science Business of \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany\f28 \par \par \uc2 \f2 The life science business of \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery.\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany completed its $17 billion acquisition of \f28 \uc2 \f2 Sigma-Aldrich\f28 \uc2 \f2  in November 2015, creating a leader in the $130 billion global life science industry.\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses -- Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials -- and generated sales of EUR 11.3 billion in 2014. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany is the world's oldest pharmaceutical and chemical company -- since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany operates as \f28 \uc2 \f2 EMD Serono\f28 \uc2 \f2 , MilliporeSigma and EMD Performance Materials in the U.S. and Canada.\f28 \par \par \uc2 \f2 All \f28 \uc2 \f2 Merck KGaA\f28 \uc2 \f2 , Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada please go to \f28 {\field{\*\fldinst{HYPERLINK "http://www.emdgroup.com/subscribe"}}{\fldrslt{\cf2 \uc2 www.emdgroup.com/subscribe}}}\uc2 \f2  to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.\f28 \par \par \uc2 \f2 Photo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160305/340775"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160305/340775}}}\uc2 \f2 \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/life-science-leader-milliporesigma-launches-new-innovations-at-pittcon-2016-300231446.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/life-science-leader-milliporesigma-launches-new-innovations-at-pittcon-2016-300231446.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE MilliporeSigma\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020160307ec370004g\par }\page {\par\fs20\b \uc2 McKesson U.S. Pharmaceutical\uc2 ; McKesson  \highlight22\uc2 Launches NEW Drug \highlight\uc2  Spend Intelligence Tool\b0\par\par\uc2 248 \uc2 words\par \uc2 4 March 2016\par \uc2 Obesity, Fitness & Wellness Week\par \uc2 OBWK\par 215\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Obesity, Fitness & Wellness Week via NewsRx.com   \par \par \uc2 2016 MAR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- \uc2 McKesson\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of its \b \highlight22\uc2 new Drug\b0 \highlight\uc2  Spend Intelligence(TM) tool. Designed by hospital pharmacists, Drug Spend Intelligence is an easy-to-use online tool that provides the information needed to identify purchase trends, evaluate the impact of price fluctuations, and implement and track clinical initiatives. \uc2 McKesson\uc2 's Drug Spend Intelligence provides access to daily data with rich analytics and customizable reports to help identify potential areas for cost containment to lower drug spend and increase savings.\par \par \uc2 "The largest expenditure in a hospital pharmacy department is drug purchases. As a result, pharmacy leaders are constantly pressured to reduce their pharmacy's drug spend and administrative time," said Yen Nguyen, Pharm.D., director of clinical analytics, McKesson Pharmacy Optimization(R). "Managing a hospital or health system's drug spend requires a clear view into the purchasing history and spending trends, and the ability to turn that information into actionable results. Drug Spend Intelligence provides access to daily data and robust analytics to help pharmacies gain insight into purchasing trends and variances and to lower drug spend, as well as free pharmacists' time to focus on medication safety and patient care."\par \par \uc2 Keywords for this news article include: \uc2 McKesson U.S. Pharmaceutical\uc2 , Therapy, Hospital.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document OBWK000020160304ec34000dn\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Maverick Industries, Inc\uc2 . to  \highlight22\uc2 Introduce \highlight\uc2  its First WiFi-Enabled Thermometer at the 2016 International Home + Housewares Show\b0\par\par\uc2 631 \uc2 words\par \uc2 4 March 2016\par 08:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par The company will showcase the \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  along with its full line of app-enabled thermometers at Booth S1425 \par  \f28 \par \par \uc2 \f2 CHICAGO, March 4, 2016 /PRNewswire/ -- \f28 \uc2 \f2 Maverick Industries, Inc\f28 \uc2 \f2 ., known over 30 years for its innovative line of high-quality consumer and professional cooking products, will \f28 \b \highlight22\uc2 \f2 introduce\f28 \b0 \highlight\uc2 \f2  its newest digital thermometer, the ET-736 WiFi Digital Chef Roasting Thermometer, at the 2016 International Home + Housewares Show, Booth S1425 from March 5-8, 2016.\f28 \par \par \uc2 The ET-736 is Maverick's first step into WiFi-enabled thermometers. The water-resistant, Android-compatible unit uses a home's router system to connect to a phone, tablet, or Kindle Fire via its accompanying smart device application and comes with two high-heat, waterproof probes. Users can select the desired doneness of food from within the app, ranging from rare to well done depending on the type of meat, and monitor the cooking progress along the way, including the temperature of the grill or oven and estimated cook time. Several timers can be programmed when preparing multiple foods at once and an alert will be sent after cooking is complete.\par \par \uc2 As a WiFi-enabled unit, consumers will have access to a library of recipes that are available for download once connected to the Internet. The ET-736 also comes with social sharing capabilities, enabling pictures and recipes to be sent to family and friends.\par \par \uc2 Additionally, Maverick will be showcasing its existing line of app-enabled thermometers at the show, including:\par \par \uc2 \f2 \par    -- ET-735 Bluetooth Barbeque Thermometer: The device's water-resistant \par       transmitter allows the connection of up to four water-resistant probes \par       for monitoring food and the grill. Users can select from 15 preset \par       temperatures when cooking specific meats, or input a custom temperature, \par       and will be alerted once cooking is complete. \par  \par    -- ET-737 Bluetooth App-Enabled Thermometer: Mount the unit directly on an \par       oven to monitor the cooking progress remotely. Once paired with its smart \par       device application, users can check-in on their food and will be alerted \par       once preparation is complete. \par  \par    -- ET-11 Direct Connect Roasting Thermometer: This device turns a tablet \par       into a roasting thermometer. Its accompanying smart device application \par       will display how long the food will take to cook in a real-time chart and \par       enables picture and recipe sharing via \f28 \uc2 \f2 Facebook\f28 \uc2 \f2  and \f28 \uc2 \f2 Twitter\f28 \uc2 \f2 . \f28 \par \par \uc2 \f2 Show attendees can also expect to see select Maverick thermometers and timers that have been recommended by the Chefs of Le Cordon Blue(R) for their excellence in innovation and food preparation. To learn more, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.maverickhousewares.com"}}{\fldrslt{\cf2 \uc2 www.maverickhousewares.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Maverick Industries, Inc\f28 \uc2 \f2 . will be exhibiting at Booth S1425 during the 2016 International Home + Housewares Show. For press inquiries or to schedule an appointment, contact Nicole Cobuzio at nicolec@lotus823.com.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Maverick Industries, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Founded in 1981, Maverick Industries entered the home appliance market with an innovative line of electronic barbecue grills designed and manufactured in New Jersey. Over the past 30 years, the company has expanded its product line to become one of the largest producers of digital thermometers in the United States. Maverick's latest WiFi and Bluetooth-enabled BBQ and roasting thermometers offer a connected cooking experience, delivering accurate and reliable temperature readings that foster food safety. To learn more about Maverick's innovative line of high-quality consumer and professional cooking products, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.maverickhousewares.com"}}{\fldrslt{\cf2 \uc2 www.maverickhousewares.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Connect with Maverick on \f28 \uc2 \f2 Facebook\f28 \uc2 \f2 , \f28 {\field{\*\fldinst{HYPERLINK "http://www.facebook.com/maverickindustriesinc"}}{\fldrslt{\cf2 \uc2 www.facebook.com/maverickindustriesinc}}}\uc2 \f2 , and on \f28 \uc2 \f2 Twitter\f28 \uc2 \f2 , \f28 {\field{\*\fldinst{HYPERLINK "http://www.twitter.com/maverickcooking"}}{\fldrslt{\cf2 \uc2 www.twitter.com/maverickcooking}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/maverick-industries-inc-to-introduce-its-first-wifi-enabled-thermometer-at-the-2016-international-home--housewares-show-300226971.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/maverick-industries-inc-to-introduce-its-first-wifi-enabled-thermometer-at-the-2016-international-home--housewares-show-300226971.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Maverick Industries, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.maverickhousewares.com"}}{\fldrslt{\cf2 \uc2 http://www.maverickhousewares.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160304ec340002i\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Syneron Candela\uc2  to  \highlight22\uc2 Introduce \highlight\uc2  New Technologies at the 2016 \uc2 American Academy of Dermatology (AAD) \uc2 Annual Meeting\b0\par\par\uc2 1,063 \uc2 words\par \uc2 3 March 2016\par 09:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Debuts include the new CO2RE Intima for gynecological and genitourinary indications for vaginal and vulvar health, an additional ultra-short PicoWay laser wavelength for comprehensive tattoo removal and a SubQ Profound applicator for the stimulation of elastin, collagen, hyaluronic acid and the treatment of adipose tissue. \par  \f28 \par \par \uc2 \f2 IRVINE, Calif., March 3, 2016 /PRNewswire/ -- \f28 \uc2 \f2 Syneron Medical Ltd\f28 \uc2 \f2 . (NASDAQ: ELOS) a global market leader in the aesthetic medical device marketplace, this week will announce three \f28 \b \highlight22\uc2 \f2 new product launches\f28 \b0 \highlight\uc2 \f2  during the 2016 \f28 \uc2 \f2 American Academy of Dermatology (AAD) \f28 \uc2 \f2 meeting in Washington, D.C. The \f28 \b \highlight22\uc2 \f2 launches\f28 \b0 \highlight\uc2 \f2  include the new CO(2) RE Intima system for gynecological and genitourinary indications, an ultra-short picosecond PicoWay laser wavelength and a Profound SubQ hand piece. With these announcements, \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2  reaffirms its best-in-class product suite that continues to address the needs of the aesthetic and wellness marketplace with energy based technology innovations.\f28 \par \par \uc2 \f2 \par    -- CO2RE Intima, a complete laser solution on \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2 's versatile \par       CO2RE(R) platform, addresses a growing need in the gynecology market for \par       women's intimate wellness. CO2RE Intima is designed to perform \par       gynecological and genitourinary treatments by stimulating healing \par       responses in the vaginal and vulva areas, while also remodeling the \par       tissue fibers in the vaginal and vulva areas. "Our launch of CO2RE Intima \par       provides physicians with additional options when using our CO2RE platform, \par       allowing us to successfully provide wellness solutions to the gynecology \par       market.  We are very pleased with feedback from our early investigators \par       and believe that the CO2RE Intima will provide compelling value to \par       patients and providers," says Shimon Eckhouse, PhD, Co-founder and \par       Chairman of the Board, Syneron-Candela. \par  \par    -- The Company is launching a third, ultra-short pulse duration 785nm \par       wavelength[1] for PicoWay(R), a leading solution for tattoo removal, \par       pigmentation correction and skin irregularities. The new ultra-short \par       wavelength is the first of its kind in the aesthetic market utilizing a \par       titanium sapphire laser for the removal of blue and green inks. The \par       innovative PicoWay laser platform delivers ultra-short pulses of energy \par       (e.g., 300 picoseconds at 785 nm) making treatments shorter and less \par       painful for patients while offering the industry's shortest pulses and \par       highest peak power. The addition of PicoWay's third wavelength completes \par       the PicoWay laser platform, allowing for the comprehensive removal and \par       treatment of all colors of tattoos and skin pigmentation issues. \par  \par    -- Profound(R), the industry's first microneedle based radiofrequency device, \par       is clinically proven to stimulate three important factors for \par       percutaneous treatment of facial wrinkles: elastin, collagen and \par       hyaluronic acid. The Company is launching a new SubQ hand piece for \par       Profound for the treatment of adipose tissue and deeper connective \par       tissue. With the launch of the new SubQ applicator, Profound is the only \par       real-time temperature controlled micro-needling radiofrequency device for \par       the treatment of both shallow and deep skin at the dermal and \par       subcutaneous layers. \f28 \par \par \uc2 \f2 "We are very pleased to be able offer such a broad array of technologically sophisticated solutions to our customers and their patients," said Amit Meridor, chief executive officer for Syneron Candela. "Our new launches represent \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2 's ongoing commitment to advancing technology and providing the widest range of solutions to the aesthetic and wellness marketplace."\f28 \par \par \uc2 \f2 Visit the \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2  booth (booth #2421) at the AAD to learn more.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2  is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO(2) RE, Profound and elo s Plus.\f28 \par \par \uc2 \f2 Founded in 2000, the corporate, R&D, and manufacturing headquarters for \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2  are located in Israel. \f28 \uc2 \f2 Syneron Candela\f28 \uc2 \f2  also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.\f28 \par \par \uc2 \f2 For additional information, please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.syneron-candela.com"}}{\fldrslt{\cf2 \uc2 http://www.syneron-candela.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS\f28 \par \par \uc2 \f2 This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the \f28 \uc2 \f2 SEC\f28 \uc2 \f2 , including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that \f28 \uc2 \f2 Syneron Medical\f28 \uc2 \f2  makes with the \f28 \uc2 \f2 SEC\f28 \uc2 \f2 , and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, \f28 \uc2 \f2 Syneron Medical Ltd\f28 \uc2 \f2 .'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing \f28 \uc2 \f2 Syneron Medical Ltd\f28 \uc2 \f2 .'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.\f28 \par \par \uc2 \f2 Contacts:\f28 \par \par \uc2 \f2 Corporate Contact\f28 \par \par \uc2 \f2 pr@syneron.com\f28 \par \par \uc2 \f2 Media Contact\f28 \par \par \uc2 \f2 Lindsay LeCain\f28 \par \par \uc2 \f2 617.986.5706\f28 \par \par \uc2 \f2 Lindsay_LeCain@lpp.com\f28 \par \par \uc2 \f2 [1] 785nm wavelength is the subject of a pending \f28 \uc2 \f2 FDA\f28 \uc2 \f2  510(k) notification.\f28 \par \par \uc2 \f2 Logo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20120528/535447"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20120528/535447}}}\uc2 \f2 \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/syneron-candela-to-introduce-new-technologies-at-the-2016-american-academy-of-dermatology-aad-annual-meeting-300230283.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/syneron-candela-to-introduce-new-technologies-at-the-2016-american-academy-of-dermatology-aad-annual-meeting-300230283.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Syneron Medical Ltd\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.syneron-candela.com"}}{\fldrslt{\cf2 \uc2 http://www.syneron-candela.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160303ec330009n\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Heron Therapeutics\uc2 ' NDA for Sustol Injection to be reviewed by \uc2 FDA\uc2  in April\b0\par\par\uc2 68 \uc2 words\par \uc2 3 March 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Heron Therapeutics\uc2  has been informed by the \uc2 FDA\uc2  that it anticipates concluding its review of the \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application of Sustol Injection, extended release, for patients suffering from chemotherapy-induced nausea and vomiting, by early April. CEO Barry D. Quartstted, "We continue to be ready for the commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  of SUSTOL in Q2, if approved." \par \par \uc2 Document FLYWAL0020160303ec33001uq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw160\pich40\picscaley100\picscalex100\picwgoal2400\pichgoal600
47
4946383961A000280070000021F904010000FF002C00000000A0002800870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF00F7091C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2C58B18336ADCC8
B1A3C78F200D12CB9469982686CA328DCC14B2A545922311AA54A90CE40D003863301C8613273186F4DCB51B768ED7B95EEEE8D173D991584F003F0B3AED19D5
A3181531028461A809408C15006A2AECE52715A154A95EA1525BE895ADAA4C2F2AF31A23AC41650160D4FD04520C80032A6E145436090DC14C2A0EC0B0ABB0DD
DA579023BF4AABD6963E8AF586D98A3B174600C604E7D65521D6E38D15310CC81838C9004E31049DD68D511A612FCA6C51157A0C39552189C35EED7EC5396FDD
DA029525AE0B97A35F182B040B0CE3357A6C0006982F1C862A1B647702EBD1FFB3E58A72DA88BDBABFFA13573600D277BDAA002D15F94165F6059E062C7D1F8E
C42AC0365026F219509A32F518745B644B11E4CE2BAE4086CA300529A5D441BCE08690784A252817007AD197DC0AD90170D261751930DF0DCD652286012482B5
8261049D969D4E62C4005D6A31F4A8D330246685DF0DF301C02241ED44585E830405374D6402B9C30B23C2FD219C2DE0ED139C64A9D422DC52F40C534B5B64DA
4261341489F6D97D5E01565B5DA81D801A4E2C0934094E3166A7A24E03F955176C3704C0A3577FC1B04F5731A860C02460C5A0184EA52D08597E5CEAB3CC6498
7A978A2B8550989E6491A5B21423A89807615ABC54D4D99F85499286AB9200FF56579DFB10F9A88E7441951C885E4107E3010008B84F188A5947645E82C20018
00FB38A56CA230C2D823560371D71B93046508991FE0D5B2696411621A26654F96F78A1F096A1B6AA8EDA4E9555E387D566490AE8975E76C62E100A256030130
067ED128138671004023D07FC06E35891844CE2686188611F8950107C4C0B05714EBBA4F2F4F4E7AD039117AD76E2FB50C434F3DCAF4025936A920658B979181
C3CB66FBB853C839CAD0A34F701A0E64B040FAA099D05C8AF9A857C5A9A1065654B3D147707E02E5A4F18BA8F1B98F9F0608DB2CC6A8B106C09C9308344C8469
613B503B98A2D20B42B67C5B8B40E7AC75DE42686F6B9087FBE02D5275AE01FF202F76F4C2279A9105D9B802ADCDA291A38F2AA6311DBC380CB45F8087F54A9F
E5344AFA8AD962E3D66E78BDBC6CCBCABE09C4CBCAAE20A4D9E899A692A6A2754D42D2EC99C48A9589FB10A817584F0509409D3CE104A0B4C10AE4A775C667A7
42E40369E2D97104CD7680808E699ADFA7E782578F2D7E84DB1D657EC04D197B05652837A87E70DE906860FD4CD032EFDA752FC189160B234B69D0E5DA72D186
5D2B8981911C890EB0956A116A05B5B19C8054C6A08344C63BFBA0C76E3405AA6CFC661FA7331741F481290941A663A87057899A134110D58542990880F2E454
A2A6B1043BB3611A80687415A4F589505AEB4A886A93181209E81C93298F7DFFDC619EB7B10E32BD588A632043BE0C798738036120646C01A670896A22B269DF
5D9005839F20663608598A24BEA697E895C87F81F24C01FFA7C626BDCB4004E9550004C49D279A8D1E8BE88D2B88510FB520B15A69C946F836A64782A48D66FB
50066542181E882867845B0CD1896008001A1DE44559B1DA3EBE56171A0D4C2F56AB61199B6739B870918EB8A90D313E08257A44061559DAC7112FB8C4EF0C44
32E718883BD4F30726094D20D1B80C424403BDC1108A317EFA5326F033121C2C050D046349343E0918C75D8D50FDA11AB0C450182DBD0B0609D4D11C05D20B73
A5E228A1F356B8CA23107AF821323403625AA471C161E0E615C34862A86AA1FFC4B64868430B990B8C44144182558550A3790AEE9C9597652526449248DE57FA
23315F79A559C02AA64092963581B40337E5215BA80AC1A45A74AC3C85D8D413C9470F57744C2DAEB3C563D292D20E5E7120C2440919092A9A7A0D4439B2421A
AE225AABBCAC4031C68991806CB4BC3836740565ACE8E592B6405750F0152C8BD05A52159B99424832821CC8E8CC05A108824A1A0F14E24404FA19FBCCE56B00
A01041265117858AE144FB4083F08CB40C02014B3AD4012341A8D393036C4D059F818BDF1653C0E0FC215C562A842DC021578348B03737DB4721DA324872B625
2DBDCC5B2D1EEB9B54D9824C958D4B412C95D3BB204855507B0887F4A13785FF588821FA080AE792A2DA8A044F40C4E8646F3512DB90D4962912E393BE28375C
8B38456BC6DDC72F9B9BBFBA08442F30601EC36250A7854123477522C60D2C561A34C4000D9328E0772D261017292347C478EF0DF06ADE23BD37137485CD326E
C2DEE1B6362E57C9DF320130890008E64E390240446FD228BBF4C82FCCDAC76C4804807A2C2331CFB926A1A2359F8D06EB3883738D18E881B1083777B87E990B
37C372D1E4DCEB9A86F18B2589419D4988462060C96B5CF791BF9414CF2FB0D1974A149CC8E2E1A4C83A990B5199F2DFE11249C2E385CD45A742976BFE648C61
83B0DF4852BC4D1AB6474F99C49D58324696F86518F97B8A18E6229D297779FFB8D36DC87123A2AF7DDCE977FB28A36BA286233C0BD8298221D090A5A3A26B2E
5319C3880696798C67BF70190DCCCCD945A341ADAE40D723CB38B14174546466C14F27881D865F04E3972B135862CA00CB0B9757BFDC7905BF8ED36BD8646DE8
4DAE407686914D09930CA24B6364CE789B734806B65101F52877223EB65E5972A7B0FD27588B4A240E604057002C2513BCD3C998ED8C6734A8206CCAA86B58A0
619D681C5BC321693243847D90E94683DD2069D08D710A923803336FFB709FBE7D866FF775044D0902F840E0ED1219C04006AEF19FA6013A708AA8DB20D0F050
4E274E6F4D6722CAA91D6E821E4E117BA77B1F995EB8C82FE2718F8FFCE40D0969723D388E11960704003B}}
\par\par \b \uc2 Health Catalyst gets $70M investment, Philips offers ICU dashboard; Health Catalyst gets $70M, Philips offers ICU dashboard\b0\par\par\uc2 Joseph Goedert \par \uc2 655 \uc2 words\par \uc2 2 March 2016\par \uc2 Health Data Management Online\par \uc2 HDMOL\par \uc2 Vol.1, No.1\par \uc2 English\par \uc2 \u169\'00\'A9 2016 Health Data Management and SourceMedia, Inc.  All rights reserved. \par \par \uc2 The first full day of HIMSS16 brought a number of vendor announcements of \b \highlight22\uc2 new products\b0 \highlight\uc2  and services. Here is a snapshot:\par \par \uc2 * Aided by a $70 million rounded of new funding from Norwest Venture Partners and UPMC, analytics firm Health Catalyst \b \highlight22\uc2 launched\b0 \highlight\uc2  its largest technology update since 2008. The nine \b \highlight22\uc2 new product\b0 \highlight\uc2  lines cover population health and accountable care, care management and patient relations, clinical analytics and decision support, research informatics, precision medicine, financial decision support, comparative effectiveness solutions and the flagship Health Catalyst Analytics Platform.\par \par \uc2 * \uc2 Philips Healthcare\uc2  launched a cloud-based clinical decision support dashboard for workflows in the ICU, called IntelliSpace Console Critical Care. The system also supports enhanced patient monitoring and tracking of quality metrics. Ambient Clinical Analytics and Mayo Clinic collaborated on the project.\par \par \uc2 * Health information management vendor Healthport has changed its name to CIOX Health. The move comes the acquisition of four companies in 2015. CIOX Health serves more than 18,000 provider sites, 100 health plans and 1 million unique requesters of patient information.\par \par \uc2 * \uc2 Salesforce\uc2  announced general availability of its Salesforce Health Cloud for patient relationship management. Features supporting personalized care include complete patient views by putting all patient information in one place, along with family information and a diagram of the extended care team, a single console for managing patients, and enabling caregivers and patients to send and receive messages, get reminders and complete surveys from any device.\par \par \uc2 TigerText has integrated its secure messaging software with the Salesforce Health Cloud, enabling cloud customers to embed the messaging service into their cloud portal. Among other uses, this will enable clinical staff to streamline care coordination and patient hand-offs in a HIPAA-compliant manner, according to the vendor.\par \par \uc2 * Analytics firm Faros Healthcare is among the new vendors announcing its entrance into the health information technology arena. The company is a spin-off from \uc2 Centerstone Research Institute\uc2 , which focuses on improving behavioral healthcare. It uses artificial intelligence technology licensed from Indiana University Research & Technology Corp. Centerstone Research co-owns the company.\par \par \uc2 Faros provides a cloud-based platform that integrates with existing EHR and population health software to aid clinicians in achieving the best patient outcomes at an optimal cost,? said Jim Stefanisc, MBA, PhD, president and co-founder of Faros. Software tools on the analytics platform recommend a course of treatment, while also considering treatment costs.\par \par \uc2 * Hospital vendor CPSI has a new program, called nTrust, enabling providers to switch their electronic health records to CPSI with no upfront costs. ?With nTrust, we help providers in acute and post-acute settings improve business operations via our TruBridge management services, while at the same time funding the purchase of their EHR with no advance payment required,? says Boyd Douglas, president and CEO.\par \par \uc2 Under the program, hospitals and senior care facilities outsource revenue cycle management operations to CPSI?s TruBridge business services. Proceeds are allocated to finance the purchase and ongoing support of either the Evident EHR for acute care providers or the American HealthTech EHR for post-acute care facilities.\par \par \uc2 * PatientKeeper, which sells a range of software products to physicians including CPOE, has integrated with National Decision Support Company, which has a guideline content delivery engine to enable physicians to access appropriate use criteria when ordering medical imaging tests.\par \par \uc2 * Aventura, a vendor of situational awareness software to secure and personalize clinical desktops, will use the single sign-on software of HealthCast. The Aventura software knows who the user of a desktop is, their location and the patient being cared for to authenticate and provide access to the electronic health records.\par \par \uc2 * Medisafe, which operates a cloud platform for medication management, has a new product called Medisafe Providers, enabling physicians, care teams and pharmacies to track patients? medication adherence between visits. Providers also can track biometric measures such as blood pressure, glucose, and weight, among others.\par \par \uc2 Document HDMOL00020161122ec320005o\par }\page {\par\fs20\b \uc2 Insights on antioxidants: keys to future development: natural and whole food ingredients continue to propel the category forward.\b0\par\par\uc2 Olivo, Lisa \par \uc2 4,744 \uc2 words\par \uc2 1 March 2016\par \uc2 Nutraceuticals World\par \uc2 NUTW\par 38\par \uc2 ISSN: 1531-0671; Volume 19; Issue 2\par \uc2 English\par \uc2 Copyright 2016 Gale Group. All rights reserved. \par \par \uc2 Antioxidants--the free-radical scavenging molecules well known for supporting a range of health indications--are now considered common and established tools in the fight for better health. While the term "antioxidant" was once seen as a trendy buzzword, today, scientifically validated, carefully crafted ingredients have emerged to solidify their stance in the health and wellness sector.\par \par \uc2 Although Mintel's Global \b \highlight22\uc2 New Products\b0 \highlight\uc2  Database reported just 2% of product \b \highlight22\uc2 launches\b0 \highlight\uc2  in the U.S. in 2014 promoted antioxidants as an ingredient, that doesn't mean growth in the market has stagnated. Rather, savvy marketers and manufacturers have redefined their message to provide consumers with more targeted and specific information on the scientifically-proven benefits that antioxidant ingredients provide for cardiovascular health, skin and anti-aging, immunity, eye health and more.\par \par \uc2 A huge factor in propelling this market forward lies in the natural appeal of antioxidants. While synthetic varieties still make up a portion of the ingredient market, natural antioxidants are spurring growth in the category, accounting for more than 30% of the overall market, according to Future Market Insights. In fact, thanks to robust sales among natural antioxidants, the global market is expected to grow at a CAGR of 5% through 2020.\par \par \uc2 Grand View Research, Inc\uc2 . predicted the global antioxidants market will reach $4.14 billion by 2022, attributing growth to prevalence in personal care products for skin and hair, as well as increased usage in fortified foods.The market research firm also underscored that growing consumer awareness of the benefits of natural antioxidants will continue to fuel the category.\par \par \uc2 "Consumers are now becoming knowledgeable and browsing past synthetic vitamins that contain antioxidants," observed Margaret Gomes, marketing director with Nature's Power Nutraceuticals Corp. (NP Nutra), Gardena, CA. "Whole food antioxidant supplements are more appealing to people as they become aware of where their supplement sources come from, and how they affect the body."\par \par \uc2 As educated consumers continue to pursue clean-label, natural and clinically proven antioxidant ingredients, leaders in the nutraceutical space are stepping up to meet the demands of this burgeoning audience.\par \par \uc2 Reaping the Benefits\par \par \uc2 While some experts worry ubiquitous antioxidant claims have diluted this already saturated market, there's no denying a powerful media message has increased consumer understanding.\par \par \uc2 "Like it or not, the media drives awareness (whether true or not) about everything consumers put in their mouths," commented Lisa Mack, director of sales and marketing, Connoils LLC, Waukesha, WI, especially when consumers are trying to align a health concern with a food group or ingredient. "Today every health ailment has a 'magic bullet' food or product that will drive consumers to flock to purchase. Antioxidants being labeled 'superfoods' was a brilliant catch phrase for fighting low immune systems, anti-aging weight loss, etc."\par \par \uc2 Aparna Kalidindi, PharmD, BCPS, sales and marketing manager with Natreon, Inc., New Brunswick, NJ, attributed the spike in interest in antioxidants to the rise in chronic disease in the U.S. "Consumers want to fight off chronic disease and signs of aging with a more natural approach," said Dr. Kalidindi. "This has led to the increase in use of antioxidant rich foods and supplements for cardiovascular disease, bone and joint disease, eye health, immune health, and even visible signs of aging. Most of these consumers are the Baby Boomers who are trying to prevent or mitigate these chronic diseases."\par \par \uc2 The stressful nature of modern life can also negatively impact health, resulting in oxidative stress in the body, according to Shaheen Majeed, marketing director of Sabinsa Corporation, East Windsor, NJ. "Our modern day lifestyle is stress ridden and leads to a number of unnecessary health disorders. Depending on the magnitude and duration of stress, the body manifests this differently. The fundamental source traced to most stress-caused chronic conditions is the production of free radicals."\par \par \uc2 Unhealthy physical and environmental stressors, ranging from chemical exposure to pollution to cigarette smoking and drug use, all negatively impact health. Consumers struggling with these stressors could benefit from antioxidant foods and supplements, Mr. Majeed added.\par \par \uc2 Simply getting older also adds to oxidative stress in the body, which is why the growing aging population is turning to antioxidant foods and supplements for support. "In a healthy person, regulators of oxidative stress and inflammation are in balance. However, in most diseases states, especially age-related diseases, this balance is shifted toward oxidative stress and inflammation with more reactive oxygen species production," explained Jeff Wuagneux, president and CEO of RFI, Blauvelt, NY.\par \par \uc2 Health-conscious consumers in the aging demographic are in most cases very aware of the link between aging and oxidative stress, and as a result are turning to antioxidant-rich foods and supplements for support, Mr. Wuagneux noted. "You can see this in one simple measurement: the huge increase in sales of kale, mostly because people believe kale is chock full of antioxidants."\par \par \uc2 He also referenced mounting scientific evidence linking oxidative stress and inflammation. "For instance, vascular inflammation and endothelial dysfunction are both a result of oxidative stress, leading to cardiovascular disease, or diabetes, where insulin resistance is associated with systemic inflammation and increased oxidative stress. Even neurodegenerative diseases such as Alzheimer's and Parkinson's have a link between the two. So the truth is, what heath objectives are not associated with need for antioxidants?"\par \par \uc2 Younger consumers are looking to antioxidants for support as well, according to Ms. Gomes of NP Nutra. "Millennials are all about everything healthy, and are really careful about what they put into their bodies, so they are probably eating more nutrient-rich foods."\par \par \uc2 Even the beloved family pet can benefit from an antioxidant boost in their diet, according to Ms. Mack. Some studies show consumers are more likely to pay higher prices supporting their pet's health and wellness than their own, she suggested. "The health and wellness industry is exploding and not just for humans. Consumers are also spending billions of dollars on their pets--from keeping their coat nice and shiny, making their food more palatable, managing weight gain and stemming the risk of cancer."\par \par \uc2 Emerging Ingredients\par \par \uc2 Antioxidant ingredients derived from nature are bountiful within the category, as consumers gravitate toward recognizable and sustainably sourced health products.\par \par \uc2 Bruce Abedon, PhD, director of scientific affairs for NutraGenesis, Brattleboro, VT, explained that while vitamins A, C and E are mainstays, botanicals such as resveratrol or "superfruits" like blueberry, acai and mangosteen also represent powerful players. Curcumin, he observed, has become popular despite some issues related to bioavailability.\par \par \uc2 Dr. Abedon also pointed to MycoFusion mushrooms--grown on high anthocyanin purple corn as the substrate--as emerging antioxidant ingredients. MycoFusion mushrooms, he said, "include either maitake, shiitake, reishi, cordyceps, agaricus, lion's mane, or chaga mushrooms, which are grown in a unique process that results in the fusion and incorporation of high antioxidant anthocyanin phytonutrients together with mushroom bioactives such as beta-glucans to form super-nutrient complexes."\par \par \uc2 RFI's whole foods garlic powder, FermaPro Black Garlic, is also graining traction in the antioxidant market. Thanks to RFI's proprietary "double fermentation" method, FermaPro Black Garlic is rich in S-allyl cysteine (SAC), as well as tetrahydro-betacarbolines, which the company said are structurally similar to flavonoids.\par \par \uc2 The SAC in black garlic is considered an "antioxidant superstar" as a result of studies suggesting its support in preventing or ameliorating oxidative stress, as well as inhibiting oxidation of lipids and proteins.\par \par \uc2 A comprehensive review of SAC and black garlic published in Oxidative Medicine & Cell Longevity in 2012 reaffirmed FermaPro Black Garlic's antioxidant potency. Results of the study confirmed SAC and black garlic's ability to scavenge free radicals, including superoxide anion, hydrogen peroxide, hydroxyl, peroxynitrite radicals as well as hypochlorous acid and singlet oxygen. The report also demonstrated SAC and black garlic's ability to induce the activity of endogenous antioxidant enzymes such as glutathione peroxidase, NAD(P)H:quinone oxidoreductase, and superoxide dismutase (SOD); chelate iron and copper ions; and inhibit pro-oxidant enzymes such as nitric oxide synthase (NOS), xanthine oxidase, NADPH oxidase and cyclooxygenase (COX).\par \par \uc2 Connoils offers a variety of antioxidant ingredients from natural sources, many with the ability to maintain shelf stability in finished products. Michelle Coluccio, director of new product development, explained that many of the products the company offers "have their own natural antioxidants helping them maintain their stability, including those rich in fat-soluble vitamin E like wheat germ, safflower and sunflower oils and oil powders for supplements." She continued, "Modern engineering and science have introduced ways to process plant-derived ingredients so they maintain their 'natural' antioxidants to support a longer shelf life and ideally can be passed along to the body once consumed. Products rich in carnosic acid, like rosemary extract, have been proven to be even more capable than A, C and E as antioxidants, natural preservatives and natural bacteria inhibitors."\par \par \uc2 Golan Raz, vice president of the Health Nutrition division at Lycored, Orange NJ, noted several tried and true antioxidant ingredients that continue to appeal to product developers and consumers: "resveratrol from grapes, lycopene form tomatoes, lutein from marigold flowers, astaxanthin from algae, grape seed extract, CoQ10, green tea, blueberry and others."\par \par \uc2 The company recently launched Lyc-O-InVision, a nutrient complex positioned for eye health. The formula includes a rich combination of antioxidants such as standardized tomato extract for lycopene, a carotenoid known for its ability to protect lutein as it is transported to the eye; lutein, an essential antioxidant concentrated in the macula, with benefits for filtering out UV rays and blue light; as well as zeaxanthin, which when combined with lutein helps increase the pigment of the macula, protecting the eye from UV rays and oxidative stress. The formula also features carnosic acid from rosemary extract, tocopherols from vitamin E, as well as copper and zinc.\par \par \uc2 Leveraging the benefits of lycopene and beta-carotene, Sabinsa provides Lycopene [beta] extracted from Momordica cochinchinensis (Gac). "The red pigment present in tomatoes, apricots, watermelons, guavas, papaya, grapefruits and rosehips that gives them their color is called lycopene," Mr. Majeed explained. "Tomatoes were considered the largest source of lycopene until Gac, native to Vietnam, was presented worldwide."\par \par \uc2 Describing the breadth of research supporting lycopene for its antioxidant capabilities, Mr. Majeed referenced clinical research demonstrating how antioxidant supplementation benefits a healthy lifestyle. "An 8-week human trial conducted with healthy subjects supplemented with 12 mg lycopene/day or a mixture of lycopene with beta-carotene and lutein (4 mg/day each) demonstrated the beneficial effects in countering oxidative DNA damage in their lymphocytes (Zhao et al, 2006)."\par \par \uc2 An additional study supplemented healthy subjects with lycopene through tomato juice, spaghetti sauce and tomato oleoresin for a period of one week each, and demonstrated a significant reduction in thiobarbituric acid-reactive substances (TBARS), which Mr. Majeed explained is a measure of lipid peroxidation. "Results indicated that lycopene is easily absorbed by cells and thereby it has positive implications in cancer prevention (Rao et al., 1998)."\par \par \uc2 NP Nutra's Ms. Gomes underscored the antioxidant potential of ashwagandha for its ability to stimulate the immune system, as well as support mental well-being. "Researchers from \uc2 Banaras Hindu University\uc2 , India, and from the Drug Research and Development Center, Calcutta, discovered that some of the chemicals in ashwagandha are powerful antioxidants," she explained. "They tested its effects on rat brains and found an increase in the levels of three naturally occurring antioxidants."\par \par \uc2 Recent scientific research has also catapulted turmeric to be considered one of nature's most potent superfoods, Ms. Gomes added. Citing a 1999 study published in the Journal Phytotherapy Research, she described results that found "the primary polyphenol in turmeric, the saffron colored pigment known as curcumin, compared favorably to steroids in the management of chronic anterior uveitis, an inflammatory eye disease."\par \par \uc2 Sabinsa also offers Curcumin C3 Complex, an extract from the rhizomes of Curcuma longa (turmeric) and standardized for a minimum of 95% curcuminoids. Discussing the benefits of curcuminoids, Mr. Majeed said, "A range of biologically potent actions ... have been reported and include antioxidant, anti-inflammatory, anti-aging and immune system support."\par \par \uc2 Another ingredient Sabinsa offers is selenium (SeleniumSeLECT)/ comprised of the amino acid methionine, in which sulphur is replaced by selenium. "Selenium is a micronutrient with a role in various processes encompassing energy utilization, immune mechanisms and antioxidant actions. It also works in synergy with vitamin E to counter lipid peroxidation in cells," said Mr. Majeed.\par \par \uc2 Derived from the dried heartwood of Pterocarpus marsupium (Indian Kino), Silbinol from Sabinsa is available in two formats, standardized for 5% and 90% pterostilbene. Pterostilbene has antioxidant and anti-inflammatory properties, and Mr. Majeed said this ingredient displays more stability than its structural analogue resveratrol.\par \par \uc2 Kyowa Hakko U.S.A, Inc., New York, NY, offers Setria Glutathione, known as the "master antioxidant," to aid in detoxification and support healthy immune function. Glutathione can be obtained two ways, according to the company: from food and as part of the body's internal production. A variety of factors including age, health conditions, lifestyle, environment and certain medications deplete the body's natural stores of glutathione, making supplementation necessary. Setria Glutathione replenishes the body's natural stores, helping to protect cells from oxidative stress and harmful toxins associated with free radicals, according to the company.\par \par \uc2 From the Sea\par \par \uc2 Numerous marine nutraceuticals are rich in antioxidants, with astaxanthin being one of the most notable success stories in this category. A natural carotenoid, astaxanthin is derived from certain marine animals and plants, including microalgae, salmon, krill, yeast and some crustaceans.\par \par \uc2 Janice Brown, technical sales/support with AstaReal, Inc., Burlington, NJ, suggested astaxanthin is unique in the antioxidant space because unlike other ingredients such as beta-carotene or vitamin C, astaxanthin is able to protect both the inner and outer portions of cells. "Beta-carotene is lipid-soluble and therefore is only found on the inner portion of the cell membrane. Vitamin C is water-soluble and can only exist on the outer portion of the cell membrane. Astaxanthin has polar ends and lipid double bonds that connect those polar ends, therefore it can span the entire cell membrane," she explained.\par \par \uc2 With more than 100 studies conducted on astaxanthin (with half of them performed in human subjects), this carotenoid has emerged as an ingredient for eye health, skin health, muscle endurance and recovery, cardiovascular health, cognitive function and more.\par \par \uc2 Recently, a double-blind placebo controlled study published in Evidence-Based Complementary and Alternative Medicine (2015) examined the anti-inflammatory effect of AstaReal when administered to elite athletes, with results indicating the ingredient helped improve immune response and reduce muscle inflammation.\par \par \uc2 In the trial, a group of 40 soccer players were supplemented with 4 mg of AstaReal or placebo for 90 days. The results showed significantly higher levels of (slgA), an immunoglobulin known to support muscle and immune function, among the athletes given AstaReal. Additionally, researchers found that AstaReal supplementation combined with training decreased the pro-inflammatory biomarker CRP, indicating lower levels of inflammation.\par \par \uc2 The blue-green algae ingredient spirulina is also noteworthy. Rich in carotenoids, antioxidants and vitamin A, in addition to protein, minerals and dietary fiber, Mintel reported spirulina has emerged as a popular superfood within the health and wellness category. While spirulina is perhaps best known as a vegan source of protein, Mintel reported that 37% of healthcare products containing spirulina boasted its antioxidant capabilities.\par \par \uc2 Berry Boost\par \par \uc2 Many berries--some familiar and others more exotic--offer a host of health benefits, with clinical research demonstrating their rich antioxidant content.\par \par \uc2 A study published in Open Chemistry (November 2015) tested red raspberry (Rubus idaeus), black raspberry (Rubus occidentalis) and blackberry (Rubus fruticosus), grown in central Europe to evaluate phenolic compounds, such as anthocyanins, in addition to antioxidant properties of fruit extracts. Results determined that black raspberries had the largest antioxidant capacity, and contained the most abundant phenolic and anthocyanin compounds. Blackberries had an even larger antioxidant capacity than red raspberry fruits, but red raspberry had a higher content of total phenolics and anthocyanins.\par \par \uc2 Mintel pointed to research suggesting blackcurrant presents an opportunity for formulators. The research firm reported a 100-gram serving of blackcurrant contains 300% of the Daily Value for antioxidant vitamin C, preventing free radicals from damaging cells. Mintel added that blackcurrants are high in anthocyanins, a compound adding to the berry's unique antioxidant profile. It also possesses flavonoids like beta-carotene, zeaxanthin and cryptoxanthin, which are known for their ability to help lower the risk of lung and mouth cancers, protect against neurological diseases, slow the aging process and fight inflammation.\par \par \uc2 Blueberries are also antioxidant powerhouses, according to the U.S. Highbush Blueberry Council (USHBC), Folsom, CA. Thomas Payne, market development consultant, pointed to findings from \uc2 USDA's Economic Research Service\uc2 , which indicated that Americans'growing appetite for a healthy and nutritious diet has aided in boosting demand for blueberries.\par \par \uc2 "Phytochemicals found in fruits, such as blueberries, continue to be investigated for their health benefits in the prevention of a range of diseases, such as cancer, heart disease, urinary tract infection, and even to slow the aging process, including memory loss," said Mr. Payne. "Studies of older laboratory animals consuming blueberry-supplemented diets have shown measurable improvements in memory, coordination and balance. Research is also uncovering neuron regeneration in older animals fed blueberries."\par \par \uc2 In 2012, research published in British Journal of Nutrition found that 75 grams of blueberries could provide statistically significant oxidative protection in vivo after a high-carbohydrate, low-fat breakfast. Though not tested directly, researchers suggested it is likely the effects were due to phenolic compounds, either directly or indirectly, as they are a major family of compounds in blueberries with potential bioactive activity.\par \par \uc2 Dr. Abedon of NutraGenesis, described the benefits of the standardized Amla extract, or Phyllanthus emblica (Emblica officinalis) marketed as Capros, which is backed by six human clinical trials. He said these studies "demonstrated how Capros' superior antioxidant properties help support cardiovascular health and provide resistance to the effects of free radicals."\par \par \uc2 One of these studies, published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy (July 2013), compared Capros against a placebo or atorvastatin (Lipitor) to evaluate its impact on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes.\par \par \uc2 Treatment with 250 mg of P. emblica twice daily, 500 mg twice daily, or 10 mg of atorvastatin saw improvement in endothelial function after 12 weeks of treatment compared with baseline. Researchers also reported a significant improvement in biomarkers of oxidative stress and systemic inflammation compared with baseline and placebo. The results suggested that P. emblica extract may be a good alternative to statins in diabetic patients with endothelial dysfunction because of its beneficial effects without the known side effects associated with the pharmaceutical.\par \par \uc2 Also harnessing the free radical scavenging power of Amla (also known as Indian Gooseberry), \uc2 Sabinsa Corporation\uc2  offers Saberry. The patented product is standardized to include a minimum of 10% of the validated biomarker beta-glucogallin. "Reporting a combined ORAC value of 358,600 [micro]mol TE/100 g, Saberry displays one of the most potent antioxidant properties in the water-soluble phytonutrient category," commented Mr. Majeed.\par \par \uc2 Saberry is reported to display benefits for liver health in comparison to the hepatoprotectant silymarin; management of diabetic retinopathy; prevention of adverse effects of heavy metal toxicity; skin lightening due to its melanogenesis inhibitory activity; and application in the hair and skin care segment based on its ability to protect cells from UV-related stress.\par \par \uc2 Category Challenges\par \par \uc2 Despite mounting research, the antioxidant market has faced growing pains in recent years.\par \par \uc2 "The main challenge of the category is that the claim 'antioxidant' is very general," commented Mr. Raz of Lycored. "Most consumers will be able to recognize that 'there is something healthy about antioxidants' and yet most of them won't be able to say what it is exactly and in what way they can benefit from consuming it. So, the lack of correlation between antioxidant consumption and a specific experience is probably the main disadvantage that this very essential group of compounds is facing."\par \par \uc2 Elyse Lovett, MBA, MS, marketing manager, \uc2 Kyowa Hakko U.S.A\uc2 ., agreed that lack of understanding by some consumers could present an obstacle to producers in the space. "I think the main challenge is educating the consumer," she said. "It is important to have strong clinical studies on the ingredients/antioxidants and deliver that information to the consumer in a fun, educational way."\par \par \uc2 New ingredients lacking the rigorous clinical substantiation that educated consumers have come to expect are likely to struggle to gain an audience, according to Ms. Brown with AstaReal. "Every year, we see new antioxidant ingredients coming into the market. Some ingredients simply do not have any studies to support antioxidant claim. It misleads the consumer." She suggested industry leaders should reach out to consumers and further educate them on the benefits of antioxidants.\par \par \uc2 Negative studies have also led to a decline in usage for certain ingredients, Natreon's Dr. Kalidindi observed, citing slumping sales of green tea and green tea supplements, resveratrol, vitamin E and beta-carotene. "Some of these supplements have declined in popularity due to skepticism over long-term health benefits and even reported negative effects in studies."\par \par \uc2 Suggesting a consumer push toward whole food ingredients, Mr. Wuagneux of RFI sees a shift away from extract antioxidants. "More consumers are choosing to get away from highly standardized supplements and move toward 'whole foods,' which provide the full matrix of nutrients."\par \par \uc2 As a specialty oil company, Ms. Coluccio of Connoils said her company hasn't seen any decline, given their specific focus. "Oxidation is a chemical reaction that is the onset of rancidity and the cultivator of free radical production in our bodies. Free radicals have the power to damage cells and impact overall homeostasis. We don't focus on what others are doing. We focus on our own objectives. As a specialty oil company, we understand that the biggest issue we face in our market segments is stability, or lack thereof. So natural antioxidants and preservatives, whether introduced prior, during, or after processing, play a key role in how we meet our customers' objectives."\par \par \uc2 Evolving Science\par \par \uc2 Multiple scientific testing methods are available to measure antioxidant capacity, but which to use and how the results are interpreted are somewhat divisive topics.\par \par \uc2 "The most widely used and accepted antioxidant testing method is the Oxygen Radical Absorbance Capacity of a product, more popularly known as the ORAC value," noted Sabinsa's Mr. Majeed. "This method involves the measurement of a fluorescent probe that loses activity when challenged by peroxyl radicals with its decay retarded by antioxidants. Thus, in this method, the higher the ORAC value of a product, the better its antioxidant capacity."\par \par \uc2 Another well recognized methodology is Trolox Equivalent Antioxidant Capacity, or TEAC. Mr. Majeed explained this process "involves the measurement of a colored intermediate in the presence of free radicals and decolorization of the same in the presence of antioxidants."\par \par \uc2 Additional methods commonly used include TRAP (Total Reactive Antioxidant Potential), FRAP (Ferric Reducing Ability of Plasma) and bleaching of crocin (from saffron extract), he added.\par \par \uc2 An emerging method is Analysis By Emitted Light-Radical Absorbance Capacity, or ABEL-RAC, explained Mr. Majeed. "The assay measures light by a protein pholasin, which emits light in the presence of free radicals and other non-radical reactive oxygen species. This method quantifies antioxidant activity along with identifying pro-oxidants and/or their formation as a function of concentration of antioxidants in the product."\par \par \uc2 Dr. Abedon of NutraGenesis discussed the difficulty in demonstrating to the consumer that antioxidants provide actual (rather than merely theoretical) health benefits through boasting test results. "Marketing companies often have been focused on reporting ORAC levels for antioxidants without indicating how these high ORAC levels translate into actual benefits in the body. This can leave the consumer confused, which can hurt sales of dietary supplements containing antioxidants." That, he said, is why it is so important that human clinical trials are conducted (in addition to in vitro ORAC testing) to demonstrate that high antioxidant levels translate into real condition-specific benefits.\par \par \uc2 Lycored's Mr. Raz similarly suggested antioxidant manufacturers and suppliers "are using the ORAC data to show the benefit of their products, but it is not correlated to biological effects--not even to in vivo (cell cultures) antioxidant effects." He added, "Carotenoids are especially not measured correctly in this method, as it is a water-based assay."\par \par \uc2 A study published in Journal of Nutrition in 2015, showed the results of a new testing method developed to measure antioxidant capacity. Scientists at the University of North Carolina (UNC) Chapel Hill Nutrition Research Institute at the NC Research Campus developed a new assay, which measures activation of antioxidant response elements (AREs), a system in the human body that turns on genes that in turn produce enzymes responsible for boosting cellular protection against free radical damage. Researchers suggested that utilization of this new method could help manufacturers examining antioxidant activity in products, offering improved nutritional information to consumers and regulators alike.\par \par \uc2 Results of the study, conducted through a partnership with the Dole Nutrition Institute, found that out of 134 extracts taken from the peels and flesh of fruits and vegetables, 107 activated AREs in human cells. Among the most effective activators included avocado peel, carrot, red pear peel, pineapple, lemon flesh, green pear peel, Red Delicious apple peel, spinach and several lettuces.\par \par \uc2 In comparing the fruit and vegetable samples with other traditional antioxidant testing methods, researchers found that some fruits and vegetables measured low in ORAC or total phenolics, yet were high in the ability to activate AREs.\par \par \uc2 Dosage & Delivery\par \par \uc2 The growing popularity of green-based beverages is among the most up-and-coming forms of antioxidant supplements on the market, according to RFI's Mr. Wuagneux. "Made with whole-food ingredients, this is one way to provide consumers with convenient means of getting antioxidant-rich fruits and vegetables into their diet."\par \par \uc2 The whole-food supplement market is growing twice as fast as the dietary supplement market overall, he added. "This is RFI's largest growth area over the last few years, as more and more companies delve into this space between functional foods and dietary supplements. Pill fatigue and convenience are also driving this growth."\par \par \uc2 Ms. Gomes of NP Nutra said plant-based protein powder mixes that include antioxidants like spirulina, acai, goji, pomegranate, camu camu, mangosteen and cacao are growing in popularity as a result of their ease of use and high nutrient content.\par \par \uc2 Mr. Raz explained that since most antioxidants are being extracted from botanical sources, once of the most popular delivery formats is the soft-gel tablet. The reason this format works best with botanical extracts, he said, "is the ability to encapsulate oil-based extracts in its relatively natural state (as oily liquids) without additional processing of spray/freeze dry."\par \par \uc2 Energy shots and drinks are also popular delivery formats, according to Natreon's Dr. Kalidindi. She also pointed to popularity in the personal care category, where antioxidants are often included in skin-care products such as eye creams and facial moisturizers.\par \par \uc2 Market Predictions\par \par \uc2 As the antioxidant market continues to evolve, Mr. Raz believes that ingredients will be tailored to more specific health indications. "In today's reality, the antioxidant category is being divided into smaller specialty categories such as skin health, hearth health, etc. So while the antioxidant category as a standalone may not continue to grow, some of the specialty categories will certainly continue to break records," he predicted. "Over the next few years, my recommendation will be to pay extra attention to skin health, as it seems this category is getting ready to bloom."\par \par \uc2 Mr. Majeed also predicted expanding opportunities for skin health, specifically in the nutricosmetic space. "The role of antioxidants in skin care has been recognized to protect skin from photo-aging and giving anti-aging benefits," he said.\par \par \uc2 Ms. Gomes anticipated continued growth as more consumers become interested in the medicinal properties that superfoods have to offer. "Consumers are turning toward natural ways of healing because they feel more comfortable putting something in their body that has fewer side effects. People use antioxidants in this way to stay healthy, and to counteract and prevent disease."\par \par \uc2 This article in a nutshell:\par \par \uc2 * Reaping the Benefits\par \par \uc2 * Emerging Ingredients\par \par \uc2 * From the Sea\par \par \uc2 * Berry Boost\par \par \uc2 * Category Challenges\par \par \uc2 * Evolving Science\par \par \uc2 * Dosage & Delivery\par \par \uc2 * Market Predictions\par \par \uc2 By Lisa Olivo\par \par \uc2 Associate Editor\par \par \uc2 Document NUTW000020160331ec310000m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Ariad Pharmaceuticals Files 8K - Regulation FD >ARIA\b0\par\par\uc2 187 \uc2 words\par \uc2 23 February 2016\par 07:45\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Ariad Pharmaceuticals Inc\uc2 . (ARIA) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on February 23, 2016.\par \par \uc2 In the press release dated February 23, 2016, the Company also provided product revenue guidance for 2016, as well as upcoming investor meetings. The information set forth under the headings "2016 Product Revenue Guidance" and "Upcoming Investor Meetings" in the press release are incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752316004696/a51285233.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752316004696/a51285233.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752316004696/0001157523-16-004696-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752316004696/0001157523-16-004696-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 February 23, 2016 07:45 ET (12:45 GMT)\par \par \uc2 Document DJDN000020160223ec2n001za\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw133\pich40\picscaley100\picscalex100\picwgoal1995\pichgoal600
47
494638396185002800F7FF00FBEAEAE6797CEB9EA1919191F0F0F0828282EEA4A6F2F2F2ADADAD9E9E9EB5B5B5D0D0D06E6E6E3333332C2C2CD8282CFBD5D6E3
696B898989F6D2D2F0AAABD30103F2B8B9A9A9A9CDCDCD9B9B9B7E7E7EFEFAFAF6D6D6B1B1B1E36165141414F4F4F4A2A1A1DEDEDEF1B5B6FAEDED666666E573
76BFBFBF8E8E8EFCF2F2C4C4C43B3B3B4A4A4AE8E8E8DD4E50BABABAFEF8F8F0B0B1DD5154DADADA616161EEEEEEDCDCDCECECECF1C2C3EAEAEAFDF4F4696969
E15B5EFDF6F6CACACAF5C9CAF8D9DA5E5E5EC8C8C8404040CE0000FBE6E6FCF0F0E88184BCBCBCB8B8B84444440C0C0CE3E3E3E88385D2D2D2D9252AF4C5C6E5
777AF9E0E0959595E9888AF8DCDDE6E6E6E36468F9DEDED8D8D8DE484C767676EBBBBCDB4448E1555AC2C2C27A7A7AE7AFB1DC3D415A5A5AEEA2A41D1D1D7070
70E77E80D72C31DF6264F4C1C2C6C6C6575757E88486A6A6A6181818E0E0E0505050E49597212121868686787878DB4045E4E4E4F5CDCE262626EEA8AAF4C7C8
C90000EEADAFD5D5D5EB9495EA9192E46E71C40000DA3136CD1619FAE4E4FFDFE0FCEDEEE25F62D6D6D6EC9597EB9798EEA6A7D41418EEA1A2737373C0C0C0FD
FBFAEA8C8EEC999AD1090D000000F6D0D1F7DEDEE77B7EE98A8DE88082F1CCCDDD3A3FFAE7E7F0AFB1EA8E90EB9C9ED51D22F2C5C7F0A7AAF2BABBEA9395FDFE
FE060606DA353AF9E6E7FAE2E2F2BDBEF2B7B8F8E4E4F8D8D9F5C2C4E04A4FF0B2B4EC9A9CFFFFFFFBFBFBFEFEFEFDFDFDFCFCFCFFFEFEFAFAFAF9F9F9FFFDFD
F8F8F8F6F6F6F7F7F7FEFDFDFDF8F8F9E1E2FEFCFCFEFFFFFDF7F7FAE5E6FBEBEBFFFEFFF9E3E3FCEEEEFFFCFCE4A8AAEFABADEC5C5FCF2025FEDADBABC0BF9B
B1B0080909F3C3C4FFE3E30F1010F1D3D2D20F12DF5A5DE8B7B9FFFEFDE04C50DF6D6FEA8487FDF5F5F5BEBFFCF1F1F3BBBDF9E5E6707D7CD8464AE78C8EF4A2
A4768786F6D3D4FAE3E4EC9294F4BFC0F8DADCEDC1C3F9DDDEF9DFDFE9AAAADA7C7EFEFBFBFBE1E1FCEFF0535453F3D8D9E68789E1575BFFFDFCF9ECEC8E9393
E8282D232323E8999BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A45324541463245354338373545323131413343304437443032394336463539432220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A32463439334235323531303231314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A45314543363134303531303131314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F70204353352E312057696E646F7773223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D22786D702E6969643A4533454146324535433837354532313141334330443744303239433646353943222073745265663A646F63756D656E7449443D22
786D702E6469643A4532454146324535433837354532313141334330443744303239433646353943222F3E203C2F7264663A4465736372697074696F6E3E203C
2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEB
EAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACAB
AAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B
6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B
2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000850028004008FF
006DE9A245B020AD5CBA66D5F255EB9F4387B374D9FA372B572E83B4784D7CC89162BE591C73E570020744C78B1DFFD962A872A0C15B1C6FE94AB9B021C759BD
4072B4C5CB66CA9F401F12A8B4A3E3964A493A3AA904E6DF824A1A66499DAAD3612D79527578E133E15F824A2B6A3CACE5A6D292890D2A4DB1396B46A54A13EB
54F2F15042A5062069F5AB34D32192B7952EFC1351E90D0A3088252CA974E09F864A2A66DD2268D167D094B36000AB4A952A4712449EC4F2E4C800050AF366ED
AD14A4EA974A05FE0DADC4C087930574DECE8C5349C1BF1780C53A6C51A9DABF036F1324C8C07C409659652A0D58CE7C0A827F3B2A6D4182408182016F277EFF
A8B4E01F83B765723D6452C9CCBF5A792AD53BB1C0CFD74A4E1C1671D1A8118F4E0E5D2041552901D344139824884900819833CC3E0558F68F1075A8F0101C1A
34504D0328F8124206FF28508708836DD14247076830C03FB948A0811930C2C84002B52000C6230CC498632F428071C74D12B0D1D8612776A081491CB5B0C509
0F1D80C210D538B0058F412043C53FF820D24D009AE0A1493783A0124514BF3C44C6208E50F1008097B54989096DC6091417686812800B98E022E79EFA69C227
47BDD06654256E1C70430E3780B054534F3D22902EBAF8B211506154F0CC3F959C424B4A76CD80E9079B725440254C8E8AC14D8F90FA4F190E30514D25A7FEFF
734225D739948574FFF046C043A322F1E7AFC0062BECB0C412AB0711040E430404D000F6D60B1D81C6C93B58B8E3CE1E8550F4D6A6BD9C02EB5017D4F2964DD9
01F6C83F2520F5DB5C0ED1C01A08D27C70DC294B0821840A2A9C40A22D0E5482840FF87EE14343EE3AC0020B6F55D30248BAF45B9EBB24CE125F0220E0BAD80D
0E29E0EC29C576ECF1C72003E5CA19FF44D0032EB8C8B38B43F890D111007670808B307A7C224F171CCCD249397D440003317B6CE0CFCAF1B8FC8F0ED8EC6100
337A30934A1AF2E0420A108800300B1EADDCA38832EF14430C10DEFCC14D32F3781308370FC96189430180F2CF19B1EC5285144600D1430469F491C92E8560FF
118116B3786347307DE839822CC7C0F0C33B0138E4C21E6D66D08F030EBCF116E50EE401C214B476E44325254C78791EA4E7F1C614416D22881AEFC507150219
A4554916FFDCF2967A1C9DE79B19959451021B41B89B294CD1E1FA50129524C0D16B6FD1FED0791D7C3C54511C8151090B60C8A881BBB13D95C7233494504210
4905950D11D49852C9103F61C06E6104FE63976FB939FB5606BDFC43CB1C95C0F4542520604FADDC570F5D10A0172BA804C6FE312A68790C0473880D47063007
0B7144047958D10CF250865378D08377C1DD3FF4710D2210211480D093555E20BB4C49605742390F605640178764A00C357408081A200D38FC43090E10A143FF
425006261060091AC04C3DAA610B48F4E30D4BA88614ABB10448842C28B84847313AC1452E4AC11BFF60C20CFAF2105DF841382C9AC10B3280041B88B00659F0
C53F7CE107183EC4163660C27BE0600311F8D18F33D8550B66F04740FE880084F4631E5BD0188A0C523D378863476E910534DA42046B4C422278F1905208A20D
96B0442004318A7FD4A31290F8C2094ED00132FE033483D8C30FA0B0073500415B79E08512A0E210E08460168B09D54FD8A02EE0B4E02973E0247BDE30AF53BC
205F274082A76C9116044013092A20186466618B5AD82207D1D95474CA138453E882736380091C2A21817FF4EB443FE9011F02F19059440059E3905750F441FF
0458C0E09F3090C706E4510B69544298C4794B3B3FD71BDCDD213ACA4B575280931F88C8CE01C7C9140826438B5BF8A227D1B9014727D38B5A6447080FF91C13
F5E7B07FB80B9EFA034C1203953C4E1E272D2CB8A24E77CAD39EFAF4A7404D091064F18F409C011054E88AE35ED1113BB88223A5A9533114D10D7174E10731E0
0431D2100555E0031D0FD98018FE410C7CFC2305A84047150261842B50A010F8408628B631017C30E31268E0400C52208A41B08311247808174CF0030BA80110
B388850726000B5630E21AEC300038A6318809444106BF10C008CE108A48F0C003AAB084175461010AC8030DA490021A8C112790CC6217B0DD854EA402147AFF
8091ACE498850E5448566240E4B70EE12D4440020C703C0417C9E08811789B027940C408DAB80967F4348B64F0D6086572483256F60F5C1897221D49C106804B
DBCBA4EA2DA79883E500438017BCC1820F994119DA9985328CC77E5B080A0708B136FDB9E155806100896A37870608D3210378035D125086C500A61A60D8952D
E2F0860410C8071F702044D8200D061028C1F015962D6C310BE47878C413B11E4A93C414A754020598090A1788B0B6C7D04084B340DE413F756006AACA5437D1
DD3F34E4AD5AFDE335469E8534DEB04E8CF2CA5FD2234A47AC673FC0D0C1C5550EC265965181F455220E3FB9155D2AF10121FE23374CCA8D036810871D30C0FF
72FDA805742AF18F8A41E61F6BE81C45DE700A98F0E22E4FF695C7A637A81C0EA7127570F18AF87409414000539530F33FE4E2A94A48237EE942E9633AC0CDA5
CC4127FBAB841C656516B908E61F09AC72537C1C6262D5E07A1D09829E1FE23E1AE0F92D799883AEE750863808D31E4410831D88208807088322B2AEC4180EB3
9853E4C02139F0D60724300084F5C621E9F20D441258006E7ACBA60EE15C6FC45509983AC40F95C8C32C46758A0F7CD08382FE1537E3578B5BC44F320DE1268A
F72DA159C80306F173C82D0E500302B8922386AA01082645117B77443230A98584042E1598FC443252E9A6C4374EE2A07AFCE320FF93314CC88792975C10CDFF
F8C7AB5640A0BF306038C5034C19E03984C0FC03016FF10347ACF016D978ABCA6C585595DF320B19DA6F09D09A85E550CA9B25D871309508FA716AEE2C69C097
149430E13558F78F1038C083D2F0D6021DA20F3E5CE127B5F8C01CE2B3039D40E2C5E822544714F001BA8CA19895E85725F2F70F9E33133965F8092DC60394BB
0FF821BC11CB38B1238DB4BC4127EC4934CE73CA9105CC210800E003233862002228E31C4BB80C0928510193F341108D7048CF67319EEB2CA595990A95081210
020424E1D9B29E6825ACE0E33270B330C7B9AFB398F9C3A137265D80F9C06A125D8BC5BB0B26A7CC69C550F716181280F61778C102624184EC3A2412443044FF
344E810209D00105E67E251F3C80F66D1D1A746A41357E1C420B02D42204F197E8BACA53BB7439A01A739051C4D711B4603985471E147103D2500DB8C30B2DE5
2EBCF70FBC8053B0611EF1F71E04700B79B602FFB0077C100A07D2087CF0687B11700FD1097C60422A48047CC00FEA13691CE116A043111A831E6F6150EE9116
21D07577F610B7906AFFF06A4397078337740A942ED10311A9520D52F11616921687771CAF2275186050BDE3609912724161825A08325CD8856018866238861E
370BE3D503D48205C1A003C1500546600CEC2005C27508316001CE452C3A708757F40B9D500555500C5F382CB8305E7BC20180F00F54700C299106E1D01196FF
2003DC050069A003EC30029FD00DBE150C02A00829F00FC1100399B00E1D410AB1000AC9F50FEF700454C001FF200FEA00089E0012D320000600125060008AB0
01B3600106300984F80F02100C0FA10500F00F7A4006AC4011E1C00864706C6AE008A320156A400131508C2460014405055490093DB0015730029200566DC201
6E6302459002D8F51032F00D1D21034CF5104D600072F010FB15016AB00A927009380012F020000F210994100E9E4004C2B009D6F010AE10050F310CCEA008AC
300264B0015030098C9002C2E0098B100BC020586D100C92100A0E410E2330027DB0082960017F100306B20823600147900C161003EF1005A9D007208109DEAC
D70947E01026200A6D020E31F00F4D20035780082E80050EC1085090128520063CE0021EA027E47005262006EEF00F9E100126300AB880032B13063FE01002B0
0A1C91093AF00A32900626800BC6D0057FA303FFB020F8600CC0800F47700624900C2E400567508C0ED10EACD85DB0200FF2C003478008E04002DBF00967600C
BF600267E00152900251A0094D7004298007D4150857A0053F00037AE010A5500540850B7E4986A8F9130101003B}}
\par\par \b \uc2 Redwood Scientific Technologies, Inc\uc2 . Redwood Scientific Technologies Designs New Oral Strip Product For Women\b0\par\par\uc2 348 \uc2 words\par \uc2 22 February 2016\par \uc2 Journal of Engineering\par \uc2 JOENG\par 3776\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Journal of Engineering via VerticalNews.com   \par \par \uc2 2016 FEB 22 (VerticalNews) -- By a News Reporter-Staff News Editor at Journal of Engineering -- \uc2 Redwood Scientific Technologies, Inc\uc2 . announced the development and \b \highlight22\uc2 launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  designed to help women balance their hormones. This product will be featuring Redwood's innovative oral strip delivery technology.\par \par \uc2 "For too long, women have gone without access to a product that helps them properly balance their hormones," said Jason Cardiff, President and CEO. "I am proud that our company will be able to help the millions of women across the country and around the world who suffer from the effects of imbalanced hormones. Our research and development team is confident that through the use of oral strip delivery technology we can truly impact the lives of women all over the world."\par \par \uc2 Oral strip delivery technology allows for the immediate delivery of medicinal ingredients into the bloodstream by way of the mouth. When oral strips enter the mouth, they dissolve within seconds and begin entering the circulatory system. In contrast to this, pills, capsules, and liquid medication take several hours to pass through the digestive system in order for their benefits to be felt. Oral strips bypass the digestive system and are not a choking hazard. Additionally, oral strip delivery technology is not as irritating or sneeze-inducing as inhalants.\par \par \uc2 The all-natural hormone balancing product for women will be formulated to not only increase sexual pleasure but also arousal and stimulation during intercourse. The upcoming product works by increasing blood flow to the erogenous zones and increasing lubrication which in turn allows women to enjoy improved sensitivity. As a result, women who take the upcoming product will be able to have faster and more pleasurable orgasms.\par \par \uc2 The name of the product and additional details will be revealed before Valentine's Day to coincide with the romantic holiday.\par \par \uc2 Keywords for this news article include: Hormones, \uc2 Redwood Scientific Technologies Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document JOENG00020160222ec2m0020g\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Study Explores the Role of Medical Affairs in Supporting a  \highlight22\uc2 New Product Launch \highlight\uc2  in the Oncology Therapeutic Area\b0\par\par\uc2 202 \uc2 words\par \uc2 19 February 2016\par \uc2 Obesity, Fitness & Wellness Week\par \uc2 OBWK\par 1323\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Obesity, Fitness & Wellness Week via NewsRx.com   \par \par \uc2 2016 FEB 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- In the pharmaceutical industry the medical affairs function plays a key role for a host of \b \highlight22\uc2 launch\b0 \highlight\uc2  activities including the identification and engagement of key thought leaders. The importance of this \b \highlight22\uc2 launch\b0 \highlight\uc2  activity is especially high in the oncology therapeutic area where most treating physicians are specialists.\par \par \uc2 To help companies focused on oncology therapies find better ways to utilize medical affairs to support product launches, research and consulting leader \uc2 Best Practices, LLC\uc2  undertook a primary research study that produced a report, "Best Practices and the Role of Medical Affairs in Oncology Launch Excellence." This study will help companies focused on oncology therapies find better ways to utilize medical affairs to develop successful launch strategies. The research delivers current data, insights and best practices in oncology launch excellence from medical affairs leaders at top biopharmaceutical companies.\par \par \uc2 Keywords for this news article include: Therapy, Oncology, \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document OBWK000020160219ec2j001ih\par }\page {\par\fs20\b \uc2 Dengue Hemorrhagic Fever; Microbix  \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Development Program to Help Combat Zika Virus\b0\par\par\uc2 646 \uc2 words\par \uc2 18 February 2016\par \uc2 Politics & Government Week\par \uc2 POLGOV\par 231\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Politics & Government Week via VerticalNews.com   \par \par \uc2 2016 FEB 25 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Week -- \uc2 Microbix Biosystems Inc\uc2 . (TSX:MBX) (the Company), an innovator of biological products and technologies, announced plans to develop and \b \highlight22\uc2 introduce new products\b0 \highlight\uc2  for use in diagnostic tests and vaccine research in response to the emergent Zika virus, which is spreading throughout the Americas and is being characterized as a crisis by health authorities.\par \par \uc2 The Zika virus is a member of the flavivirus family, which includes the mosquito-borne Dengue Fever virus. Microbix is the world's leading supplier of Dengue antigen to diagnostics manufacturers and the Company recently added three new strains of this virus to its product line. Currently, healthcare workers are testing for both viruses in persons suspected of being infected.\par \par \uc2 Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus, including native molecular controls, live and inactivated forms of the antigen, and related biological materials. These products will aid in the development of assays with high specificity and low cross-reactivity to related tropical diseases, including Dengue, that are spreading into formerly temperate climates as the geographic range of host mosquitos expands.\par \par \uc2 The \uc2 World Health Organization\uc2  (WHO) reports the Zika virus is spreading rapidly in the Americas, and it is being linked to babies born with abnormally small heads and other possible birth defects. Approximately one in 200 babies born in Brazil have been affected since the onset of the crisis in late 2015. The Director General of the WHO has declared an international public health emergency as the mosquito-borne Zika virus has gone from being "a mild threat to one of alarming proportions."\par \par \uc2 Vaughn Embro-Pantalony, Microbix' CEO and President commented, "The close relationship between Zika and Dengue viruses places Microbix in a unique position to help meet the challenges of this emerging health threat. Our expertise in growing Dengue virus at large scale, together with our processes for delivering diagnostic products for Dengue, will allow us to efficiently produce these new Zika virus products once their development is complete. We believe our products will be pivotal for the accurate diagnosis of this infection, which will help health authorities more effectively respond to this crisis, and will benefit patients as well as those at risk."\par \par \uc2 Dr. Mark Luscher, Microbix' Senior Vice-President and Chief Scientific Officer explained, "Zika virus infection may progress without symptoms or it may be associated with a mild fever or rash, making it very difficult to detect the presence of the virus early in the infectious phase. Microbix' virus products are often used to detect antibodies produced by the body during infection. Such antibodies last long after the infection is gone, and thus are a vital indicator to health care professionals that a person has been infected with the virus. In the case of Zika, this information may be critical to the health of the individual and an unborn child. The need for this type of health information has already led to Microbix' Rubella, Toxoplasmosis and CMV products being used to test women of childbearing age throughout the world."\par \par \uc2 "The Zika virus will be cultured and purified as a basis for immune testing for current or past infection," continued Dr. Luscher. "Microbix is also producing a Red Controls(TM) Zika preparation to help reference laboratories in Zika-affected countries. We intend to complete development of these Zika-related products as soon as possible."\par \par \uc2 Keywords for this news article include: Virology, Zika Virus, RNA Viruses, Dengue Fever, Arbovirus Infections, Flavivirus Infections, Mosquito-Borne Illness, Flaviviridae Infections, Dengue Hemorrhagic Fever, Government Agencies Offices and Entities.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document POLGOV0020160218ec2i000j2\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Best Practices in Launching a Specialty-Care Blockbuster Franchise in Hepatitis C\b0\par\par\uc2 219 \uc2 words\par \uc2 17 February 2016\par \uc2 Biotech Week\par \uc2 BIWK\par 281\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016, Biotech Week via NewsRx.com   \par \par \uc2 2016 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- \uc2 Gilead Sciences\uc2 ' drug, Sovaldi, held out great promise for Hepatitis C patients and the organization. For Gilead, the product held out the promise of a blockbuster and the beginning of a dominant Hepatitis C franchise, given that Harvoni, the next generation treatment, would be approved a year later. The two drugs rewrote \b \highlight22\uc2 new product launch\b0 \highlight\uc2  history for the biopharmaceutical industry.\par \par \uc2 A recent study by benchmarking firm \uc2 Best Practices, LLC\uc2 , looks at how Gilead countered the backlash over Sovaldi's $84,000 cost and how payers adjusted to the product's price tag. Additionally, the study reviews the predatory patent challenges that Gilead faced after it became clear it had a blockbuster, and how Harvoni helped propel the company's Hepatitis C franchise.\par \par \uc2 The related report, "Launching a Specialty-Care Blockbuster Franchise in Hepatitis C: How Sovaldi & Harvoni Rewrote New Product Launch History," will provide leaders with a playbook of the strategies and tactics Gilead used to accelerate Sovaldi's path to success.\par \par \uc2 Keywords for this news article include: \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document BIWK000020160217ec2h00019\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Zimmer Biomet Holdings Files 8K - Regulation FD >ZBH\b0\par\par\uc2 200 \uc2 words\par \uc2 10 February 2016\par 16:56\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Zimmer Biomet Holdings Inc\uc2 . (ZBH) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on February 04, 2016.\par \par \uc2 On February 4, 2016, the Company issued a press release announcing the launch of the offering by the Selling Stockholders and the Company's concurrent share repurchase. On February 5, 2016, the Company issued a press release announcing the pricing of the offering by the Selling Stockholders. Copies of these press releases are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1136869/000119312516457688/d133775d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1136869/000119312516457688/d133775d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1136869/000119312516457688/0001193125-16-457688-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1136869/000119312516457688/0001193125-16-457688-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 February 10, 2016 16:56 ET (21:56 GMT)\par \par \uc2 Document DJDN000020160210ec2a003w2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw270\pich40\picscaley100\picscalex100\picwgoal4050\pichgoal600
47
49463839610E012800F700002E2E2E24242421212185C231FCFCFCD2E9B3E8E8E8F1F8E8B7B7B7282828A1A1A1C3E19A2B2B2B005521F0F0F04A4A4A00450CB0
B0B0868686696969F4F4F43A7C54B9B9B9ACACACE1E1E1BAD2C42A2A2A003B01004A13D5E4DC616161E3E3E3D6D6D6D9D9D9D0D0D08EC6418282821C1C1CCACA
CA8AB199C9DED39C9C9C474747A6A6A6D3D3D38A8A8A2222228AC43A6E6E6E414141CBE5A81111117272725D5D5D1A1A1AF0F8F69A9A9ABABABA9CBCAA585858
ADD675DDEEC5545454F6F6F69797978E8E8EA3D16395CA4D9F9F9F424242C5D9CE0C0C0C262626B6DA849ACD5482AD94BDBDBD7EBE2590BBA5848484C6C6C698
9898C4C4C4F9FCF51616167ABC1EEBEBEBDEDEDEFCFEFA7474749191916A9E83E2F1CE075B298C8C8C4C8A67A2C2B0EEEEEE565656E4EEE9D5EAB96666661818
1838383814141400521EE6F3EE505050939393CCCCCC7ABD207E7E7E6B6B6B707070578C6939764B4D4D4D6464647CBD223E3E3E82C02C73A2851C6A3CE9F4DA
7B7B7BD4D4D4797979CECECE525252A4A4A4C1C1C14C4C4C6C6C6C3C3C3C005825C8C8C87A7A7AE4F2D2808080195727D6EABA6399793A3A3A8888885E5E5EFF
FFFF1A6333FCFFFF010101AAAAAA1463330059265A5A5A8CC53DBDDE8FA7C5B3A6D2682A6B3D75B916B3D97F87C335004E18DBE8E10040050E59274444443535
353F815B002D003636363131311F1F1F3737371E1E1E3333333434343232323030308DC63FB5B5B5959595E7E7E7B2B2B2A8A8A8DDDDDDF9F9F9ECECECC3C3C3
E4E4E4AFAFAFBFBFBFDBDBDBF2F2F2FEFEFE84C12FBEBEBEB3B3B3AEAEAEFAFAFAFBFBFBEDEDED8BC53CE5E5E5F3F3F3B4B4B4DCDCDCC2C2C2A9A9A977777794
9494DADADA8CC63E80BF29F8F8F8F7FAF8005A28E6E6E68CC53ECDE1CFAAD46F7FBF27F9FBFAF9FDFD437D56ADCCBDB2CDBE08542354906F7FAE96E8F1EDC6E8
866FA0829DC1AEB9D5BF92B49DFEFFFED8EBBE8CC63DDEEEE791B7A0FDFDFD98BAA6216F43307651D0EAA576BA18EEF7E3F1F6F3A6D65789C438EEF4F174A68B
7CA98FDCE9E3DCEBE581C02C21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A32413642423944333530463031314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3241
364242394434353046303131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3239453841453032353046303131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3241364242394432353046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000000E01280040
08FF0023091C48B060412EF60C2A5CC8B0A1C38710234A9C48B1A2C58B18336A2CF8C98EAC1703126D1C884CC2191B2504246000A0650201256C1449B1104A19
1A38E3D4393472621B2A545A091D4AB468D119B01C3C4C41A9C4501B545844E2C56006514ACF7A6ADDAA70CF364FF584891D4B56D800502364C91A01AA8A396D
E24671984BB72E0454694E582BF88C4A2A53804D95A0C55044162614089639124015ABC0A6583140124000154105734C78E5C20C15A7AB4A001590CA8FB2826B
660458BD6A060281B7CE002D41498BC01D0220AF9A2050C11117AB031CE11DE94A0DCB258EB00A16E9C20C01C15BAD9216A9568C0490A9D88AF4A14E002A3642
7FFF5E2375A004C6C1A9C05A96F9797017338645EA8506FAEA233E049A00B4EAB3F812627CB0103041DC6199194241D58A2B348050D1140459230904D71862A1
210D848282462CF0E1487F01C4F20A64904936030E03E5E2430081C1D24A2F111DF3CB3095D04242162A0010D82BAB0021D07190B1F44B43B8E946DC2D25B8B2
A3001234648B00AA0406402CB854775D76DB19B4830B9005B0462440AC3222600914911841BE4019982B02EC12C92C01C012180367185010068530905D0E913C
C06260549010492E84161A490B258C994A095940F4C528A3486284414B4040A121A1743146443F31F057642E1402C542CD9CA101642D8510C9312B66D7244124
94FF0099068E5861103C74FC690A8F3E46026460ADC0E0509181ED065B9281A902C0900C3D1925605356691D76819540834106A4726AB5340521666065FEC097
0D639AC2A69B70CA0998A7BCDC996776114412041A90A91280080BA930030377F8E0C30A162D504F36077065F0C10827ACF0C20C13C409356AC9920935646844
021A8F01960A2B01AC72C71A6B1422DD2B9FEE8A061104BD41458B2F364C900968A051C2CC343B06D91900D04CF311B128E5105325AC223454524D0B991959BA
ACF44432646247326945DCC4003208548E38975E68C8251C8C52C1A40FAD3043B91AC312407DA9ECD00233C828A4C04D77E808D82B00D4F0461634C0A02A1354
3CFF9B0A2CAB1082C015068040842909646C0A03B0D4F2636E80B972C71974AA528219092430036191100B98B19120A92460AAC4608A9C485021000354DC014F
24CE4A49A595D402C64ACE1EAC9083022AACA238E28528E56DB9659E39509ACF9ADBE69B7106767B0025D4A0C00524B0846A022608240D70192F0A8909B91C73
C51B6A4696800BCD5034CF281542104A85175E324A230A5F80442C907126C5A0AD02E6228C0539461D6600808CB1C2052E5803096C01020CD060153BEAD1E320
13AC6141EE73474216E996E5A4F299225AB43BDA0514F20659CDE90EC620C2B7C864A682206F4DCB4BD79C52D12E82E0494F808282341A031957C4E0012A08A2
10FF8738C40734E4141CD89044E2110A54F06322087001B94A462212FD6D0645B0D540AAA10233FCAE5A8DDA0115CE0099540040000238559CD680BFB9ADC236
BEBAA0292A482439824E74C9E260B33C0842A3A5220112F0410952B18AFBADC680B138420B084283197C31162B71850D76E0031C2A0F5DCD5B170DDD65495350
018091D085BE6CE6BFF305406E7FA14200B277112C0843134B8BA52C6749CB5A3AE40099C8871D3EA130038480052208819D6C49CC621A33615C184032D4420D
4E8C040A1DFB621535F60A2A3C4017050142A2FCD7B2A589A025D30C278912A00260844D83A68805001C64B4C020ED98F01C08199A308D88C9620023C8883304
A0FF2EC020A19C0A9180194C61AF980420693030E1E94A201F63D60082D51296C1DA099877C6D36558D08430E819357BAA6504C9A8C210B810892D6C406B5ABB
442836D0890C30A40FD6739E00548080634484060A0DA72A1230AA4838800E3388C5A752A10A06688001AE28192B4A00000C0CE457E90CC01510708402464E00
28EB9C1D33383A53D8A005C07045091417003A302776D09A1D451107044CC84A44545C6AF004323C70B5104D1E3C17F3FA29003EE4601501F85B15537184570D
84085458452AFE6246CAE8E92FACD09CA01EC28821D8811A4D480241C87152AD5D830310F8423F28E2001FEC8B8A56844502CC60031FF47420C1E8DF42932610
02FFA480047C800326EE70D78278E082AF1080022658A21214C1170BF19C29EE88CEC83040002D608F41D0FA41B55E2930013062418861837E0AE609F25A21E2
7A2B90175E1593FD74C52A0C2B1065C0426E80A1C2084D5082E441B24A05718064E60480D34C041DA368C025506A080EC8E3753DC9450802E10715400F16BF63
051524AA225DFD8F217F20842A3E1300C6EDEABDAA2819AF880B186B59D048C7EAAAB2AED0C1E4F5F1BA151DA1411091537EE54285C4236F24CC7BC9BDCEB086
03B96176A0508B04B4113038B34F7002E002ABB6A81011C90004D2108A519C2312A2E8C406047C21086C62223F40401C24790480350401F45A52BC8C215BC0C5
CBFF86461D6A02A54B103F2874C471A4A04419A25CE6AA588F0BA1EE8B6B670A33DC4221138028605CB08348D042BCC573615E6398C9C56DD286EF0214665C01
5F53A021085AE9000436B00587F8630E1B4803042A201164105271B72B410058F18035A8201625480019B3931581D0C02FCE9BCC0E68E0810B68B364A908C00E
981506620CC206A610F12AA240E239EE39B95B4D711E9915683E5AB7764A2A411C08028C2204D67636F0804088A1E868275004C0D045040A2180DFE955869A04
B240840C2800B6E008256A051D72A0946A80001A50822C1ACAB0906018210F7BB1881AE6A1838AACC00709909906A2F497A296000D09D8013318020241A2A1C3
00FFD040022881098184400CA20940E6BE438558C4217D11A0C40C8042054A3C803945A004CF7BDEE886DC41E83CA7C4972281039DF37C064770104356E074A0
1C6106AAFA4000844E894108C4008438DBEA52FE71470CD72021D0572BA60400F824C00FC688C4CA9F4E090B44E21955A7C211A8E0548234233943A7C4D90982
8015D587250060C0778C1B8DB86B840705B8A8E4274F796372A11E42A8BCE637CFF98409811BDC887CE7474FFAD247A4004DC8C400948005AED4E202590084E9
5AF28A18F8001AB33067E57941021248E0F7C00FBEF085FF062D88CB2126F043F07BEF380704E10DC1CF02BE4CAF342C0C6100B298861D16D01328DC810A0940
6DFF194DF11D48B4AD20293882535A411B332BED9B9D16E734C9A9FB86AC009DEA64278C0B4D5BEA2F6C011EA116F9200B05931106B05CBF930AAF9000ABA101
24534654000905D102E4C24DA0E432F0277FF2477FE7D455F91742EED47FFE873007300D03183176A05918E10077800425220074300BBC600CC6800108000936
10621A830409C062BE066D16184B0600044090020AA0002990842AD0491AB00644900238108538100D81900B0FC1043B30015A38016550074EB55616358215D1
030B50008C40066898866AC808ECC009FF10312390096E800FE9A0036070877898877778024BB029047101C0562D28B21035400902500A591001BC40006D500C
08FFB006E0860424C004B3C00C11304C05A10C08A0057C000365500670E00741300B5A541052500CB3908ACCD00B9848010A900575000998A155281609187001
08908B0870016D4010CEF00413B0034FC01CCA400C086001C8988BEC01866F1609261004305007134002765710207001A9988A11900336451006500CCC908DB3
500C76C20B11108EA9580CAF1509C3200170500770408D0F410139E00534F08934200117E05F0AD10343500F03D00EC93090044990F5B416DCF00FF41009EBD3
000EF99010092972E08705810040082E77707E11110766A00A641339AAA02C01B03F02010C13703900000B1FB92BAEA00148D18B03E156215954ABC0134F3003
5CFFA23C59D567C4B102540000334905E3C60200D037805156CC11014C35930CC000E9B356542002D8E00A687064FE8339D317095E5002B13093017007C62310
C3B094219933CE1009CC2000401992255007918000ABD05D24020B58E43304C1048EA01A5DB5260C707283A8108920046E804F1EB516C2E0063C0021E0300A69
306029D500A3100A79E00D0D41006BA05825E202AD30082D800098B8101ED014A484640180127AD7501330039FC20AAF50025C7206AA6003BAE63C33702D2406
008E1005D7F1189CC600364013B4582C5C052C24A008549031CA52023F073BDE262DFBC70AB0A001026003DF110067A05433B048E1956361B96393865EC9F200
67FF703E9F6103B1F03B5F693CCE9138D1960AAD404E74D09A36733B4730780A610F3CD00478300223F00255A0047B301015B001F06321970099A4A00E12110C
903003D1364DAAA0012E2033850003AFA11062606125508DB0F500946003ADE0024880066F6010268004F0155C7C92671AC369AC20002E50070AE00C268000D4
119C18A46DB69392B160032AD002C46002BE2008AF2368DF462236A00804610531706EC0F21A75C542DDC963F75669A9D0A3A0361038D00AF96303C420101E70
9C1AD30A4547107C3048B68306B6D91053F009B25031036104EEE3981692069DF06516010F249000E0B79783050B3660036C401015C63217A810CB707C06C107
17FF8967501519AB5004D8846DB5884781110BAD7068DDE662471A18BF69100EE00884D69691A00590A663544A69FD8454762910BC7007DB125FF1C207685032
ABE0960A41038D8A06EE2711E3B00174DA65273012BA400C6FB00600B00A6680047E1A191AB00AD357A841D810CDB00230F000A6601928B176BBB62B12C4A225
766D0AC1933A4A500C20207BC4A9CE49686620630501035C0A2EA5100C2970AA53FA9D3E966F9C941DCE000FE0942C3100080F30B004BB0645B0970CB0741121
0A69C001C17A210DC0012E6530C0300C70B03ABFA36B7622ADA7D34D014402D3E9298BF50AD01300B4E208E5E2A87244477C966DA1834ECAC26D0A61A4EB2A42
24FF5463854001386657F79A3C55BAAA97166499165F8710023CE43C0090394ABBB44C9B3912B10FC0AA6AA7A00710700974CA0196700F16810B5E000756D810
6F70918021005FCA6616E6B103D10263B39AADF000B3F0B50211B611D42B8FCAB2942A9CE51AB32D263B35EB4EEE4A10D09053E41409F5CA9D92E6B3AAFA63FB
9A435660643B52025AE000BA30B9945BB995AB910DA10F96005AA1100F03710372B001EF6321A125113970062E50020C1059B1A02A0C91022BA31B4CC03FBA22
49CDD81B81783A02B08E0341028DFAAD752BAE5AE2B2964A508036B3CD09828061037F49106BA02B82212C513A5E8AAA1FF88A6F96A66FB638B49E64773E401A
81FF210035C0102C100120500B70EB104EB0011BF00DE5B010E1400AA3B035A3F00E12F1068EE43C32070DC3C00BCB500D0ED00C517006B31618EEB90304506D
2D81000816098810AFA48304E591227580A66E44B72B2BBC0541AE2FFB67323B5DC9BB56D8517F02510C66E08109E020382000E50200F74210B8F04725F3B38A
8B699D4405C5608B1AA00143058374661EB242939470BB06110CA4B00115F71093D008A330651D201150D00A050C19EFC58046F691AC80069890C0253C506564
36B4010D22B00A7BC931A650031E5004D091B4DDCA23D406AED6766278DBC1DBB6B769D5B71C137EAD30014CF00B117099DD9333ACF401FF4A9A00A00231E002
09FFA001E70943E0A9AF369C1D00640CA9B158B6B31A4580096C5402B0F01767C054FCA8104BA007EE501128B0080DD00D13C1026B8006AB107FE397330B37A9
0421027CAA83905102701009D2C03AB84C4D1A00726D600BB55A2D9315BC729CA374BC411F5C10341B4289F703569097409992D4041F7E50101FB0610FA831A9
C00047B003065003B59BB8902CB4377C810E30013203CBD1A60AF0A10252D7704F9C11C18002EB60116D900259E00331900A49657B34900259D910C3D0027500
0874200690903B77290175B00398500624B0027D1709D8A0055A400B1C1D040AF03A17D0021CCDD140EA10B720D223DD026FC6028F30D2B4100D5A40CB0A0102
2D5E100D23CD066CD036C0900241400B2D70960321025A30013E30086290052BD0AA0541002B30010F500A8350066C20753F40043D9DD24E15024160D31CAD05
40A0D40E80031B3DD21230CF056102B400033E10446B50062D6001E92B100101003B}}
\par\par \uc2 BUSINESS\par \b \uc2 The heart of \uc2 Boston Scientific\uc2  skips a beat // Sales of cardiac devices missed fourth-quarter projections, but  \highlight22\uc2 new products \highlight\uc2  are coming in \u8217\'20\'1916.\b0\par\par\uc2 JOE CARLSON; STAFF WRITER   \par \uc2 STAR TRIBUNE (Mpls.-St. Paul)\par \uc2 644 \uc2 words\par \uc2 5 February 2016\par \uc2 Star-Tribune\par \uc2 MSP\par \uc2 METRO\par 1D\par \uc2 English\par \uc2 Copyright 2016. The Star Tribune Company.  All rights reserved.   \par \par \uc2 A worse-than-expected dip in sales of pacemakers and implantable defibrillators is leaving its mark on \uc2 Boston Scientific\uc2 , but the situation is expected to improve for the device maker later this year with \b \highlight22\uc2 new product launches\b0 \highlight\uc2 .\par \par \uc2 The Massachusetts-based med-tech manufacturer, which employs more than 5,000 people in Plymouth and Arden Hills, saw its stock price fall more than 3 percent at one point Thursday after announcing that revenue from heart-rhythm devices fell short of expectations for the quarter.\par \par \uc2 The Cardiac Rhythm Management division was the only one at the company to see a sales decline in the quarter.\par \par \uc2 Boston Scientific\uc2  reported $1.98 billion in total sales for the quarter that ended Dec. 31, which was 5 percent higher than the same period last year after removing the effect of acquisitions and divested businesses, which is known as organic growth.\par \par \uc2 \u8220\'20\'1COur overall performance as a company was quite good,\u8221\'20\'1D Chief Executive \uc2 Mike Mahoney\uc2  said. \u8220\'20\'1CWe grew at 5 percent organically and about 10 percent per quarter with the impact of acquisitions. CRM was a little bit slower, and that was in line with what we thought it would be.\u8221\'20\'1D\par \par \uc2 Analysts had been expecting the\par \par \uc2 sales of pacemakers and defibrillators to slip by about 2 percent during the quarter. Instead, the tally fell by about 6 percent, to $440 million during the quarter.\par \par \uc2 Boston Scientific\uc2  executives had predicted the sales decline, following \uc2 Medtronic\uc2 \u8217\'20\'19s launch of pacemakers and defibrillators that are compatible with magnetic resonance imaging scanners. \uc2 St. Jude Medical\uc2 , in Little Canada, has reported a similar slowdown in its non-MRI-compatible heart-rhythm machines.\par \par \uc2 Mahoney said \uc2 Boston Scientific\uc2  plans to launch a MRI-safe pacemaker system in the second quarter of 2016, among other product approvals are expected later in the year that will benefit the division.\par \par \uc2 For the fourth quarter 2015, the company reported a net loss of $142 million. But that includes the effect of setting aside $456 million during the period for increased legal expenses.\par \par \uc2 In late January, the Court of Special Appeals of Maryland declined \uc2 Boston Scientific\uc2 \u8217\'20\'19s appeal to throw out a jury verdict for unpaid royalties totaling $309 million. The verdict went in favor of Mirowski Family Ventures, LLC, a group that receives royalties allegedly owed to Dr. Michel Mirowski, the now-deceased owner of the patent to the implantable defibrillator.\par \par \uc2 Boston Scientific\uc2  also set aside an undisclosed amount to cover potential settlement costs related to some of the 35,000 lawsuits filed against the company by women who say they were injured by its pelvic-mesh products.\par \par \uc2 More than 135,000 such lawsuits have been filed against a half-dozen companies that sell the devices. \uc2 Boston Scientific\uc2  now has $1.9 billion in accumulated legal reserves.\par \par \uc2 Removing the fourth-quarter expenses related to litigation, debt payments, and changes from acquisitions and divestitures, the company reported adjusted net income of $362 million for the quarter, which was about 10 percent higher than the same period last year. On a per share basis, the company\u8217\'20\'19s adjusted earnings of 26 cents was a penny above what analysts had been expecting.\par \par \uc2 For the full year of 2016, the company is projecting between $7.9 billion and $8.1 billion in revenue, which would represent growth of 6 to 8 percent.\par \par \uc2 That would compare with 2015 net sales of $7.5 billion, which was 8 percent growth over the prior year.\par \par \uc2 The company predicts adjusted earnings per share in a range of $1.03 to $1.07 for 2016. Adjusted earnings per share were 93 cents last year, 10 percent above the prior year.\par \par \uc2 Joe Carlson \u8226\'20\'22 612-673-4779\par \par \uc2 Twitter: @_JoeCarlson \par \par \uc2 Document MSP0000020160206ec2500018\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Study Explores the Role of Medical Affairs in Supporting a  \highlight22\uc2 New Product Launch \highlight\uc2  in the Oncology Therapeutic Area\b0\par\par\uc2 387 \uc2 words\par \uc2 5 February 2016\par 18:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 CHAPEL HILL, N.C., Feb. 5, 2016 /PRNewswire/ -- In the pharmaceutical industry the medical affairs function plays a key role for a host of \b \highlight22\uc2 launch\b0 \highlight\uc2  activities including the identification and engagement of key thought leaders. The importance of this \b \highlight22\uc2 launch\b0 \highlight\uc2  activity is especially high in the oncology therapeutic area where most treating physicians are specialists.\par \par \uc2 To help companies focused on oncology therapies find better ways to utilize medical affairs to support product \b \highlight22\uc2 launches\b0 \highlight\uc2 , research and consulting leader \uc2 Best Practices, LLC\uc2  undertook a primary research study that produced a report, "Best Practices and the Role of Medical Affairs in Oncology \b \highlight22\uc2 Launch\b0 \highlight\uc2  Excellence." This study will help companies focused on oncology therapies find better ways to utilize medical affairs to develop successful \b \highlight22\uc2 launch\b0 \highlight\uc2  strategies. The research delivers current data, insights and best practices in oncology \b \highlight22\uc2 launch\b0 \highlight\uc2  excellence from medical affairs leaders at top biopharmaceutical companies.\par \par \uc2 This report will help oncology launch leaders better understand:\par \par \uc2 \f2 \par    -- How medical affairs is involved in the launch process in leading Pharma \par       and Biotech companies \par  \par    -- Strategies for effective thought leader (TL) segmentation and \par       relationship management \par  \par    -- Challenges in managing successful medical affairs launch support \par  \par    -- Industry drivers regarding new product commercialization \par  \par    -- Critical strategies for allocating medical affairs launch budget \par       effectively \f28 \par \par \uc2 \f2 For this study, \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  relied on data and interviews involving 11 executives from leading life sciences companies. The study analyzes companies that focus on oncology therapies.\f28 \par \par \uc2 \f2 To access the full 36-page report or to download a complimentary summary: \f28 {\field{\*\fldinst{HYPERLINK "http://www3.best-in-class.com/rr1409.htm"}}{\fldrslt{\cf2 \uc2 http://www3.best-in-class.com/rr1409.htm}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 For related research, visit our \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  Web site at \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/"}}{\fldrslt{\cf2 \uc2 www.best-in-class.com/}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 ABOUT BEST PRACTICES, LLC\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/study-explores-the-role-of-medical-affairs-in-supporting-a-new-product-launch-in-the-oncology-therapeutic-area-300216192.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/study-explores-the-role-of-medical-affairs-in-supporting-a-new-product-launch-in-the-oncology-therapeutic-area-300216192.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160205ec25000cd\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Redwood Scientific Technologies Designs New Oral Strip Product For Women\b0\par\par\uc2 423 \uc2 words\par \uc2 5 February 2016\par 17:43\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 LOS ANGELES, Feb. 5, 2016 /PRNewswire/ -- \uc2 Redwood Scientific Technologies, Inc\uc2 . announced today the development and \b \highlight22\uc2 launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  designed to help women balance their hormones. This product will be featuring Redwood's innovative oral strip delivery technology.\par \par \uc2 "For too long, women have gone without access to a product that helps them properly balance their hormones," said Jason Cardiff, President and CEO. "I am proud that our company will be able to help the millions of women across the country and around the world who suffer from the effects of imbalanced hormones. Our research and development team is confident that through the use of oral strip delivery technology we can truly impact the lives of women all over the world."\par \par \uc2 Oral strip delivery technology allows for the immediate delivery of medicinal ingredients into the bloodstream by way of the mouth. When oral strips enter the mouth, they dissolve within seconds and begin entering the circulatory system. In contrast to this, pills, capsules, and liquid medication take several hours to pass through the digestive system in order for their benefits to be felt. Oral strips bypass the digestive system and are not a choking hazard. Additionally, oral strip delivery technology is not as irritating or sneeze-inducing as inhalants.\par \par \uc2 The all-natural hormone balancing product for women will be formulated to not only increase sexual pleasure but also arousal and stimulation during intercourse. The upcoming product works by increasing blood flow to the erogenous zones and increasing lubrication which in turn allows women to enjoy improved sensitivity. As a result, women who take the upcoming product will be able to have faster and more pleasurable orgasms.\par \par \uc2 The name of the product and additional details will be revealed before Valentine's Day to coincide with the romantic holiday.\par \par \uc2 About \uc2 Redwood Scientific Technologies, Inc\uc2 .\par \par \uc2 Redwood Scientific Technologies, Inc\uc2 . (Redwood), headquartered in Claremont, California, develops and markets \uc2 FDA\uc2  registered OTC drugs that can be delivered through the use of thin film technology. Redwood utilizes patent pending sublingual strip delivery technology to enhance the effectiveness and absorption rate in the treatment of medical conditions. The company is aggressively expanding its customer population through national television advertising campaigns while driving consumer awareness and increasing retail expansion.\par \par {\field{\*\fldinst{HYPERLINK "http://www.redwoodscientific.co/"}}{\fldrslt{\cf2 \uc2 http://www.redwoodscientific.co/}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/redwood-scientific-technologies-designs-new-oral-strip-product-for-women-300216213.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/redwood-scientific-technologies-designs-new-oral-strip-product-for-women-300216213.html}}}\par \par \uc2 SOURCE \uc2 Redwood Scientific Technologies, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.redwoodscientific.co"}}{\fldrslt{\cf2 \uc2 http://www.redwoodscientific.co}}}\par \par \uc2 Document PRN0000020160205ec25000c0\par }\page {\par\fs20\uc2 C\par \b \uc2 SHOT Show featured; products worth a try\b0\par\par\uc2 Tom Claycomb; Outdoors contributor \par \uc2 929 \uc2 words\par \uc2 4 February 2016\par \uc2 Idaho Press-Tribune\par \uc2 IDAHPT\par 01\par \uc2 English\par \uc2 Copyright 2016 Idaho Press-Tribune (Nampa, ID), All rights reserved. Distributed by NewsBank, inc. \par \par \uc2 I by no means can cover all the \b \highlight22\uc2 new products\b0 \highlight\uc2  shown at the 2016 Shooting, Hunting and Outdoor Trade (SHOT) Show last week in Las Vegas unless I write a book, but I will highlight the products that caught my eye. They had 100 new companies allowed in this year stuck in a hallway outside the Press Room alone, not including all the \b \highlight22\uc2 new products introduced\b0 \highlight\uc2  by the existing companies.\par \par \uc2 Puma SGB Knives is coming out with a new boning knife and, in fact, a whole line of processing combination kits. They had a few prototypes for demos. I'm excited about this line, since I'm helping him develop it. The project is moving fast, so hopefully they're in the marketplace soon.\par \par \uc2 Leupold came out with a new VX-3i scope, which is an improvement on their already-popular VX-3 line of scopes.\par \par \uc2 ThermaCELL\uc2 . Along with its normal line of outstanding gear, it has some new rechargeable heat pads (hands).\par \par \uc2 Walker's introduced a new earmuff that is much thinner than its original muff, which makes them easier to use while shooting trap.\par \par \uc2 Tenzing, as usual, had a nice line of packs on display. I picked up a TZ 3000 to help me haul gear at shows.\par \par \uc2 Crosman came out with a new gun they call the airbow, which is an airgun that shoots arrows. It was fun to shoot.\par \par \uc2 My Topo maps, as usual, owns the map market. They have some cool new apps.\par \par \uc2 Irish Setter boots. It came out with an insulated line of its popular lightweight Vapr Trek boots.\par \par \uc2 There were a lot of new shooting gloves, but the ones that I picked up to test were made by Mechanix.\par \par \uc2 Camp Chef came out with a backpacking stove called the Stryker 100.\par \par \uc2 Camp Chef also came out with a pellet stove that has a lot more/better features than a Traeger.\par \par \uc2 Otis had too numerous to mention new gun cleaning items.\par \par \uc2 Rise Armament came out with a moderately priced trigger for people on a tighter budget.\par \par \uc2 Stevens had an economical 12 ga. auto that shot nicely.\par \par \uc2 Savage came out last year with a .17 HMR auto with a rotary clip. Their original straight clip wouldn't feed regularly, but I believe the rotary clip ought to be a vast improvement and Savage is the first to figure out how to make a .17 HMR auto.\par \par \uc2 Go-Pro has a super small camera with all kinds of accessories to mount it while filming. I didn't measure it, but it can't be over 2 inches square.\par \par \uc2 Sig Sauer\uc2  came out with a nice AR called the Predator that I will have to test.\par \par \uc2 Sig Sauer\uc2  came out with a new airgun line.\par \par \uc2 Compass 360 has a new line that competes with Frogg Togg. I'll be testing and writing about this soon.\par \par \uc2 A new women's clothing company named Girls with Guns was there. Katy will be testing out some of their clothing soon.\par \par \uc2 Weston has some cool processing equipment. I'm going to have to try out one of their grinders.\par \par \uc2 King's Camo appears to be growing. I have to check out some of its gear.\par \par \uc2 International Supplies had a unique tripod that was attached to a belt that strapped around your waist. You extended the tripod and could use it sitting down, kneeling or standing up. They also had some nice hard gun cases.\par \par \uc2 I noticed a lot of electronic gizmos that were Blue Tooth-compatible or at least hooked into your cellphone. Altus had an electronic call, MyTopo maps had apps, etc.\par \par \uc2 Then there were a ton of side events. Monday was Media Day at The Range, and Tuesday night was a State of the Industry Dinner at which Ron Spomer won the Grits Gresham Outdoor Communicator award.\par \par \uc2 Then there were multiple breakfasts, lunches and suppers the rest of the week, with everything winding down Friday afternoon. Whew, I have a lot of emails to catch up on now.\par \par \uc2 Tom Claycomb s hoots the new Crosman airbow at the SHOT Show in Las Vegas in January.\par \par \uc2 Submitted by Tom Claycomb\par \par \uc2 Tom Claycomb s hoots the new Crosman airbow at the SHOT Show in Las Vegas in January.\par \par \uc2 Submitted by Tom Claycomb\par \par \uc2 Tom Claycomb is working with Puma SGB to develop a new line of processing knives. The prototypes arrived just in time to be able to demo it at the SHOT Show in Las Vegas in January.\par \par \uc2 Submitted by Tom Claycomb\par \par \uc2 Tom Claycomb is working with Puma SGB to develop a new line of processing knives. The prototypes arrived just in time to be able to demo it at the SHOT Show in Las Vegas in January.\par \par \uc2 Submitted by Tom Claycomb\par \par \uc2 Tom Claycomb.\par \par \uc2 Tom Claycomb s hoots the new Crosman airbow at the SHOT Show in Las Vegas in January. Submitted by Tom Claycomb Tom Claycomb s hoots the new Crosman airbow at the SHOT Show in Las Vegas in January. Submitted by Tom Claycomb Tom Claycomb is working with Puma SGB to develop a new line of processing knives. The prototypes arrived just in time to be able to demo it at the SHOT Show in Las Vegas in January.Submitted by Tom Claycomb Tom Claycomb is working with Puma SGB to develop a new line of processing knives. The prototypes arrived just in time to be able to demo it at the SHOT Show in Las Vegas in January.Submitted by Tom Claycomb Tom Claycomb. \par \par \uc2 Document IDAHPT0020160204ec2400034\par }\page {\par\fs20\uc2 Business\par \b \uc2 Ahead Of Boston Scientific Q4 Results\b0\par\par\uc2 485 \uc2 words\par \uc2 3 February 2016\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2016 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - Medical devices maker \uc2 Boston Scientific Corp\uc2 . (BSX) has been consistently delivering on and exceeding financial goals, propelled by innovative \b \highlight22\uc2 new product launches\b0 \highlight\uc2 . However, the fourth-quarter and full-year 2015 results are expected to reflect FX headwinds.\par \par \uc2 The company is set to publish its fourth-quarter results before the bell on Thursday, February 4, with analysts polled by \uc2 Thomson Reuters\uc2  estimating earnings of $0.25 per share on revenue of $1.99 billion. Analysts' estimate typically exclude certain special items.\par \par \uc2 For Q4...\par \par \uc2 The company estimates sales for the fourth quarter of 2015 in a range of $1.97 billion - $2.01 billion, and GAAP earnings in a range of $0.10 - $0.13 per share. On an operational basis, consolidated fourth-quarter sales are expected to grow year-over-year in a range of 9% - 10% and on an organic basis, sales are seen to grow year-over-year in a range of 4% - 5%.\par \par \uc2 Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related net charges and amortization expense, are estimated in a range of $0.23 - $0.25 per share.\par \par \uc2 If current foreign exchange rates hold constant, the company expects the estimated headwind from FX should be about $80 million - $90 million, or 410 - 460 basis points, relative to the prior year fourth quarter.\par \par \uc2 For Fiscal 2015...\par \par \uc2 The company now sees full-year 2015 revenue in the range of $7.470 billion - $7.510 billion, compared to prior guidance of $7.275 billion - $7.375 billion. FX headwind is expected to be roughly $475 million - $485 million for 2015.\par \par \uc2 Earnings on a GAAP basis is seen in a range of $0.02 - $0.05 per share, compared to prior outlook range of $0.28 - $0.34 per share. Adjusted earnings are now projected in a range of $0.90 - $0.92 per share, while the previous forecast was for $0.88 - $0.92 per share.\par \par \uc2 Analysts expect full-year earnings of $0.92 per share on sales of $7.49 billion.\par \par \uc2 Q3 Overview\par \par \uc2 For the third-quarter, the company incurred a loss of $198 million or $0.15 per share, compared to profit of $43 million or $0.03 per share last year.\par \par \uc2 Adjusted earnings were $0.24, compared to $0.20 in the previous year. On average, 25 analysts polled by \uc2 Thomson Reuters\uc2  expected earnings of $0.23 per share for the quarter.\par \par \uc2 Net sales rose to $1.888 billion from $1.846 billion. Analysts expected revenues of $1.86 billion.\par \par \uc2 Sales growth represented 9% operational revenue growth and an increase of 2% on a reported basis.\par \par \uc2 Third-quarter results reflect the high performance of the company's global teams, the continued diversification of its portfolio into higher-growth end markets, and the balanced growth across its businesses.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2016 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020160203ec23002jp\par }\page {\par\fs20\uc2 A\par \b \uc2 The best new gear at the 2016 SHOT Show\b0\par\par\uc2 Tom Claycomb; Outdoors Commentary \par \uc2 947 \uc2 words\par \uc2 29 January 2016\par \uc2 Idaho State Journal\par \uc2 IDAHOSJ\par 07\par \uc2 English\par \uc2 Copyright 2016 Idaho State Journal. All Rights Reserved. Distributed by NewsBank, Inc. \par \par \uc2 As I discussed in last week's article, I said I'd run a review of \b \highlight22\uc2 new products introduced\b0 \highlight\uc2  at this year's SHOT Show.\par \par \uc2 By no means can I cover all the \b \highlight22\uc2 new products\b0 \highlight\uc2  unless I write a book. But I will highlight the products that caught my eye. This year, there were 100 new companies stuck in a hallway outside the press room. And that's not including all the \b \highlight22\uc2 new products introduced\b0 \highlight\uc2  by the existing companies.\par \par \uc2 \u8226\'20\'22 Puma SGB Knives is coming out with a new boning knife, as well as a whole line of processing combination kits. They had a few prototypes for demos. I'm excited about this line because I'm helping them develop it. The project is moving fast, so hopefully they'll be on the market soon.\par \par \uc2 \u8226\'20\'22 Leupold came out with a new VX-3i scope, which is an improvement on its already popular VX-3 line.\par \par \uc2 \u8226\'20\'22 Along with its normal line of outstanding gear, ThermaCell has some new rechargeable heat pads designed for your hands.\par \par \uc2 \u8226\'20\'22 Walker's Game Ear introduced a new earmuff that is much thinner than its original muff, which makes them easier to use while shooting trap.\par \par \uc2 \u8226\'20\'22 Tenzing, as usual, had a nice line of packs on display. I picked up a TZ3000 to help me haul gear at shows.\par \par \uc2 \u8226\'20\'22 Crosman came out with a new gun it calls the airbow, which is an airgun that shoots arrows. It was fun to shoot.\par \par \uc2 \u8226\'20\'22 MyTopo maps owns the map market. It has some cool new apps.\par \par \uc2 \u8226\'20\'22 Irish Setter boots came out with an insulated line of its popular lightweight Vaprtrek boots.\par \par \uc2 \u8226\'20\'22 There were a lot of new shooting gloves, but the ones that I picked up to test were made by Mechanix.\par \par \uc2 \u8226\'20\'22 Camp Chef came out with a backpacking stove called the Stryker 100. The company also came out with a pellet stove that has a lot better features than a Traeger.\par \par \uc2 \u8226\'20\'22 Otis had so many new gun cleaning items \u8212\'20\'14 there were too many to list.\par \par \uc2 \u8226\'20\'22 RISE Armament came out with a moderately priced trigger for those on a tighter budget.\par \par \uc2 \u8226\'20\'22 Stevens had an economical 12-gauge automatic that shot nicely.\par \par \uc2 \u8226\'20\'22 Savage came out last year with a .17 HMR auto with a rotary clip. Its original straight clip wouldn't feed regularly, but I believe the rotary clip ought to be a vast improvement. The company is the first to figure out how to make a .17 HMR auto.\par \par \uc2 \u8226\'20\'22 \uc2 GoPro\uc2  has a super-small camera with all kinds of accessories to mount while filming. I didn't measure it, but it can't be more than 2 inches square.\par \par \uc2 \u8226\'20\'22 SIG Sauer came out with a nice AR called the Predator that I will have to test. It also came out with a new airgun line.\par \par \uc2 \u8226\'20\'22 Compass 360 has a new line that competes with Frogg Togg. I'll be testing and writing about this soon.\par \par \uc2 \u8226\'20\'22 A new women's clothing company named Girls with Guns was there. Katy will be testing out some of the clothing soon.\par \par \uc2 \u8226\'20\'22 Weston has some cool processing equipment. I'm going to have to try out one of its grinders.\par \par \uc2 \u8226\'20\'22 King's Camo appears to be growing. I have to check out some of its gear.\par \par \uc2 \u8226\'20\'22 International Supplies had a unique tripod that was attached to a belt that strapped around your waist. You extended the tripod and could use it sitting, kneeling or standing. The company also had some nice hard gun cases.\par \par \uc2 Then there were all the side events at the SHOT Show. Monday was Media Day at The Range. On Tuesday night, the State of the Industry Dinner was held, where Ron Spomer won the Grits Gresham Outdoor Communicator Award. Then there were the multiple breakfasts, lunches and suppers the rest of the week, with everything winding down Friday afternoon.\par \par \uc2 Whew, I have a lot of emails to catch up on now.\par \par \uc2 Tom Claycomb lives in Idaho and has outdoors columns in newspapers in Alaska, Idaho, Utah, Nevada, Colorado and Louisiana. He also writes for various outdoors magazines and teaches outdoors seminars at stores like \uc2 Cabela's\uc2 , \uc2 Sportsman's Warehouse\uc2  and Bass Pro Shop.\par \par \uc2 A close-up of the new Puma SGB boning knife. They will be made out of German steel so should be a step above the rest.\par \par \uc2 Tom Claycomb/For the Journal\par \par \uc2 A close-up of the new Puma SGB boning knife. They will be made out of German steel so should be a step above the rest.\par \par \uc2 Tom Claycomb/For the Journal\par \par \uc2 We received the prototypes the Friday before the show. Owner Bob Carpenter made a shadow box to demo one of the kits in.\par \par \uc2 Tom Claycomb/For the Journal\par \par \uc2 We received the prototypes the Friday before the show. Owner Bob Carpenter made a shadow box to demo one of the kits in.\par \par \uc2 Tom Claycomb/For the Journal\par \par \uc2 Tom Claycomb.\par \par \uc2 A close-up of the new Puma SGB boning knife. They will be made out of German steel so should be a step above the rest.Tom Claycomb/For the Journal A close-up of the new Puma SGB boning knife. They will be made out of German steel so should be a step above the rest.Tom Claycomb/For the Journal We received the prototypes the Friday before the show. Owner Bob Carpenter made a shadow box to demo one of the kits in.Tom Claycomb/For the Journal We received the prototypes the Friday before the show. Owner Bob Carpenter made a shadow box to demo one of the kits in.Tom Claycomb/For the Journal Tom Claycomb. \par \par \uc2 Document IDAHOSJ020160201ec1t000ae\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Synergy Pharmaceuticals\uc2  files new NDA for Plecanatide\b0\par\par\uc2 66 \uc2 words\par \uc2 29 January 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Synergy Pharmaceuticals\uc2  announced the company has filed with the \uc2 FDA\uc2  its first \b \highlight22\uc2 new drug\b0 \highlight\uc2  application for plecanatide in chronic idiopathic constipation. The plecanatide NDA for CIC is supported by positive results from two phase 3 clinical trials which Synergy completed in 2015. If approved, Synergy plans to \b \highlight22\uc2 launch\b0 \highlight\uc2  plecanatide with the CIC indication in the first quarter of 2017. \par \par \uc2 Document FLYWAL0020160129ec1t0058x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E6000000126D26619E2B65A0759AC1A4BCD63D72A91C5B9A004189D2DCEA638BB80D5295235D9BF2F5F96892BC00498EE3EAF2BBCEE144
79AD0C4D914075AB00458CABC2D95383B3EDF1F7002B7B145998003381D9E3EED4E0EC8CABCC9BB5D2E9EDF4DDE6F0FDFDFE5876AAF5F8FB5B85B4003C86CEDA
E8F9FAFCC2D4E5356CA5145596CAD8E7C9D5E57CA1C5B3C8DE195496003E88386EA65A8AB6003A8595B0CF105596134D9183A5C882A2C692ADCD034C90B1C5DC
497AAE1452944D80B1497EB009498F326AA47096BEB9CADF00438BFAFCFD82ABCB0025783068A3001F74557EB004468D115194104F9206488E3A70A888A7C92F
66A1316DA55F8BB8346AA41A5797135797E3E8F17F9DC313478E466CA4C0CFE209458CFDFAFD00307F758FBA1D5F9C4370A706428AF9F8FB1550933672A9366A
A33A6FA700438C3B67A20837833670A70A3D87003783EFF0F68EB0CE1D5898366FA7B9C0D94B76AB043D873E5E9B5687B50004631A3D871F64A16B80B1E1E3EE
3878AD004C90004B90FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A34366630613966352D386133622D343234632D396663612D3936616631646366333836312220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A30363644394339303343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A30363644394338463343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A34366630613966352D386133622D343234632D396663612D393661663164636633383631222073745265
663A646F63756D656E7449443D22786D702E6469643A34366630613966352D386133622D343234632D396663612D393661663164636633383631222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF80064D060A850A1270198687898B1206568B833592848B649685122F9987559D888A86A18E909594864D608B0A64
ABA32FAF9A9C8E120256312A140E7D072A13120E0E7E3070053AC20E300131C9CA5141BB7E0E07290244C31407670BD87E444B0555DE07400535BBBD4C05C1BC
3055C7C2C40BCDC93002D1C90766D7D9446701BC812B60801C900956B0A9232888829F3E305E446842C40F31031180545416A0801387D4A2C490462D45106F14
883CE9F7CDC98405072C1E9010A14A4C883D22308949AC4A040915E74DF838EDDE199207829C1C462D868003C306C2940924029C9B07C844E8D143D743183925
1CE8430C4EC6B11C27A42C2AE0C90190D5FF82C0F05740C0DC3E449C445800E3E1CC9A7D7BF5E0B193ECBB9F3C612C18BAF15E012270A9A480EA47DB93287721
BF2CE1B72A9CC0079A6C8591C18A3B894DC6963D5BB4E312902516D8E5E5A044102407A02AA322A044C5BC130CC0A0A08D269936BBC04E9C41BC8D4F2E300C2F
8803A384B0030190ECA24684F75D0A30823C8DEA92AF5F9A9FBFE6EC31B634C4173CC44A8FE004ED32B570B33B6883815A802850E5B6440A060478805E7C29D3
86043C54819C0E336810470F30404541061300D1863B1D31A703065E4891C2867D505082491A10D18703330490E0374BECC5592F34551118588445E740061944
8498617064181347051037CD4C043C80C2FF03091C110703136040010A0DC0E002014744B0820A040E47040A200073C4000C6CB1010459609081096C9E10C611
2B34704400414830C4061CB810041A0D407000063C3CC017023F78A1810F7FE4A08103C0994723607DA8130119AA51A002133EC9E7476C132CA1A232023C0612
0C480041C0073A0CF0870C06FC61C71107B8B1C31104800000A23E48D0D70C0674F1C719186050010801E0F00701498011020D24ACA1CC0903A031C1827FB4A0
C3071F24810303251C61EC70AE62C0C40D7F9840C40C088256637438F1901A5907F400460629502A5D861B1DD0D66B472291C2112E700040120C74E0C5AA491C
F0071477B8602B0F7F04A0C1431890C001FF080304BBC3033A00A0C71F33F4B0EA111A0C7701014C50D0460D7F880040037FB431C0056D3891C31F90ADAAC201
39B0B9C00CC18126DA0B7DF9E18B4EAAC16040013C7A4A16A74E835AC05B47A63019C0081CD1C4082D68F08712492CF0071600B88080B6213411DD011A40E081
072E607044050CCC708412219410C01F75005082890C7820250C0AFC7183175A803CC0070E2AF1474A21E44004062C60C1420206A4F72885912AA7693119F560
DA308A75DA9800314076A4525061E082095EA4E06A1B7F4C51051217B40040050FA0214411355438C806423400C2116D7000BB173E8C5005C41DC830810670FC
91F1A612FC91C01D1D847084107F448101FFF8B9FDD14012127C10C50E10C0A06E0444779ED3BB6509599A30F7795A54144FA85E121594394207FEB081130CC1
0B0EB8C01F3E0002F3DD81002338C21CFE50030DAC83081CE0C119DC0007204080031AF002C4A2C084313CE00A03700212B8D61F0D04E10F2040C0D700402E10
34F00149F9830592F0842BC000055B38824C98C003CEF564228959006B4A2314FD85E40C54FB1F6528E0BA114CC1071AC0800A0CA70029FC4108004000020060
813F6824024B60C205F0A086224C2109C3CAE214FE000326FC410B008043104AC0801B60E0000698C008763005381C410174BB45F7A8B08013C8000042D84312
B0F0801950433414FA8A44C46211A5D167FF48A55946911A1385C9C02505B8F1071338C0020078A1421168992BDDF08636B040601638410052C0040C3CE10F15
A8C0D71A76BC25B4600444B0C21F62008418B8EF042D380223B327823B68A00C14C0811B30000011FC41052558D51DB000CC1530400216D449748EF8B9C538E1
5344B854004CD7AF1850A62948984B65883035026C400307580212A2B02A0CC0C00D154842AD00F0833F44A03AE3BB800720C830B3A1C1092208010C94D9801E
94E06F2318C01204E085C2D901037549420718C09F0182CB02006001F13C108228CC60349DCC54D294F8CE2319000C068882465697026F302A06008A4A380290
04176C00037A918013100684B111938C7FFF20C31F5D87000D00400E02AB801B9630033C1DA17AAF2AC170184000186860657F20810A0200030C74E003255000
B98813822934E10F7AB8C3112EF0060330619DA00342D2E6E9C40388C40A09610AA9ECC99403C4209F51A1C004025002D7C12E385E609912307086B1952D6BAA
DAC00358508215ECC00B47B801039200857231E0022F484201FE7005137481044968A0392340BB1C38C13A18906D10664082C71D20042D5001039EC09F5B96CC
303E51ECD316E344C7C47374D4609D3F9CA24FA9CC8502064042013EE3001D08C0004F608200C0409A02A4A00A7190410322108029D8E02D2A10404726D0801F
F0070931088205A6D000174D20020C168EFF10CC60C94D2D6000706843069E504721BCC0094FD041099A6007BB74D22C9C6CE2E95277A1D11D200E023882A15E
59802078010396748E7CEA9A041B14840237568314D8700429D9CD002A38C2C05C59063668208B49C8021F783CB00094010686D240947BF9E4241CF2C92B3254
1E800022FED0010C47384284EA9887342BA05B2FF8013ABD40E70044E04F5E4809FF5477BFA408A0094F58C34AAA40A100F0802F53C05C1F34C0851F7480077F
AC41019EF0842A08007E1A10400B165082383C21081110820ABC508208C8C0079C26820690A0DF3478812CE099400290800E2F48600037C8C02B75108509B701
09452442814365050C00C1071390021C4AFF00061FF860097A9BC01AE21084994CE0094B6086FF32B0339324618E7F08F7032470841DFC610B6830370230F002
05867B000088E51F5EF0D7441D8103B33B41B8FF100205688005FB26007F8C156E1030C13A44304019FFF00300386EDF39405F114686EF0E34E10AFB5E981362
106E020080005F24990B0A0E832C853B013B630A11B81D84C9602001FC86C003FE4083DDFD81035E18A0098EE0813FAC409827F875B86BC0B23F3CA00A10C837
0C57808219C0FC021508C11FA4E0808E6FE00F6FF8630C9820B63F0441030C2857D2FFC00303485D06F73E960656404014843B005385A11384390058E1FB0F63
A8421226106E3B20B03223056A371CF0F2FF3F8C20095FF8C30E14FA872100A0E75B98810CF50080077CC000CDA560D1FF90869BD94103FA0E6C167B2E873B98
3B055DEFE61F3CE005A7604000E18EC26EFFB080238C80E6094418BEB190047CEB0103E18E40D5C3CD03720D200964F8C30914580000CC3E0A5ED8E71990A082
C8FAA1620B04400B569F84A44320093D47C00BB660F41700200B6058780DECF86E1A7C6D09274F18067AFE87E6D3D90EE136C21192A01200653ADC4A206F0B80
011887055E707BA33573D1846F42D006B7C703C3F745E4044613340443A03D00907952A001DA80541B651A958101DB7702F886003D20016EF77D3D070280B26F
0DF021B337080B54042C70819B767B61D7FF001A4002528775EC1600E4572E12400698B11FB0F70702503DB4D70661D7356127044DD0400BA878E02605533502
238000C22427038403B505055E003E53E70507B01273C14414B0042A505BFB860241D00620070100E07E26C01FDB176E50106FE116041033043D177603300361
D771E4F6707F800006700464D040E1160318F0105EB037B4D72A7F800406D0846067385E6002D5920432B46FB3F24226D0730A44035E602C22D05C2CD006B253
89BE54843B6205693835CD750161F8072C402B8A073087480449700761B06F447084052036103041E166016D30712837010EE0057740076EE72A477007006004
E1C67AD4D006990754E146021420859908FF5C5737005EF001C0C48922900430C30186780336170165B40147E045E16369FAE40056C0044BB059DFB64049508B
33D07310E00520B7024460072DE0044A180094C80476C401747075B33371196350166004649005B7D7000E700311E005C2640207500240A00004153194B80049
808E8128754A1046AB178580454E4300030475013DF08909E089193706257084CAA801919286A5F10474557817C00437F3001AE07E0F000371A801F8365AE106
0747487430740020A77450D0060AD006E6D63E9CE803F6D80689B7020035012AB07070F002E15600C307053DE0926DA0401D80019C4802A535066DB04545E005
37B32A1A30067F8002C2F44D9438054450FF03D4200104620036417830A77C1357012F136EB737364790740C808E20200130A3798607040F6701A097712A104B
274091015170B78705BED40300C75B121000335704FA663EE0C76F9B19054770755320327F106286A70299E703855304338001B73701C4D9711810230BD0150E
D1071513022B700120F00662B00C2DA040D0D404D5497F0860071450000C740887A90112800027C09608C0011B70010C100514B0527FC00009E01C16C0886FC0
0531D0036D73989B250670E07645700138D006EE5901137701242025107A032F70811EB9011FC059E4670D6A0703E6660129F00008D04050A00113F019F7D30B
4D50004030032519653F600347B0043DD2FF0652E06F25A5038F501F07E03E025602251221A5A45625D90665100047E00419D02D05A0A42590014B8001319020
4440047AF302AA8640D941867D50024910053FD059BCD006701007E77220D811000780A56AF50406506133D00675310315D20662100106C0194C141AF0831C14
10325B311607E00536000C68A10136200540B00B07D006A85321D3D02200F216D581046C4A0D1A40072F111D40C6A99F112933200665C01EA2CA0502C005AA71
005839039C7111A9A40D251005BDC10B073003D6801C2592147C0119A34A107DB12319F0179C83134804249FF434F394122B720048E01670916053C44FB30123
9D7A1E80F1154464AAECB453A6B322F700FFAD45D17253B40DD50A19C57817E5601545E300973234EB142FC76A3441A25832B10005D058A8734FDD516D4C4101
66980DE5513444B02E32B11EF18A623C7100EE942F6D61248C42AEFF7A064508789B45B09E513414200160600505103F0E40010A3001A9310D2B272426BB344E
4404CCC0AF51400573210C14600D312B0C551AACEDF5B13A22B205F02E216B0528CB282ABB112C2BAE8C220093F1AF54008BC2001038AB03EB15AC221B030620
0012D0033CC26D2E82B53C325706C0B55A0B072A90B5735505639BB501F00256C0236B1B00675B1A06100060AB0260509D645BB7730B54731B00624BB60160B6
599B01697BB66D0BB65610B779BB00647006B74C10008100003B}}
\par\par \uc2 Pharmaceuticals\par \b \uc2 Scilex preparing for  \highlight22\uc2 launch \highlight\uc2  of first product\b0\par\par\uc2 John George   \par \uc2 510 \uc2 words\par \uc2 29 January 2016\par \uc2 Philadelphia Business Journal\par \uc2 PHIL\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Scilex Pharmaceuticals is ramping up, albeit cautiously, to \b \highlight22\uc2 launch\b0 \highlight\uc2  its first pain medicine.\par \par \uc2 The Malvern company signed a deal with Massachusetts-based Inventiv Health, which will supply Scilex with about 90 sales representatives to promote its pain medicine to doctors should its \b \highlight22\uc2 new drug\b0 \highlight\uc2  candidate, Ztlido, receive Food and Drug Administration approval. A decision by the FDA is expected in May.\par \par \uc2 Anthony P. Mack, president and CEO of Scilex, said the company is also planning to triple its internal staff to 60 from 20 people \u8212\'20\'14 again contingent on Ztlido being approved. The new hires will include account managers, who will interact with managed care companies and other health insurers, and regulatory affairs and compliance personnel.\par \par \uc2 Mack co-founded Scilex in September 2012 with William Pedranti, the company\u8217\'20\'19s COO. Pedranti was previously vice president and general counsel for Spectrum Pharmaceuticals. Mack was previously CEO at ProSolus Pharmaceuticals, a Miami company also founded that specializes in transdermal patch research and development and manufacturing. Mack sold ProSolus last summer to \uc2 Mission Pharmacal Co\uc2 . of San Antonio.\par \par \uc2 \u8220\'20\'1CThe team there wasn\u8217\'20\'19t set up to do commercialization and I wanted to get back to my roots, which was in commercial sales,\u8221\'20\'1D Mack said, previously a manager at Purdue Pharma, Endo Pharmaceuticals and Novartis. \u8220\'20\'1CThe premise for starting Scilex was, from the start, to look for products where we can differentiate ourselves. We are not going to compete with larger pharmaceutical companies.\u8221\'20\'1D\par \par \uc2 Ztlido is a lidocaine patch \u8212\'20\'14 formulated as a single layered analgesic tape \u8212\'20\'14 developed as a treatment of postherpetic neuralgia, also known as after-shingles pain. An estimated million cases of shingles, a painful inflammation caused by the same virus as chickenpox, are diagnosed each year in United States.\par \par \uc2 Scilex licensed the technology used for Ztlido from a Japanese pharmaceutical developer whose identity is being kept confidential. Ztlido is formulated with a fraction of the dose of lidocaine found in Endo International\u8217\'20\'19s Lidoderm product. Endo, which is based in Ireland and has its U.S. headquarters in Malvern, lost its patent protection for lidocaine about two years ago.\par \par \uc2 He said what separates Ztlido from other transdermal patches is its pliability and flexibility. Those attributes make Ztlido easier to attach to the skin in areas affected by shingles.\par \par \uc2 \u8220\'20\'1CIt really hugs the skin which is important because if you don\u8217\'20\'19t have skin contact you don\u8217\'20\'19t have drug delivery,\u8221\'20\'1D said Mack. The Ztlido patch is designed to be worn on the skin for 12 hours. After it is removed, the medicine continues to work for another 12 hours.\par \par \uc2 Scilex has raised $7 million in publicly disclosed stock sales, and raised additional capital \u8212\'20\'14 the amount of which is being kept confidential \u8212\'20\'14 from its largest backer: \uc2 Itochu Chemical Frontier Corp\uc2  of Tokyo. \uc2 Itochu\uc2  has worked closely with Scilex as an adviser and development partner for Ztlido.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=philadelphia&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Philadelphia Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PHIL000020160129ec1t00005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Agenus Inc\uc2  Files 8K - Other Events >AGEN\b0\par\par\uc2 230 \uc2 words\par \uc2 21 January 2016\par 08:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Agenus Inc\uc2 . (AGEN) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on January 21, 2016.\par \par \uc2 Agenus Inc\uc2 . (the "Company") announced today that the \uc2 U.S. Food and Drug Administration\uc2  cleared the Company's investigational new drug application for AGEN1884, an immune checkpoint modulator ("CPM") antibody that binds to cytotoxic T-lymphocyte antigen-4, or CTLA-4. Clearance was also received for a second CPM antibody partnered with \uc2 Incyte Corporation\uc2  for INCAGN1876, which targets glucocorticoid-induced TNFR-related protein, or GITR. Both clinical trials are expected to begin in the first half of 2016.\par \par \uc2 The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1098972/000115752316004239/a51263511.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1098972/000115752316004239/a51263511.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1098972/000115752316004239/0001157523-16-004239-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1098972/000115752316004239/0001157523-16-004239-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 January 21, 2016 08:16 ET (13:16 GMT)\par \par \uc2 Document DJDN000020160121ec1l002ft\par }\page {\par\fs20\b  \highlight22\uc2 New products \highlight\uc2 : elastomer boasts strength and flexibility.\b0\par\par\uc2 99 \uc2 words\par \uc2 19 January 2016\par \uc2 Chemical Engineering Progress\par \uc2 CHEPRO\par \uc2 English\par \uc2 (c) 2016 Elsevier Engineering Information    \uc2 www.ei.org\par \par \uc2 NuSil Technology\b \highlight22\uc2 introduces\b0 \highlight\uc2  its new silicone with up to 50% higher tensile strength than other silicone elastomers available in the market. The \b \highlight22\uc2 new product\b0 \highlight\uc2  is ideal for use in developing medical devices due to its elongation potential, strength and low durometer. It also eliminates the strength gap that prevents producers from upgrading from latex to silicone in some applications such as mechanical pumps. Original Source: Chemical Engineering Progress, {\field{\*\fldinst{HYPERLINK "http://www.aiche.org/cep/"}}{\fldrslt{\cf2 \uc2 http://www.aiche.org/cep/}}}\uc2 , Copyright American Institute of Chemical Engineers 2016.\par \par \uc2 Chemical Engineering Progress\par \par \uc2 Website: {\field{\*\fldinst{HYPERLINK "http://www.aiche.org/cep"}}{\fldrslt{\cf2 \uc2 http://www.aiche.org/cep}}}\par \par \uc2 Document CHEPRO0020160127ec1j00002\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E60000CA4A54F9ECEBE0969BF4DADBBA1121AC0000F2D3D4CC515AEDC2C5BE212DB3000BB60518C22D39CE5961D67379F6E2E3B80D1ED4
6C73CA494DD1626CFDF9F8BB1424C8454AB10004BC1B24B7071ADB858BBE1E2CBF2431C12935EAB9BBE8B1B4C63D44E7AEB1BE2230D87B81FCF5F6B9131CDF92
96C53941E6A9ADFFFDFDDC8A8EC3313AB60417D05D66B80A1CF8E5E6BC1928E3A1A4C4353EBD1C2AFBF1F1C02633C43541F0CBCDD2676DA50000B50215BA1420
C9464CC3303DE4A4A9C12C36E29B9FB60914FEFDFBC73F46DE8D93F1CFD1ECBDC0DA8085C53946C84248C02832FDF8F6B40010E9B5B8C63C43C63D49B7091BEF
C8C9B90F1FC73F4BF3D6D7C8414DC4383FCD6162B80E1ABC1629EEC5C7B50510BF262EFCF5F2FCF3F2F6E0DFFAF0EEC23439F5DDDFB70D16C4343CF3D8D7D060
64BF2533BD1A2BC23037C73D47BB1224FAEEEFC3333CC74147F8E9E8C4353BBB1626C12C329C0000FCF3F4DE908FECC1C0B8061BBA1720C12838B4090FBE1F2F
FEFBFBBA1423BA1323FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A38626361373663392D363138342D343661342D396436382D3831633536376638656232332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A38363837393630353343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A38363837393630343343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A38626361373663392D363138342D343661342D396436382D383163353637663865623233222073745265
663A646F63756D656E7449443D22786D702E6469643A38626361373663392D363138342D343661342D396436382D383163353637663865623233222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF8079301D331B1B0971221D6886883535851B7B71351C8686591D099733681D977B683384867B301B8B8D89A98771
1CAC938F917B5995971B999B869D9FA5A2A492A7AC095909C3597E361C4E1B1004150B33163052047D2C1C1615D5042C3F20DCDD324ECE7E5219562B2E047E10
50203FEB7E2E10431CEB7D190416CDCF193049A8595B90608839762C948023C090C50A10CE089C4B27CF9D9B3450D8D173A3045F460B09D655F8E7A643071810
FC409B210106143FD73848A8E0C28F9F053F9210484960818C2110A498CB704246451743306A9462A1C3CB7C152488C8A072010C09339EB248C083A6CD843A79
3A7413D40F810C328CB23B37A44DC67610FF4A52F5F3924702AAD0AE1A122174A5843819FA5C1321E16C053F2C3A2481E0A24F3732493240E8236581152B0BAC
314E92868535175278286101334305000958F419C912C682C30425F481D207B1121E521A775B61811E65CB273248E903214312199EFBD06B4A7A2401BBAA47C6
C1BAA0D233161B5A9A8E29C18FE96E3FC8F2F40942F8502B6DF4B573C15181F075166AB058C044C7F4D419EA6FC0CDC405142622F04080029E2DD0811B0B7CC7
C40A49D0630E14974121140471A5F799144974B0406915D8B5C06A565157C1191C5480DD5FA62156436181F5C4C06293F564851BC25196811332E8A39C0B49AC
C0041468287081053F3051C0060C289086FF7C1760908702706CB0CE022E70C0831E05307046015CF0E082024154A04341504C56D9650B0C575C126D24079A05
A3A9149804A98178956B151070C619D1A0580177044091274E408D27437942E5768285F360F8430123D071C3004760C1840226D0F0C6124E14A040046C905006
80625051C40B5A6CC144145EB01182120520F1C704059C40850D4C9C97233B9BADE02686F271C8C3062C5430D29DAFB523021A8441E5870E4A482085A0DDA4E1
866F52B070020869DAE8C40A99ED98C40F2C1410C20330A0F0471B398CF047034E88F1400135FC7184137F0870410F1AFCE10003052040821407FC61420E00FC
11C216073C508502D3E2A8A30B2EF0E0ABFF35128AD69C6912106B6C8878E63383964EC090E202B705EA58060C147A1E0812AEF76DB8A065485A014D0CA0C018
603890C300761819C61F222041811C39D4F1C1053998F1C71647BE5BC005265050000F7F74B102145F3C8C0E19EA2DD719C6FB049BCF741EB3D6D26B31C55743
6E87E9D081048CE5E9D010657AEB44B78C0D01EE853C74409A1FE6BE50400114449083185A5C70C10A7FD810C71F57E4A003141904518717155CF083BF09402A
4401007CF1020E17BCF0C4054EB441B30B1630A003C64C71401A5422F6D127607F6253D80622B08358071630E6D80269C09CD239279C90663BEFFCAD1C04CC95
76811D2F9C21C00D505CC0870F0530D1C6FF1F382800C41F0084AF090E5EC0708108FE5E50800A564710850046042106125C80FD19043CE80C4C32C203F9AC26
03682B965F7807A80C5807313FC08D6E16B08221602B032070DE849032369A00304EF9F003067CF0872818EC024AA0010AC2C7803F8C407EE773C016DC508016
2C210E0550C31F0E70380D2C6107232802081EC0832844000399699404C885313F486543F9B8CA0C4C038DECF0CE368579098920C883BA9DA50DCAB31108F6B6
41BF658626A1119C9C9C7801140CA0005060C30AC5F081A9C98A87467240FC0A80031A2C000B056B80FCDC05C83728200A3EB083203F533106DC2E63B63BE074
66F09A05A688052B52999E6CF783E24D70FF054E9090B7AC601EC680800167840F07A088C08E15C0036F2C00158C90833784A0000468C00E2FE00223994A7E38
60031C66708677C9CF04A36B8017F8F88732F480096894801A43E8213B69A777D971162671432D17886003BC315E4FC05823B65821397D73E43320B9B10E11EB
9545B8C018A2A0851CBC007C1C185A071AA0050C6C410586ACA1103A95801D16600B315842011A100005C8E00F7F60407FA4B0C4DB714C041B936260AAE8272C
4E2B4F0E64400D644000DDA0E504319BD61076358FB8FC4047045CA59CD0B6A1027CE001419841BE72703EA409E00F17C01A0F7280002AC8CF011480001398F0
060F5CA004A8CA410B680002057820A217FF080D084D33AC0FF9C564C6620161BC73186F7073650FE1C0194073BC719473014338A76620302ECF54202312B0DD
4C3BF621C211A1991428C30E8E1400120CE00F2D28C00EB4400131FCA10A0528411DD8E09D0B80206B34A0011772A04B06E4408F6750803475B046BE5A133082
D98A802ED9812EBAC06E69C0DB1E38B016B490524D50684B1237A2A1013EA74ED2E10125C30A83031C20020DD8C2051820872D3840002B28401AC2A0001C00E1
513668C306A6D00E296040061A384209780900005009034F80019C36769F4AF609AC8391CD253B294E0A3A811ED6390708D23035C7B1C0022790DF16D6A0000C
9C250EE5E25248B020BF194C014B41C8C2FF0514A0063CE4E0C20518C310B2A0801CCC21074A58CC163C9C032EA8C105415000017480013C38EE7005C003832B
B08602E4E0043D385C10A4B08504608909258D0317269C05A86D00009D73DCE3003086A961010A6DB0604A48740E19A4010D00E00100F8870116D8A0013DD081
1922C080CE95A00144E06106F690657B20E1005C50800D8E203B2D4F010011D8C0058270DC0670810910B800127010012B5C600DC461010F7030850440A10018
18810618B0E73820C1014E50C0131AB0072820170900E080620F90E50E30A1070D38402F7B90E52A382F0EE525400740E0203D4DE50456284004200AD1076000
677F40C0169AF0070314400460E0F51172FF50B03F9802A20228800166A5000AF03A0533B8C00D788D020514A05F10FDC20698302D2E38ED5D52E5F51F805080
38F061560538AC094AF000751321085580280A724042074CEDAA7FF8C2020AD0EC0960A046813AC31E2E93015DFF41084678C1BA73F0816217E0A7C63EDF0D2A
CE0705C8CAD9F0FBC30B1260046A5BFB014588C2A7FE108010A4E0B104D0F761D99D812160A003109DC205BCF08722D801A2707E370EE2FD87185CA0087F1880
09FFD0033FF47A0C21706101825006882E41D409436C5689E3823630C024A071381D0AA0C726E420EAB48C41B099306DC53D20004A6801444510F23F0CE1A713
B880B52B273F127A80E28F6DE11F727085FFA25FA02DB582A8152C0051FE9260DD586003F964692FA20F1DE83107BA0A5C988382528006E8431844917001E2E4
D60A7B10013E9819801CF4CB07392879DA8B8D0104885C0439284102E44EB40D28FBA70DC00244719083819F2FF4423AB7090E07050B9081050A3801D0B30E30
891FE1028F4FACC43540740760FF5D9977E111385F3023945C71BCAFC2058AB3526CD0761EDFFE031FA8F0072A6C000BB69FFD1716CA6B07608174100503F512
004210055735025CB0047F007AFEC67BF902691DA00510650078800136E019D1A778C514510A007A1AA00074E02F25F0057FC07D87F501389073314702246000
15E76F75F0072A60027F4004640751EA67FF1CCFB7492D85019BC76B376068EA82003CD57346026E06C36C10E50409630724C4804C1082101503FFE78045103A
1B506F104543307101E313519FF3074EC0051E0882257874324879BCD604B1526C6A976CD1B67907E0348D936F7F800405701C9EA1276B453D5B2077347001EE
720305A02E6C486C54307073C0032FF70710F07181F30746D06C88A50042F00747D420173007F30451B472617F657825A500BAC4748267066340821A7001A097
5887F54212F701D356392948050EA80267B7434EF34676880409F037667106CDC0038FB26B0150437FC0060AA0764650006A77035830011A30061C00516D9007
10250AF5870587456DEFE66F05C0021340FF045C80078FE700049066E6D2732C303B256005D6888D7F002B6FE04296886EF4070425E05838D02F1EE071C99800
D3868994D7884BC0041F27480A602C1492071CE006A8E4706C800734F80217703E5FB00543A800F467060500511DF0857417701AE989D526830AB0010A406C46
A000D3D600F9960217A04745E01EFC30011095077B005100B00310A502781000F62879CB87741380354BA000D5C80717F053E4A3777F60071547348287031090
00D3E20727D0013F701784B36B7F4001EFF6019F0551D65682AFB480F5F8003B908244033F5D3006A598776709511C50308D0551360001BDF678DC770233B06D
7F802E6920717C70964347422970963650FF00FCA853E85301618901E7D600BED77105A08000009910754BD4F3097B50137D500013200445C0065F000458B005
72A001A047012A20641B4042F567064100006F206E5920045AA00071600014B0990630006210003480044160028F470311C004BB4782EBF68E33A0003F770300
900663F0032694026F70040A50602170896C30742ED00429A001185072E828062F90065B607B5560037F800217C002C4D60243F00006E0584470016EB04AD621
1D6E40004C401F31060078500052900741700132102405800630B0035C70160BA0030E2107B962290AB00227A0033A401F0AB05FB8C4A079185D5B9007836505
359019F4C00472B00777202404D00661C0FF4B68802532700050F30C4CB00110511F67F1033F7007AB59A043900040E6074B65013E321F0AE00279451A247236
1DD31FBDD41AA6C10217800716C03B52D0A54EB006CE401F0F311F94A1033FE016190005ED48060CA00F5C1A0481532CDD13046E005C4C300649305C6282052B
E00E87910122E023A475131C0036520001172A032BA00352000D4C700269D01F15E00E5B79392E703943102C7C1818C2E555BBB31D62C52271F30374F35A3D41
06432019DE92231BE406D223211525277D40275EC502C5D565BD930033C15A9EE4182C105B65B20DDA42466274313451313F405AB3B10F18651352B02C71D055
83CA125744A8161028369101F4551367F1FF1031535256C0528BBA5F9ED10E04204D83F35AD0511B1930039B592C74E1AB2301AFC4931B660105B14521FB6A05
4E601EE70A8C41C103B2631335C10318551B2E10070C200243B001AFB113D20056259500DBFA1225453C8C61162EC00088E2B164200399C1101040A97B281143
102712510111FB213BA15E78B2131BA0132DE20221D6B125D53265E2B1E3F03C3B811E252B1110491A12E107F6B021143B041D800471300335B02722D0038410
B56730B535B001568BB57BB0B53DC0012260B567D00322A0562452033DB0077B42221DC0005A2BB50CC000502BB5548B065E9BB55EAB705E0BB6624BB6617BB6
69BBB6AFD003737BB5716BB7743B033D100108003B}}
\par\par \b \uc2 Boston Scientific\uc2  unveils disposable device that finds, destroys kidney stones (Video)\b0\par\par\uc2 Don Seiffert   \par \uc2 470 \uc2 words\par \uc2 15 January 2016\par \uc2 Boston Business Journal Online\par \uc2 BOSBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 This week, \uc2 Boston Scientific\b \highlight22\uc2 launched\b0 \highlight\uc2  a \b \highlight22\uc2 new device\b0 \highlight\uc2  it believes will change treatment for the 460,000 people who undergo procedures to treat kidney stones each day throughout the world.\par \par \uc2 The Marlborough-based company is touting the device as the first digital, single-use ureteroscope that, when inserted into the patients' urethra, can to find, remove and destroy kidney stones. \uc2 Karen Prange\uc2 , senior vice president of Boston Scientific (NYSE: BSX) and president of the company's urology and pelvic health unit, said the disposable device addresses problems of inconsistent performance of reusable devices that breakdown after multiple uses.\par \par \uc2 Prange says there are various methods to address serious kidney stones. For example, open surgery as well as less-invasive devices that enter through the back are common approaches. A ureteroscope is less invasive than both of those, consisting of a catheter that enters through the urinary tract and enables a doctor to find and then remove or break up the stone.\par \par \uc2 The company's new LithoVue Single-Use Digital Flexible Ureteroscope can be controlled by the doctor. The end curls in both directions (see attached video), bending up to 270 degrees to better navigate the canals of a kidney. An even smaller tube within the catheter allows a doctor to insert laser fibers to see inside the kidney. It also includes a tiny basket that can be used to grab a stone and remove it.\par \par \uc2 Boston Scientific\uc2  has made urology products for decades, but has never launched a ureteroscope until this week. Prange says the decision to develop a disposable version came out of complaints about reusable ones, such as the fact that on average they need costly repairs after fewer than 12 uses. Those repairs can cost more than $6,000 at a time. The delays for patients due to non-working equipment occur "several" times a day, according to the company, and cost the health care system $830 per delay.\par \par \uc2 The company says the new device could save hospitals and health care providers money in the long run, but Prange did not disclose the price of the LithoVue device, saying only that it's priced "competitively" to reusable models. It was developed over the past few years by engineers and scientists at \uc2 Boston Scientific\uc2 , and is manufactured in Indiana and California.\par \par \uc2 Prange said \uc2 Boston Scientific\uc2 's urology division generated about $535 million in revenue in 2014, before the company acquired \uc2 AMS\uc2  Urology last year. The company now expects the division to contribute $1 billion in revenue.\par \par \uc2 This contains video. To view the video, please visit {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/boston/blog/bioflash/2016/01/boston-scientific-unveils-disposable-device-that.html?ana=factiva"}}{\fldrslt{\cf2 \uc2 the original source}}}\uc2 .\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=boston&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Boston Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document BOSBJO0020160115ec1f0008f\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 ProPhase Labs\uc2  Files 8K - Other Events >PRPH\b0\par\par\uc2 231 \uc2 words\par \uc2 15 January 2016\par 06:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 ProPhase Labs Inc\uc2 . (PRPH) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on January 13, 2016.\par \par \uc2 On January 13, 2016, \uc2 ProPhase Labs, Inc\uc2 . issued a press release discussing the current cold season and announcing the \b \highlight22\uc2 launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  line, TK Supplements TM. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.\par \par \uc2 The information in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/868278/000149315216006792/form8-k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/868278/000149315216006792/form8-k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/868278/000149315216006792/0001493152-16-006792-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/868278/000149315216006792/0001493152-16-006792-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 January 15, 2016 06:04 ET (11:04 GMT)\par \par \uc2 Document DJDN000020160115ec1f000zx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw221\pich40\picscaley100\picscalex100\picwgoal3315\pichgoal600
47
4946383961DD00280070000021F904010000FC002C00000000DD002800870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0001C400407020C115040B26340800E1C287071336046060624587112F529CC8
5120C48E1E1546FCC810A3C59326116AD4D8916149892E139A8C3932234A892A6FCADC9833E5C7830610C6086A80A8508F03870A0C8A74E98AA2499926F56860
E8D3A3519D4A454AD46853AB45AF7EEDFA74AA598A60B1524DFB75A957AB5ADF4AAD8AD6A95DA543CF4EA50B572F5DBE48F16E3438F02945C3210B57647A51A3
41C6891B2E1E585131C1AE21254B7E5A596663CE990D8BED7CB8744ECB99A96A0E79B471E9ADAE2D1E3D0C59344FA2221F1BAEDD197145858C0D836D8A7B2FED
B554470B67ED3AE854CDC32923145EDC74E5E29D092787AABA7A0CC1D2AF87FF5F8EBB3A59EF97B71BFD8DBDE976F2B4577C2FFDBC3EF0D64257882D7C193FEC
CDC96DC4987DD2D5A59D6D80B9A7D26C963934D555904DA49D470E6AB620856FD1A7D0815E5DA8D87EF76128DB7240C587DB717BEDD61D75C4A9A81D652906B8
5D88339275DF6F4399471972E69988DE642806B7D87B9D95C71574E6F9E6DF8AD50927DD6ECBC9B71A7A1C6E56644331BA06A1687F9D36DA8ECB29E69557EEB9
C4607F1A16181E80071E37664E2DAE271B7B888D37A465675929928A0B36A71F6E62F108A18425EA56249C595E8558991ABE29649D35C2166576213ABA1B7A01
16C8546431AEA91CA0A01E49E66F380C0443002542A602A6FC0568000C001CFF70EAA94DA98067A6F10DD62281E9BDA8AB76EBFD79D8AD054E5AA34262416A27
8672829A947F55DE8A9894980D94031038E07040A90DC890AD0338E4A0ED4907ACDA638101AC4A910AE11EB0C2010E1C27114E3F424AE9BD509AE8AA6A3B8E49
558F9C1EEB6642FF01BBA480AD11AC27436D05586EAC40442CF1C414FF104050B0C65A21C6000400EB0131789CEE0346486C440E00C0AA82BBFB28A3CC3E994C
7243AF6866A59C86F93EE89A5EC99D161A8E878901CD3ED08841E883004C52CF3E2D1B3DC93E93E4FCDAA05C266C1031FB182DE70A9F643DF56290AA702D103F
443C06D93A94FD43DAD8764C940A4BA51CC0C52B0380031007145476C43FACFFFDB1704C07CE341AD31DBA127C06ABF65E485ACAF91800991033F3960088C174
264C2B15E10D82334D0C005867B2E1E8A4AD19AC474C4F32E5534BCFAC55E17FA65BD1DD140351B21A7B47BCEA5301C8DA10DD6FFF10C450B61E91830139C0A1
831121AB4077B94CDFB0C20D2F674D9A67ADFE24EF4327A229D1A62319C4B4D1BA420E75E5FBA0612153818B319018A2632EFAF729312CDBBC9BC24FD16F18BD
2CC6A2E9410C0CCA852A00D8EA00408881BB044236205CEB547083D5C5CA6500D905206238684805228632E765CC00BB2B48E61282B57D24E406C4808632D447
10317CE206937099D1C4508F154287182E535F4EC4408C1A3E257231C05C41FF32A18C7A30808733C3DC3E8821BA45A1A1650018A18D9EB88FDF70046B32ABA1
D1A6F70931588E7C31844626A21239D0298318BF99C418A743C4A2016068E48B010EA1A13AE9A42B6F6F43C0C9E0B6AA00C4000869B09D4A2EF614B835456249
39D9C96255B78194EB0044C99C544668B97D2C0D8A49EB5CCB04A73AF4756E224A8C5E1405F794CE0D4D7D9DA31400AAE7B58818066BCA18582803A7BE46088E
7043BB65433469C251AA2F06828BE5D28CC6394B06AE34EBF2184170000707DA058140489B4756D6C80AC26D6F19540102D4804103121082D6148814C5B98F99
8D8F202F539F121152BD24328D9C75BC1C008AA93EF7AD32730379593D2AF2FFB4560E134B9AE9E7F920A7358FBC6C7ECFC11A3406024B0050711241C15C3D06
D2CF52C26C9EE73CE7CB94F1BE7B1AED9CA04B5F7F2A082B0506616D3FB8CCC5FE5836232C079C926129106E80AA1B48EC78EACA1B0C18E3B1110A059F97CB04
119788BE583A1493968386274FF8CEA719352183DB084801B0B44EC271A447DD0730B306CC582266A3EB33DFFC38A7542A42B5951E1DA5415EA63A381AE09D5F
2DE756853AD47A84A46E207400DF52BA02951D809B11935BAC1C5937004C4C993268600E9C37903EA62C6F16558AF94C584997D55019A27BDAE78E6A54CBD9F5
899FABCC3BE5B79A7F46D6A0221DA5D61073CEB98A542C661549483BE959CEFF5E669C51659A43D2A9DAAD462406FEDBAACB863BBF0A82F0617FE4601F1DC937
2034320727CBDBAA5400C8B4D1CAA61C3C8E6D76BA8211AA200DF27C6B2FE7F544A3DAD2A8C524A7413017CB4A6A87B7ECBC2841A23ACAC99506A4C58CE5A198
C6D1CBA88EB44BB5DC535FB659F17E54AB15795923DEE8B5A8FEC67F6A9D17880E3036C50227B17BF3D81F4198408D35A0B9054160F250F6316A0E05553DDD47
348249C2CB5191A2982C6F43928ACECB5D527CFCAD8739BDC64FFE96B0954CAB472648A3C498B1D2439EE4EF3B434710193FCDAEEFF3B1E7765945842C0D955E
A3E270EB9B4998C5B09C54819BC4729703BF32D08146F818DE0C6B40826098FF6C1E492CD950D63BD578ACA49D53461C092250F93AB5C9446B215C276BC999AD
B77DF7D4219F0327D48116731F832274FADCDB3DE00A4E744C465F5903EDA05C5EB422A24CB46A053D650867D5730CF363C9CA76B6BEB90D6E3205C244AE8503
8F39E03BB4D34107AB326603823028CA8CD546E645A3F9ACA6200EF109D03252A1F09DC87E8C431346240B13F7148421FCDB944928549712799BD88449B66C8D
1DB74202410676BB691F4F150323E800086AA8CCDD3238B61CE8F50746F801EF3EDCB7E31D06782283A0329743C18B11A46EB3520D6720141CDAAC6946DA950A
E5BE74A23F21ED33FCFB55CD443511AA818A5A20A78DE120F2183F1AF0DECEFFA426AF1B289094DEADE5CB7CF7B50E2E67077A506E6FD3A9322D83F03B4A90A7
1EA41BAA32461E255D2739D2628F6600A391B2BC463249EA0D8E2264904195A7429ABA0DC230A49670A7CC6D6F4E69C1A19983230020072833EC0FB68590BF36
B07928CF200141484842AE4BBA95F19D32690583855764802BF35805BFF399BE5C08525B0F4B748E4D99BFD4482D886312B1AC34A8B33887EB57BF92A620C42E
8965709AC9259B0A48861018045620A16FDB002526B75929F3D757D19A1FBD6834760DE406333CC0FF0E208900A4210C31B80123D2107C46A041061913031A8C
B67C347CC7756280C124C420BDFF55C5690EFDEEA98A932C116D49F3C81A8FFF40B0D22C65010728390154C4C73FD20ADE3DDDEF7E0EC8E66C76182C4F0631B8
D60FFC4D36B5752C06DC247FD305591BA17C3B170638E7450221333384063080032AE07C351503CE730303812AD44710BAD7640190092A2006A59241EAB37C02
3146461303694053D31520DCF5785FF37D22622458051F24E2744F72796181712A311F08D14715D17946806E5E7100CA836F0E713729957F1DA30265C33619B4
3620C4484431740B7700CBE73A37506BCE170606F81DCAB70267100032B302CE0742372084318080B7C70505F14BEE0343B89734626000B83787B826092D0437
EEE27EDB5741F6222C30C23D8D0222315079535374E01716C86688C8441B3AFFE511D7D2583B333125D631BEB67363E64024D63112943105523933035108B17C
10F53FB897860E5539553182F6C4053700423190414CB17CCCE745DF311F73483E68100061502A08B88B0EF5303A4552B2D3147DF777A8C21F9255884F9738B1
E1748051885A621B75312461A22F416700322076E1626F9E883646307417831B1FA3766B633B17987079F3478FE41110E436B391371E9137776448D248398D65
7055C11403441B3BC77E41A72E8AE17AD3B48E68624D8F0849306823606222F2A17E5B6716609320F79879245211C88500B9735332004D38B024EFB219D4D540
659303E0416B7D223B57012BC8A87237D719B4D219AF7731C7E8109D281903FFC78952484839777014E43CC7F5584E07417B086B69827E8D912585327E46F219
FCB23A4E591D2AC03B6757327BD5402503817FC7897AB83B24057F4D689526D33638A72E865177E5B87D8C347785D48E1EE1313921787D527A78B57DEBA681DE
84734201704009941DE33BB1518EC172285A1715A3E1905657182EF2295C7718906440D0E54069F06E64A306F12737DF64775F494D673667FD8766E8A67381B7
7D86419A3C052B09E7488245813AC76EF3B832BC531476472BB06914254658EEC8936F092B7DC5896D378FA5D72737027264721758F5244FD9292207207A8803
3F6048BE1603CBA36F04A14CB2F23C407931BA090339C04DEE3666E2E8832AFF209029D3278D0437BDD397CA1470C9B41875631804A402B4A99074F17577A787
3A298FD6E992059731B2C29FC2261D310134902118C181883DA37080527545D1142043280F2310A8D2256619943030955B193205E12D3820037C042A8DA419BA
391AE5B23245F27A75A353085248FB734774471177A43106F19374775C440937B851707421748C5452225115D7F82117F12224022CBA82710A2A276D46140F53
1E80071C33299E73375DEE971006C9A46569008FD447262A37D4245D8571A3DF246C85F471A8A9923E5AA0D9692AECF96B224377612A19213A77389719F6712E
02E282FFC125B7912CAE31A574479ABB3970C056626C398544917025667740FF19925DE98EDEE458418991C8249A3D1992B47200D609A3A9F9949C2A74AEF99A
2D8A9146C992FCB115C651355BD19801E317C489A00C6197DAE9890E378FEB428C69892C816A773FE931147489BF6A90C2B82A1F42A81CC33B1F033CAD771825
5648A0AA81B6529EF7298F7B11907089A8F5B8527A79284AB92681C8335AA22B2BDAA75ABA93C7D88EBE11A98445775E69728F11A184257805094EEF622BEBC6
93E9324D24851B82D7A83E6A72C8CA89E248AA30CAA0D8899DC6A527D7F97541219F06D7A4C0239C5A972145AA21C322722BDA258419ADD28577CEAA18C1663A
A5A7100B9B170614A2BC738141296C0DF7A514418F12E49516C1A586D37654297A15A6A2A92545AA23FA832AFA1B349A8C1B215DBCB91506D91642B23F30B822
7DBA7470513ABE1110003B}}
\par\par \uc2 Business\par \b \uc2 3M\uc2  puts millions into StrongArm\b0\par\par\uc2 By Khristopher J Brooks   \par \uc2 1,150 \uc2 words\par \uc2 12 January 2016\par \uc2 Democrat & Chronicle\par \uc2 DMCR\par \uc2 1\par A6\par \uc2 English\par \uc2 (c) Copyright 2016, Democrat & Chronicle. All Rights Reserved.   \par \par \uc2 The team that brought us sticky notes and scotch tape has poured millions of dollars into a young company started by two \uc2 Rochester Institute of Technology\uc2  graduates.\par \par \uc2 3M\uc2  has invested in \uc2 StrongArm Technologies\uc2  , a company with Rochester roots that moved to New York City. StrongArm's co-founders met while studying at \uc2 RIT\uc2  and now say the \uc2 3M\uc2  money will help them hire more employees and \b \highlight22\uc2 launch new products\b0 \highlight\uc2 .\par \par \uc2 The money is cool, but the most exciting part about the \uc2 3M\uc2  deal is that the company "believes in our vision and our abilities and our ideas and concepts," said \uc2 Sean Petterson\uc2 , StrongArm co-founder.\par \par \uc2 Petterson and StrongArm co-founder \uc2 Justin Hillery\uc2  met at \uc2 RIT\uc2  in 2012. Moments later, they started the prototype of the product and company. The premise was simple: Blue-collar workers depend on their body for their livelihood and there needs to be something developed to help them lift all day without destroying their body.\par \par \uc2 From there Petterson and Hillery created the V22, basically a vest that reallocates heavy loads from injury-prone parts of the body to stronger areas. The vest also forces the user into proper lifting posture to avoid potential back strain or injury.\par \par \uc2 Petterson had an extra motivation behind creating the vest. Growing up on Long Island, his father was a blue-collar worker who died suddenly while on a construction site job.\par \par \uc2 StrongArm set up shop in Rochester in 2012. In 2013, the company grabbed $900,000 in investments, a third of which came from Excell Partners . Petterson said the Excell money helped him make prototypes, pay for laboratory validation, hire workers and get memberships to trade organizations.\par \par \uc2 One of Excell's top officials said the firm gave StrongArm money, in part, because they were solving a longstanding industry problem.\par \par \uc2 "I saw a passionate team developing a brand-new approach to fix a problem that hurts millions of workers and costs companies billions of dollars a year," said Rami Katz, the firm's chief operating officer. "The founders are everything we look for when evaluating investments \u8212\'20\'14 a significant and marketable technological innovation, an upstate New York base and a fantastic team."\par \par \uc2 StrongArm Technologies\uc2  joins a growing list of Rochester-born companies that recently landed large investments from major corporations. In November, \uc2 Datto Inc\uc2  . landed a $75 million from a California firm.\par \par \uc2 A local expert who helps startups mature said today's Rochester startups can draw lessons from StrongArm.\par \par \uc2 Rich Notargiacomo leads Venture Creations, the \uc2 RIT\uc2  business incubator designed to groom Rochester startups. Notargiacomo said every company's path to success is different, but StrongArm leaders made a couple of moves early that catapulted the business. Those moves included entering several state and local business plan competitions and listening to all the feedback from coaches and mentors.\par \par \uc2 "They were vacuums of knowledge," Notargiacomo said. "They were out doing their pitch and doing it again and again and again. And I always tell people, the more you pitch, the better you get at it."\par \par \uc2 Petterson and his company are trying to solve the workplace accident problem, a situation that has plagued companies with manual labor jobs since the beginning of time. Companies lose workdays from employees out with injuries and employees are unable to work because they have to endure rehab.\par \par \uc2 In 2014, there were 365,580 work-related accidents nationally in musculoskeletal disorders, the label that the \uc2 U.S. Bureau of Labor Statistics\uc2  uses to encompass sprains or strains from heavy lifting. New York keeps statewide data on work-related accidents, even down to the Finger Lakes region numbers, but they aren't categorized well enough to show heavy lifting incidents.\par \par \uc2 A majority of those accidents came from freight workers, stockers, material movers, nursing assistants, tractor trailer drivers, janitors/maids and stock clerks. Of those incidents, employees were sidelined for an average of 13 days.\par \par \uc2 These employees are people Petterson call "the industrial athlete."\par \par \uc2 "They work just as hard as a professional athlete," he said, calling the blue-collar worker under-appreciated and overworked. "They put their body to the test for 10 hours a day."\par \par \uc2 Alan Hedge, a professor at Cornell University and an ergonomics expert, said the most common workplace injury is people hurting their lower back because they aren't lifting with their legs. Most times, workers injure their backs because they're lifting too much weight, they start the lift in a twisting motion or they try to lift something from the ground to high places.\par \par \uc2 People also injure themselves by lifting heavy amounts in rapid succession over and over throughout the day.\par \par \uc2 "If you're lifting very quickly, there isn't much time for the body to recover," the professor said.\par \par \uc2 Hedge said it's in the best interest for companies to train employees on how to lift properly. Otherwise, an employee will get injured and a company will pay four weeks' worth of workers' compensation on average.\par \par \uc2 Hedge said he has never seen an ergonomic lifting vest like that of \uc2 StrongArm Technologies\uc2  . However, he noted that Lumo, a company in California, has created a belt that helps lifters use the right posture.\par \par \uc2 Last year, StrongArm moved to the Navy Yard neighborhood of Brooklyn, just steps away from warehouses that are StrongArm customers. There, the company has 11 employees, a mix of engineers and designers. StrongArm still contracts with a manufacturer in Henrietta to make the soft part of the vests.\par \par \uc2 In the startup world, landing a multimillion-dollar investment from a major company is equivalent to a home run. The move introduces a startup's product to a larger customer base and it gives the startup staff direct access to experienced business leaders who can offer advice for growth.\par \par \uc2 Notargiacomo at \uc2 RIT\uc2  noted that a Rochester startup can stay in Monroe County and still land major investments.\par \par \uc2 "Do you have to leave Rochester to make it big?" Notargiacomo said. "The answer is no."\par \par \uc2 Petterson said he met \uc2 3M\uc2  officials during a trade show in Atlanta. A conversation with them went well and the company invited him to headquarters about half a dozen times in 2014. After a few meetings, Petterson said he realized "those quickly became investment meetings."\par \par \uc2 Petterson said the \uc2 3M\uc2  money will allow StrongArm to hire six more Brooklyn employees and unveil three new products in 2016. He wouldn't go into specifics about the new products to come.\par \par \uc2 3M\uc2  is StrongArm's first company-based investment. Neither \uc2 3M\uc2  nor StrongArm would confirm how much the investment was, but data from the Upstate Venture Association of New York says the deal is worth $2.91 million.\par \par \uc2 "We are impressed with the worker-focused ergonomic solutions developed by StrongArm," Dan Chen, a 3M director over business development, said in a statement. "We look forward to our work together in advancing worker safety."\par \par \uc2 KJBROOKS@Gannett.com\par \par \uc2 Document DMCR000020160112ec1c0003e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw2\pich2\picscaley100\picscalex100\picwgoal30\pichgoal30
47
494638376102000200F70000000000800000008000808000000080800080008080C0C0C0C0DCC0A6CAF0402000602000802000A02000C02000E0200000400020
4000404000604000804000A04000C04000E04000006000206000406000606000806000A06000C06000E06000008000208000408000608000808000A08000C080
00E0800000A00020A00040A00060A00080A000A0A000C0A000E0A00000C00020C00040C00060C00080C000A0C000C0C000E0C00000E00020E00040E00060E000
80E000A0E000C0E000E0E000000040200040400040600040800040A00040C00040E00040002040202040402040602040802040A02040C02040E0204000404020
4040404040604040804040A04040C04040E04040006040206040406040606040806040A06040C06040E06040008040208040408040608040808040A08040C080
40E0804000A04020A04040A04060A04080A040A0A040C0A040E0A04000C04020C04040C04060C04080C040A0C040C0C040E0C04000E04020E04040E04060E040
80E040A0E040C0E040E0E040000080200080400080600080800080A00080C00080E00080002080202080402080602080802080A02080C02080E0208000408020
4080404080604080804080A04080C04080E04080006080206080406080606080806080A06080C06080E06080008080208080408080608080808080A08080C080
80E0808000A08020A08040A08060A08080A080A0A080C0A080E0A08000C08020C08040C08060C08080C080A0C080C0C080E0C08000E08020E08040E08060E080
80E080A0E080C0E080E0E0800000C02000C04000C06000C08000C0A000C0C000C0E000C00020C02020C04020C06020C08020C0A020C0C020C0E020C00040C020
40C04040C06040C08040C0A040C0C040C0E040C00060C02060C04060C06060C08060C0A060C0C060C0E060C00080C02080C04080C06080C08080C0A080C0C080
C0E080C000A0C020A0C040A0C060A0C080A0C0A0A0C0C0A0C0E0A0C000C0C020C0C040C0C060C0C080C0C0A0C0C0FFFBF0A0A0A4808080FF000000FF00FFFF00
0000FFFF00FF00FFFFFFFFFF21F90400000000002C000000000200020000080600FF09FC1710003B}}
\par\par \b \uc2 Boston Scientific Corp\uc2  at JPMorgan Healthcare Conference Q&A session - Final\b0\par\par\uc2 4,232 \uc2 words\par \uc2 12 January 2016\par \uc2 CQ FD Disclosure\par \uc2 FNDW\par \uc2 English\par \uc2 \u169\'00\'A9 2016 by CQ-Roll Call, Inc. All rights reserved.   \par \par \uc2 Presentation\par \par \uc2 MIKE WEINSTEIN, ANALYST, JPMORGAN: Maybe, Mike, as a starting point, you guys had a slowing again in your fourth quarter coming off of the third quarter, which performance was very strong, and the Company had mentioned four \b \highlight22\uc2 new product launches\b0 \highlight\uc2  which are underway or forthcoming. Talk about how you're feeling overall about the business and the health of your end markets.\par \par \uc2 MIKE MAHONEY\uc2 , PRESIDENT, CEO, \uc2 BOSTON SCIENTIFIC CORP\uc2 .: I feel very, very good. The business through the third quarter, I highlighted 5% operational growth, about 7% with the impact of M&A, strong margin improvement. And I'm really pleased, just with the ability for our portfolio teams to drive the key product launches and platforms. So I touched on it. We've got Quad coming in 2016, and a MRI pacemaker, great progress with Synergy. So our team's done a really nice job in delivering on our platforms for growth on time. And we've seen some benefit from the reimbursement improvements with S-ICD. So we'll hear about Watchman coming up here, but the Company is delivering on our expectations, and we look forward to continuing it.\par \par \uc2 MIKE WEINSTEIN: Keith, I'd be interested in some of the feedback you've gotten from some of your US colleagues on Synergy's performance and how they view it. And I'm talking the key performance versus traditional drug-eluting (inaudible), any feedback you've raised.\par \par \uc2 KEITH DAWKINS\uc2 , CHIEF MEDICAL OFFICER, BOSTON SCIENTIFIC CORP.: Yes, I think key performance is the main driver, coupled with efficacy and safety. We know from the EVOLVE pivotal trial data, very low stent thrombosis rate, and as you all know, this is a topic of hot debate, the stent thrombosis rate relating to this and BBS. So we have a predictable rollout of Synergy in the US. We're looking at about a 50% mix between Synergy and Promus PREMIER by the end of 2016. And we think the polymer and drug dissolution within three months of delivery really resonates with cardiologists, because they're looking at the ability to be able to reduce the need for dual antiplatelet therapy in a number of their patients. And as I think many of you know, we have agreement with the \uc2 FDA\uc2  to do a short dual antiplatelet therapy study with Synergy as the post-market study, which has already started.\par \par \uc2 MIKE WEINSTEIN: And Keith, could you just give us a sense of where you guys are in the launch and how the pace of this launch might compare to prior BS launches?\par \par \uc2 KEITH DAWKINS\uc2 : Well, we have now, obviously, two products in the US. The plan is not to replace 100% of the market with Synergy. We think we can do a tiered, segmental approach to the US market. And we think this resonates with cardiologists to use a different platform for different patients. As you know from Mike's presentation earlier, this is a premium product. We're commanding a significant price premium for that, as we have done in Europe. And we're very confident that the mix and the launch of the product is going according to plan.\par \par \uc2 MIKE WEINSTEIN: And I think the comment in the third-quarter call was that -- and correct me here; I'm doing this off memory -- but the expectation was that 12 months post-launch, it would be more than half your mix? Is that what the comment was?\par \par \uc2 KEITH DAWKINS\uc2 : I think we said about 50% of the mix, and that is on track.\par \par \uc2 MIKE WEINSTEIN: Okay, (inaudible). Mike, as you look at 2015 and you look at the performance of your business, part of what strikes me over the course of the year was the outperformance of some of the business and the people and focuses on (inaudible). And over the last couple of years, it seems the revitalization of the endoscopy business. You have endoscopy, urology, obviously, with the acquisition of the (inaudible) business. So could we maybe just start there and then talk a little bit about the endoscopy business, what's riding so that it's obviously on the third quarter to, let's talk about the \uc2 AMS\uc2  transaction and how you're feeling about that?\par \par \uc2 MIKE MAHONEY\uc2 : Yes, so some are like--happy to. In my comments over the last three or four years, we've intentionally, we want to grow CRM and we want to grow DES. We've been intentionally shifting the mix of the Company into faster-growth markets, and we've really put a lot of investment in our medical-surgical segment and done a disproportionate amount of M&A in medical-surgical, peripheral vascular, and EP, which are really very strong markets. And it shows through the Company.\par \par \uc2 Our endoscopy business has had accelerated growth each quarter through the third quarter. Spyglass Digital is really a unique platform, and not only is it a platform that we can sell and help GI customers with, but it drives through our core business. That business is our most global business, but very underweight in the emerging markets. And so over the past three years, we've built lots of training capabilities to train physicians in the emerging markets. We're doing a joint venture in China with Frankenman, a general surgery company. Many general surgeons want to do less interventional approaches. So that business has a rich pipeline. We're a market share leader there, and we're moving into additional adjacencies in endoscopy to grow that, like endoscopic ultrasound.\par \par \uc2 You touched on \uc2 AMS\uc2 . That will be close to a $1 billion company for us. And we have, really, a leadership position across BPH, ED, stone, and urinary incontinence, And a really big opportunity to grow that outside the US in neuromod. Neuromodulation is a very talked-about area. There's a lot of companies in there now. But at the end of the day, we're the market share leader in the US with the rechargeable. We continue to outperform the market growth rate through the third quarter. And we've got a very rich pipeline in that business and expanding into deep-brain stimulation. So that med-surg segment, coupled with PI and EP, you know, CRM and DES will do their job of growing faster than market and driving margins, but we're really doing a nice job at diversifying the growth of the Company.\par \par \uc2 MIKE WEINSTEIN: It seems like the EI business has, and this is all context, because I think the expectation on the street, including my own, was that the EI business would slow over the course of 2015 because of the emerging (inaudible) there, that the concern was that that would start to slow the growth you were seeing in your core cardiovascular business. And it looks like the acquisition of the \uc2 Bayer\uc2  business has really helped that business overall. So maybe if you just want to spend a few minutes on that.\par \par \uc2 MIKE MAHONEY\uc2 : Yes, you summarized it really well. The \uc2 Bayer\uc2  acquisition, much like \uc2 AMS\uc2 , was likely a underperforming asset at \uc2 Bayer\uc2 , and they sold it because it didn't have the appropriate fit. It was an ideal fit for us. It added atherectomy and thrombectomy. We have a very strong clinical sales-oriented global sales force, and we've really accelerated the growth of that legacy business within \uc2 Bayer\uc2  in our hands.\par \par \uc2 And importantly, our R&D teams are in the throes of very nearly launching new products in that \uc2 Bayer\uc2  platform. So we're revitalizing that portfolio. So that's been a very nice acquisition for us, and we do have a nice alliance with Bard in drug-eluting balloon in the US. We sell our own platform outside the US. And we'll be the only company when we launch in Europe that offers both the drug-eluting stent and a balloon as well thrombectomy and atherectomy in a full suite of products. So our portfolio in PI is very rich, and that CeloNova acquisition is a nice little tuck-in to treat liver cancer.\par \par \uc2 MIKE WEINSTEIN: So you were talking about Watchman briefly earlier. Just help frame your expectations going into the CMS (inaudible)?\par \par \uc2 MIKE MAHONEY\uc2 : So on Watchman, the team has really worked hard in partnering in terms of our response. Maybe, Keith, if you can provide additional color, but we have submitted all the appropriate materials. We get a answer back no later than February 8. But irrespective of if there's improvements or modifications in that, we're very comfortable with the $500 million market opportunity that we've laid out for Watchman as is. And that assumes about a 2% penetration rate of the available patient population, which is quite low. So we think in a downside scenario, where the market opportunity is a $500 million market, and the great news is we have approval, the device is driving terrific clinical results, and the launch has gone extremely well. And we've also delivered on our commitments of launching into over 100 sites in 2015 in our training goals. So we have nice momentum, and even in a risk-adjusted model, we see a $500 million marketplace for Watchman. Any other comments?\par \par \uc2 KEITH DAWKINS\uc2 : Yes, I think -- I mean, we clearly have a unique position in the market. We have a multiyear lead in the US. We've already got a next-generation Watchman FLX, which the pivotal trial will start in the US in the first half of this year. That has CE Mark already. The data that Mike referred to, Vivek Reddy's paper, which you should look at in JACC, which shows the cost effectiveness of Watchman against Warfarin and, importantly, against NOACs, is a very important study.\par \par \uc2 And the $500 million opportunity that we've laid out is very modest in terms of the penetration. So we'll anticipate some clarification around the contraindicated word from CMS on February 8. But we think the puts and takes that we'll get in that CMS communication won't alter our prediction of the market size.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Follow-up on Synergy, so the traction you've seen so far in the US market, I guess, (inaudible) has more advantages over today than some of the products from (inaudible) or from Abbott? I mean, can you break down how much (inaudible) so far?\par \par \uc2 KEITH DAWKINS\uc2 : Well, I think we were on a good platform from the point of view of market share in the US prior to the Synergy launch. I think Promus PREMIER got a lot of interest from cardiologists. And I think the whole Synergy story also resonates with cardiologists, as it did in Europe. So we have good market share in Europe in the countries in which we've launched it, and we anticipate the same here in the US.\par \par \uc2 In Europe, we actually have three -- we still have three drug-eluting stents to segment the market. Here, we'll have two. The acute performance has to be the number-one driver. if you can't get the stent across the lesion, you can forget about talking about polymeral drug or anything else. And the acute performance, I think, is second to none. And as you know, thin strap, very visible, very conformable, and then the dug and polymer goes away. And we'll look forward to presenting the pivotal trial two-year results, EVOLVE II, at ACC. We've already got the four-year results presented and published for the first new study, which incidentally showed zero percent thrombosis at four years.\par \par \uc2 MIKE WEINSTEIN: Should we assume that Absorb gets approved in the US?\par \par \uc2 KEITH DAWKINS\uc2 : Well, we obviously can't comment on the competition. We can, but we won't. There's a panel, we understand, and obviously, the panel would determine the way forward for BES.\par \par \uc2 MIKE WEINSTEIN: We asked you, on the other side of the structural heart business, which is transacted about--really one question at the end of the day is in 2016 will, what will convince the street you're going to be a meaningful player in that market?\par \par \uc2 KEITH DAWKINS\uc2 : Well, I think the street on the whole has dismissed \uc2 Boston Scientific\uc2 . But we're very serious about this. This, as Mike said, is our biggest investment from the R&D point of view. We are growing share significantly, with the fastest-growing trans-femoral valve in Europe. The valve is -- it sounds a bit trite -- but the valve is unique. I mean, it is the only valve that is fully repositionable and replaceable. It is the only valve that what you see is what you get. When you put the valve in, before you release it is exactly the same from the hemodynamics and from the position point of view, as after you've released it. That is absolutely unique.\par \par \uc2 And then paravalval leak, we're best in class, and I think that includes the competitor valves. So we're very excited with the pivotal trial that completed on time, December of last year, 1,000 patients, first head-to-head trial against another valve in the US. And we started fifth, and we ended up third, which I think just reflects the power of the team, one of the best teams in \uc2 Boston Scientific\uc2 .\par \par \uc2 We've got two new valve sizes that are coming in -- Lotus Edge that will come in in Europe in the second half of this year, which is 14 French compatible, with a new delivery system. So we're very excited and feel that this, as one piece of our structural heart portfolio, will really resonate with interventional cardiologists and implanters.\par \par \uc2 MIKE WEINSTEIN: And do you think you guys into (inaudible), do you think you guys are prepared to provide more color on how that business is doing? For the first time in 2015 you guys talked about total structural heart and where it might finish at the year. Any preliminary thoughts on giving the street more visibility on the Quarter 4 performance?\par \par \uc2 DAN BRENNAN\uc2 , EVP & CFO, BOSTON SCIENTIFIC CORP.: Yes, I think at this point, the category of structural heart is probably where we'll stay as opposed to breaking out the individual specifics of each of the products within there.\par \par \uc2 MIKE WEINSTEIN: Any reason that you'll start to break out the businesses separately?\par \par \uc2 DAN BRENNAN\uc2 : We always think of competitive dynamics and laying out numbers on a silver platter for everyone to see. I think the structural heart gives a good visibility, and Mike talked about it in his comments in the broader session that it's going to become a much more significant part of \uc2 Boston Scientific\uc2 . And I think you can get a sense of that in the structural heart context without having to break it out individually.\par \par \uc2 MIKE WEINSTEIN: Can you maybe just talk about market shares in geographies in which you compete today and where are you still limited, either from a reimbursement standpoint in specific geographies, one or two, from size?\par \par \uc2 KEITH DAWKINS\uc2 : So we won't break out the detail around that. Suffice it to say that we've had implants now in Latin America, obviously North America, Europe, and Asia. We think we can address 80% or more of the market with our existing three sizes. And when we introduce the 21-millimeter valve and then the 29-millimeter valve, in that order, that will complete the size matrix, which will cover all the necessary sizes for patients around the world.\par \par \uc2 We've deliberately in Europe targeted high-volume accounts, and we've been very pleased with the way our market share has gone in those accounts. This is obviously a transfemoral device, and we think transapical is dwindling in terms of a method of access. We have data now for alternative routes, including direct aortic and subclavian, and you'll hear more of that data coming out in 2016.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: (inaudible ? microphone inaccessible)\par \par \uc2 DAN BRENNAN\uc2 : Yes, so we haven't disclosed that. So the great news is in Europe, we have a DCB and a DES. In the US, we have a strategic alliance with Bard where we've expanded the number of accounts that we distribute the product for. So that alliance is going well. And we'll provide additional guidance in terms of our DCB plans for the US in the future.\par \par \uc2 KEITH DAWKINS\uc2 : I think it's worth saying that there are a number of technologies that can be used in the peripheral space. As you know, the treatment of peripheral vascular disease is under-penetrated, and we're the only company that has the range of products, from bare metal stent, drug-eluting stent, drug-coated balloon, atherectomy. So we think it's an exciting area of growth, as is reflected in our 2015 Q3 figures.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Follow-up on your structural. You've already talked about the 14 French system. Is there a need to still continue to downsize, or is 14 French probably where it's at today and additional control (inaudible)?\par \par \uc2 KEITH DAWKINS\uc2 : Yes, I mean, we need to get the size to 14, which is our aim without changing some of the unique features of Lotus. I think, to drive size down less than 14, you run the risk of compromising the leaflet's integrity in the long term. Of course, everybody at the moment is focused on short-term acute performance. If and when we see the partner IIA results in at ACC, if the intermediate results are favorable, you're then looking at long-term treatment, and you can have valves that fail, leaflets that fail late because you've compressed them to get down less than 14. I think most operators think 14 as a watermark is very satisfactory for the majority of patients.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Can you talk about mitral, and specifically repairs or replacement and any plans you have going forward in those areas?\par \par \uc2 MIKE MAHONEY\uc2 : So the question's on mitral repair, mitral market repair versus replacement? (Laughter)\par \par \uc2 KEITH DAWKINS\uc2 : There would be a question of financials on that.\par \par \uc2 MIKE MAHONEY\uc2 : For the webcast.\par \par \uc2 KEITH DAWKINS\uc2 : Nice, okay. So we have an investment in a company called MValve, which I think you all know. This is a docking solution which works with the Lotus valve. And the mitral space is likely to be larger in terms of the opportunity than the TAVR or TAVI market. But there's much more heterogeneity in this space. So you have a spectrum of types of disease affecting the mitral valve. It's a much more complicated valve, and the surgeons took many years to really understand the valve.\par \par \uc2 So we think -- we have this investment in MValve, which is a replacement strategy. We think we'll need a toolkit to address the spectrum of mitral valve disease. And we think the market will take some time to develop. Of course, there's been a really -- a few months ago, $1.5 billion roughly spent on about 80 patients, 40 of whom are dead -- so this is going to be a long runway for us to sort this out. We think the opportunity is large, but we think the challenges will also be large. It won't be so clean a disease as treating aortic stenosis because many of these patients live quite a long time. They just don't die suddenly, like aortic stenosis.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: So do you plan to add to your portfolio (inaudible)?\par \par \uc2 KEITH DAWKINS\uc2 : Well, we have an active BD team who's looking at all --\par \par \uc2 MIKE MAHONEY\uc2 : Also, beyond our BD, we have just a lot of capabilities internally in structural heart. So our Watchman team, we know more about atrial appendage than most of our competitors maybe combined. And then our TAVR program has been in place for five years now. So we have so many capabilities. We have delivery system capability. We have a lot of internal capability beyond M&A opportunities that we continue to scan.\par \par \uc2 So to us, the most exciting over the next five years is clearly Watchman and our TAVR platform. If you start looking at years 3 to 10, we will be a player in mitral. It's structural heart, where it's a big part of our focus. So you'll see us continue to advance capabilities in mitral.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: If I can ask two quick, fast questions. The first one for you is the guidance for 2015 did not assume essentially the R&D tax credit. It wasn't embedded; it wasn't front and center. Medtronics updated their guidance for it. Any comments you want to give. When you guys had spelled out what the impact of (inaudible) was.\par \par \uc2 DAN BRENNAN\uc2 : Right, exactly. So for us, our guidance for 2015 was 13% for an overall effective tax rate. Obviously, we need to close the books and figure out the final impact. It looks like it will be about over, a little bit over 100 basis points for the Company. But as opposed to taking that down to 12%, it looks like we will reinvest that in our tax structure, which will give us more flexibility in the long term relative to capital structure.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: So for the 4Q 2015, you'll reinvest the, essentially the R&D tax credit?\par \par \uc2 DAN BRENNAN\uc2 : Yes, so I think the 13% still holds for 2015, in summary, yes.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: We were assuming -- again, you were not guiding to it, but we were assuming, just keeping it in our model, the extension of the R&D tax credit. You're saying you have reinvested that?\par \par \uc2 DAN BRENNAN\uc2 : Right. It's worth 100 basis points. We'll reinvest it and hope to come in around 13%, yes.\par \par \uc2 MIKE MAHONEY\uc2 : Yes, with that committed to our double-digit EPS aspirations going forward and aspirations reality, and it just drives more flexibility in our capital structure going forward.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Yes, understood.\par \par \uc2 DAN BRENNAN\uc2 : And then you just basically, you take the 100 basis points off that number going forward.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Okay.\par \par \uc2 DAN BRENNAN\uc2 : In future years.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Right, and your guidance documents that.\par \par \uc2 DAN BRENNAN\uc2 : Exactly, yes.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: And then the next question would be on the med tech tax and your thoughts -- not your thoughts on that, but it's (inaudible), but in terms of how would you view it?\par \par \uc2 MIKE MAHONEY\uc2 : Yes, so we're pleased that it's been repealed. It's only been repealed; it hasn't been eliminated. And so innovation is important for us. We anticipate investing a significant portion of that dollars back in the business through, whether it be innovation and R&D in structural heart, venture investments, collaborations with universities -- it really just to continue to invest and to grow our pipeline to advance science for life as a company. So expect to see a significant portion of that med device tax be reinvested in the business.\par \par \uc2 MIKE WEINSTEIN: Last question. Just several years ago, you (inaudible). Any thoughts on getting back in the (inaudible) space?\par \par \uc2 MIKE MAHONEY\uc2 : We look at spaces all the time. We want to be -- what's key to us is can we be category leaders and can we have unique innovation that customers will pay for? And so those are the screens that we look at, and we send lots of different adjacencies through that.\par \par \uc2 MIKE WEINSTEIN: We'll go ahead and wrap it up. Thanks.\par \par \uc2 MIKE MAHONEY\uc2 : Thank you.\par \par \uc2 [Thomson Financial reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.\par \par \uc2 In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies' most recent \uc2 SEC\uc2  filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.\par \par \uc2 THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON FINANCIAL OR THE APPLICABLE COMPANY OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.]\par \par \uc2 Document FNDW000020160113ec1c0063l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: \uc2 TESARO\uc2  Outlines Business Priorities and Strategic Outlook for 2016\b0\par\par\uc2 1,443 \uc2 words\par \uc2 11 January 2016\par 08:15\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 TESARO\uc2  Outlines Business Priorities and Strategic Outlook for 2016 \par \par \uc2 \f2 \par    -- U.S. commercial \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of VARUBI(TM) (oral rolapitant) well underway \par  \par    -- Data from niraparib NOVA and QUADRA registration trials expected in Q2 \par       2016 \par  \par    -- Niraparib \f28 \b \highlight22\uc2 \f2 New Drug\f28 \b0 \highlight\uc2 \f2  Application (NDA) submission planned for 2H 2016 \par  \par    -- Investigational \f28 \b \highlight22\uc2 \f2 New Drug\f28 \b0 \highlight\uc2 \f2  (IND) application for TSR-042 (anti-PD-1 \par       antibody) submitted \par  \par    -- IND for TSR-022 (anti-TIM-3 antibody) planned for submission in Q2 2016 \f28 \par \par \uc2 WALTHAM, Mass., Jan. 11, 2016 (GLOBE NEWSWIRE) -- \uc2 TESARO, Inc\uc2 . (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today outlined its business priorities and strategic outlook for 2016.\par \par \uc2 "2015 was an extraordinary year for \uc2 TESARO\uc2 , as we obtained \uc2 FDA\uc2  approval for and launched our first product, VARUBI(TM), in the United States, and we look forward to bringing VARUBI to additional patients in 2016," said \uc2 Lonnie Moulder\uc2 , CEO of TESARO. "We are entering 2016 in a strong position and anticipate the achievement of multiple milestones with our pipeline, including the availability of the first pivotal data from our niraparib clinical programs and the initiation of clinical trials for our immuno-oncology antibody candidates. We are confident that we have a significant opportunity to build meaningful shareholder value as we continue to execute on our mission of providing transformative therapies to people bravely facing cancer."\par \par \uc2 VARUBI(TM) (Rolapitant)\par \par \uc2 VARUBI is a selective and competitive antagonist of human substance P/neurokinin-1 (NK-1) receptors. \uc2 TESARO\uc2  launched VARUBI in late November of 2015, following \uc2 FDA\uc2  approval for use in combination with other antiemetic agents in adults, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.\par \par \uc2 TESARO\uc2  anticipates achieving the following milestones related to VARUBI in 2016: \par \par \uc2 \f2 \par    -- Continue to execute on the VARUBI commercial launch in the United States; \par  \par    -- Submit the NDA for intravenous (IV) rolapitant in Q1; and \par  \par    -- Submit the oral rolapitant Marketing Authorization Application (MAA) to \par       the \f28 \uc2 \f2 European Medicines Agency\f28 \uc2 \f2  (EMA) in Q2. \f28 \par \par \uc2 \f2 Niraparib Franchise\f28 \par \par \uc2 \f2 Niraparib is a potent, oral PARP inhibitor that is currently being evaluated in three ongoing pivotal trials. \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  is building a robust niraparib franchise by assessing activity across multiple tumor types and by evaluating several potential combinations of niraparib with other therapeutics. The ongoing development program for niraparib includes a Phase 3 trial in patients with ovarian cancer (the NOVA trial), a registrational Phase 2 treatment trial in patients with ovarian cancer (the QUADRA trial), and a Phase 3 trial for the treatment of patients with BRCA-positive breast cancer (the BRAVO trial). In addition, a Phase 3 trial of niraparib in first-line ovarian cancer (PRIMA) and a Phase 1/2 clinical trial designed to evaluate the combination of niraparib plus KEYTRUDA(R) (pembrolizumab) in patients with triple-negative breast cancer or ovarian cancer are slated to begin during the first quarter. Several collaborator-sponsored studies are also underway, including combination trials of niraparib plus enzalutamide, bevacizumab, and temozolomide, in patients with prostate cancer, ovarian cancer, and Ewing's sarcoma, respectively.\f28 \par \par \uc2 \f2 Patient treatment continues in the Phase 3 NOVA trial, and based upon the most recently observed event rate, \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  continues to expect data to be available in the second quarter of 2016. Enrollment of the QUADRA trial of niraparib for the treatment of patients with ovarian cancer who have received three or more prior lines of chemotherapy continues, and initial response rate data from this trial is anticipated to become available in the second quarter. A niraparib NDA submission is planned for the second half of 2016.\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  anticipates completing the following milestones related to niraparib in 2016: \f28 \par \par \uc2 \f2 \par    -- Initiate patient enrollment in the Phase 3 clinical trial of niraparib in \par       first-line ovarian cancer (PRIMA) in Q1; \par  \par    -- Initiate patient enrollment in the niraparib/KEYTRUDA(R) (pembrolizumab) \par       combination trial in Q1; \par  \par    -- Report data from the Phase 3 NOVA trial and from the QUADRA trial of \par       niraparib in Q2; \par  \par    -- Submit the NDA for niraparib in 2H; and \par  \par    -- Continue to enroll the Phase 3 BRAVO trial of niraparib in breast cancer \par       patients with germline BRCA mutations throughout 2016. \f28 \par \par \uc2 \f2 Immuno-Oncology Portfolio\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 TESARO\f28 \uc2 \f2 's antibody drug candidates targeting PD-1, TIM-3, and LAG-3 continue to advance, and the Investigational New Drug (IND) application for TSR-042, our anti-PD-1 antibody candidate, has been submitted to the \f28 \uc2 \f2 U.S. Food and Drug Administration (FDA)\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  anticipates completing the following milestones related to its immuno-oncology portfolio in 2016: \f28 \par \par \uc2 \f2 \par    -- Initiate a Phase 1 clinical trial of TSR-042 in Q1; \par  \par    -- Submit the IND for TSR-022 (anti-TIM-3 antibody) in Q2; \par  \par    -- Select a clinical candidate targeting LAG-3 in 1H 2016; \par  \par    -- Identify a dose and schedule for TSR-042 by YE 2016; and \par  \par    -- Select bispecific clinical candidates targeting PD-1/TIM-3 and PD-1/LAG-3 \par       in 2016. \f28 \par \par \uc2 \f2 Year-End 2015 Cash Position\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  ended 2015 with approximately $230 million in cash and cash equivalents (unaudited).\f28 \par \par \uc2 \f2 About VARUBI(TM)\f28 \par \par \uc2 \f2 VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. The inhibitory effect of a single dose of VARUBI on CYP2D6 lasts at least seven days and may last longer. Avoid use of pimozide; monitor for adverse events if concomitant use with other CYP2D6 substrates with a narrow therapeutic index cannot be avoided. Please see full prescribing information, including additional important safety information, available at \f28 {\field{\*\fldinst{HYPERLINK "http://www.varubirx.com"}}{\fldrslt{\cf2 \uc2 www.varubirx.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 An intravenous formulation of rolapitant is also being developed. \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  licensed exclusive rights for the development, manufacture, commercialization, and distribution of VARUBI (rolapitant) from \f28 \uc2 \f2 OPKO Health, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 TESARO\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.tesarobio.com"}}{\fldrslt{\cf2 \uc2 www.tesarobio.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 To the extent that statements contained in this press release are not descriptions of historical facts regarding \f28 \uc2 \f2 TESARO\f28 \uc2 \f2 , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectation to have NOVA and QUADRA data in the second quarter of 2016, our expectation to file the niraparib NDA in the second half of 2016, the expected timing of initiation of our PD-1 and TIM-3 clinical trials, the expected timing of the IND submission for TSR-022, the expected timing of selecting a LAG-3 clinical candidate and bispecific candidates targeting various combinations, the expected timing of the oral rolapitant MAA filing and the NDA filing for IV rolapitant, the expected timing of initiation of various other clinical trials involving niraparib, and our opportunity to build meaningful shareholder value. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, competition from other pharmaceutical companies, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and actions by regulatory authorities, patient accrual and event rates for clinical trials, and other matters that could affect the timing of availability of data from or initiation of our clinical trials, uncertainties regarding regulatory approvals, uncertainties regarding certain expenditures, and other matters that could affect the availability or commercial potential of our drug candidates. \f28 \uc2 \f2 TESARO\f28 \uc2 \f2  undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see \f28 \uc2 \f2 TESARO\f28 \uc2 \f2 's Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. \f28 \par \par \uc2 \f2 \par Investor/Media Contact: \par  \par Jennifer Davis \par Sr. Director, Corporate Development & Investor Relations \par +1.781.325.1116 or jdavis@tesarobio.com \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 January 11, 2016 08:15 ET (13:15 GMT)\f28 \par \par \uc2 Document DJDN000020160111ec1b001tb\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 New  \highlight22\uc2 Launch \highlight\uc2  Study Details Current Pharmaceutical Industry Spending for Key Activities Before and During a  \highlight22\uc2 New Product Launch \highlight\b0\par\par\uc2 560 \uc2 words\par \uc2 8 January 2016\par 18:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 CHAPEL HILL, N.C., Jan. 8, 2016 /PRNewswire/ -- Pharmaceutical companies can no longer afford to rely solely on past experiences when budgeting for a \b \highlight22\uc2 new product launch\b0 \highlight\uc2  in today's fast-changing, highly competitive market.\par \par \uc2 Similarly, the list of \b \highlight22\uc2 launch\b0 \highlight\uc2  activities has grown and priorities have shifted in this new \b \highlight22\uc2 launch\b0 \highlight\uc2  landscape, affecting traditional spend and timing models for key \b \highlight22\uc2 launch\b0 \highlight\uc2  activities. For instance, medical affairs, digital marketing, health economics, & payer activities are growing in importance while field-based promotional investments such as samples and \b \highlight22\uc2 launch\b0 \highlight\uc2  meetings are being reduced, according to a new \b \highlight22\uc2 launch\b0 \highlight\uc2  study by research and consulting leader \uc2 Best Practices, LLC\uc2 .\par \par \uc2 The study also demonstrates the impact payers are having on a new product launch: For new drugs launched between 2011 and 2013, companies in the study spent an average of $1.9 million on managed markets/market access activities during launch year. Meanwhile, for new drugs launched 2014-17, companies in the study have spent or will spend $2.7 million on managed markets/market access activities during launch year.\par \par \uc2 "Winning Necessary Resources for a Successful Product Launch" will help pharmaceutical companies develop effective launch and pre-launch activity budgets to ensure successful U.S. market entry for new products. This comprehensive benchmark study investigates current costs as well as budget and staffing allocations required for a successful drug launch. The data in the study will serve as a reference or comparison point for brand and marketing leaders as they develop budgets and allocate funds for their new brands.\par \par \uc2 Key insights and metrics in the study include:\par \par \uc2 \f2 \par    -- Industry average cost for new pharmaceutical product launch \par  \par    -- Average cost for multiple specialty, single specialty and primary product \par       launches \par  \par    -- Percentage of budget allocated to 12 key marketing, education and market \par       access activities during and prior to launch \par  \par    -- Timing for conducting 50+ activities \par  \par    -- FTE Allocated to key launch activities \par  \par    -- Anticipated budget & activity trends \par  \par    -- Top 3 success factors for launch \f28 \par \par \uc2 \f2 This report provides exclusive new data on the cost of launching a pharmaceutical product in today's market. The study identifies current investment levels needed for marketing programs, educational activities and market-access efforts required to bring a new successful drug to market.\f28 \par \par \uc2 \f2 For this study, \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  engaged 34 marketing & commercial leaders from 27 leading pharmaceutical, biotech, and life sciences companies.\f28 \par \par \uc2 \f2 To access the full 120-page report or to download a complimentary summary: \f28 {\field{\*\fldinst{HYPERLINK "http://www3.best-in-class.com/rr1402.htm"}}{\fldrslt{\cf2 \uc2 http://www3.best-in-class.com/rr1402.htm}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 For related research, visit our \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  website at \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/"}}{\fldrslt{\cf2 \uc2 www.best-in-class.com/}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 ABOUT BEST PRACTICES, LLC\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  is a leading benchmarking and advisory services firm serving pharmaceutical and medical device companies worldwide. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 's clients include all the top 10 and most of the top 50 pharmaceutical companies. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/new-launch-study-details-current-pharmaceutical-industry-spending-for-key-activities-before-and-during-a-new-product-launch-300201759.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/new-launch-study-details-current-pharmaceutical-industry-spending-for-key-activities-before-and-during-a-new-product-launch-300201759.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160108ec18000cj\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Ortho Tri-Cyclen Lo\b0\par\par\uc2 Da Hee Han, PharmD   \par \uc2 208 \uc2 words\par \uc2 6 January 2016\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2016 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Norgestimate and Ethinyl Estradiol Tablets, 0.18mg/0.025mg, 0.215mg/0.025mg, and 0.25mg/0.025mg, the generic version of Janssen's Ortho Tri-Cyclen Lo tablets.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-inc/manufacturer/256/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Norgestimate and Ethinyl Estradiol Tablets, 0.18mg/0.025mg, 0.215mg/0.025mg, and 0.25mg/0.025mg, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/janssen-pharmaceuticals-inc/manufacturer/213/"}}{\fldrslt{\cf2 \uc2 Janssen}}}\uc2 's {\field{\*\fldinst{HYPERLINK "http://www.empr.com/ortho-tri-cyclen--lo/drug/2548/"}}{\fldrslt{\cf2 \uc2 Ortho Tri-Cyclen Lo}}}\uc2  tablets. It received final approval from the \uc2 Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product.\par \par \uc2 RELATED: {\field{\*\fldinst{HYPERLINK "http://www.empr.com/generics-news/teva-launches-generic-birth-control-tablets/article/462777/"}}{\fldrslt{\cf2 \uc2 Teva Launches Generic Birth Control Tablets}}}\par \par \uc2 Norgestimate and Ethinyl Estradiol Tablets are intended for the {\field{\*\fldinst{HYPERLINK "http://www.empr.com/oral-contraceptives/article/123837/"}}{\fldrslt{\cf2 \uc2 prevention of pregnancy}}}\uc2 . It consists of norgestimate (a progestin). and ethinyl estradiol (an estrogen). Combination oral contraceptives reduce the risk of becoming pregnant primarily by suppressing ovulation. Other mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.\par \par \uc2 Norgetimate and Ethinyl Estradiol Tablets consist of 7 tablets of 0.18mg/0.025mg, 7 tablets of 0.215mg/0.025mg, 7 tablets of 0.25mg/0.025mg, and 7 inert tabs.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020160107ec1600003\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Biological Safety Testing Market by Application, Product & Test - Global Forecast to 2019\b0\par\par\uc2 897 \uc2 words\par \uc2 6 January 2016\par 15:50\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 NEW YORK, Jan. 6, 2016 /PRNewswire/ -- The biologics safety testing market is growing at a favorable rate. The major drivers for the market include growth of the pharmaceutical and biological industries and an increasing number of \b \highlight22\uc2 new drug launches\b0 \highlight\uc2 . Over the years, the number of drug approvals in North American countries has increased. Between 2001 and 2010, the \uc2 FDA\uc2  approved 225 drug applications and \uc2 Health Canada\uc2  approved 99. In addition, according to WIPO, Europe accounted for 3,822 of the pharmaceutical and 1,998 of the biotechnology patents granted in 2012. Furthermore, according to \uc2 OECD\uc2  estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970. This will spur the growth of biologics safety testing market.\par \par \uc2 The global pharmaceutical industry is expected to grow at a CAGR between 5% and 8%. According to the IMS Institute of Healthcare Informatics, the global biologics market has increased from $46 billion in 2002 to $169 billion in 2012. Biologics accounted for 11% of the total sales of drugs in 2002, which increased to 18% in 2012. It is estimated that this figure will rise to 20% by 2017, with a total market value of $221 billion. According to \uc2 Ernst & Young\uc2 's Global Biotechnology Report 2013, companies in biotech centers in the U.S., Europe, Canada, and Australia achieved revenues of about $90 billion in 2012. This was an 8% increase over their revenues in 2011. According to \uc2 OECD\uc2  estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Biologics safety testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the biologics safety testing market.\par \par \uc2 This report segments the global biologic safety testing market based on product, type of test, application, and geography. The product segments included in the report are instruments, kits & reagents, and services. Based on test, this market is categorized into adventitious agents detection test, bioburden tests, cell line authentication and characterization tests, endotoxin tests, residual host contaminant detection tests, sterility testing, and other tests (efficacy tests, toxicity tests, stability tests). The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissues & tissue products, and vaccines and therapeutics.\par \par \uc2 The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). Asia is further divided into China, India, Japan, and the Rest of Asia. North America includes Canada and the U.S.\par \par \uc2 A combination of bottom-up and top-down approaches were used to calculate market sizes and growth rates of the global biologics safety testing market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of their biologics safety testing market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.\par \par \uc2 The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and the growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the biologic safety testing market. The competitive landscape covers growth strategies adopted by industry players over the last three years, and includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.\par \par \uc2 Reasons to Buy the Report:\par \par \uc2 The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.\par \par \uc2 The report provides insights on the following:\par \par \uc2 -- Product Development/Innovation: Product portfolios of top players in the biologic safety testing market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the biologic safety testing market\par \par \uc2 -- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the biologic safety testing market\par \par \uc2 -- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biologics safety testing products across geographies\par \par \uc2 -- Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the biologics safety testing market\par \par \uc2 Read the full report: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com/p02947101-summary/view-report.html"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com/p02947101-summary/view-report.html}}}\par \par \uc2 About Reportlinker\par \par \uc2 ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.\par \par {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 __________________________\par \par \uc2 Contact Clare: clare@reportlinker.com\par \par \uc2 US: (339)-368-6001\par \par \uc2 Intl: +1 339-368-6001\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/biological-safety-testing-market-by-application-product--test---global-forecast-to-2019-300200535.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/biological-safety-testing-market-by-application-product--test---global-forecast-to-2019-300200535.html}}}\par \par \uc2 SOURCE Reportlinker\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 Document PRN0000020160106ec16000lk\par }\page {\par\fs20\b \uc2 Teva  \highlight22\uc2 launches \highlight\uc2  generic birth control pill\b0\par\par\uc2 John George   \par \uc2 149 \uc2 words\par \uc2 5 January 2016\par \uc2 Philadelphia Business Journal Online\par \uc2 PHIBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Teva Pharmaceutical Industries Ltd\uc2 . \b \highlight22\uc2 launched\b0 \highlight\uc2  its first \b \highlight22\uc2 new product\b0 \highlight\uc2  of the new year Tuesday with the \b \highlight22\uc2 launch\b0 \highlight\uc2  of its generic equivalent an oral contraceptive used by women to prevent pregnancy.\par \par \uc2 The product, which Teva (NYSE: TEVA) is selling in a 28-day blister pack dispenser in the United States, is a generic version of Janssen Pharmaceuticals Ortho Try-Cyclen Lo tablets.\par \par \uc2 The contraceptive generated annual U.S. sales of about $448 million for Janssen, a subsidiary of \uc2 Johnson & Johnson\uc2  (NYSE: JNJ), according to the health data firm \uc2 IMS Health\uc2 .\par \par \uc2 * {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/philadelphia/news/2016/01/04/genesis-sells-18-assisted-living-kansas-cre.html"}}{\fldrslt{\cf2 \uc2  Genesis sells 18 assisted living facilities for more than $54M}}}\par \par \uc2 Teva, based in Israel, has its North American headquarters in North Wales, Pa.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=philadelphia&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Philadelphia Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PHIBJO0020160105ec150002t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 REGENXBIO\uc2  Files 8K - Other Events >RGNX\b0\par\par\uc2 214 \uc2 words\par \uc2 30 December 2015\par 08:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 REGENXBIO Inc\uc2 . (RGNX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 30, 2015.\par \par \uc2 On December 30, 2015, \uc2 REGENXBIO Inc\uc2 . (the Company) issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  has granted Rare Pediatric Disease Designation to the Company's investigational gene therapy product candidate, RGX-111, for the treatment of mucopolysaccharidosis Type I (MPS I). MPS I is a rare neurodegenerative disease caused by deficiency of the -l-iduronidase gene.\par \par \uc2 A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1590877/000119312515416776/d112869d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1590877/000119312515416776/d112869d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1590877/000119312515416776/0001193125-15-416776-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1590877/000119312515416776/0001193125-15-416776-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 30, 2015 08:16 ET (13:16 GMT)\par \par \uc2 Document DJDN000020151230ebcu00100\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Minerva Neurosciences\uc2  Files 8K - Regulation FD >NERV\b0\par\par\uc2 274 \uc2 words\par \uc2 29 December 2015\par 16:07\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Minerva Neurosciences Inc\uc2 . (NERV) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 29, 2015.\par \par \uc2 On December 29, 2015, \uc2 Minerva Neurosciences, Inc\uc2 . (the "Company") issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  has accepted the Company's Investigational New Drug application for MIN-101 for the treatment of schizophrenia. The Company also announced that it has completed enrollment in its ongoing European Phase IIb clinical trial of MIN-101.\par \par \uc2 A copy of the above referenced press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information, including the information contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1598646/000119312515416057/d111858d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1598646/000119312515416057/d111858d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1598646/000119312515416057/0001193125-15-416057-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1598646/000119312515416057/0001193125-15-416057-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 29, 2015 16:07 ET (21:07 GMT)\par \par \uc2 Document DJDN000020151229ebct0025q\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Zyvox Tablets - Quick Facts\b0\par\par\uc2 168 \uc2 words\par \uc2 29 December 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Mylan N.V\uc2 . (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Linezolid Tablets, 600 mg, which is the generic version of \uc2 Pfizer\uc2 's Zyvox Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application or ANDA for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.\par \par \uc2 Linezolid Tablets, 600 mg, had U.S. sales of approximately $457.8 million for the 12 months ending Sept. 30, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 269 ANDAs pending \uc2 FDA\uc2  approval representing $100.8 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Fifty of these pending ANDAs are potential first-to-file opportunities, representing $35.6 billion in annual brand sales, for the 12 months ending June 30, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151229ebct002s1\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Best Practices & Lessons Learned in Cardiovascular Product  \highlight22\uc2 Launches \highlight\b0\par\par\uc2 232 \uc2 words\par \uc2 18 December 2015\par \uc2 Drug Week\par \uc2 DRGW\par 70\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015, Drug Week via NewsRx.com   \par \par \uc2 2015 DEC 25 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- The biopharmaceutical sector has seen many \b \highlight22\uc2 new product launches\b0 \highlight\uc2  in the last few years, including some notable \b \highlight22\uc2 new drugs\b0 \highlight\uc2  targeting the cardiovascular therapeutic area. Recent market entries have illustrated that there are a critical core set of factors for cardiovascular products as well as other therapeutic areas.\par \par \uc2 According to research by \uc2 Best Practices, LLC\uc2 , more than half of the Total Benchmark Class - 64 percent - favor spending 101 percent to 150 percent of the market leader's investment level during product \b \highlight22\uc2 launch\b0 \highlight\uc2 . Investment requirements are even higher in the competitive Cardiology market, where 83 percent of respondents assessed required resource levels to be 121 percent to 200 percent of Market Leader levels.\par \par \uc2 The related report, "Success Factors and Failure Points in Cardiovascular Product Launches," explores each aspect of this framework for launch success and provides a cardiovascular segment as well as a data segment representing other therapeutic areas combined. This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.\par \par \uc2 Keywords for this news article include: Therapy, Cardiology, Cardiovascular, \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document DRGW000020151218ebci00008\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Antares Pharma Files 8K - Other Events >ATRS\b0\par\par\uc2 172 \uc2 words\par \uc2 18 December 2015\par 09:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Antares Pharma Inc\uc2 . (ATRS) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 14, 2015.\par \par \uc2 In December 2015, the \uc2 FDA\uc2  approved the Company's ANDA for 4 mg/0.5 mL and 6 mg/0.5 mL Sumatriptan Injection USP in adults for the acute treatment of migraine and cluster headache when a clear diagnosis has been established.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1016169/000156459015011560/atrs-8k_20151214.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1016169/000156459015011560/atrs-8k_20151214.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1016169/000156459015011560/0001564590-15-011560-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1016169/000156459015011560/0001564590-15-011560-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 18, 2015 09:01 ET (14:01 GMT)\par \par \uc2 Document DJDN000020151218ebci001ov\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Acura Pharmaceuticals Files 8K - Other Events >ACUR\b0\par\par\uc2 213 \uc2 words\par \uc2 17 December 2015\par 16:30\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Acura Pharmaceuticals Inc\uc2 . (ACUR) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 17, 2015.\par \par \uc2 On December 17, 2015 we issued a press release announcing that we are advancing our lead LIMITX(tm) oral abuse deterrent drug candidate using the opioid hydromorphone HCl (LIMITX Hydromorphone) into clinical testing and that we expect to submit an Investigation New Drug Application (IND) to the \uc2 US Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) before the end of 2015, which IND will become effective 30-days after submission unless questioned by the \uc2 FDA\uc2 . A copy of the press release is attached hereto as Exhibit 99.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/786947/000114420415071516/v427278_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/786947/000114420415071516/v427278_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/786947/000114420415071516/0001144204-15-071516-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/786947/000114420415071516/0001144204-15-071516-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 17, 2015 16:30 ET (21:30 GMT)\par \par \uc2 Document DJDN000020151217ebch003vy\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Egalet Files 8K - Other Events >EGLT\b0\par\par\uc2 173 \uc2 words\par \uc2 15 December 2015\par 08:27\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Egalet Corp\uc2 . (EGLT) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 15, 2015.\par \par \uc2 On December 15, 2015, \uc2 Egalet Corporation\uc2  (the "Company") issued a press release announcing that it has submitted a new drug application for its product candidate ARYMO ER to the \uc2 U.S. Food and Drug Administration\uc2 , a copy of which is filed herewith as Exhibit 99.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1586105/000110465915084799/a15-24978_28k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1586105/000110465915084799/a15-24978_28k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1586105/000110465915084799/0001104659-15-084799-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1586105/000110465915084799/0001104659-15-084799-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 15, 2015 08:27 ET (13:27 GMT)\par \par \uc2 Document DJDN000020151215ebcf001sg\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw133\pich40\picscaley100\picscalex100\picwgoal1995\pichgoal600
47
494638396185002800F7FF00FBEAEAE6797CEB9EA1919191F0F0F0828282EEA4A6F2F2F2ADADAD9E9E9EB5B5B5D0D0D06E6E6E3333332C2C2CD8282CFBD5D6E3
696B898989F6D2D2F0AAABD30103F2B8B9A9A9A9CDCDCD9B9B9B7E7E7EFEFAFAF6D6D6B1B1B1E36165141414F4F4F4A2A1A1DEDEDEF1B5B6FAEDED666666E573
76BFBFBF8E8E8EFCF2F2C4C4C43B3B3B4A4A4AE8E8E8DD4E50BABABAFEF8F8F0B0B1DD5154DADADA616161EEEEEEDCDCDCECECECF1C2C3EAEAEAFDF4F4696969
E15B5EFDF6F6CACACAF5C9CAF8D9DA5E5E5EC8C8C8404040CE0000FBE6E6FCF0F0E88184BCBCBCB8B8B84444440C0C0CE3E3E3E88385D2D2D2D9252AF4C5C6E5
777AF9E0E0959595E9888AF8DCDDE6E6E6E36468F9DEDED8D8D8DE484C767676EBBBBCDB4448E1555AC2C2C27A7A7AE7AFB1DC3D415A5A5AEEA2A41D1D1D7070
70E77E80D72C31DF6264F4C1C2C6C6C6575757E88486A6A6A6181818E0E0E0505050E49597212121868686787878DB4045E4E4E4F5CDCE262626EEA8AAF4C7C8
C90000EEADAFD5D5D5EB9495EA9192E46E71C40000DA3136CD1619FAE4E4FFDFE0FCEDEEE25F62D6D6D6EC9597EB9798EEA6A7D41418EEA1A2737373C0C0C0FD
FBFAEA8C8EEC999AD1090D000000F6D0D1F7DEDEE77B7EE98A8DE88082F1CCCDDD3A3FFAE7E7F0AFB1EA8E90EB9C9ED51D22F2C5C7F0A7AAF2BABBEA9395FDFE
FE060606DA353AF9E6E7FAE2E2F2BDBEF2B7B8F8E4E4F8D8D9F5C2C4E04A4FF0B2B4EC9A9CFFFFFFFBFBFBFEFEFEFDFDFDFCFCFCFFFEFEFAFAFAF9F9F9FFFDFD
F8F8F8F6F6F6F7F7F7FEFDFDFDF8F8F9E1E2FEFCFCFEFFFFFDF7F7FAE5E6FBEBEBFFFEFFF9E3E3FCEEEEFFFCFCE4A8AAEFABADEC5C5FCF2025FEDADBABC0BF9B
B1B0080909F3C3C4FFE3E30F1010F1D3D2D20F12DF5A5DE8B7B9FFFEFDE04C50DF6D6FEA8487FDF5F5F5BEBFFCF1F1F3BBBDF9E5E6707D7CD8464AE78C8EF4A2
A4768786F6D3D4FAE3E4EC9294F4BFC0F8DADCEDC1C3F9DDDEF9DFDFE9AAAADA7C7EFEFBFBFBE1E1FCEFF0535453F3D8D9E68789E1575BFFFDFCF9ECEC8E9393
E8282D232323E8999BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A45324541463245354338373545323131413343304437443032394336463539432220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A32463439334235323531303231314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A45314543363134303531303131314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F70204353352E312057696E646F7773223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D22786D702E6969643A4533454146324535433837354532313141334330443744303239433646353943222073745265663A646F63756D656E7449443D22
786D702E6469643A4532454146324535433837354532313141334330443744303239433646353943222F3E203C2F7264663A4465736372697074696F6E3E203C
2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEB
EAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACAB
AAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B
6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B
2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000850028004008FF
006DE9A245B020AD5CBA66D5F255EB9F4387B374D9FA372B572E83B4784D7CC89162BE591C73E570020744C78B1DFFD962A872A0C15B1C6FE94AB9B021C759BD
4072B4C5CB66CA9F401F12A8B4A3E3964A493A3AA904E6DF824A1A66499DAAD3612D79527578E133E15F824A2B6A3CACE5A6D292890D2A4DB1396B46A54A13EB
54F2F15042A5062069F5AB34D32192B7952EFC1351E90D0A3088252CA974E09F864A2A66DD2268D167D094B36000AB4A952A4712449EC4F2E4C800050AF366ED
AD14A4EA974A05FE0DADC4C087930574DECE8C5349C1BF1780C53A6C51A9DABF036F1324C8C07C409659652A0D58CE7C0A827F3B2A6D4182408182016F277EFF
A8B4E01F83B765723D6452C9CCBF5A792AD53BB1C0CFD74A4E1C1671D1A8118F4E0E5D2041552901D344139824884900819833CC3E0558F68F1075A8F0101C1A
34504D0328F8124206FF28508708836DD14247076830C03FB948A0811930C2C84002B52000C6230CC498632F428071C74D12B0D1D8612776A081491CB5B0C509
0F1D80C210D538B0058F412043C53FF820D24D009AE0A1493783A0124514BF3C44C6208E50F1008097B54989096DC6091417686812800B98E022E79EFA69C227
47BDD06654256E1C70430E3780B054534F3D22902EBAF8B211506154F0CC3F959C424B4A76CD80E9079B725440254C8E8AC14D8F90FA4F190E30514D25A7FEFF
734225D739948574FFF046C043A322F1E7AFC0062BECB0C412AB0711040E430404D000F6D60B1D81C6C93B58B8E3CE1E8550F4D6A6BD9C02EB5017D4F2964DD9
01F6C83F2520F5DB5C0ED1C01A08D27C70DC294B0821840A2A9C40A22D0E5482840FF87EE14343EE3AC0020B6F55D30248BAF45B9EBB24CE125F0220E0BAD80D
0E29E0EC29C576ECF1C72003E5CA19FF44D0032EB8C8B38B43F890D111007670808B307A7C224F171CCCD249397D440003317B6CE0CFCAF1B8FC8F0ED8EC6100
337A30934A1AF2E0420A108800300B1EADDCA38832EF14430C10DEFCC14D32F3781308370FC96189430180F2CF19B1EC5285144600D1430469F491C92E8560FF
118116B3786347307DE839822CC7C0F0C33B0138E4C21E6D66D08F030EBCF116E50EE401C214B476E44325254C78791EA4E7F1C614416D22881AEFC507150219
A4554916FFDCF2967A1C9DE79B19959451021B41B89B294CD1E1FA50129524C0D16B6FD1FED0791D7C3C54511C8151090B60C8A881BBB13D95C7233494504210
4905950D11D49852C9103F61C06E6104FE63976FB939FB5606BDFC43CB1C95C0F4542520604FADDC570F5D10A0172BA804C6FE312A68790C0473880D47063007
0B7144047958D10CF250865378D08377C1DD3FF4710D2210211480D093555E20BB4C49605742390F605640178764A00C357408081A200D38FC43090E10A143FF
425006261060091AC04C3DAA610B48F4E30D4BA88614ABB10448842C28B84847313AC1452E4AC11BFF60C20CFAF2105DF841382C9AC10B3280041B88B00659F0
C53F7CE107183EC4163660C27BE0600311F8D18F33D8550B66F04740FE880084F4631E5BD0188A0C523D378863476E910534DA42046B4C422278F1905208A20D
96B0442004318A7FD4A31290F8C2094ED00132FE033483D8C30FA0B0073500415B79E08512A0E210E08460168B09D54FD8A02EE0B4E02973E0247BDE30AF53BC
205F274082A76C9116044013092A20186466618B5AD82207D1D95474CA138453E882736380091C2A21817FF4EB443FE9011F02F19059440059E3905750F441FF
0458C0E09F3090C706E4510B69544298C4794B3B3FD71BDCDD213ACA4B575280931F88C8CE01C7C9140826438B5BF8A227D1B9014727D38B5A6447080FF91C13
F5E7B07FB80B9EFA034C1203953C4E1E272D2CB8A24E77CAD39EFAF4A7404D091064F18F409C011054E88AE35ED1113BB88223A5A9533114D10D7174E10731E0
0431D2100555E0031D0FD98018FE410C7CFC2305A84047150261842B50A010F8408628B631017C30E31268E0400C52208A41B08311247808174CF0030BA80110
B388850726000B5630E21AEC300038A6318809444106BF10C008CE108A48F0C003AAB084175461010AC8030DA490021A8C112790CC6217B0DD854EA402147AFF
8091ACE498850E5448566240E4B70EE12D4440020C703C0417C9E08811789B027940C408DAB80967F4348B64F0D6086572483256F60F5C1897221D49C106804B
DBCBA4EA2DA79883E500438017BCC1820F994119DA9985328CC77E5B080A0708B136FDB9E155806100896A37870608D3210378035D125086C500A61A60D8952D
E2F0860410C8071F702044D8200D061028C1F015962D6C310BE47878C413B11E4A93C414A754020598090A1788B0B6C7D04084B340DE413F756006AACA5437D1
DD3F34E4AD5AFDE335469E8534DEB04E8CF2CA5FD2234A47AC673FC0D0C1C5550EC265965181F455220E3FB9155D2AF10121FE23374CCA8D036810871D30C0FF
72FDA805742AF18F8A41E61F6BE81C45DE700A98F0E22E4FF695C7A637A81C0EA7127570F18AF87409414000539530F33FE4E2A94A48237EE942E9633AC0CDA5
CC4127FBAB841C656516B908E61F09AC72537C1C6262D5E07A1D09829E1FE23E1AE0F92D799883AEE750863808D31E4410831D88208807088322B2AEC4180EB3
9853E4C02139F0D60724300084F5C621E9F20D441258006E7ACBA60EE15C6FC45509983AC40F95C8C32C46758A0F7CD08382FE1537E3578B5BC44F320DE1268A
F72DA159C80306F173C82D0E500302B8922386AA01082645117B77443230A98584042E1598FC443252E9A6C4374EE2A07AFCE320FF93314CC88792975C10CDFF
F8C7AB5640A0BF306038C5034C19E03984C0FC03016FF10347ACF016D978ABCA6C585595DF320B19DA6F09D09A85E550CA9B25D871309508FA716AEE2C69C097
149430E13558F78F1038C083D2F0D6021DA20F3E5CE127B5F8C01CE2B3039D40E2C5E822544714F001BA8CA19895E85725F2F70F9E33133965F8092DC60394BB
0FF821BC11CB38B1238DB4BC4127EC4934CE73CA9105CC210800E003233862002228E31C4BB80C0928510193F341108D7048CF67319EEB2CA595990A95081210
020424E1D9B29E6825ACE0E33270B330C7B9AFB398F9C3A137265D80F9C06A125D8BC5BB0B26A7CC69C550F716181280F61778C102624184EC3A2412443044FF
344E810209D00105E67E251F3C80F66D1D1A746A41357E1C420B02D42204F197E8BACA53BB7439A01A739051C4D711B4603985471E147103D2500DB8C30B2DE5
2EBCF70FBC8053B0611EF1F71E04700B79B602FFB0077C100A07D2087CF0687B11700FD1097C60422A48047CC00FEA13691CE116A043111A831E6F6150EE9116
21D07577F610B7906AFFF06A4397078337740A942ED10311A9520D52F11616921687771CAF2275186050BDE3609912724161825A08325CD8856018866238861E
370BE3D503D48205C1A003C1500546600CEC2005C27508316001CE452C3A708757F40B9D500555500C5F382CB8305E7BC20180F00F54700C299106E1D01196FF
2003DC050069A003EC30029FD00DBE150C02A00829F00FC1100399B00E1D410AB1000AC9F50FEF700454C001FF200FEA00089E0012D320000600125060008AB0
01B3600106300984F80F02100C0FA10500F00F7A4006AC4011E1C00864706C6AE008A320156A400131508C2460014405055490093DB0015730029200566DC201
6E6302459002D8F51032F00D1D21034CF5104D600072F010FB15016AB00A927009380012F020000F210994100E9E4004C2B009D6F010AE10050F310CCEA008AC
300264B0015030098C9002C2E0098B100BC020586D100C92100A0E410E2330027DB0082960017F100306B20823600147900C161003EF1005A9D007208109DEAC
D70947E01026200A6D020E31F00F4D20035780082E80050EC1085090128520063CE0021EA027E47005262006EEF00F9E100126300AB880032B13063FE01002B0
0A1C91093AF00A32900626800BC6D0057FA303FFB020F8600CC0800F47700624900C2E400567508C0ED10EACD85DB0200FF2C003478008E04002DBF00967600C
BF600267E00152900251A0094D7004298007D4150857A0053F00037AE010A5500540850B7E4986A8F9130101003B}}
\par\par \b \uc2 Talyst\uc2 ; \uc2 Talyst \highlight22\uc2 Launches \highlight\uc2  Two  \highlight22\uc2 New Products \highlight\uc2  at ASHP Midyear Clinical Meeting 2015\b0\par\par\uc2 412 \uc2 words\par \uc2 14 December 2015\par \uc2 Journal of Engineering\par \uc2 JOENG\par 452\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Journal of Engineering via VerticalNews.com   \par \par \uc2 2015 DEC 14 (VerticalNews) -- By a News Reporter-Staff News Editor at Journal of Engineering -- \uc2 Talyst\uc2 , a market leader in pharmacy automation and long-term care solutions, will be exhibiting at the 2015 \uc2 American Society of Health-System Pharmacists\uc2  (ASHP) Midyear Clinical Meeting in New Orleans, LA from December 6 - 10. The company will be displaying both its Acute Care pharmacy automation technology as well as its Long-Term Care automation and business enhancement solutions.\par \par \uc2 Talyst\uc2  will be introducing two \b \highlight22\uc2 new products\b0 \highlight\uc2  at the ASHP Midyear Meeting, the first is the AutoPack(R) DEN model packager. The DEN is a fully automated oral solid packager with a reduced footprint for pharmacy convenience. The DEN can package up to 33 different oral solids at one time, in addition to an AutoCanister which can be used to dispense half-dose, infrequently used and oddly shaped tablets.\par \par \uc2 The second new product being released is the AutoFreeze(R) +H, an access controlled freezer used for securely storing frozen medications. The AutoFreeze +H maintains centralized control and reporting, and is scalable to meet expanding pharmacy needs as well as service satellite locations. Additional Acute Care products on display include AutoPharm(R) Enterprise medication inventory management software, AutoCarousel(R) medication storage automation, AutoVault and AutoCool + H secured storage solutions, automated vial filling technology, software for managing IV kitting and compounding medications as well as a newly updated version of AutoPharm Mobile software.\par \par \uc2 Finally, \uc2 Talyst\uc2 's long-term care division will be on hand to speak with hospitals who are interested in expanding their revenue by providing outpatient pharmacy services to long-term care facilities through its \uc2 Talyst\uc2  Certified Hospital InSite(R) Pharmacy (TCHIP) program and the InSite System.\par \par \uc2 "ASHP Midyear is an important event for us, and we are excited to be launching two new products at this years show," said \uc2 Carla Corkern\uc2 , Chief Executive Officer of Talyst. "As the only company that wakes up thinking about inpatient hospital pharmacy, we understand the needs of pharmacy management and staff and look forward to connecting with both current and future customers."\par \par \uc2 To learn more about our products and solutions, visit \uc2 Talyst\uc2  at booth #1319. For information about ASHP, please visit {\field{\*\fldinst{HYPERLINK "http://connect.ashp.org/midyear/home"}}{\fldrslt{\cf2 \uc2 http://connect.ashp.org/midyear/home}}}\uc2 .\par \par \uc2 Keywords for this news article include: \uc2 Talyst\uc2 , Hospital, Software, Technology.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document JOENG00020151214ebce0023e\par }\page {\par\fs20\b \uc2 Spherix Global Insights, GmbH; Pulmonologists Report High Unmet Need For  \highlight22\uc2 New Products \highlight\uc2  To Treat Idiopathic Pulmonary Fibrosis IPF, Despite The Recent  \highlight22\uc2 Launches \highlight\uc2  Of Roche's Esbriet And \uc2 Boehringer Ingelheim\uc2 's Ofev\b0\par\par\uc2 321 \uc2 words\par \uc2 14 December 2015\par \uc2 Respiratory Therapeutics Week\par \uc2 RTWK\par 5\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Respiratory Therapeutics Week via NewsRx.com   \par \par \uc2 2015 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Feedback gathered from therecently released Market Dynamix: Idiopathic Pulmonary Fibrosis (IPF) reveals that IPF remains a challenging disease to treat, especially as most diagnosed patients are in the later stages of this progressive disease. Furthermore, there is a concern that following \uc2 FDA\uc2  approval for both Esbriet and Ofev, future treatments will have an even higher threshold of efficacy to reach, potentially slowing down the arrival of new molecules.\par \par \uc2 Multiple companies including Afferent, \uc2 Biogen\uc2 , FibroGen, Gilead and \uc2 MediciNova\uc2  are currently developing future therapies for the treatment of IPF. However, physicians have very little awareness about the future therapy options, and what potential benefits they may bring. Beyond specialist treatment centers, physicians continue to debate the benefits of using older steroid-based therapies, and outside of established guidelines, patients themselves continue to investigate other treatment options, including stem cell innovations. Over 80% of physicians included in this study state that the primary goal for treatment remains to slow the progression of this disease, a goal that continues to be aspirational.\par \par \uc2 Market Dynamix: Idiopathic Pulmonary Fibrosis is based on responses to an online survey of 100 IPF-treating pulmonologists and 15 in-depth qualitative interviews with international thought leaders conducted during the fourth quarter of 2015. Further insight into the IPF market can be gleaned from an upcoming Spherix deliverable: RealWorld Dynamix: Idiopathic Pulmonary Fibrosis which is based on in-depth analysis of approximately 800 IPF patient records.\par \par \uc2 Keywords for this news article include: Respirology, Lung Diseases, Respiratory Tract Diseases, Spherix Global Insights GmbH, Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document RTWK000020151214ebce0000k\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Zogenix\uc2  Files 8K - Other Events >ZGNX\b0\par\par\uc2 665 \uc2 words\par \uc2 14 December 2015\par 16:06\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Zogenix Inc\uc2 . (ZGNX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 14, 2015.\par \par \uc2 On December 14, 2015, \uc2 Zogenix, Inc\uc2 . ("\uc2 Zogenix\uc2 ") announced that the \uc2 U.S. Food and Drug Administration\uc2  (the "\uc2 FDA\uc2 ") has accepted \uc2 Zogenix\uc2 's investigational new drug ("IND") application for \uc2 Zogenix\uc2 's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. The active IND now allows \uc2 Zogenix\uc2  to initiate its planned Phase 3 program for ZX008.\par \par \uc2 The Phase 3 program for ZX008 will consist of two randomized, double-blind placebo-controlled studies that will include two dose levels of ZX008 (0.2 mg/kg/day and 0.8 mg/kg/day, up to a maximum daily dose of 30 mg), as well as placebo. \uc2 Zogenix\uc2  intends to enroll 105 subjects in each of the two studies, with 35 patients in each treatment arm. One study will be conducted primarily in the United States and Canada, and the other will be a multi-national study, conducted primarily in Europe. The primary endpoint will be the change in frequency of convulsive seizures as compared to placebo. The key secondary endpoints include 40% and 50% responder analyses and convulsive seizure-free interval.\par \par \uc2 Zogenix\uc2  aims to initiate the U.S.-based pivotal clinical trial for ZX008 prior to year-end, which \uc2 Zogenix\uc2  expects would position it well to generate top-line results in 2016.\par \par \uc2 ***\par \par \uc2 Zogenix\uc2  cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as "believes," "indicates," "will," "plans," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on \uc2 Zogenix\uc2 's current beliefs and expectations. These forward-looking statements include statements regarding the timing of the commencement of Phase 3 clinical studies for ZX008 and the report of top-line results from such studies. Actual results may differ from those set forth in this report due to the risk and uncertainties inherent in \uc2 Zogenix\uc2 's business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as ZX008, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies may not be predictive of future results; \uc2 Zogenix\uc2 's reliance on third parties to conduct its clinical trials, enroll patients, manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that could result in recalls or product liability claims; \uc2 Zogenix\uc2 's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; and other risks described in \uc2 Zogenix\uc2 's filings with the \uc2 Securities and Exchange Commission\uc2 . You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and \uc2 Zogenix\uc2  undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1375151/000119312515402506/d103220d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1375151/000119312515402506/d103220d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1375151/000119312515402506/0001193125-15-402506-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1375151/000119312515402506/0001193125-15-402506-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 14, 2015 16:06 ET (21:06 GMT)\par \par \uc2 Document DJDN000020151214ebce00344\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Instratek Reports 10th Straight Year of Record Revenue Growth and  \highlight22\uc2 Launch \highlight\uc2  of ToeTac(TM)\b0\par\par\uc2 462 \uc2 words\par \uc2 11 December 2015\par 11:26\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 HOUSTON, Dec. 11, 2015 /PRNewswire/ -- Instratek, a privately held medical device company focused on minimally invasive endoscopic surgery and extremity implants, announces record revenue growth for the 10(th) straight year. The company recorded solid year over year revenue growth of its extremity endoscopy business and extremity implants, including the recently released nitinol fixation staple, STAPiX(TM).\par \par \uc2 "We released STAPiX about 6 months ago and are extremely pleased with the market response. Today we are announcing the release of our newest product ToeTac for the treatment of hammertoe deformities," said Jeff Seavey, President and CEO of Instratek. ToeTac is currently being \b \highlight22\uc2 launched\b0 \highlight\uc2  and is anticipated to fuel the continued growth of the company for 2016. "Our foot print in the extremity market continues to expand and we will make every opportunity to innovate with \b \highlight22\uc2 new products\b0 \highlight\uc2  focused in the extremity market."\par \par \uc2 The ToeTac implant is a one-piece, cannulated PEEK device that threads into the middle phalanx and pressfits into the proximal phalanx, providing a stable construct for PIP fusions. PEEK is a non-resorbable polymer that mimics the stiffness of bone and has high fatigue strength.\par \par \uc2 ToeTac kits are sterile, single-use, and fully disposable providing the most advanced hammertoe implant solution for surgeons and individual patient needs. Extremity surgeons demand proven performance and surgically efficient products. With the introduction of ToeTac, Instratek is the first company to provide a sterile solution that includes a cannulated PEEK implant and reamers together in one kit. The Cup & Cone style reamers create congruent concave-convex surfaces maximizing bony contact surface area.\par \par \uc2 This device is intended for orthopaedic and podiatric surgery. ToeTac is available in the U.S. through Instratek's distributor-based sales force and by contacting Instratek directly. Visit:\par \par {\field{\*\fldinst{HYPERLINK "http://www.instratek.com/toetac.php"}}{\fldrslt{\cf2 \uc2 http://www.instratek.com/toetac.php}}}\par \par \uc2 ToeTac is the latest addition to Instratek's innovative product solutions for foot & ankle and hand surgery. Other innovative products include STAPiX nitinol staples, Jones-FX fifth metatarsal screws, Mini Cannulated Titanium Headed & Headless screws, CMC Cable FIX(TM), Endotrac-Endoscopic Carpal Tunnel Release System, Endoscopic Trigger Finger Release, Endoscopic Plantar Fasciotomy, Endoscopic Gastrocnemius Release, Endoscopic Decompression of the Intermetatarsal Nerve, and the Sub-Talar Lok arthroereisis implant.\par \par \uc2 Instratek is a global medical device company, specializing in the development, manufacturing, and marketing of endoscopic instrumentation and surgical implants for the field of extremity surgery. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.instratek.com"}}{\fldrslt{\cf2 \uc2 www.instratek.com}}}\uc2 .\par \par \uc2 Contact: Marketing Department 1.800.892.8020\par \par \uc2 info@instratek.com\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/instratek-reports-10th-straight-year-of-record-revenue-growth-and-launch-of-toetac-300191830.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/instratek-reports-10th-straight-year-of-record-revenue-growth-and-launch-of-toetac-300191830.html}}}\par \par \uc2 SOURCE Instratek\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.instratek.com"}}{\fldrslt{\cf2 \uc2 http://www.instratek.com}}}\par \par \uc2 Document PRN0000020151211ebcb00096\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Rapid Expansion in Nutricosmetic Products Market Fuels Increased Sales Opportunities & High Margin Growth Potential Led by  \highlight22\uc2 New Product Launches \highlight\uc2  & Large Retail Store Distribution Partnerships\b0\par\par\uc2 1,631 \uc2 words\par \uc2 10 December 2015\par 08:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 CORAL SPRINGS, Florida, December 10, 2015 /PRNewswire/ --\par \par \uc2 The U.S. & global growing population of the individuals within the age group of 40-60 years is driving the market for nutricosmetic, anti-aging products and other skin-care/treatment products indicating demographic conditions will propel the sector for nutricosmetic ingredients market owing to increasing preference for products which detain signs of aging, improve skin firmness, reduce wrinkles and more. Leading companies focused on skin-care, cosmetic products of note are \uc2 RiceBran Technologies\uc2  (NASDAQ: RIBT), \uc2 Nu Skin Enterprises, Inc\uc2 . (NYSE: NUS), \uc2 Coty Inc. (NYSE: COTY)\uc2 , \uc2 DS Healthcare Group, Inc\uc2 . (NASDAQ: DSKX), \uc2 Herbalife LTd\uc2 . (NYSE: HLF) and \uc2 Avon Products, Inc\uc2 . (AVP)\par \par \uc2 RiceBran Technologies\uc2  (NASDAQ: RIBT), a global leader in the production and marketing of value added products derived from rice bran, began to focus on the emerging nutricosmetics market as a significant, high margin growth opportunity for its rice bran, rice bran oil and rice bran derivative products in late 2014. Today the Company announced that it has shipped a nutricosmetics order to a large retail chain customer with over 4,000 stores throughout the United States. The two new hand cream products formulated with rice bran oil were developed by RBT in conjunction with the retail chain's product development team. Those hand creams will be available in a select number of stores immediately with a larger roll out anticipated to take place in 2016. In addition to its 4,000 store footprint, the retail chain also sells its branded products through 30,000 additional independent retail locations. RBT sees the nutricosmetics product category as a significant high margin growth opportunity and is in various stages of development with other high value customers for additional nutricosmetics product launches in the coming quarters.\par \par \uc2 Read the full RiceBran Press Release at: {\field{\*\fldinst{HYPERLINK "http://www.financialnewsmedia.com/profiles/ribt.html"}}{\fldrslt{\cf2 \uc2 http://www.financialnewsmedia.com/profiles/ribt.html}}}\par \par \uc2 Skin care products made with rice bran and rice bran oil are known to make skin appear younger, less wrinkled and more evenly toned. Rice bran oil is naturally rich in nutrients such as gamma oryzanol, tocopherols and tocotrienols. These nutrients can fortify skin cells and help protect the skin from oxidative stress. Rice bran and rice bran oil have been used for centuries in cosmetic and beauty products in Japan dating back to the Geishas. Rice bran based products are credited with providing more beautiful and younger looking skin. Today, the most beautiful women in Japan are still known as 'nuka bijin' or rice bran beauties. \uc2 Mark McKnight\uc2 , SVP of Sales and Marketing at RBT, says: "According to NEXT: THE NATURAL PRODUCTS INDUSTRY FORECAST 2016, booming nutricosmetics markets in Japan and Europe have greatly contributed to success of the overall global nutricosmetics market, which is estimated to reach $5.5 billion by the year 2018. America is also starting to catch on and \uc2 RiceBran Technologies\uc2  expects to capitalize on emerging opportunities in nutricosmetic creams and lotions, exfoliants and 'beauty-from-within' products based on rice bran formulations."\par \par \uc2 In other Nutri-Cosmetic Products news and happenings around the sector: In connection with its annual investor day, \uc2 Nu Skin Enterprises, Inc\uc2 . (NYSE: NUS) last week reiterated its fourth-quarter and full-year 2015 outlook and announced financial guidance for 2016. "We have generated positive momentum this quarter with the initial introduction of ageLOC Me and ageLOC Youth," said \uc2 Truman Hunt\uc2 , president and chief executive officer. "Last month we had a strong response to the introduction of ageLOC Youth in the Americas, and this month, we are introducing ageLOC Me in South Korea and Japan. We believe the excitement among our sales leaders and consumers for both new products bodes well for our growth prospects in 2016." The company reiterated fourth-quarter 2015 revenue guidance of $570 to $590 million and earnings per share of $0.70 to $0.73. The company anticipates 2016 revenue of $2.29 to $2.33 billion representing growth of 5 to 7 percent in local currency, with a projected negative foreign currency impact of 4 percent. Earnings per share in 2016 are estimated to be $3.25 to $3.40.\par \par \uc2 Coty Inc. (NYSE: COTY) \uc2 announced in November that it had entered into a definitive agreement to acquire the personal care and beauty business (the "Beauty Business") of \uc2 Hypermarcas S.A\uc2 . (BM&FBovespa:HYPE3) for approximately $1.0 billion (R$3.8 billion) in cash. The transaction will be funded with a combination of cash on hand and available debt facilities. COTY closed up on Wednesday at $28.26 on over 1.4Mil shares traded by the market close. COTY was up slightly in the After Market on Wednesday as well.\par \par \uc2 DS Healthcare Group\uc2 's (NASDAQ: DSKX) flagship products are now selling in \uc2 Walmart\uc2  (NYSE: WMT), one of Brazil's largest retailers. With this addition, DS Laboratories further expands its global retail footprint as part of the company's omni-channel approach and continued dedication to delivering its breakthroughs to consumers worldwide.\par \par \uc2 In a FOX Business Network Exclusive, \uc2 Charlie Gasparino\uc2  has learned \uc2 Herbalife\uc2 's (NYSE: HLF) legal team is upping the pressure against hedge fund activist \uc2 Bill Ackman\uc2 . The company's legal counsel sent a letter to Ackman's \uc2 Pershing Square Capital\uc2  Investment's outside research firm, OTG Research Group, demanding that they stop soliciting confidential, proprietary and privileged information from both current and former \uc2 Herbalife\uc2  employees. The letter cites Ackman and his campaign against \uc2 Herbalife\uc2  describing his research tactics as troubling and improper. Read the full article at {\field{\*\fldinst{HYPERLINK "http://www.foxbusiness.com/investing/2015/12/08/herbalife-attorney-warns-ackman-team-to-steer-clear-employees/"}}{\fldrslt{\cf2 \uc2 http://www.foxbusiness.com/investing/2015/12/08/herbalife-attorney-warns-ackman-team-to-steer-clear-employees/}}}\par \par \uc2 Avon Products, Inc\uc2 . (AVP) (the "Company") last week issued the following statement in response to the press release issued on December 3, 2015 by \uc2 Barington Capital Group\uc2  ("Barington"): We are aware that Barington has made a public announcement expressing its views on our business. \uc2 Avon\uc2  welcomes open communication with and feedback from our shareholders. Our Board of Directors and management team regularly review a wide range of options regarding our business and operations and take into account the views of \uc2 Avon\uc2  shareholders. We remain focused on taking strategic actions to drive sustainable, profitable growth, address changing and challenging industry dynamics, create opportunity for our Representatives and enhance value for all \uc2 Avon\uc2  shareholders. This includes the actions we have taken and continue to take to drive improved performance in the North American business.\par \par \uc2 FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit {\field{\*\fldinst{HYPERLINK "http://www.financialnewsmedia.com"}}{\fldrslt{\cf2 \uc2 http://www.financialnewsmedia.com}}}\uc2  for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on \uc2 Facebook\uc2 : facebook.com/financialnewsmedia and \uc2 Twitter\uc2 : twitter.com/FNMgroup.\par \par \uc2 DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by \uc2 RiceBran Technologies\uc2  by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.\par \par \uc2 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the \uc2 Securities and Exchange Commission\uc2 . You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.\par \par \uc2 Contact Information:\par \par \uc2 Company: FN Media Group, LLC\par \par \uc2 Contact email: editor@financialnewsmedia.com\par \par \uc2 U.S. Phone: +1-(954)345-0611\par \par \uc2 URL: {\field{\*\fldinst{HYPERLINK "http://www.financialnewsmedia.com"}}{\fldrslt{\cf2 \uc2 http://www.financialnewsmedia.com}}}\par \par \uc2 SOURCE FN Media Group, LLC\par \par \uc2 Document PRN0000020151210ebca00081\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Titan Pharmaceuticals Files 8K - Other Events >TTNP\b0\par\par\uc2 198 \uc2 words\par \uc2 10 December 2015\par 06:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Titan Pharmaceuticals Inc\uc2 . (TTNP) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 09, 2015.\par \par \uc2 On December 9, 2015, \uc2 Titan Pharmaceuticals, Inc\uc2 . issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  has scheduled a meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) on Jan. 12, 2016 to review the New Drug Application for Probuphine(R) for the maintenance treatment of opioid addiction.\par \par \uc2 A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/910267/000114420415070178/v426648_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/910267/000114420415070178/v426648_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/910267/000114420415070178/0001144204-15-070178-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/910267/000114420415070178/0001144204-15-070178-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 10, 2015 06:01 ET (11:01 GMT)\par \par \uc2 Document DJDN000020151210ebca001cq\par }\page {\par\fs20\b \uc2 BRIEF: \uc2 Spectranetics\uc2  closes on $110M financing\b0\par\par\uc2 By Wayne Heilman, The Gazette (Colorado Springs, Colo.)   \par \uc2 Tribune Content Agency, LLC\par \uc2 192 \uc2 words\par \uc2 9 December 2015\par \uc2 The Gazette (Tribune Content Agency)\par \uc2 KRTGT\par \uc2 English\par \uc2 Distributed by Tribune Content Agency   \par \par \uc2 Dec. 09--Colorado Springs-based medical laser manufacturer \uc2 Spectranetics Corp\uc2 . said Monday it closed on $110 million in debt financing from MidCap Financial Trust and Silicon Valley Bank to replace a previous financing from \uc2 Wells Fargo Bank\uc2  to support the company through the \b \highlight22\uc2 launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  line.\par \par \uc2 The financing includes a $60 million, five-year loan with interest-only payments for the first two years and a $50 million revolving line of credit. The deal requires the company to maintain cash or cash equivalents totaling $10 million and achieve certain net revenue thresholds.\par \par \uc2 "This financing strengthens our cash position and secures the availability of capital resources through the U.S. Stellarex launch and below and allows us to make the necessary investments to capitalize on our attractive pipeline," said \uc2 Stacy McMahan\uc2 , the company's chief financial officer, in a news release.\par \par \uc2 -----\par \par \uc2 ___\par \par \uc2 (c)2015 The Gazette (Colorado Springs, Colo.)\par \par \uc2 Visit The Gazette (Colorado Springs, Colo.) at {\field{\*\fldinst{HYPERLINK "http://www.gazette.com"}}{\fldrslt{\cf2 \uc2 www.gazette.com}}}\par \par \uc2 Distributed by Tribune Content Agency, LLC.\par \par \uc2 Copyright (c) 2015, The Gazette (Colorado Springs, Colo.)\par \par \uc2 Document KRTGT00020151209ebc900007\par }\page {\par\fs20\uc2 Business\par \b \uc2 Spectranetics\uc2  closes on $110M financing\b0\par\par\uc2 122 \uc2 words\par \uc2 8 December 2015\par \uc2 The Gazette\par \uc2 CSP\par n/a\par \uc2 English\par \uc2 \u169\'00\'A9 2015 The Gazette. Provided by ProQuest Information and Learning. All Rights Reserved.   \par \par \uc2 Colorado Springs-based medical laser manufacturer \uc2 Spectranetics Corp\uc2 . said Monday it closed on $110 million in debt financing from MidCap Financial Trust and Silicon Valley Bank to replace a previous financing from \uc2 Wells Fargo Bank\uc2  to support the company through the \b \highlight22\uc2 launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  line.\par \par \uc2 The financing includes a $60 million, five-year loan with interest-only payments for the first two years and a $50 million revolving line of credit. The deal requires the company to maintain cash or cash equivalents totaling $10 million and achieve certain net revenue thresholds.\par \par \uc2 "This financing strengthens our cash position and secures the availability of capital resources through the U.S.\par \par \uc2 Read more on Colorado Springs Gazette\par \par \uc2 Document CSP0000020151209ebc800015\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Eagle Pharmaceuticals Files 8K - Regulation FD >EGRX\b0\par\par\uc2 388 \uc2 words\par \uc2 8 December 2015\par 12:37\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Eagle Pharmaceuticals Inc\uc2 . (EGRX) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 08, 2015.\par \par \uc2 Approval of BENDEKA\par \par \uc2 On December 8, 2015, \uc2 Eagle Pharmaceuticals, Inc\uc2 ., or the Company, along with \uc2 Teva Pharmaceutical Industries Ltd\uc2 ., or Teva, announced that the \uc2 U.S. Food and Drug Administration\uc2 , or \uc2 FDA\uc2 , has approved BENDEKA , (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.\par \par \uc2 Milestone Achievement\par \par \uc2 On December 8, 2015, the Company announced that it has achieved the milestone which entitles the Company to receive a $15 million payment from Teva resulting from the \uc2 FDA\uc2  approval of BENDEKA , and that the Company will receive a 20% royalty on net sales of BENDEKA\par \par \uc2 A copy of the press releases regarding the approval of BENDEKA and the milestone achievement are furnished as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended. As such, this information shall not be incorporated by reference into any of the Company's reports or other filings made with the \uc2 Securities and Exchange Commission\uc2 . The furnishing of the information in this current report is not intended to, and does not, constitute a determination or admission by the Company that the information in this current report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/827871/000110465915083556/a15-24697_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/827871/000110465915083556/a15-24697_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/827871/000110465915083556/0001104659-15-083556-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/827871/000110465915083556/0001104659-15-083556-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 08, 2015 12:37 ET (17:37 GMT)\par \par \uc2 Document DJDN000020151208ebc8002rz\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 SRI Biosciences and \uc2 Stanford Cancer Institute \highlight22\uc2 Launch \highlight\uc2  Drug Discovery Program\b0\par\par\uc2 544 \uc2 words\par \uc2 8 December 2015\par 09:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 MENLO PARK, Calif., Dec. 8, 2015 /PRNewswire/ -- A new collaborative program between scientists at SRI Biosciences, a division of \uc2 SRI International\uc2 , and physician-researchers from \uc2 Stanford Cancer Institute\uc2  (SCI) will pursue development of novel compounds to treat multiple forms of cancer and other conditions.\par \par \uc2 This SRI Biosciences-Stanford Drug Discovery and Development Program has been created in response to a significant drop in the early pipeline of innovative \b \highlight22\uc2 new drugs\b0 \highlight\uc2 , and builds on a history of partnerships among investigators from both institutions. The combined basic research, drug discovery and drug development expertise of researchers from SCI and SRI Biosciences has successfully advanced numerous projects, and the new program adds structure, support and coordination to such efforts.\par \par \uc2 Previous collaborations have yielded new therapeutic candidates, including Tirapazamine, an experimental anticancer drug discovered by SRI and SCI investigators and brought to Phase III clinical trials. Several other SRI-SCI developed compounds are currently undergoing preclinical testing.\par \par \uc2 Recently, Stanford professor of Neurology and Neurological Sciences, \uc2 Stanford University\uc2  School of Medicine Tony Wyss-Coray, Ph.D., and SRI Biosciences director of Medicinal and Synthetic Chemistry Mary Tanga, Ph.D., jointly discovered and developed a small molecule agonist of the TGF-beta signaling pathway for Alzheimer's disease. The new agent has successfully moved through preclinical development and is continuing into clinical trials.\par \par \uc2 "The SCI-SRI Biosciences collaboration provides a fully integrated engine for taking ideas to the investigational new drug (IND) stage and beyond," said Nathan Collins, Ph.D., executive director of the Pharmaceutical and Chemical Technologies Section in SRI Biosciences. "Our focus is on developing 'first-in-class' drugs and delivering improved outcomes for patients."\par \par \uc2 The program brings together teams of multidisciplinary scientists in both discovery and refinement of novel compounds and targets, and it provides access to the critical scientific infrastructure necessary for disease mechanism understanding and target discovery, and drug discovery and development through clinical safety and proof of concept.\par \par \uc2 "Advances in genomic and molecular analysis of individual patients and their cancers are creating new therapeutic opportunities," said Stanford Cancer Institute Director Beverly S. Mitchell, M.D. "We are excited to work with the skilled SRI Biosciences researchers to enhance our drug development efforts."\par \par \uc2 The program will be co-led by Sanjay V. Malhotra, Ph.D., FRSC, associate professor of radiation oncology at Stanford, and Nathan Collins. Together they will coordinate and support a diverse and evolving group of investigators and technical experts to advance promising projects.\par \par \uc2 About SRI Biosciences\par \par \uc2 SRI Biosciences, a division of \uc2 SRI International\uc2 , integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. \uc2 SRI International\uc2 , a research center headquartered in Menlo Park, California, creates world-changing solutions making people safer, healthier and more productive.\par \par \uc2 About \uc2 Stanford Cancer Institute\par \par \uc2 SCI is a National Cancer Institute-designated Cancer Center dedicated and resourced to catalyze the vast scientific, technological and human capabilities of \uc2 Stanford University\uc2  and Stanford Healthcare to advance understanding of cancer and rapidly translate research discoveries into improved prevention strategies, diagnostics and therapies.\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/sri-biosciences-and-stanford-cancer-institute-launch-drug-discovery-program-300189442.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/sri-biosciences-and-stanford-cancer-institute-launch-drug-discovery-program-300189442.html}}}\par \par \uc2 SOURCE \uc2 SRI International\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.sri.com"}}{\fldrslt{\cf2 \uc2 http://www.sri.com}}}\par \par \uc2 Document PRN0000020151208ebc8000dx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 InVivo Therapeutics Files 8K - Other Events >NVIV\b0\par\par\uc2 528 \uc2 words\par \uc2 3 December 2015\par 08:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 InVivo Therapeutics Holdings Corp\uc2 . (NVIV) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 01, 2015.\par \par \uc2 On December 3, 2015, the Company issued a press release announcing that it has received conditional approval from the \uc2 U.S. Food and Drug Administration\uc2  to convert its ongoing pilot study into a pivotal probable benefit study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 Cautionary Note Regarding Forward-Looking Statements\par \par \uc2 This Current Report on Form 8-K and the press release filed herewith contain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements" for purposes of these provisions, and include statements regarding conditional approval of the company's pivotal probable benefit study and the expected timing of enrollment in the study and subsequent HDE approval and commercialization. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties that could cause future results to differ materially from current expectations, including company's ability to obtain final approval from the \uc2 FDA\uc2  and to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company's ability to commercialize its products; the expected benefits and efficacy of the company's products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Additional risk factors are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other filings the Company makes with the \uc2 Securities and Exchange Commission\uc2 , including quarterly reports on Form 10-Q and current reports on Form 8-K. All forward-looking statements included in this Current Report on Form 8-K and the press release filed herewith are made as of the date hereof, based on information available to the Company as of the date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1292519/000110465915082606/a15-24460_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1292519/000110465915082606/a15-24460_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1292519/000110465915082606/0001104659-15-082606-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1292519/000110465915082606/0001104659-15-082606-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 03, 2015 08:04 ET (13:04 GMT)\par \par \uc2 Document DJDN000020151203ebc3001pm\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Talyst \highlight22\uc2 Launches \highlight\uc2  Two  \highlight22\uc2 New Products \highlight\uc2  at ASHP Midyear Clinical Meeting 2015\b0\par\par\uc2 504 \uc2 words\par \uc2 2 December 2015\par 12:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 KIRKLAND, Wash., Dec. 2, 2015 /PRNewswire/ -- \uc2 Talyst\uc2 , a market leader in pharmacy automation and long-term care solutions, will be exhibiting at the 2015 \uc2 American Society of Health-System Pharmacists\uc2  (ASHP) Midyear Clinical Meeting in New Orleans, LA from December 6 - 10. The company will be displaying both its Acute Care pharmacy automation technology as well as its Long-Term Care automation and business enhancement solutions.\par \par \uc2 Talyst\uc2  will be introducing two \b \highlight22\uc2 new products\b0 \highlight\uc2  at the ASHP Midyear Meeting, the first is the AutoPack(R) DEN model packager. The DEN is a fully automated oral solid packager with a reduced footprint for pharmacy convenience. The DEN can package up to 33 different oral solids at one time, in addition to an AutoCanister which can be used to dispense half-dose, infrequently used and oddly shaped tablets.\par \par \uc2 The second new product being released is the AutoFreeze(R) +H, an access controlled freezer used for securely storing frozen medications. The AutoFreeze +H maintains centralized control and reporting, and is scalable to meet expanding pharmacy needs as well as service satellite locations. Additional Acute Care products on display include AutoPharm(R) Enterprise medication inventory management software, AutoCarousel(R) medication storage automation, AutoVault and AutoCool + H secured storage solutions, automated vial filling technology, software for managing IV kitting and compounding medications as well as a newly updated version of AutoPharm Mobile software.\par \par \uc2 Finally, \uc2 Talyst\uc2 's long-term care division will be on hand to speak with hospitals who are interested in expanding their revenue by providing outpatient pharmacy services to long-term care facilities through its \uc2 Talyst\uc2  Certified Hospital InSite(R) Pharmacy (TCHIP) program and the InSite System.\par \par \uc2 "ASHP Midyear is an important event for us, and we are excited to be launching two new products at this years show," said \uc2 Carla Corkern\uc2 , Chief Executive Officer of Talyst. "As the only company that wakes up thinking about inpatient hospital pharmacy, we understand the needs of pharmacy management and staff and look forward to connecting with both current and future customers."\par \par \uc2 To learn more about our products and solutions, visit \uc2 Talyst\uc2  at booth #1319. For information about ASHP, please visit {\field{\*\fldinst{HYPERLINK "http://connect.ashp.org/midyear/home"}}{\fldrslt{\cf2 \uc2 http://connect.ashp.org/midyear/home}}}\uc2 .\par \par \uc2 About \uc2 Talyst\par \par \uc2 Talyst\uc2  is a leader in pharmacy automation hardware and software solutions. Our products provide enterprise-wide medication management across your entire health system to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2015, \uc2 Talyst\uc2  has installed automated solutions in more than 500 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. We offer a powerful software platform with a suite of hardware components to meet your enterprise-wide needs. Follow us on \uc2 Twitter\uc2  @Talyst_Inc or visit us at {\field{\*\fldinst{HYPERLINK "http://www.talyst.com"}}{\fldrslt{\cf2 \uc2 www.talyst.com}}}\uc2 .\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/talyst-launches-two-new-products-at-ashp-midyear-clinical-meeting-2015-300186733.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/talyst-launches-two-new-products-at-ashp-midyear-clinical-meeting-2015-300186733.html}}}\par \par \uc2 SOURCE \uc2 Talyst\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.talyst.com"}}{\fldrslt{\cf2 \uc2 http://www.talyst.com}}}\par \par \uc2 Document PRN0000020151202ebc2000h8\par }\page {\par\fs20\b \uc2 CR7 Drive.( \highlight22\uc2 New Products \highlight\uc2 )(Herbalife24  \highlight22\uc2 launched \highlight\uc2 )(Brief article)\b0\par\par\uc2 123 \uc2 words\par \uc2 1 December 2015\par \uc2 Nutraceuticals World\par \uc2 NUTW\par 123\par \uc2 ISSN: 1531-0671; Volume 18; Issue 10\par \uc2 English\par \uc2 Copyright 2015 Gale Group. All rights reserved. \par \par \uc2 The Herbalife24 line from Herbalife, Los Angeles, CA, has debuted CR7 Drive-a contemporary take on the traditional sports drink without any artificial flavors or sweeteners. Tried, tested and formulated with professional athlete Cristiano Ronaldo, CR7 Drive is an isotonic beverage formulated to provide three components necessary for performance: enhanced hydration, metabolism-supporting vitamin B12, and energy.\par \par \uc2 The formula contains just 50 calories per scoop, and an optimal high glucose to fructose ratio, according to the company. CR7 Drive enhances hydration with 320 mg of vital electrolytes, such as sodium, potassium and magnesium, which are typically lost during exercise. The drink features a light Acai Berry flavor without the use of artificial flavors or sweeteners.\par \par \uc2 Document NUTW000020160115ebc10000u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Pulmonologists Report High Unmet Need For  \highlight22\uc2 New Products \highlight\uc2  To Treat Idiopathic Pulmonary Fibrosis (IPF), Despite The Recent  \highlight22\uc2 Launches \highlight\uc2  Of Roche's Esbriet And \uc2 Boehringer Ingelheim\uc2 's Ofev\b0\par\par\uc2 442 \uc2 words\par \uc2 30 November 2015\par 15:54\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Roughly half of surveyed pulmonologists treating patients with IPF have concerns about tolerability and side effects with currently available options, according to Spherix Global Insights, GmbH \par  \f28 \par \par \uc2 \f2 ZUG, Switzerland, Nov. 30, 2015 /PRNewswire/ -- Feedback gathered from the recently released Market Dynamix: Idiopathic Pulmonary Fibrosis (IPF) reveals that IPF remains a challenging disease to treat, especially as most diagnosed patients are in the later stages of this progressive disease. Furthermore, there is a concern that following \f28 \uc2 \f2 FDA\f28 \uc2 \f2  approval for both Esbriet and Ofev, future treatments will have an even higher threshold of efficacy to reach, potentially slowing down the arrival of new molecules.\f28 \par \par \uc2 Multiple companies including Afferent, \uc2 Biogen\uc2 , FibroGen, Gilead and \uc2 MediciNova\uc2  are currently developing future therapies for the treatment of IPF. However, physicians have very little awareness about the future therapy options, and what potential benefits they may bring. Beyond specialist treatment centers, physicians continue to debate the benefits of using older steroid-based therapies, and outside of established guidelines, patients themselves continue to investigate other treatment options, including stem cell innovations. Over 80% of physicians included in this study state that the primary goal for treatment remains to slow the progression of this disease, a goal that continues to be aspirational.\par \par \uc2 Market Dynamix: Idiopathic Pulmonary Fibrosis is based on responses to an online survey of 100 IPF-treating pulmonologists and 15 in-depth qualitative interviews with international thought leaders conducted during the fourth quarter of 2015. Further insight into the IPF market can be gleaned from an upcoming Spherix deliverable: RealWorld Dynamix: Idiopathic Pulmonary Fibrosis which is based on in-depth analysis of approximately 800 IPF patient records.\par \par \uc2 About Spherix Global Insights\par \par \uc2 Spherix Global Insights is a newly established business intelligence and market research company headquartered in Zug, Switzerland with US offices in Cambridge, MA. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.\par \par \uc2 All company, brand or product names in this document are trademarks of their respective holders.\par \par \uc2 For more information\par \par \uc2 Contact:\par \par \uc2 Katharina Skwara, Marketing Manager\par \par \uc2 Telephone: +41 (0) 41 747 18 76\par \par \uc2 Email: info@spherixglobalinsights.com\par \par {\field{\*\fldinst{HYPERLINK "http://www.spherixglobalinsights.com"}}{\fldrslt{\cf2 \uc2 www.spherixglobalinsights.com}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/pulmonologists-report-high-unmet-need-for-new-products-to-treat-idiopathic-pulmonary-fibrosis-ipf-despite-the-recent-launches-of-roches-esbriet-and-boehringer-ingelheims-ofev-300185515.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/pulmonologists-report-high-unmet-need-for-new-products-to-treat-idiopathic-pulmonary-fibrosis-ipf-despite-the-recent-launches-of-roches-esbriet-and-boehringer-ingelheims-ofev-300185515.html}}}\par \par \uc2 SOURCE Spherix Global Insights, GmbH\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.spherixglobalinsights.com"}}{\fldrslt{\cf2 \uc2 http://www.spherixglobalinsights.com}}}\par \par \uc2 Document PRN0000020151130ebbu000jq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Cumberland Pharma Files 8K - Other Events >CPIX\b0\par\par\uc2 163 \uc2 words\par \uc2 24 November 2015\par 17:23\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Cumberland Pharmaceuticals Inc\uc2 . (CPIX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 24, 2015.\par \par \uc2 On November 23, 2015, \uc2 Cumberland Pharmaceuticals Inc\uc2 . (the "Company") issued a press release announcing the launch of Caldolor (R) (ibuprofen) Injection in Australia. A copy of the press release is furnished as Exhibit 99.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1087294/000162828015008980/a8k-caldolorlaunchinaustra.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1087294/000162828015008980/a8k-caldolorlaunchinaustra.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1087294/000162828015008980/0001628280-15-008980-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1087294/000162828015008980/0001628280-15-008980-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 24, 2015 17:23 ET (22:23 GMT)\par \par \uc2 Document DJDN000020151124ebbo003ym\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan Reports  \highlight22\uc2 Launch \highlight\uc2  Of Generic FazaClo Orally Disintegrating Tablets\b0\par\par\uc2 176 \uc2 words\par \uc2 24 November 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Mylan N.V\uc2 . (MYL) Tuesday reported the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.\par \par \uc2 Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, had U.S. sales of about $51.1 million for the 12 months ending September 30, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 272 ANDAs pending \uc2 FDA\uc2  approval representing $101.8 billion in annual brand sales, according to \uc2 IMS Health\uc2 .\par \par \uc2 Fifty of these pending ANDAs are potential first-to-file opportunities, representing $36.1 billion in annual brand sales, for the 12 months ending June 30, says \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151124ebbo003mo\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Breckenridge Announces Final Approval for Dutasteride Soft Gelatin Capsules\b0\par\par\uc2 218 \uc2 words\par \uc2 20 November 2015\par 11:15\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 BOCA RATON, Fla., Nov. 20, 2015 /PRNewswire/ -- \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announced the final approval by the \uc2 U.S. Food and Drug Administration\uc2  of the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Dutasteride Soft Gelatin Capsules 0.5mg, which is AB rated to Avodart(R), a drug marketed by GlaxoSmith Kline. Avodart(R) annual sales totaled $467 million based on recent \uc2 IMS Health\uc2  sales data. Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Breckenridge will \b \highlight22\uc2 launch\b0 \highlight\uc2  the product immediately.\par \par \uc2 About Breckenridge:\par \par \uc2 Breckenridge Pharmaceutical, Inc\uc2 . is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays and powders. {\field{\*\fldinst{HYPERLINK "http://www.bpirx.com"}}{\fldrslt{\cf2 \uc2 www.bpirx.com}}}\par \par \uc2 * The brands listed are trademarks of their respective owners.\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/breckenridge-announces-final-approval-for-dutasteride-soft-gelatin-capsules-300182574.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/breckenridge-announces-final-approval-for-dutasteride-soft-gelatin-capsules-300182574.html}}}\par \par \uc2 SOURCE \uc2 Breckenridge Pharmaceutical, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.bpirx.com"}}{\fldrslt{\cf2 \uc2 http://www.bpirx.com}}}\par \par \uc2 Document PRN0000020151120ebbk000ba\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Breckenridge Announces Approval for Rabeprazole Sodium Delayed-Release Tablets\b0\par\par\uc2 425 \uc2 words\par \uc2 19 November 2015\par 12:47\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 BOCA RATON, Fla., Nov. 19, 2015 /PRNewswire/ -- \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announces the final approval by the \uc2 U.S. Food and Drug Administration\uc2  of the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Rabeprazole Sodium Delayed Release Tablets. The product is being manufactured and supplied by Rubicon Research Private Limited, and will be available in 20mg strengths and pack sizes of 30's, 90's and 500ct. Rabeprazole DR Tablets are AB rated to Aciphex(R), which is indicated for the treatment, healing and maintenance of GERD in Adults and Adolescent Patients 12 Years of age and older and the healing of Duodenal Ulcers in Adults has annual sales of $128 million based on \uc2 IMS Health\uc2  sales data, as of September 2015. The product \b \highlight22\uc2 launch\b0 \highlight\uc2  plans are being finalized and the first shipment will occur shortly.\par \par \uc2 About Breckenridge:\par \par \uc2 Breckenridge Pharmaceutical, Inc\uc2 ., is a privately-held own label Distributor that performs pharmaceutical research and development as well as marketing and distribution in the U.S. The company markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, and powders. {\field{\*\fldinst{HYPERLINK "http://www.bpirx.com"}}{\fldrslt{\cf2 \uc2 www.bpirx.com}}}\par \par \uc2 About Rubicon Research Private Limited.\par \par \uc2 "Rubicon is technology driven \uc2 pharmaceutical product development\uc2  company. Rubicon is engaged in research, development, and manufacturing of both OTC and Rx branded and specialty generic products. Rubicon has demonstrated excellence in product development across dosage forms such as Oral Solids, Oral Liquids and Topical formulations. Rubicon carries out Innovative Research programs that include development of differentiated products based on proprietary technology platforms such Orally Disintegrating Tablet Technology, Gastroretentive Solubilized Drug Delivery System and Extended Release Oral (Solid and Liquid) Systems. The technologies are all IP protected and Rubicon has numerous patents application and a few issued patents which gives freedom to operate to our partner companies. Rubicon has a state-of-art commercial manufacturing plant which has been successfully inspected by USFDA and UKMHRA. " For further information, please visit {\field{\*\fldinst{HYPERLINK "http://www.rubicon.co.in"}}{\fldrslt{\cf2 \uc2 www.rubicon.co.in}}}\par \par \uc2 ACIPHEX(R) is a registered trademark used by \uc2 Eisai Inc\uc2 . under license from Eisai R&D Management Co., Ltd.\par \par \uc2 (c)2013 \uc2 Eisai Inc\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/breckenridge-announces-approval-for-rabeprazole-sodium-delayed-release-tablets-300182004.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/breckenridge-announces-approval-for-rabeprazole-sodium-delayed-release-tablets-300182004.html}}}\par \par \uc2 SOURCE \uc2 Breckenridge Pharmaceutical, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.bpirx.com"}}{\fldrslt{\cf2 \uc2 http://www.bpirx.com}}}\par \par \uc2 Document PRN0000020151119ebbj00114\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Gurnet Point Capital  \highlight22\uc2 Launches New Drug \highlight\uc2  Development Company, Boston Pharmaceuticals, with $600 Million Commitment\b0\par\par\uc2 1,075 \uc2 words\par \uc2 19 November 2015\par 08:30\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2015  Business Wire. All Rights Reserved.   \par \par \uc2 New Venture will Partner with Academic, Biotechnology and Biopharmaceutical Groups to Develop New Medicines\par \par \uc2 \f2 \par CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 19, 2015-- \f28 \par \par \uc2 Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by \uc2 Christopher A. Viehbacher\uc2 , today announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.\par \par \uc2 With a differentiated combination of proven industry expertise and dedicated capital, Boston Pharmaceuticals will partner with academic, biotechnology and biopharmaceutical groups to acquire clinical assets at various stages of their development. The company is composed of a small team of clinical development experts operating with the efficiency of a small company and building a substantial portfolio of clinical and commercial assets. Boston Pharmaceuticals is agnostic to therapeutic area specialization, focused instead on validated mechanisms of action of targeted diseases and efficiently achieving robust clinical and regulatory endpoints. The group will assume the risk of clinical development in de-risking the clinical assets and creating value for patients. The company's focus is around:\par \par \uc2 \f2 \par    -- Development phase of drug R&D \par  \par    -- Small team of clinical development and regulatory experts \par  \par    -- Virtual development through service providers and external experts \par  \par    -- Validated mechanism of action of targeted diseases \par  \par    -- Robust clinical endpoints \par  \par    -- Sale or commercialization of clinical programs \f28 \par \par \uc2 \f2 By leveraging the executive team's network of external partners and service providers, the company will develop and launch products from drug development companies and labs worldwide. Through careful selection of disease areas and mechanisms of action, Boston Pharmaceuticals intends to build a valuable portfolio of clinical stage products focused on delivering medicines that greatly improve current treatment options to provide patients with breakthrough solutions for complex diseases.\f28 \par \par \uc2 \f2 The company will be led by two executives with deep experience in the development and commercialization of novel medicines -- \f28 \uc2 \f2 Christopher Viehbacher\f28 \uc2 \f2 , the Managing Partner of Gurnet Point Capital and the former CEO of Sanofi, as its Chairman, and \f28 \uc2 \f2 Dr. Robert Armstrong\f28 \uc2 \f2 , the former head of external R&D at Chorus (\f28 \uc2 \f2 Eli Lilly\f28 \uc2 \f2 ), as its CEO.\f28 \par \par \uc2 \f2 Commenting on Boston Pharmaceuticals' focused approach, Viehbacher stated, "This is a new way to develop and to bring to market innovative medicines. We believe that the combination of our dedicated capital pool and extensive industry expertise will give Boston Pharmaceuticals a significant competitive advantage in this space. In today's world of enhanced scientific progress, but constrained financial resources for R&D, Boston Pharmaceuticals offers an efficient means to de-risk and unlock value in early stage assets that might not otherwise be developed. The company has significant capital resources from Gurnet Point Capital and a long-term investment horizon, meaning Boston Pharmaceuticals can focus resources toward the development of innovative medicines in a unique way."\f28 \par \par \uc2 \f2 Robert Armstong, Boston Pharmaceuticals' CEO, noted, "The company seeks to put novel medicines that are IND-ready or beyond into its development framework. We are acquiring molecules outright or through licensing, to take on the risk of development. Our principle focus is to develop these assets through to proof-of-concept, and often through late-stage clinical trials, registration and commercialization. Boston Pharmaceuticals' objective is to subject each new product to the most rigorous studies, establishing clinical benefit and minimizing development risks. We aim to have a large portfolio of programs encompassing both large and small molecules across multiple therapeutic areas. By not having any imperatives other then the successful development of its molecules, Boston Pharmaceuticals will be in the most unbiased position to exploit their full potential."\f28 \par \par \uc2 \f2 About Gurnet Point Capital\f28 \par \par \uc2 \f2 A unique fund founded by Ernesto Bertarelli and led by \f28 \uc2 \f2 Christopher Viehbacher\f28 \uc2 \f2 . Its mission is to help entrepreneurs build their businesses through the investment of long-term capital as well as the experience and expertise of the fund's team. Gurnet Point Capital invests across all stages of product development through to commercialization, and represents a hybrid of venture and private equity investment strategies. These strategies rely on the core tenet that even the earliest of technologies needs to present a clear commercial thesis, both benefiting patients and the healthcare system as a whole. The fund has an initial allocation of $2 billion.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Christopher A. Viehbacher\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Christopher A. Viehbacher\f28 \uc2 \f2  is the Managing Partner of Gurnet Point Capital, the healthcare and life sciences investment fund established in 2013. The former CEO of Sanofi, during his six year tenure with the company Viehbacher completed over $30 billion of acquisitions, including \f28 \uc2 \f2 Genzyme\f28 \uc2 \f2 . Prior to \f28 \uc2 \f2 Sanofi\f28 \uc2 \f2 , Viehbacher spent 20 years with \f28 \uc2 \f2 GlaxoSmithKline\f28 \uc2 \f2 , ultimately as President of GSK's North American pharmaceutical division. He was a Member of the Board of Directors of \f28 \uc2 \f2 GSK plc\f28 \uc2 \f2  and Co-President of GSK's Portfolio Management Board. Viehbacher began his career with \f28 \uc2 \f2 Price Waterhouse Coopers\f28 \uc2 \f2  and qualified as a Chartered Accountant. Viehbacher has been Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (\f28 \uc2 \f2 PhRMA\f28 \uc2 \f2 ), as well as President of the European Federation of Pharmaceutical Industries and Associations. He has received France's highest civilian honor, the Legion d'Honneur.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Dr. Robert Armstrong\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 Rob Armstrong is the Chief Executive Officer, board member, and co-founder of Boston Pharmaceuticals. With over twenty years of experience working in research and development in the biopharmaceutical industry, Rob has been involved in the discovery and clinical development of programs across multiple disease areas.\f28 \par \par \uc2 \f2 Rob created and led the small molecule R&D organization at \f28 \uc2 \f2 Amgen\f28 \uc2 \f2  in Thousand Oaks, CA. He subsequently co-led research at Lilly as Vice President of Global Medicinal Chemistry, was head of the translational medicine group Chorus, and was Vice President of Global External R&D. He served on the finance and scientific advisory boards of Lilly BioVentures.\f28 \par \par \uc2 \f2 Prior to working in industry, Rob was a tenured Professor of Chemistry and Biochemistry at the University of California at Los Angeles. Rob received his BS in chemistry at UCSD, his Ph.D. in chemistry at CSU, and was an \f28 \uc2 \f2 NIH\f28 \uc2 \f2  postdoctoral fellow at Harvard.\f28 \par \par \uc2 \f2 Rob is an advisor to Gelesis and serves on the board of directors of early stage biotechnology companies Curza Therapeutics, Cloud Pharmaceuticals, Entrega Bio, and Artax Biopharma.\f28 \par \par \uc2 \f2 View source version on businesswire.com: \f28 {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20151119005697/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20151119005697/en/}}}\uc2 \f2 \f28 \par \par \uc2 Document BWR0000020151119ebbj000ng\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Radius Health Files 8K - Regulation FD >RDUS\b0\par\par\uc2 292 \uc2 words\par \uc2 17 November 2015\par 09:56\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Radius Health Inc\uc2 . (RDUS) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 17, 2015.\par \par \uc2 On November 17, 2015, \uc2 Radius Health, Inc\uc2 . (the "Company") announced that it had submitted a Marketing Authorization Application in Europe for abaloparatide-SC. The Company also announced that it now plans to submit a New Drug Application to the \uc2 United States Food and Drug Administration\uc2  for abaloparatide-SC by the end of the first quarter of 2016. A copy of the press release discussing this announcement is furnished as Exhibit 99.1 to this current report on Form 8-K (the "Current Report").\par \par \uc2 The information in Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1428522/000110465915079536/a15-23587_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1428522/000110465915079536/a15-23587_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1428522/000110465915079536/0001104659-15-079536-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1428522/000110465915079536/0001104659-15-079536-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 17, 2015 09:56 ET (14:56 GMT)\par \par \uc2 Document DJDN000020151117ebbh0022q\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic AXERT Tablets - Quick Facts\b0\par\par\uc2 163 \uc2 words\par \uc2 17 November 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - Mylan N.V. (MYL) reported the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Almotriptan Tablets USP, 6.25 mg and 12.5 mg, the generic version of Janssen Pharmaceutical's AXER.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, used for the acute treatment of migraine attacks in adult patients with a history of migraine with or without aura.\par \par \uc2 In adolescents aged 12 to 17 years, it is indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more when untreated.\par \par \uc2 lmotriptan Tablets USP, 6.25 mg and 12.5 mg, had U.S. sales of $29.2 million for the 12 months ending September 30, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151117ebbh003s5\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan Reports  \highlight22\uc2 Launch \highlight\uc2  Of Generic Viramune XR Extended-Release Tablets, 100 Mg\b0\par\par\uc2 164 \uc2 words\par \uc2 16 November 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - Mylan N.V. (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Nevirapine Extended-release Tablets, 100 mg, the generic version of \uc2 Boehringer Ingelheim\uc2 's Viramune XR.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in children 6 to less than 18 years of age.\par \par \uc2 The launch adds to Mylan's growing portfolio of ARV medicines across the globe. About 50 percent of those being treated for HIV/AIDS in the developing world rely on a Mylan product.\par \par \uc2 Nevirapine Extended-release Tablets, 100 mg, had U.S. sales of $67 thousand for the 12 months ending Sept. 30, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151116ebbg003xq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic GLUCOTROL XL tablets\b0\par\par\uc2 99 \uc2 words\par \uc2 16 November 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Glipizide Extended-release Tablets, 5 mg and 10 mg, the generic version of \uc2 Pfizer\uc2 's (PFE) GLUCOTROL XL. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide Extended-release Tablets, 5 mg, and 10 mg, had U.S. sales of approximately $70.7 million for the 12 months ending September 30, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 Document FLYWAL0020151116ebbg002bi\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Lipocine Files 8K - Regulation FD >LPCN\b0\par\par\uc2 192 \uc2 words\par \uc2 12 November 2015\par 16:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Lipocine Inc\uc2 . (LPCN) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 12, 2015.\par \par \uc2 On November 12, 2015, \uc2 Lipocine Inc\uc2 . issued a press release to announce that the \uc2 U.S. Food and Drug Administration\uc2  ("\uc2 FDA\uc2 ") has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 28, 2016, for completion of the review of the New Drug Application ("NDA") for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420415064689/v424567_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420415064689/v424567_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420415064689/0001144204-15-064689-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420415064689/0001144204-15-064689-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 12, 2015 16:04 ET (21:04 GMT)\par \par \uc2 Document DJDN000020151112ebbc0042a\par }\page {\par\fs20\b \uc2 Teleflex Incorporated\uc2 ; \uc2 Teleflex \highlight22\uc2 Introduces \highlight\uc2  Comfort Flo(R) Plus Cannula for Heated High Flow Nasal Cannula Therapy\b0\par\par\uc2 386 \uc2 words\par \uc2 9 November 2015\par \uc2 Respiratory Therapeutics Week\par \uc2 RTWK\par 10\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Respiratory Therapeutics Week via NewsRx.com   \par \par \uc2 2015 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- \uc2 Teleflex Incorporated\uc2  (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of the Comfort Flo(R) Plus High Flow Nasal Cannula. This \b \highlight22\uc2 new product\b0 \highlight\uc2  addition expands the company's portfolio of Heated High Flow Nasal Cannula Therapy (HFNCT) solutions and is designed to enhance patient comfort.\par \par \uc2 Inspired by the physicians and clinicians who help develop our products, the Comfort Flo(R) Plus Cannula is designed to enhance the overall patient experience by offering silicone nares, an optional chin strap to encourage closed mouth treatments, which may increase positive end pressure (PEP)3, and a bifurcated head strap for a secure fit during patient movement.\par \par \uc2 "\uc2 Teleflex\uc2  is dedicated to connecting clinicians with technology that helps improve patient outcomes and advances respiratory care," said James Ferguson, President of the Respiratory Division at Teleflex. "The addition of the Comfort Flo(R) Plus Cannula supports the growing utilization of High Flo Nasal Cannula Therapy and further demonstrates our commitment to developing products that improve the quality of people's lives."\par \par \uc2 HFNCT has been shown to improve pulmonary compliance, reduce work of breathing and wash out dead space leading to improved fraction of alveolar gases.1 A new study from The New England Journal of Medicine suggests treatment with HFNCT can improve survival rates among patients with Acute Hypoxemic Respiratory Failure compared to treatment with standard Oxygen Masks or Non-Invasive Ventilation.2 About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. \uc2 Teleflex\uc2  employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.\par \par \uc2 Keywords for this news article include: Therapy, Technology, Respiratory Care, \uc2 Teleflex Incorporated\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document RTWK000020151109ebb90000x\par }\page {\par\fs20\b \uc2 Elanco Animal Health\uc2 ; Elanco Expands Parasiticide Portfolio in US with  \highlight22\uc2 New Product \highlight\uc2  for Heartworm Disease, Intestinal Parasites\b0\par\par\uc2 376 \uc2 words\par \uc2 9 November 2015\par \uc2 Pharma Business Week\par \uc2 PHBW\par 59\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Pharma Business Week via NewsRx.com   \par \par \uc2 2015 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Elanco Animal Health\uc2  has \b \highlight22\uc2 launched\b0 \highlight\uc2  Interceptor(R) Plus (milbemycin oxime/praziquantel) in the United States. Interceptor Plus is a monthly chewable tablet that prevents heartworm disease caused by Dirofilaria immitis and protects against intestinal parasites including adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis, Toxascaris leonina), adult whipworm (Trichuris vulpis) and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis and Echinococcus granulosus) in dogs.\par \par \uc2 Interceptor Plus is chicken flavored, making it a good choice for dogs with beef allergies. Dosing is easy, with more than 96% overall acceptability. It is safe for use in dogs and puppies 6 weeks of age and older that weigh 2 pounds or more.\par \par \uc2 "Interceptor Plus is a great choice for dog owners with active, outdoor dogs," according to Dr. Stephen Connell, Director, Technical, Academic and Consumer Services. "Dogs that play in dog parks or frequently visit boarding or grooming facilities where they interact with other dogs also can benefit from Interceptor Plus."\par \par \uc2 Interceptor Plus is approved by the \uc2 FDA\uc2  and available only through veterinarians. The product is supported by an Elanco product guarantee. "This is another product that supports Elanco's commitment to helping pets live longer, healthier, higher-quality lives," Connell said.\par \par \uc2 Elanco, a division of \uc2 Eli Lilly and Company\uc2 , provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. With a global presence of approximately 7,000 people and offices in more than 40 countries, Elanco anticipates, serves and supports the diverse and evolving needs of its customers -- from veterinarians to food producers to all those concerned with animal health -- to help them address the challenges of a diverse and changing world. Together with our customers, we are committed to raising awareness about global food security and celebrating and supporting the human-animal bond. Additional information about Elanco is available at {\field{\*\fldinst{HYPERLINK "http://www.elanco.com"}}{\fldrslt{\cf2 \uc2 www.elanco.com}}}\uc2  or follow us @Elanco.\par \par \uc2 Keywords for this news article include: \uc2 Elanco Animal Health\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document PHBW000020151109ebb90003f\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Sanofi\uc2  expects up to 18 new projects are on track to arrive on market by 2020\b0\par\par\uc2 51 \uc2 words\par \uc2 6 November 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Up to 18 \b \highlight22\uc2 new products\b0 \highlight\uc2  are on track to arrive on the market by 2020. Among these, \uc2 Sanofi\uc2  projects that six key \b \highlight22\uc2 launches\b0 \highlight\uc2  could generate aggregate peak sales of EUR 12B - EUR 14B by 2025. \par \par \uc2 Document FLYWAL0020151106ebb6001ba\par }\page {\par\fs20\uc2 Business\par \b \uc2 Sanofi\uc2  Targets Sales CAGR Between 3% And 4% At CER Over 2015-2020 - Quick Facts\b0\par\par\uc2 245 \uc2 words\par \uc2 6 November 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Sanofi\uc2  (SNYNF, SNY) announced the company expects to deliver a sales compound annual growth rate (CAGR) of between 3% and 4% over 2015-2020, with a target of mid-single digit growth in the second half of the period. \uc2 Sanofi\uc2  does not expect to show any meaningful bottom line growth over 2016-2017. Beginning in 2018, however the company expects to grow Business EPS faster than sales.\par \par \uc2 Sanofi\uc2  said its long term strategy rests on four pillars: reshape the portfolio, deliver outstanding \b \highlight22\uc2 launches\b0 \highlight\uc2 , sustain innovation in R&D and simplify the organization. Up to 18 \b \highlight22\uc2 new products\b0 \highlight\uc2  are on track to arrive on the market by 2020. Among these, \uc2 Sanofi\uc2  projects that six key \b \highlight22\uc2 launches\b0 \highlight\uc2  could generate aggregate peak sales of 12 billion to 14 billion euros by 2025.\par \par \uc2 Sanofi\uc2  expects its simplification of the organization worldwide and a more focused portfolio should allow cost savings of 1.5 billion euros by 2018, which will be largely reinvested to support growth initiatives. The company said the move to five GBUs will start to be implemented beginning in January 2016. \uc2 Sanofi\uc2  plans to reshape its plant network with increased emphasis on the growing biologics portfolio.\par \par \uc2 Sanofi\uc2  said the company will explore strategic options for its animal health and European generics businesses.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151106ebb6001me\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 PuraCap(R) Pharmaceutical LLC  \highlight22\uc2 Introduces \highlight\uc2  New EpiCeram-L(TM) Lip Care\b0\par\par\uc2 595 \uc2 words\par \uc2 4 November 2015\par 08:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 SOUTH PLAINFIELD, N.J., Nov. 4, 2015 /PRNewswire/ -- PuraCap Pharmaceutical LLC announced today the introduction of a \b \highlight22\uc2 new product\b0 \highlight\uc2 , EpiCeram-L(TM) Lip Care, a unique lip care formulation with an exclusive delivery system for the treatment of dry lip conditions. PuraCap Pharmaceutical is the maker of EpiCeram(R) Controlled Release Skin Barrier Emulsion, a leading prescription product indicated for the treatment of dry skin conditions and management of burning and itching associated with various skin conditions including atopic dermatitis. The introduction of EpiCeram-L adds to PuraCap's growing portfolio of dermatology products.\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20151103/283446"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20151103/283446}}}\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20151103/283447"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20151103/283447}}}\par \par \uc2 EpiCeram-L Lip Care is a unique lip care formulation with an exclusive delivery system developed specifically for severely chapped, dry, or cracked lips. EpiCeram-L Lip Care uses patented MultiSal(TM) technology to deliver 3 essential lipids -- ceramides, free fatty acids and cholesterol in an all natural, steroid-free, paraben-free, fragrance-free, and color-free formulation. EpiCeram-L Lip Care is available exclusively through prescribing healthcare professionals.\par \par \uc2 "PuraCap has a strong, growing portfolio of dermatology products and EpiCeram-L Lip Care is an exciting new addition," said Dahai Guo, CEO of PuraCap Pharmaceutical LLC. "We have listened to the needs of our customers and are pleased to introduce EpiCeram-L Lip Care."\par \par \uc2 "Now there is a new option for patients who suffer from severely chapped, dry or cracked lips," says Elise Klein, Vice President and General Manager of PuraCap's Branded Rx division. "We look forward to continuing to meet the needs of our physicians and patients." Physicians will be able to dispense EpiCeram-L directly to their patients from the office, which will make it very easy for patients to get the lip balm and begin treatment immediately. EpiCeram-L will be distributed through a patented web based ordering system. The program is designed to provide physicians easy access to PuraCap's growing portfolio of dermatology products.\par \par \uc2 About PuraCap Pharmaceutical LLC\par \par \uc2 PuraCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing, and bringing affordable, world-class quality products to their customers. The PuraCap corporate structure supports a two-pronged approach for global growth with dedicated companies in the areas of prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC and private label brands. PuraCap Pharmaceutical continues to innovate using our soft gel expertise and developing other soft gel options. Go to {\field{\*\fldinst{HYPERLINK "http://www.puracap.com"}}{\fldrslt{\cf2 \uc2 www.puracap.com}}}\uc2  for more information.\par \par \uc2 Forward-Looking Statement\par \par \uc2 All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which PuraCap Pharmaceutical LLC does business, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.\par \par \uc2 Media Contact:\par \par \uc2 Elise Klein\par \par \uc2 Vice President and General Manager\par \par \uc2 Branded Rx Products\par \par \uc2 Email\par \par \uc2 908-941-5456\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/puracap-pharmaceutical-llc-introduces-new-epiceram-l-lip-care-300171911.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/puracap-pharmaceutical-llc-introduces-new-epiceram-l-lip-care-300171911.html}}}\par \par \uc2 SOURCE PuraCap Pharmaceutical LLC\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.puracap.com"}}{\fldrslt{\cf2 \uc2 http://www.puracap.com}}}\par \par \uc2 Document PRN0000020151104ebb40009v\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw132\pich40\picscaley100\picscalex100\picwgoal1980\pichgoal600
47
494638396184002800F70000C7C7C7FDFDFDF8F8F8444444FEFEFE3535353F3F3FFCFCFC8B8B8B6E6E6E4B4B4BF5F5F5B9B9B94545459090909D9D9D85858575
7575F0F0F07F7F7FF7F7F7888888484848565656FBFBFBBEBEBECCCCCCC5C5C5737373EFEFEF9B9B9B404040414141636363E5E5E5BFBFBF0909098A8A8AD8D8
D8D6D6D6AEAEAE9898987272729292924F4F4FABABAB525252B3B3B3B5B5B5E8E8E80F0F0F111111E6E6E6010101CACACAC2C2C2B2B2B2D1D1D1C8C8C8E3E3E3
ACACAC5D5D5D8E8E8ECBCBCB9595957D7D7DA2A2A2656565C6C6C6616161CDCDCDFAFAFA3737373B3B3B282828434343E7E7E71D1D1D272727EAEAEA1B1B1BE1
E1E11818182D2D2DE0E0E0151515E9E9E9F6F6F6C3C3C32F2F2FDFDFDFD0D0D0D2D2D28484840C0C0CA8A8A8B1B1B1AFAFAF161616F9F9F9BCBCBC4A4A4A9696
96EBEBEBA9A9A91E1E1E8686865F5F5FA7A7A74949494E4E4ED3D3D3787878050505EEEEEE6A6A6A5E5E5EF4F4F42626261C1C1C3838389999991A1A1A3C3C3C
E2E2E2828282F2F2F2545454ADADAD939393B4B4B49F9F9FDCDCDCEDEDED6F6F6FA6A6A6F3F3F37474742525255C5C5C141414202020DBDBDB12121203030364
64645959590606064C4C4C3939398181813434346767673333335050505151510404048F8F8FC9C9C92E2E2E8C8C8C3636360E0E0ECECECE5A5A5A6D6D6D8989
89464646BABABA7B7B7B3232329494944242425353533A3A3A3E3E3E222222DDDDDD7E7E7E8D8D8D707070B6B6B6070707D7D7D73D3D3D7C7C7C4D4D4D242424
5B5B5BDADADA6969691717176666661919195757571F1F1FA0A0A0C4C4C4767676474747A5A5A5A1A1A1C1C1C1D4D4D4313131686868101010D9D9D96C6C6CA4
A4A4919191626262C0C0C0797979BDBDBD232323606060E4E4E47777772929299C9C9C9797972B2B2B838383080808303030BBBBBB7171715555558787878080
806B6B6BB7B7B7B0B0B09E9E9EB8B8B80A0A0A1313132C2C2CA3A3A30202029A9A9AECECEC5858582A2A2A7A7A7A0B0B0BD5D5D50D0D0DCFCFCFAAAAAAF1F1F1
DEDEDE212121000000FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E332D633031312036362E3134353636312C20323031322F30322F30362D31343A35363A32372020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F702043533620284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969643A4443
4146383242323542383131314534383933303943334630433644304245372220786D704D4D3A446F63756D656E7449443D22786D702E6469643A444341463832
4233354238313131453438393330394333463043364430424537223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E63654944
3D22786D702E6969643A4443414638324230354238313131453438393330394333463043364430424537222073745265663A646F63756D656E7449443D22786D
702E6469643A4443414638324231354238313131453438393330394333463043364430424537222F3E203C2F7264663A4465736372697074696F6E3E203C2F72
64663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9
E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9
A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A69
6867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A29
2827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C00000000840028000008FF00FF
091C48B0A0C18308132A5CC8B0A143841D323C517806D992690F330AE402A21110810462A13124E541460C587E9CC8E1E986B80DB100C140C500158C3C661668
6CB80F8C9939486CF90B74D0C39A249CFCF9BB26F04513526B5818B8042B982A3A30768E49A3D49F035EFE6A745591F1C8B0AE68D53841DB75D94E8639D8FA03
75B0015B2702B788918B36538C8C0CD03203120A2D078D14DCB04D26F015DA2C72DE3A0C82B64242555DED10FC84B6C53F645DAB88789801EDB67F75C075CDB5
13CCE381B2D02290ECF047E5847FBA66215806AD068110BA5AC858A9AB65448FBA76D989066D928194BB12A5CDD006DA12092575654650015A00026990FFE81A
26A3903570CEFCEBE0ACABA99D5FD09E1A68096D27C904AE0418288201181304D9D615040941D39512BC7D37102B5DB55190237334B28B2A73ECF0CF182678D2
C21CCEB8F1CF023374B588158EDC92C3289E5813C53F42CCD2C2210FA8818A403CA055C6407DA0350B41020061802A256040D0012864E1C03F1E40E1CF14377C
D1045A05F4229011684D50D02A4828B142245DED4290050A0A6448577158F8CF1517282596525E50500D5BCF1D51455733C421D705FFA489D612028581D67002
A981D60A032D3367574E04500826AC84E8CF1A89F0C50B08A149F00F17685932900453F0E54F1AFB09344098FF7482161B978648C21BFF5CD29536FF54FF2094
521F5CC848572B3C935457861020D0034A91F0C54028FC3950705D992150368EB6E08052438CC0969D78083189527AD0F0CF069DFD730B5A7D0C6497529990B1
44577708292AA9D1A045577BFE4422D0075D3520902B5DD58AC15E4A5999005A800C04AC3F84126BAC405DA0F5D13F9B2825C63F8474B5C13FEEA0E5CC3F09D3
2A50146BFA331B151D07F12B5A009AD2951E470C346A57E009540B5A8908AA1459FF30A894BDFFE092AF404F2A7558605D0D311026FEB0F3D74038A0D5CA40C6
A0B5CA3F4474C5CB99C9F933CE3FDE7515CD3F8EFA83E73FFC5CF70F1F9074558D407874C502705D897185CAA472DBD5053D74E58340A7743580403A2BFF6580
40777415C199FCFAA399409DCA4BD00B683531CD05F3FC82563CFFA8D0D591FFD8A1D4736B74354907FF38A6141A026921B608762A95CA3FF7B82B50055DB5E3
07DC2C0F645D576548EB8F0B0365ED4F01029DEBB7405C2935789E6871F1CF1B4A115150D29EA2A50FC55D31205071FE40F1CF395D852310130AFC729F40A388
CDC4ACFEAC9E075AD6FFE34357A21442BB522DFFA3015ADEFC13830E03F9B0AB3F991008A586F78F6B084E2083404B0AFE111CE015E4655D51441E7C408C9529
051DFF40CB031021047BB0E91FDAE88A0210328BF174255C56508DCFFE010CDF0824105D21C1D1FE61417FD48F4A5D090541322005B638104C0484C501FFFF01
B2AE14E11FE1F047370CA23BA5AC8D6D5DC1422FA2E70F2FFCA31E5DF983418C1038B62CA7105EE88A31FE312EA53C4320DDE80A38B4B5AEDA0944404A01D4F6
3687BDDF0984125DF95B018798B31CBE8C04A02B4813FD214773A0C50672538A288651800628A00DB3F1455796461053F9E30E9DE81A6B242083AE5849115DA9
811604E2013265637E361C0800D0A238E135E11F8BE88A037DA7C7B5186F2019F30709B872448390012D0E12487DBAB2056AB8D02021E88A87060287AE182183
5D39CC020EE50F59FC23189E3BE53F88D1154E988986A482A052A481B5AED82074B214880BF22810CDDD5220AB644B560C7203B42C9381DF19A4F30C32FF847A
0D04015D01C63F1C8196C109A0872B949C5220B1A2CF74930FA8AC5F32D07282F82825040231403A19B6B37F28418C0401656610E209B468E29F68218231BB82
838360037702B95F57006402B4D0E21F07E8A2D5FE513CA5B0EA1F2DE80A3C1A0A4E37FEA31C2733821095B28E8C6E544FFEA8D53FE8D1954410A4195542483C
9D389012A045073255CA6C0CA21DA50843202FBD99409E819604FC830067518A5B0B10263F75E504111D480B95820D1884D24CF8528A0363A9318F76C5AD0301
044511A203B46C02A55DC9803CD0A245E808AD6E4AE981403EAA946694AEAD0259AA3F8E480AB41C42208720550DEBD7377F7C61A2CEC4695CEDF88FD2FF2A05
0402C9C26109728630FA03B78C458B2E0682D4AE78067D24608240F8E00FEF61D61F425B40D57E2B9077A0E51C02B1A53F24F10F69A005A3FF00025A3220AE30
9D002D0748015A4A4180DC74050F02E11201F7104D81CCAE9CFE5820429481163DFEE31B1AFC47DEBAB20681286636EB544A2F39AB941570E35A5D2905E2BAA2
D9F37A8E0AFF40025AEE400E811CE398ADE80A4681163DBCB0B02BA7F90733EA6B17E0254D06F243883A043310CB49E71F3542CB1E3A250301FC43BBC09D0615
7787533D7465B8FF60015A6430DD06FD03114AEA0A1CC030407FF0492049600B23E8DB1532D000A14AC1418E958204B028C5123502AF4144908A5BA1E5FF481E
80075ADA71DA64CA851A31F0205A48900F09940D2DC248B03F64200B4DA00512043A4327D1A2805D28A50C78553215AD34103914A62B2310C190879C055036F5
208CF3C72FA0A00731D8C901C2F0471382118C9E29970E6C19C43FC220030B6842139B70431508B58546740513FF48875218D1C91A4881D45010C576FF410357
F903129629C5279427906AB822044528423330E10B43184308812CC80B1230010CFFC3060F78C10D040103221423255BD8800E6E61027AD741BC7B524814A840
81238C610156C8C1440440F0822FE0000221430286500E88320403370083720522822874A00E0517C01804B0002A10950BCAB01475466E90610250E424FF4FB9
467CA5F29613E41E664047A85C4EF39ADBFCE638CF79439EF0003478C013FF78C237504E901C9801050FD0D63708E1F237F8000D3E7608052630B17F08E00BEA
C041058AA1F38C64E2181D988120FE31089D182406F8F0000A1A6185748C8620F240046DFCC00EC43E0409AC11882FA440016E98A3EB0FE9011DFEE10D0C3A6F
0C8040854C06F2096B04C00B2F88451DEC070A6B082009EFA0C20BFEA10C2CFC83013730C5133A20887322A400D31148061E607A1D20600472E0011B1CF10F68
884C20A0F81BED1700032148E91F6440800D46019E16307D0B6C98C8CD9B8187077C400034E8070568E101363CE2070399021C1CB0407AE4C0082CD800FF1A76
B08B11F4E213FF88C7DE0CE0022C304001839842C10C6224E88420000AD041065CB08117E0A018ABB007FFE00BD6241066E00DE440207480005A700C0B800009
C00058E001B84509B370030D9001DF54733D80270E500518300F72A0026480024F24109F601902F107395004882500A7C00707700C043002BC330470F00F7060
0001A00CA3741005F0349B551E8610028BF01E02110B13E020E4D63F95F00627C0048AA01EBA300E94405EFF100D27A502E1B20DAC903237D700F03501A2E007
48600519400E3CA01E03C1081E30107BF00313F00AFF600572500044200078100379A019A47053C4A03D0720721D900228270583A301DDB009F5F00F6DFFE000
DA400902C10103C00048F00F74000D03910B69301097501EA100060AB01C022008AEF00F94B00872100395801D362701A53007289008845008C2D01F8D60012A
4001E4D30A08B01F4F40072D150415200EFFE000114000C4D00728C0013B00016A2010D29008C8F07634200913F706BAA00258600E0B0404C99007A811013EF0
0C3C8009C5400B375002D1081C17F01BFFB00C0EC00DA8B20C0990075BF00FA9300829B002822004E2F083357700FB2100BE122A73002097705AFF2024188070
04B91F04B00012C98B67B21F019091A1B20051671018400004609002810112C072018008BE4290FF100004A09219490060F80F14705FFF70049387531614F921
6F03780451016C40082960053C3994241710003B}}
\par\par \b \uc2 Sagent 3Q revenues increase 15 percent\b0\par\par\uc2 Globe Newswire   \par \uc2 237 \uc2 words\par \uc2 3 November 2015\par \uc2 Daily Herald\par \uc2 DHLD\par 0\par \uc2 English\par \uc2 Copyright 2015 Daily Herald   \par \par \uc2 SCHAUMBURG \u8212\'20\'14 \uc2 Sagent Pharmaceuticals\uc2  said business growth and the recent acquisition of Omega laboratories helped boost the niche drugmaker third quarter 2015 revenues by 15 percent.\par \par \uc2 The company reported revenues of $75.2 million during the quarter. an increase of $9.8 million over the same period in 2014. The increase was driven by the $7.3 million from the addition of Omega on Oct 2014, as well the \b \highlight22\uc2 launch\b0 \highlight\uc2  of \b \highlight22\uc2 new products\b0 \highlight\uc2  since Sept. 30, 2014.\par \par \uc2 \u8220\'20\'1COur extensive base business offering, inherent operating leverage and flexibility of our partnership model for product development and supply will enable us to drive significant value over the next several years from the new product pipeline,\u8221\'20\'1D said \uc2 Allan Oberman\uc2 , Sagent\u8217\'20\'19s Chief Executive Officer.\par \par \uc2 \u8220\'20\'1CThis is further supported by the positive backdrop of strong growth and demand for generic injectable and related hospital pharmaceutical products which should provide additional opportunities for growth in the future,\u8221\'20\'1D Oberman added.\par \par \uc2 Gross profit for the third quarter of 2015 was $24.4 million, or 32.4 percent of net revenue, compared to $18.8 million, or 28.7 percent of net revenue, in the third quarter of 2014.\par \par \uc2 For the remainder of 2015, the company anticipates net revenue to be in the range of $305 to $330 million and adjusted gross profit as a percentage of net revenue in the range of 25 percent to 28 percent.\par \par \uc2 Document DHLD000020151104ebb300056\par }\page {\par\fs20\uc2 Business\par \b \uc2 GSK Plans To File Up To 20  \highlight22\uc2 New Drugs \highlight\uc2  For Approval Within Five Years\b0\par\par\uc2 363 \uc2 words\par \uc2 3 November 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 GlaxoSmithKline Plc\uc2  (GSK, GSK.L) said that it has the potential to file up to 20 \b \highlight22\uc2 new drugs\b0 \highlight\uc2  with regulators for approval before 2020.\par \par \uc2 Seven of the drugs assets are in advanced late-stage development (with the potential to \b \highlight22\uc2 launch\b0 \highlight\uc2  before 2020) with the remainder, being in earlier development, notably in the areas of oncology, immuno-inflammation and respiratory disease.\par \par \uc2 In 2016/2017 GSK has the potential to start phase II development of ~30 new molecular entities (NMEs) and product line extensions (PLEs) and to start phase III development of about20 NMEs and PLEs.\par \par \uc2 At a presentation to investors in New York today, GSK described a deep portfolio of innovation, focussed across six core areas of scientific research and development: HIV & Infectious diseases, Oncology, Immuno-Inflammation, Vaccines, Respiratory and Rare Diseases. Around 40 new potential medicines and vaccines were profiled, supporting the Group's outlook for growth in the period 2016-2020 and the significant opportunity the Group has to create value beyond 2020.\par \par \uc2 The portfolio represents some of the latest scientific achievements from GSK's R&D organisation and its more than 1,500 company and academic collaborations. The company believes approximately 80% of the medicines and vaccines presented have the potential to be "first-in-class" with novel mechanisms of action. As a result, many of these potential medicines and vaccines may offer benefits beyond current standards of care and, in some cases, could radically transform how patients are treated.\par \par \uc2 GSK also profiled a number of significant material opportunities in late-stage development, including: Nucala (mepolizumab) for treatment of severe eosinophilic asthma, Shingrix (zoster), a candidate vaccine for the prevention of shingles, sirukumab for the treatment of rheumatoid arthritis, daprodustat for anaemia, cabotegravir for HIV, a candidate combination vaccine for the prevention of bacterial meningitis and a new inhaled triple therapy for treatment of COPD.\par \par \uc2 During the period 2021-2025, GSK has the potential to file up to 20 additional innovative assets, now in clinical development.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020151103ebb3004jx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Alnylam reports results from ongoing Phase 2 studies for patisiran and revusiran\b0\par\par\uc2 323 \uc2 words\par \uc2 3 November 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Alnylam \b \highlight22\uc2 announced new\b0 \highlight\uc2  results from its ongoing Phase 2 open-label extension studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin for the treatment of TTR-mediated amyloidosis. TData from the patisiran Phase 2 OLE study provided continued evidence following 18 months of dosing that patisiran has the potential to halt neuropathy progression in patients with Familial Amyloidotic Polyneuropathy. The company is announcing that it expects to complete enrollment in the APOLLO Phase 3 trial of patisiran over the next three to four months, supporting a potential \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application filing in 2017 if the study is positive.\par \par \uc2  In addition, initial data from the revusiran Phase 2 OLE study showed robust and sustained knockdown of serum TTR, and was found to be generally well tolerated in the majority of patients with TTR cardiac amyloidosis - including patients with Familial Amyloidotic Cardiomyopathy and Senile Systemic Amyloidosis - out to 10 months of treatment. New results for patients who reached the 18-month endpoint as of a data cut off of September 22, 2015, showed that neuropathy impairment scores were essentially unchanged from baseline values after 18 months of treatment. Specifically, there was a mean increase in mNIS+7 of only 1.7 points, which compares favorably to an estimated increase in mNIS+7 of 22 to 26 points at 18 months based upon analysis of historical data sets in untreated FAP patients with similar baseline characteristics. At 18 months, patisiran administration was associated with a statistically significant and clinically meaningful mean 4.9 m/mm3 increase from baseline in sweat gland nerve fiber density from distal thigh skin biopsy samples as read histologically by a central lab in a masked manner. Serum TTR levels were also measured throughout the OLE study, and showed sustained TTR knockdown of up to 96% and a mean maximal knockdown of 93% for over 21 months. \par \par \uc2 Document FLYWAL0020151103ebb3001b9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: \uc2 RX Safes \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Availablity\b0\par\par\uc2 836 \uc2 words\par \uc2 29 October 2015\par 08:38\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 RX Safes\b \highlight22\uc2 Announces \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Product\b0 \highlight\uc2  Availablity\par \par \uc2 Company Expands Product Offerings in Personal and Professional Healthcare\par \par \uc2 HENDERSON, NV--(Marketwired - Oct 29, 2015) - \uc2 Rx Safes, Inc\uc2 . (OTC PINK: RXSF), the developer of autonomous fingerprint healthcare security products, announced today that it has officially added a new product to its professional healthcare security product offerings, the Rx FieldLOCK.\par \par \uc2 The Rx FieldLOCK is a heavy duty steel forged, fingerprint padlock that stores up to 64 unique biometric users, 5 of which can be registered as administrators of the lock. Rx FieldLOCK also offers access via pin code to an additional 32 users as a back-up feature. Unlike traditional padlocks, there is no key required to unlock Rx FieldLOCK making access more secure, convenient and expeditious under high stress situations. Rx FieldLOCK has been primarily designed for use by EMS personnel, law enforcement, ambulance crews and fire departments to securely lock up a variety of cases used to transport medications and equipment in the field. "Medical personnel are required by law to secure controlled substances in the field. This lock can also be used to secure various types of medical equipment such as stethoscopes, blood pressure cuffs and other valuable healthcare tools usually transported in portable cases and bags by EMS workers. There is a high rate of theft of these small but necessary tools of the trade and the Rx FieldLOCK is the perfect portable security solution," commented \uc2 Faruk Okcetin\uc2 , a Director of \uc2 Rx Safes, Inc\uc2 . and a Medical Device Distributor.\par \par \uc2 "Consistent with our efforts to offer fingerprint security products to deal directly with the multi-billion dollar a year problem of drug diversion, I am happy to announce that the Rx FieldLOCK is available immediately for bulk order purchase," stated Lorraine Yarde, CEO of RxSAFES, Inc. This is the first of our professional healthcare line of products designed to thwart and deter drug diversion and theft in the field. We will be offering the product to healthcare facilities, ambulance corps, fire departments and other state and local EMS and law enforcement agencies. We are also taking steps to have the Rx FieldLOCK included on the appropriate Federal Governments GSA schedule to facilitate streamlined purchase of the product by Government Agencies. "In addition, there is opportunity for the application of the Rx FieldLOCK product in other large global industries and we plan to establish relationships with distribution partners who can help offer the product to other markets," added Ms. Yarde.\par \par \uc2 For order information and pricing, please contact the company by email at sales@rxsafes.com, by telephone at 1-844 RX SAFES Ext:1, or visit the company's website at {\field{\*\fldinst{HYPERLINK "http://www.rxdrugsafe.com/"}}{\fldrslt{\cf2 \uc2 http://www.rxdrugsafe.com/}}}\par \par \uc2 About \uc2 Rx Safes, Inc\uc2 .\par \par \uc2 Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.rxdrugsafe.com"}}{\fldrslt{\cf2 \uc2 www.rxdrugsafe.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements for RXSF:\par \par \uc2 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the \uc2 Securities and Exchange Commission\uc2 .\par \par \uc2 Like us on \uc2 Facebook\uc2  at {\field{\*\fldinst{HYPERLINK "https://www.facebook.com/rx.drugsafe"}}{\fldrslt{\cf2 \uc2 https://www.facebook.com/rx.drugsafe}}}\par \par \uc2 Follow us on \uc2 Twitter\uc2  at {\field{\*\fldinst{HYPERLINK "https://twitter.com/RxDrugSAFE"}}{\fldrslt{\cf2 \uc2 https://twitter.com/RxDrugSAFE}}}\par \par \uc2 Investor Relations Contact:\par \par \uc2 Rx Safes, Inc\uc2 .\par \par \uc2 Email: Email Contact\par \par \uc2 Telephone: 1-844-RXSAFES Ext 4\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 October 29, 2015 08:38 ET (12:38 GMT)\par \par \uc2 Document DJDN000020151029ebat00207\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Elanco Expands Parasiticide Portfolio in US with  \highlight22\uc2 New Product \highlight\uc2  for Heartworm Disease, Intestinal Parasites\b0\par\par\uc2 519 \uc2 words\par \uc2 28 October 2015\par 14:23\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 GREENFIELD, Ind., Oct. 28, 2015 /PRNewswire/ -- \uc2 Elanco Animal Health\uc2  has \b \highlight22\uc2 launched\b0 \highlight\uc2  Interceptor(R) Plus (milbemycin oxime/praziquantel) in the United States. Interceptor Plus is a monthly chewable tablet that prevents heartworm disease caused by Dirofilaria immitis and protects against intestinal parasites including adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis, Toxascaris leonina), adult whipworm (Trichuris vulpis) and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis and Echinococcus granulosus) in dogs.\par \par \uc2 Interceptor Plus is chicken flavored, making it a good choice for dogs with beef allergies. Dosing is easy, with more than 96% overall acceptability. It is safe for use in dogs and puppies 6 weeks of age and older that weigh 2 pounds or more.\par \par \uc2 "Interceptor Plus is a great choice for dog owners with active, outdoor dogs," according to Dr. Stephen Connell, Director, Technical, Academic and Consumer Services. "Dogs that play in dog parks or frequently visit boarding or grooming facilities where they interact with other dogs also can benefit from Interceptor Plus."\par \par \uc2 Interceptor Plus is approved by the \uc2 FDA\uc2  and available only through veterinarians. The product is supported by an Elanco product guarantee. "This is another product that supports Elanco's commitment to helping pets live longer, healthier, higher-quality lives," Connell said.\par \par \uc2 Elanco, a division of \uc2 Eli Lilly and Company\uc2 , provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. With a global presence of approximately 7,000 people and offices in more than 40 countries, Elanco anticipates, serves and supports the diverse and evolving needs of its customers -- from veterinarians to food producers to all those concerned with animal health -- to help them address the challenges of a diverse and changing world. Together with our customers, we are committed to raising awareness about global food security and celebrating and supporting the human-animal bond. Additional information about Elanco is available at {\field{\*\fldinst{HYPERLINK "http://www.elanco.com"}}{\fldrslt{\cf2 \uc2 www.elanco.com}}}\uc2  or follow us @Elanco.\par \par \uc2 Important Safety Information\par \par \uc2 Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Interceptor Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, depression/lethargy, ataxia, weight loss, convulsions, weakness, and salivation. Please see full product information below.\par \par \uc2 Interceptor, Elanco and the diagonal bar are trademarks owned by or licensed to \uc2 Eli Lilly and Company\uc2 , its affiliates or subsidiaries.\par \par \uc2 (c) \uc2 Eli Lilly and Company\uc2 , its affiliates or subsidiaries. USCAHINP00019\par \par \uc2 \f2 \par  \par Contact:  Christina Gaines, Elanco, 317-276-3845 \par           Sharon Polk, McCormick Company, 816-584-8444 \par  \f28 \par \par \uc2 \f2 Photo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20151028/281483-INFO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20151028/281483-INFO}}}\par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/elanco-expands-parasiticide-portfolio-in-us-with-new-product-for-heartworm-disease-intestinal-parasites-300168077.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/elanco-expands-parasiticide-portfolio-in-us-with-new-product-for-heartworm-disease-intestinal-parasites-300168077.html}}}\par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Elanco Animal Health\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.elanco.com"}}{\fldrslt{\cf2 \uc2 http://www.elanco.com}}}\par \par \uc2 Document PRN0000020151028ebas000p1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E600004578ACB3C8DD668DB9759CC2BCCEE16892BC00468C0B4E9224619E00498EC1D3E42A66A1215E9C0D53953C73A8002B7CEDF2F7D1
DDEA003984F2F5F9316BA41458982D68A3ACC2DA145496D9E3EE003482CED9E8024D91EAEFF598A9CA5383B26F96BEA2BCD6F5F8FB8DACCC7BA1C599B4D1D5E0
ECFDFDFEE1E9F2175A992764A0C8D5E5DDE6F094B3D0001A7211529411559605498F396EA6F8FBFC82A2C61D5C9B00076594B0CE1C5A9920559600146EE7ECF4
4C81B1476EA6094B905785B45E88B6003E88C0CEE100267983A6C8E5EBF3002F7F0B478E1F5D9B9DB9D4F1F2F720609D5F8CB887A9CAFBFBFDC9D8E702519316
4D921757981556971A5C9AA6BED7002076517EAFA2B4D14B7DAF3366A10E4F93E5ECF304428A5689B62468A2ABBED7145395115C9B02478D14468D8DA5C70A3F
888FAECD07448B163381195898DFE8F1A8C0D94C65A00000505780B1294D91C7CBDF1B5E9B819EC32F6FA790B7D33F5E9BF7F6FAE1EEF57B92BC0D589800448B
00428A004A8F004B90FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A63646561643966392D303862652D343866332D383962362D3239643737326364653433352220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A37314231433530363343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A35433146443533343343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A63646561643966392D303862652D343866332D383962362D323964373732636465343335222073745265
663A646F63756D656E7449443D22786D702E6469643A63646561643966392D303862652D343866332D383962362D323964373732636465343335222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF804807290D850D075215860D5B898B5B6A308F528B0D2F848B2F94865B6198855B539F878E9CA5A0919395978FAC
9C9E8F18A35B312A15080D067D7E7C5B161C09BB7C612A7EC17D7C382A09C1097C354BBA7D097B0848BA7E06060853D806630B30DEB507D87C070BC0C22FC5C1
BC6ACBC7C9D17DD3D5D7F509DB52DE6316DDBB0CC458904B18BA1429CAF9E1B58582425E1816F830E007198E0531A4EDA981C040B36A0C3C66DB86639C05297B
16EEF1B1E00545860E53F27A21F1251F291632D64BD6B1191F063DA791ECB7408D4C812D65F6A2B005030C774B7DF059C8876646AA6A2C68ABC853A4330408F8
2418A902079F80314E4EF5B3D2C28BB54BFFB7C07D61C187529C572DAAD8FA35EC586D086A9CCDE64FCD5AA46FA9FA60CAA74285750EE146CCCB47CD823114A9
41F3BAA7AC8620C6C6D4E866608F40157217060922E745CA3D41D88DE1C3C140100C2ABA4CED13042F1F3EDAD4A458BDC7748D9263138C4180630F5A0B4677AD
6C09B7616AC7332948A53A2527458B16301BDB83A4E7F82F648C7CF1F1C0808A17416A6BE842278C043F1C1E04E1116508073F416C41C7111A18C041103EE4A4
016D08AA80196C417044CD542449101049837DA3964A092606536A7D38D64B5D9261F45D659765B65134C9B977440E2C742042017B6C1100132E0CD081051A00
11401046C83081121DBCF100071B1430C4FF0D6BF860C500040C21C31F00B860410608486084007F1410240B116CC04200129C114281DB44974D5A52AC359D87
E730B6900115BC008376704D912257352CC017790CEC915C675348D081021230F1870C437430800D34FC01840D24AC31840F7F9C49C41F07ECF1C70F3A5CF047
0F2E5CB0810E59FC8185113C28A1829625FC91C4100D207006044C386085024F3CD05973CFB5C9A15BD545A6D2165454805A9E2656B4D19ED42011D25FEE21F1
80037FC06185014F7CD028083AB4F007183A0C60C210209C608615664400C0149FEAC046A643B410810B3CFCC1C2163840A0C267176480281F3A0820021F4618
B1C20A0F20609874694DE1E601C452659DFF642AA450C155BCE8291E32482C60DA780C044AED0248209C6F0E154821016C4590F04015196CD005135C48308012
DA0471841C189CE0850E01EC9081CE26E8C0040A2C00B0C7042A482984003BC0F7000D10048130AF63480CF13F6E26981A4CDBF1120646185420CF140E9E58C3
5E2A228184A064A5DC8711A90230DB1E7C048142092E8480450002640181154CCCD08704EC20F8C7D04F9440000002243D80103754310604086870F90B773860
840123ECF0DB0304ACA1F5D7C2B2257675161C3097898EED649978CE84FC67C9746BB38060BB1801C01F0B68A01A1F223C1A40196F2860AE0B05CCC0475A3148
D0C01F1F58D1410120605140AF6728A085FF090E640080116544E9A86D0240009B1111303CD64A146030B1055B28F5424CDC355BFB4DD0E203125430327DF0EE
6476CB86060AF0071CDC476B489800086C108012F82D000480DE045E80001FACE67A2030420668B0050560210246284006341081126CC0013A200016DC100705
04015D590B82014CA0002350232DF61BD6D8A2A294C97C4744F0C09D001150C03D30A006BD738F59D01203455141877B58420C50F02836286008A20A800B9870
0202F2013607F803085CD042A2FD418C05E8800BE6F0870CE060082B98C008FE2004233C00041D78860484F00423F061311EDA03C53A4515BAD8A57F7931C014
609082B619E327041CD4125276B2291266FF0141C0560EFC48800168AF8B4FD0C11BFEA000A5FDC10C1AD0C00AAEC007ECE9C0044980D41F2EA0031070610814
F803A78230A61244C0043704240EB680C7270C2106F5BB5FFE1AC93F64E8292F7B98821C525083AB5003285ED90614FF020E60AD690118D000087530A52C7C4B
074FB8800BB6F08742A6EA0336D0C21FB2F082C7DDB20443181E017A5904B96CE00FD570020374608719A4C00A0598400C80B4821E568C2DBE602444281083BB
340B64B6A880573049376A04268A16F0245282680420FCA108BB3482048A4084211020000F78801044D00023442A026F3CA43F3740003E68A003112898085E30
C73F48E00727D882064057A526ECE06546FF5040040E303645C64E7F1C558AC7DC26B2B4E5E3274C6C11739CF3C9879D134E46F8C019BC208120ECC1010008C2
000D20012D00C1364670C0190AE0C13EC8000612C8425E8380000B48400600F8CD0B64600000C820087D3080166A80130B042308140042D96AF455AA60A02E29
4186142C898CB769A37626FDD7033460040D2C6109403242101270802048000A7DD0C003C680190E48600866A083116CA0036D48E0657BB08215745B3DDE0C41
0743600B0708E682031CE03E1C88A51834A0032300E801E8D1C16C8D8A8423B8E00150886547692BDC2E7C412EC295400560E047DAF2A10131E8AF5D19E0275D
38E69B0808820A1C20031950000DD69381FF0370930519A4006108204101BAA081042C01005988811A004081203440000E0842051C400107084005080B83170A
20030D18D70C3C00C10F0C098C18F8E00500C8D5672C6006347C800914D0801AA68000005C110105A0800416C06007384003BF6DF1021040010A34D8C22D6E31
1D7C56E07AEC970F6009820608204C6112C10A08106601C630812EF5B2CD105043E0FE904171FD81020BF8C3041EA0A836874007C36B3300ACE00313B4790405
1A033A326068C4EAB3CD6492000BFE3000171C14706C6EF30D8CC0813A13E101946E3302B0D566119CAF45FB058B69D6FC8708CCEB0F72E08030AFA08119EC53
0227F84315800AB800F0D9057E1E00A606FFADA8133C810B0380DF1BD91C8127E92B04C2A4C003AE51853FA0C0D892B2025023006E6F51BA091A78C21F40FD87
3528409800D0409D41300414E82B022CB8AB3009D0013E4BC02363C0011510E21103D03A0F2E10C11F1CE0292A4940E13CB08030ADD086A076BBCFC204430E04
FD002EED4003D38581C2E190863F6C400349F883076CC0660018E0003180C01F0460034A17C000F07E0017FED00254FFE106566033BBCB70CB3F3041024EE074
BDFF4082E90EC10B7F704210B85404006D030993C4C61E34F0EE3C3C20DB0C80F7C3678E0161D6C10AE8D540AC14E0821B08B3487FC81A09FEB0832EC8940A32
47940B7428AA195040071A50410D342072FF353256054190F8A71EB002593DC0D103D0C1BB6F30047597C1068D27C101EA3C80A5D360EF0F80FA1F1E50F11D24
400227AD5D3614A9EE22D8BB094198D23E35A07026C4509819D0C2101E80ED000C615E9B0683129CB0072E097A0D576E82302720837FCB9EE912F0C1182450F8
334880B60FA003BCC5CD730DD89B049217B604DECD0600F8BA00129079E7D710F73F8C40071FF8C3091C80ED2748800A53C4CE373A026E619EC1083820764957
003A70048EF60733C0007BF6046AF70767A06E7147686DB670B3252A729653C6372EA3130485D7790B6104C144254300545510039B067EEF56054137810A5020
F376546D96040533817F70053100456626FF5263A0026160046C460263C70338873D07707E436003565007C2244F29F704567006923200C2B40312B803149002
1EE10236902F75D40747180578006F328501BE0602B3E5024F076F23B84B2CC4743A20043FE702EF76015D67037A5067B0676F44D0617C20856BD06D1D900376
510F2102033B2805BEC5664DC07D039000C2F40146A0049FB2072420003A102919B024C7262E57207B1D20811080062EA00129300002F0003F204C54E0004410
055DA070F4167B4947736F900424264C3DA0039FE673796003EFC66E0330774230045050672430049BD68B471004A998013DE06BDE121063A0310E336B6C7606
41B0039C1604C2F40363204C5A1068A3E7FF5227372F1847022F106C9FA8281D00030012677F80001B770231806D65E00230758A9CB5694DF000400502DC2829
12506723B0862530069B76062EC06634207BBD356F4B47026320030F107F1390038D4703D965003E800008E112D3406B1320730B37048EE60449370138C00075
B60375C60646D06D42806C7FD004B747850C8469FE4877FD260456B029220053C403032F3004B172020AB7705600874EE06B54A2037B8480C294056FF8074480
749FC20749D779F6D66614A07861B04719601B6CE21436110455C005283001B3140407C000E066021F805832C07E3310000830049152023F69675C1200092000
48656F21A060EFC64A0C2069CAE76D3CF0FF0253001B5D7006BE862BCF1505A1B6066F104B51C0060A27410F1003A2728C58B06E2FF06E4CF000010001190053
14200722800206200322C00248200160A37AF4E30312703A46A002FC650487A0483E9000320505727004F7611B12B049FF76201A30054BD0377D230148B00409
A3073D15057220010F700030E09689115F46B00057F400CC80200DA00741F0007C807F46E00362B00743900316B007FF767A2FB00463401C064005F0C19F52D0
297D832060E307D8A14814001FC541A0D394001A800608F01041800615201E7C250522A3431DC30FA5B11AA34121CFB504C2B238CB190613A30268B020D9A19B
D03519B0F15C17311BC06100528088D4A0FF352A80880BBA1C5B001A0910045DB00023EA18F49348BEF0481BD5515C713B99F11322A32208603223F13B19020E
12C3211460A22AB1486085A47C30567CF2A4977440E3A1029C4418393A187B90165A6A0C75720009EA265BB0001AB507A7A5A46CB15A1FB31199241407241482
7716993510579A0D8BD1A62F873F32B10777F24899754DDFF12C982114E5E111806A37999500693A274074183E400530901415F172749A5A06D000DE31AA30C0
5AFDD9A799550326530FE224A8CCC00DBB3116D4511109C0012AC0489985AA4A9A59ABFA3106900262FAAAB19A59D62016D3900008D026F9E0070B70A5D37000
1E291169E318DA5403D95A01D08903DDFA3DADDD5A014BB0648EE118227AAE1590020C30AE298004E34A05F07AAEDB1AAE7200AEF42A076A30AEE53A05EA9AAE
E7CAAEEE3AAFE72AAF6190AFD61A08003B}}
\par\par \b \uc2 St. Elizabeth launching effort to test promising  \highlight22\uc2 new drugs \highlight\b0\par\par\uc2 Barrett J. Brunsman   \par \uc2 619 \uc2 words\par \uc2 27 October 2015\par \uc2 Business Courier of Cincinnati Online\par \uc2 CINBCO\par \uc2 English\par \uc2 \u169\'00\'A9 2015 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 St. Elizabeth Healthcare has received a $500,000 donation to help fund the \b \highlight22\uc2 launch\b0 \highlight\uc2  of a Clinical Research Institute, which will make promising \b \highlight22\uc2 new drugs\b0 \highlight\uc2 , medical devices and procedures that are being tested available to patients.\par \par \uc2 The institute could help St. Elizabeth remain the dominant medical provider in Northern Kentucky. \uc2 UC Health\uc2  and Christ Hospital are {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/cincinnati/news/2015/04/03/christ-hospital-pumps-millions-into-medical-center.html"}}{\fldrslt{\cf2 \uc2  touting their research efforts}}}\uc2  while also investing {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/cincinnati/news/2013/10/31/uc-health-breaks-ground-for-new.html"}}{\fldrslt{\cf2 \uc2  millions of dollars in competing medical facilities}}}\uc2  south of the Ohio River.\par \par \uc2 Tony Zembrodt, president of Global Technology Transfer, and his wife, Geraldine, made the first major gift to fund the St. Elizabeth Clinical Research Institute. The Covington couple pledged to give an additional $500,000 if St. E raises a total of $5 million by the end of August 2016 to get the institute up and running.\par \par \uc2 "We look forward to reaching that goal and expanding care options for patients in our region," said Garren Colvin, CEO of St. Elizabeth Healthcare.\par \par \uc2 The initial donation from the Zembrodts will help St. E pay for startup costs, new medical equipment, advanced computer and data systems, and some of the patient-related costs not covered by research fees.\par \par \uc2 "Clinical research opens the door to a better way to prevent, detect and treat disease with the introduction of new drugs, medicines, medical devices and surgical techniques," said Dr. D.P. Suresh, a cardiologist who is physician leader of the Clinical Research Institute at St. Elizabeth.\par \par \uc2 The goal is to conduct Phase III clinical research involving drugs, devices and procedures that otherwise might not be available in Greater Cincinnati for five to 10 years. For example, large groups of patients would be able to participate in clinical trials to confirm the effectiveness of a promising drug, monitor its side effects, compare it to commonly used treatments and gather other information that would ensure its safe use by others.\par \par \uc2 The institute would be based in offices on the Edgewood campus of the St. Elizabeth hospital system.\par \par \uc2 The institute is expected to collaborate with \uc2 Northern Kentucky University\uc2 's {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/cincinnati/news/2015/07/14/first-look-nku-shares-plans-for-97m-health.html"}}{\fldrslt{\cf2 \uc2  planned Health Innovation Center, which will accommodate}}}\uc2  NKU's fast-growing College of Health Professions in nearby Highland Heights. Construction on NKU's $97 million project began Oct. 21, and it will be complete in 2018. St. E invested $8 million to build and equip the St. Elizabeth Healthcare Simulation Center inside the NKU facility.\par \par \uc2 St. E's Clinical Research Institute also is expected to boost the health system's collaboration with the \uc2 Mayo Clinic\uc2 , which enables St. Elizabeth patients to {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/cincinnati/print-edition/2015/05/22/why-cincinnati-s-cancer-economy-is-soaring.html"}}{\fldrslt{\cf2 \uc2  participate in national trials coordinated by the medical center}}}\uc2  in Rochester, Minn.\par \par \uc2 "After visiting the \uc2 Mayo Clinic\uc2  recently, we became convinced that St. Elizabeth is and will be offering unique research opportunities to our community," Tony and Gerry Zembrodt said in a joint statement released by St. Elizabeth. "We are both excited and honored to contribute to the future of St. Elizabeth as the premium hospital in the area."\par \par \uc2 The health system operates St. Elizabeth hospitals in Edgewood, Florence, Fort Thomas and Williamstown as well as a Covington ambulatory center with a 24/7 emergency room, a Falmouth drug and alcohol treatment center and 111 primary care and specialty office locations in Kentucky, Ohio and Indiana.\par \par \uc2 The Zembrodts donated $1 million earlier this year to Thomas More College to {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/cincinnati/news/2015/02/27/alums-donate-1m-to-greater-cincinnati-college.html"}}{\fldrslt{\cf2 \uc2  help build a center to support the academic achievements}}}\uc2  of students. Tony Zembrodt graduated from the Crestview Hills college in 1965 and is on its board of trustees. His wife is a 1966 graduate.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=cincinnati&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Cincinnati Business Courier for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document CINBCO0020151027ebar0002t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Teleflex \highlight22\uc2 Introduces \highlight\uc2  Comfort Flo(R) Plus Cannula for Heated High Flow Nasal Cannula Therapy\b0\par\par\uc2 662 \uc2 words\par \uc2 27 October 2015\par 06:45\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2015  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par WAYNE, Pa.--(BUSINESS WIRE)--October 27, 2015-- \f28 \par \par \uc2 \f2 Teleflex Incorporated\f28 \uc2 \f2  (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced today the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of the Comfort Flo(R) Plus High Flow Nasal Cannula. This \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  addition expands the company's portfolio of Heated High Flow Nasal Cannula Therapy (HFNCT) solutions and is designed to enhance patient comfort.\f28 \par \par \uc2 Inspired by the physicians and clinicians who help develop our products, the Comfort Flo(R) Plus Cannula is designed to enhance the overall patient experience by offering silicone nares, an optional chin strap to encourage closed mouth treatments, which may increase positive end pressure (PEP)(3) , and a bifurcated head strap for a secure fit during patient movement.\par \par \uc2 "\uc2 Teleflex\uc2  is dedicated to connecting clinicians with technology that helps improve patient outcomes and advances respiratory care," said James Ferguson, President of the Respiratory Division at Teleflex. "The addition of the Comfort Flo(R) Plus Cannula supports the growing utilization of High Flo Nasal Cannula Therapy and further demonstrates our commitment to developing products that improve the quality of people's lives."\par \par \uc2 HFNCT has been shown to improve pulmonary compliance, reduce work of breathing and wash out dead space leading to improved fraction of alveolar gases.(1) A new study from The New England Journal of Medicine suggests treatment with HFNCT can improve survival rates among patients with Acute Hypoxemic Respiratory Failure compared to treatment with standard Oxygen Masks or Non-Invasive Ventilation.(2)\par \par \uc2 About \uc2 Teleflex Incorporated\par \par \uc2 Teleflex\uc2  is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation -- a relentless pursuit of identifying unmet clinical needs -- to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. \uc2 Teleflex\uc2  employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.\par \par \uc2 Teleflex\uc2  is the home of Arrow(R) , Deknatel(R) , Hudson RCI(R) , LMA(R) , Pilling(R) , Rusch(R) and Weck(R) -- trusted brands united by a common sense of purpose.\par \par \uc2 Forward-Looking Statements\par \par \uc2 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the \uc2 Securities and Exchange Commission\uc2 , including our Annual Report on Form 10-K.\par \par \uc2 Teleflex\uc2 , the \uc2 Teleflex\uc2  logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, Weck and Comfort Flo are trademarks or registered trademarks of \uc2 Teleflex Incorporated\uc2  or its affiliates, in the U.S. and/or other countries.\par \par \uc2 (c) 2015 \uc2 Teleflex Incorporated\uc2 . All rights reserved. MC-001752\par \par \uc2 \f2 \par  \par  \par References: \par     1.    Dysart K, Miller TL, et al. Research in High Flow Therapy: \par           Mechanisms of Action. Respiratory Medicine 2009 103, 1400 -- 1405 \par               i. Cited in support of HFNC benefits, excluding CPAP. The \par               Comfort Flo Humidification System is not intended for use as a \par               CPAP device. \par     2.    Frat JP, Thille AW, Mercat A, et al. High-Flow Oxygen through Nasal \par           Cannula in Acute Hypoxemic Respiratory Failure. The New England \par           Journal of Medicine 2015: DOI: 10.1056/NEJMoa1503326 \par     3.    Hirst KR, Patel A, Vines DL. Evaluation of Bronchial Pressures and \par           Tidal Volume Using Three Different Adult High Flow Nasal Cannula \par           (HFNC) Devices. AARC 2011 Open Forum # 13 Presentation. \par               i. Cited in support of PEP effect only \par  \par  \f28 \par \par \uc2 \f2 View source version on businesswire.com: \f28 {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20151027005015/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20151027005015/en/}}}\par \par \uc2 Document BWR0000020151027ebar00030\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw133\pich40\picscaley100\picscalex100\picwgoal1995\pichgoal600
47
494638396185002800F7FF00FBEAEAE6797CEB9EA1919191F0F0F0828282EEA4A6F2F2F2ADADAD9E9E9EB5B5B5D0D0D06E6E6E3333332C2C2CD8282CFBD5D6E3
696B898989F6D2D2F0AAABD30103F2B8B9A9A9A9CDCDCD9B9B9B7E7E7EFEFAFAF6D6D6B1B1B1E36165141414F4F4F4A2A1A1DEDEDEF1B5B6FAEDED666666E573
76BFBFBF8E8E8EFCF2F2C4C4C43B3B3B4A4A4AE8E8E8DD4E50BABABAFEF8F8F0B0B1DD5154DADADA616161EEEEEEDCDCDCECECECF1C2C3EAEAEAFDF4F4696969
E15B5EFDF6F6CACACAF5C9CAF8D9DA5E5E5EC8C8C8404040CE0000FBE6E6FCF0F0E88184BCBCBCB8B8B84444440C0C0CE3E3E3E88385D2D2D2D9252AF4C5C6E5
777AF9E0E0959595E9888AF8DCDDE6E6E6E36468F9DEDED8D8D8DE484C767676EBBBBCDB4448E1555AC2C2C27A7A7AE7AFB1DC3D415A5A5AEEA2A41D1D1D7070
70E77E80D72C31DF6264F4C1C2C6C6C6575757E88486A6A6A6181818E0E0E0505050E49597212121868686787878DB4045E4E4E4F5CDCE262626EEA8AAF4C7C8
C90000EEADAFD5D5D5EB9495EA9192E46E71C40000DA3136CD1619FAE4E4FFDFE0FCEDEEE25F62D6D6D6EC9597EB9798EEA6A7D41418EEA1A2737373C0C0C0FD
FBFAEA8C8EEC999AD1090D000000F6D0D1F7DEDEE77B7EE98A8DE88082F1CCCDDD3A3FFAE7E7F0AFB1EA8E90EB9C9ED51D22F2C5C7F0A7AAF2BABBEA9395FDFE
FE060606DA353AF9E6E7FAE2E2F2BDBEF2B7B8F8E4E4F8D8D9F5C2C4E04A4FF0B2B4EC9A9CFFFFFFFBFBFBFEFEFEFDFDFDFCFCFCFFFEFEFAFAFAF9F9F9FFFDFD
F8F8F8F6F6F6F7F7F7FEFDFDFDF8F8F9E1E2FEFCFCFEFFFFFDF7F7FAE5E6FBEBEBFFFEFFF9E3E3FCEEEEFFFCFCE4A8AAEFABADEC5C5FCF2025FEDADBABC0BF9B
B1B0080909F3C3C4FFE3E30F1010F1D3D2D20F12DF5A5DE8B7B9FFFEFDE04C50DF6D6FEA8487FDF5F5F5BEBFFCF1F1F3BBBDF9E5E6707D7CD8464AE78C8EF4A2
A4768786F6D3D4FAE3E4EC9294F4BFC0F8DADCEDC1C3F9DDDEF9DFDFE9AAAADA7C7EFEFBFBFBE1E1FCEFF0535453F3D8D9E68789E1575BFFFDFCF9ECEC8E9393
E8282D232323E8999BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A45324541463245354338373545323131413343304437443032394336463539432220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A32463439334235323531303231314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A45314543363134303531303131314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F70204353352E312057696E646F7773223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D22786D702E6969643A4533454146324535433837354532313141334330443744303239433646353943222073745265663A646F63756D656E7449443D22
786D702E6469643A4532454146324535433837354532313141334330443744303239433646353943222F3E203C2F7264663A4465736372697074696F6E3E203C
2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEB
EAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACAB
AAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B
6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B
2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000850028004008FF
006DE9A245B020AD5CBA66D5F255EB9F4387B374D9FA372B572E83B4784D7CC89162BE591C73E570020744C78B1DFFD962A872A0C15B1C6FE94AB9B021C759BD
4072B4C5CB66CA9F401F12A8B4A3E3964A493A3AA904E6DF824A1A66499DAAD3612D79527578E133E15F824A2B6A3CACE5A6D292890D2A4DB1396B46A54A13EB
54F2F15042A5062069F5AB34D32192B7952EFC1351E90D0A3088252CA974E09F864A2A66DD2268D167D094B36000AB4A952A4712449EC4F2E4C800050AF366ED
AD14A4EA974A05FE0DADC4C087930574DECE8C5349C1BF1780C53A6C51A9DABF036F1324C8C07C409659652A0D58CE7C0A827F3B2A6D4182408182016F277EFF
A8B4E01F83B765723D6452C9CCBF5A792AD53BB1C0CFD74A4E1C1671D1A8118F4E0E5D2041552901D344139824884900819833CC3E0558F68F1075A8F0101C1A
34504D0328F8124206FF28508708836DD14247076830C03FB948A0811930C2C84002B52000C6230CC498632F428071C74D12B0D1D8612776A081491CB5B0C509
0F1D80C210D538B0058F412043C53FF820D24D009AE0A1493783A0124514BF3C44C6208E50F1008097B54989096DC6091417686812800B98E022E79EFA69C227
47BDD06654256E1C70430E3780B054534F3D22902EBAF8B211506154F0CC3F959C424B4A76CD80E9079B725440254C8E8AC14D8F90FA4F190E30514D25A7FEFF
734225D739948574FFF046C043A322F1E7AFC0062BECB0C412AB0711040E430404D000F6D60B1D81C6C93B58B8E3CE1E8550F4D6A6BD9C02EB5017D4F2964DD9
01F6C83F2520F5DB5C0ED1C01A08D27C70DC294B0821840A2A9C40A22D0E5482840FF87EE14343EE3AC0020B6F55D30248BAF45B9EBB24CE125F0220E0BAD80D
0E29E0EC29C576ECF1C72003E5CA19FF44D0032EB8C8B38B43F890D111007670808B307A7C224F171CCCD249397D440003317B6CE0CFCAF1B8FC8F0ED8EC6100
337A30934A1AF2E0420A108800300B1EADDCA38832EF14430C10DEFCC14D32F3781308370FC96189430180F2CF19B1EC5285144600D1430469F491C92E8560FF
118116B3786347307DE839822CC7C0F0C33B0138E4C21E6D66D08F030EBCF116E50EE401C214B476E44325254C78791EA4E7F1C614416D22881AEFC507150219
A4554916FFDCF2967A1C9DE79B19959451021B41B89B294CD1E1FA50129524C0D16B6FD1FED0791D7C3C54511C8151090B60C8A881BBB13D95C7233494504210
4905950D11D49852C9103F61C06E6104FE63976FB939FB5606BDFC43CB1C95C0F4542520604FADDC570F5D10A0172BA804C6FE312A68790C0473880D47063007
0B7144047958D10CF250865378D08377C1DD3FF4710D2210211480D093555E20BB4C49605742390F605640178764A00C357408081A200D38FC43090E10A143FF
425006261060091AC04C3DAA610B48F4E30D4BA88614ABB10448842C28B84847313AC1452E4AC11BFF60C20CFAF2105DF841382C9AC10B3280041B88B00659F0
C53F7CE107183EC4163660C27BE0600311F8D18F33D8550B66F04740FE880084F4631E5BD0188A0C523D378863476E910534DA42046B4C422278F1905208A20D
96B0442004318A7FD4A31290F8C2094ED00132FE033483D8C30FA0B0073500415B79E08512A0E210E08460168B09D54FD8A02EE0B4E02973E0247BDE30AF53BC
205F274082A76C9116044013092A20186466618B5AD82207D1D95474CA138453E882736380091C2A21817FF4EB443FE9011F02F19059440059E3905750F441FF
0458C0E09F3090C706E4510B69544298C4794B3B3FD71BDCDD213ACA4B575280931F88C8CE01C7C9140826438B5BF8A227D1B9014727D38B5A6447080FF91C13
F5E7B07FB80B9EFA034C1203953C4E1E272D2CB8A24E77CAD39EFAF4A7404D091064F18F409C011054E88AE35ED1113BB88223A5A9533114D10D7174E10731E0
0431D2100555E0031D0FD98018FE410C7CFC2305A84047150261842B50A010F8408628B631017C30E31268E0400C52208A41B08311247808174CF0030BA80110
B388850726000B5630E21AEC300038A6318809444106BF10C008CE108A48F0C003AAB084175461010AC8030DA490021A8C112790CC6217B0DD854EA402147AFF
8091ACE498850E5448566240E4B70EE12D4440020C703C0417C9E08811789B027940C408DAB80967F4348B64F0D6086572483256F60F5C1897221D49C106804B
DBCBA4EA2DA79883E500438017BCC1820F994119DA9985328CC77E5B080A0708B136FDB9E155806100896A37870608D3210378035D125086C500A61A60D8952D
E2F0860410C8071F702044D8200D061028C1F015962D6C310BE47878C413B11E4A93C414A754020598090A1788B0B6C7D04084B340DE413F756006AACA5437D1
DD3F34E4AD5AFDE335469E8534DEB04E8CF2CA5FD2234A47AC673FC0D0C1C5550EC265965181F455220E3FB9155D2AF10121FE23374CCA8D036810871D30C0FF
72FDA805742AF18F8A41E61F6BE81C45DE700A98F0E22E4FF695C7A637A81C0EA7127570F18AF87409414000539530F33FE4E2A94A48237EE942E9633AC0CDA5
CC4127FBAB841C656516B908E61F09AC72537C1C6262D5E07A1D09829E1FE23E1AE0F92D799883AEE750863808D31E4410831D88208807088322B2AEC4180EB3
9853E4C02139F0D60724300084F5C621E9F20D441258006E7ACBA60EE15C6FC45509983AC40F95C8C32C46758A0F7CD08382FE1537E3578B5BC44F320DE1268A
F72DA159C80306F173C82D0E500302B8922386AA01082645117B77443230A98584042E1598FC443252E9A6C4374EE2A07AFCE320FF93314CC88792975C10CDFF
F8C7AB5640A0BF306038C5034C19E03984C0FC03016FF10347ACF016D978ABCA6C585595DF320B19DA6F09D09A85E550CA9B25D871309508FA716AEE2C69C097
149430E13558F78F1038C083D2F0D6021DA20F3E5CE127B5F8C01CE2B3039D40E2C5E822544714F001BA8CA19895E85725F2F70F9E33133965F8092DC60394BB
0FF821BC11CB38B1238DB4BC4127EC4934CE73CA9105CC210800E003233862002228E31C4BB80C0928510193F341108D7048CF67319EEB2CA595990A95081210
020424E1D9B29E6825ACE0E33270B330C7B9AFB398F9C3A137265D80F9C06A125D8BC5BB0B26A7CC69C550F716181280F61778C102624184EC3A2412443044FF
344E810209D00105E67E251F3C80F66D1D1A746A41357E1C420B02D42204F197E8BACA53BB7439A01A739051C4D711B4603985471E147103D2500DB8C30B2DE5
2EBCF70FBC8053B0611EF1F71E04700B79B602FFB0077C100A07D2087CF0687B11700FD1097C60422A48047CC00FEA13691CE116A043111A831E6F6150EE9116
21D07577F610B7906AFFF06A4397078337740A942ED10311A9520D52F11616921687771CAF2275186050BDE3609912724161825A08325CD8856018866238861E
370BE3D503D48205C1A003C1500546600CEC2005C27508316001CE452C3A708757F40B9D500555500C5F382CB8305E7BC20180F00F54700C299106E1D01196FF
2003DC050069A003EC30029FD00DBE150C02A00829F00FC1100399B00E1D410AB1000AC9F50FEF700454C001FF200FEA00089E0012D320000600125060008AB0
01B3600106300984F80F02100C0FA10500F00F7A4006AC4011E1C00864706C6AE008A320156A400131508C2460014405055490093DB0015730029200566DC201
6E6302459002D8F51032F00D1D21034CF5104D600072F010FB15016AB00A927009380012F020000F210994100E9E4004C2B009D6F010AE10050F310CCEA008AC
300264B0015030098C9002C2E0098B100BC020586D100C92100A0E410E2330027DB0082960017F100306B20823600147900C161003EF1005A9D007208109DEAC
D70947E01026200A6D020E31F00F4D20035780082E80050EC1085090128520063CE0021EA027E47005262006EEF00F9E100126300AB880032B13063FE01002B0
0A1C91093AF00A32900626800BC6D0057FA303FFB020F8600CC0800F47700624900C2E400567508C0ED10EACD85DB0200FF2C003478008E04002DBF00967600C
BF600267E00152900251A0094D7004298007D4150857A0053F00037AE010A5500540850B7E4986A8F9130101003B}}
\par\par \b \uc2 Stryker Spine; Stryker Spine to Feature Expanding Portfolio of Procedural Solutions at the \uc2 North American Spine Society\uc2  Meeting\b0\par\par\uc2 253 \uc2 words\par \uc2 26 October 2015\par \uc2 Journal of Engineering\par \uc2 JOENG\par 1570\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Journal of Engineering via VerticalNews.com   \par \par \uc2 2015 OCT 26 (VerticalNews) -- By a News Reporter-Staff News Editor at Journal of Engineering -- The Spine Division of \uc2 Stryker Corporation\uc2  announced that it will feature its expanding suite of procedural solutions for spinal surgery, including 10 \b \highlight22\uc2 new products launched\b0 \highlight\uc2  in the first half of 2015, during the \uc2 North American Spine Society\uc2  (NASS) 30th annual meeting in Chicago, October 14-17 (booth #1123).\par \par \uc2 Stryker Spine offers one of the most comprehensive and diverse product portfolios for the treatment of degenerative and complex spinal disorders. The Company is committed to pioneering innovative technologies for traditional and minimally invasive surgical techniques. Its suite of leading-edge products includes implants, instruments, and biologics for the cervical, thoracic, and lumbar spine.\par \par \uc2 "This is an exciting time for Stryker Spine," said Brad Paddock, President of Stryker Spine. "Our expanding portfolio of spinal procedural innovations and differentiated technology demonstrate our accelerated commitment to bringing state-of-the-art technology to physicians and their patients. Surgeons in increasing numbers are choosing Stryker Spine technologies. We will continue to expand and strengthen our leadership position in this segment and are thrilled to showcase our 10 new additions at this industry meeting. We believe these new offerings prove our continued commitment to our customers and future customers."\par \par \uc2 Keywords for this news article include: Technology, Stryker Spine.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document JOENG00020151026ebaq002jg\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Impax\uc2  receives \uc2 FDA\uc2  approval for generic guanfacine\b0\par\par\uc2 140 \uc2 words\par \uc2 21 October 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Impax Laboratories\uc2  announced that the \uc2 FDA\uc2  has approved its generic version of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg and 4 mg. Fred Wilkinson, president and CEO of Impax stated, "Since the resolution of the warning letter at the Hayward facility in early September, the \uc2 FDA\uc2  has approved three generic products from this facility in the last five weeks. Generic guanfacine was one of the products waiting for the resolution of the warning letter and we did not include it in the 14 potential generic product \b \highlight22\uc2 launches\b0 \highlight\uc2  for 2015. We are now evaluating the viability of this very competitive multi-player market and potential commercialization of this product. Additionally, we will continue to work with the \uc2 FDA\uc2  toward approval of our pending Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications at our Hayward facility." \par \par \uc2 Document FLYWAL0020151021ebal009kh\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw226\pich40\picscaley100\picscalex100\picwgoal3390\pichgoal600
47
4946383961E2002800F7000091A2D21D61AEEFF0F8005BAA6681C0C4CCE81460ADF8F8FC3468B2DADEF0125FADACB8DEC7CEE9758CC79EACD88599CE5A8BC3E8
EAF64871B7DEE2F28D9ED0F3F4FA8094CB2D66B1FCFCFE99A9D6E7E9F5889BCFB2BCE05576BA456EB62163AF6A84C2A0AED9788FC8BCC5E45F7DBEC0C8E6CAD0
EAF4F5FB014EA21860AE6C86C32C61AE0A5EAC7088C4D4D9EE9CAAD796A6D54485C08295CC005DACF1F2F9397EBDCCD2EBD0D6EC3066B1607EBE6883C1386AB3
2964B0C2CAE7EDEDF75A7ABC7C91C92562AEC8CFE93168B2406DB54C73B83E6CB40058A8BBC3E395A4D4F0F1F9F6F8FCE0E3F3EDEEF88FA0D2638CC5BEC7E5B8
C1E3B5BFE2D5DAEFD2D8EDA8B5DCD9DDF07990C8B0BBE0E3E6F45778BC4A72B8A6B2DBD2D7EDE4E7F4F8FAFDCFD5EC5879BC5376BAE1E4F34282BF426EB64180
BD427EBCC8D0EAFEFEFEF5F8FBD6DBEFB6C0E27E92CAE5E8F55478BB4E74B98A9CD0AAB6DD1A5FADA4B0DA0D5FAD3D82BF5174B9BFC8E63A6BB44681BE627EBF
4670B76380C06E88C4054DA2DCE0F28497CD055EACC1CAE6BDC6E52263AFA2AFDA738AC6F5F7FBF0F5FA5175BA7C92CA0A4CA1748BC60E5CABABB8DE5B7BBD0A
5CAB7289C54169B20057A80054A60053A50056A80056A70051A4F2F6FB0055A70055A64183BF0052A4005CAB788EC7004FA30052A5DCE0F195A6D5FBFCFEF6F7
FBFAFAFDF2F3F9E2E5F45275BAF7F7FBEEEFF8F2F6FA2764B0C6CDE8F2F3FAB4BEE14182BEF3F7FBEAECF6EBECF7034EA2DDE1F1D8DCEFEBEDF7ACB7DDB9C2E3
FAFBFDADB9DE95A5D43C6BB4F6F6FBC3CBE8FAF9FC416EB6FBFBFD2563AFC4CBE7BBC4E4CDD3EBDADDF0A9B6DDB0BADFABB7DEA6B3DCA5B2DBB6BFE1D7DCEFA7
B4DC97A7D55073B8EAECF7DEE1F24E7DBD6480C0416DB55D7CBE4181BD5C7CBD96A4D34183BE607CBD11499FF3F5FB4B6FB67187C3909ED0085DAC436FB6065A
AA5176BA5175B9EEF3F9A7B3DB95A8D40059A9F1F6FAD9DEF0FCFCFDA5B4DBFDFDFE93A3D3EBF1F8637ABCF1F3FA557DBDAFBBDFE5EAF55573B894A5D47389C5
597ABC045BAAFFFFFF0058A921F90400000000002C00000000E20028000008FF00C9F51B48B0A0C18308132A5CC8B0A1C38710234A9C48B1E24381FF326ADCC8
B1A3C78F20438A1C49B2A4C9932853AA5C597220CB973063CA9C49B3664D973673EADCC9B3674F9C3E830A1D4A5428D0A248932A5D2AF228D3A750A3FEEC27B5
AAD5AB2F9D62DDCAB5EB3FAD5EC38A5D0A76ACD9B353D1AA5DBBB32CDBB7704DBA8D4BB72EC7B976F3C6C5ABB7AF5ABE7E038B052CB8F056C255295D5A4CE9A4
E2C62B296DAA44B91226C886432A5E7C097347B09C2C59E284A9B4E98FA6535FDE7829B5E78C98448BBEC49192A5509406E8BE14AA92E64AA132E9E6146AD3A6
4CC8932B4F2E2A23254F982EC041A74842804CBE35DA96CD9DB676EEE02BBDFFFE175BF4269095928B5ECEDE136D4CC97D3F4F4EDB52724EFF3685B2A45BB7A7
F31E69C58E076F745046001F2498A028967897D1001728A860218EB8F70F25C51492602103784609025A882186161760E25C259FEC210D1651B488853461B033
5E7E9C6C61813352ECA28B3446EC000428400629242822E8400926971080C514A89C608A0F4238B183258D51624088228AD8011C823478E10C6F6429E6963378
B68911216AC1C3788D656301284090708D08430A29C221C56C32C49B226CC1490A4482B24821FFECD1062816F0210A0E6D44D3621448BC8000807751559B0CA5
D0904B2A6E68E0A91B5D0050CE009D65148712A9A412012D11B89145081260FF52C91E59A4E20514AF7DE8C50927DC528E6F9B7C620113ABF863ECB1FEC45266
479C4860022AC81AAB8203D1566B6C159EE4510031D6FAD3840C32FE334014AB28D1E40907C0E2C6023B984849062728418329A61CB0CA01A6FCBA1126AE8081
4A051310612247980C3386B4C578D1EDB11684220817C60E220A250F180B4E009584D184B12450404BB54A8861498096B236AEB1A754B3062E599C72EC0D3948
C6091F07F8734A173D74A184B1AB5C53C9002EFB238283CE0D4087B1058867C93026F813CF180B3400820E1B20E18F211D727449113BFB63853A873CC0863F16
B0720B033DE06185B14ABCD24330C9F8734D1F0EA8A003087D6C0046B5CE0CFFB009257B18EB83210E18E303DBE888878DB1A558D14501361C2C46761A7122C2
B16B0441B946A184E04F2ABF540283B15EBC1DCC206B1C7BCC0C9678606C044658528EB119B0B3C907B8F883C4D1FEA0D24B033A88F0CC186F8CFC59C91BD9C2
4DC4AECC5007027DBC3001CA4EB0630936ACF893C50A8CB0A3C82BAFF36149CDFE6C335E2516183B426F9050E38F30717C9089259489928916905C581B15C61A
12C47E9EC8C41B64D0880F882214DFA047C42A618B5028C0092AF0473436B1850C0021009C185DB41CC08E1A196B1928C8842724400863754110989883B1A690
820114C71500E0037E5823016411C26F1CF10405FCE1025770421AC67A4003FF43810273F4C258072887253E110B63C9E00F3930961642A3859D956014FE5845
0BE65709D16C010103AB944742410A63C9E112A4E184282A7181231A0B089520C2CEC610002465020758F4870CC667AC98752413E250DF1FF210017F1CA00F9C
98E14646D3914B0CA16627E0C1E644310051FCED1F96204129FCC1804FD4C711A9EB010B3660AC510460056B8B560B2C11417F48E13C94C8840776260C1D7822
05C662C011684309F1B0A3917088963EF4A7914C38C11FB8B8C00F8318464B04617AFE08442C2FA73B51E8C21FAFA8A327E2F0B92AE4321398E925A5C4D81132
1AAB17E1720E27D8B1006301C3158540C6E73E30305B3C8376FF00461FC7E3FF891618EB188CE04010393123D410A166ABE081229DB34812C483939EFC4726A8
C90003C8C058F128033B7A502D64D4A195AFCCC82678E00263492213B8F4870006B0114A8CE712C1AC052E36E98F2B8451A2C7BC05022A01447F6CE0A6A29087
B190F1894AFC220BFEF0023A4AEA045160620623F047012EEA8F2928607321018B39FD81CE5C29207BFE9087019A960A7A5E481451F5070030D1857D76A49F1F
C4062CFC818C148C732497C001F9A2C183FF7C24930FEDE46266300863BD420115F3C70406C0875C582B1B2005502526514853F4411429F5C7004A4334AD0553
09122800E3BCE189621E73143BED692FC679893CD0940897A8C4318C650C25FF34A108A39140CD0ED14A7F38C00099B82BC9C65846AEA6B3A5DC54EC0584304F
1365A20327F047053A60093CB89523A20081B1B000046325211429A104734B69810F40A7238085686C8B00D6571840123488852248204F6B852070AE84652500
60AC60FCE3129935400A52F009E301D358457045028CD584709416A7FE402D4F8DC5813F84E2C2E7B94461FD4181D0F4D61F42B80C2502914516F0600A2F0302
0F3271D3E311F79CC7D5C8266AE80F0D1441B4A92804272E1186839DE21004E5A83FFCC8114B686193AF78813FC091030377C4A52ED5DA0E14762C266480083B
6E68603DE989DEBA570B7130E643BB2584C5B9B21297A803B5FC61021CE027FFB3C918C528AC0004276B04A6C63A4728B6500B6351C1871096704F59610213D8
A0071240337E99E0C93AF4D9581BC8C43F04913B2C1C2163D0AAB2211050AAE196B3B85DEDC826CCAC84064021C25B7840D334D08B58B954C8445EA4188AA581
92A2E20758D5C8003AA00210F063A1FFE0442162F18568456307944BAF60E16A58034082093CE0C182BB450323182B164540C209E231085090EA429985052A68
E08F6648FAC97930962ABAD802F26181CBA74D2DE3C0018E038003120DBA40659B7C09CFF94309C570E90E8CB587F778A004D13D561A1C3084D59093235B0D35
C1D2FDEF469CDA053AA880B11A608B815102D6E3B104248CE506FEC102DF1FFFD94477D90C5EAD6D02127428E4B1601186192A9BCBFE6CB616B88A892D80F504
1CA0405A6147613F182B1793408176321B0631DCC1022F3877473EA16EDF6CF3584E8865BC270C6238A8220CBED8827828E10B63A90337AA301613F0B35F7F44
A0E1B0E1441FEEB1B16369400CC2D52AA8632C521AD7E2071CD5C005D2A73D04CCF0E31CE367CEA161357F0041EA1CA9C40E0E668296D7668D79B8C2B4FDE106
C363D2A1EA15850E8EC58014ECDC1F710805081EDAB04994C0B0D6F6070738D14E3607004094C86C2F2BE189AC79640655BF102578E78F063062EB3D8D0576E8
97354BFC609356B8001B916884F330C11FBE88B273C0598E405C5FED85788DFFDE613C1E4C50950963FDF71D36D144BA16C35D42064167FFC1EC1EF474178AF1
C848F9577990F4F24FCE702C91F6795B165B12F031AE3400A7E70F2090090D000A9EB00532E70F19F00BC6220577044D0E9035B9772C2CC5501F017CFEB06E19
710906706AFE000C454062827681B80719973000A2E50F2A100A8D208028A00AA620370FD65295B009018005C7D2029D357EC6F51A2688546A957E21230AFAF6
4F91801FE0E30F4E205CF5A702D1150F90D01CA276622C371298C00228F802E075738B31008D270F05337390001D39A001C8020714F74A96900DE4E30B04F50F
99F581222182249811953004D3060663D382F935463BC45503F07AC6620228FFE0395DF001C27567828080005084C8C3397BE71997600910632C0810004D1332
3F080941C30CB6D37E37E0701AC16C36F00933D805C5006CF9E185426079FF956BFF100AE3E05D65087A822551FBE0349142078FB60A7B80029B9058C66203E4
3087E761096D702C22201E7BF8642DE6879B6309D32000281361F27688B55109AEB03134D00215600AD1150192C05C2FF06089E41195C0888780892FE60F0BF0
5F50761E7130661450091FC05CA4D84BA4642C1480092BE70F6D402550460947B066C7F007D3500FB4B5535096119C40523C1451FF350461D0200DC909018006
FFA608BE6186FA3385C87200DE100A040046405033F190039E107BB1004B98FFB066A570059C60001ED890F9B703C4F40FDA5864A3772C86280504D590981009
17E00951602C1FF30A19200C35362F5A303294200689D619505609D8406E4D10700FB711A1900414F609FD21081DC000C7220575600946D0674A6092175209EA
702C818003B7C03881C002BAF1093C505CC567099BA00341E30332F0019F20238D41040B960029E07101200050400229C002E460007C3083EA603CA2900D9B24
049F30309B500670782C02400294B07A4C500694000AA71008964102C67203D9914228E80FA0E093C6C298FD31035B300286808B82107C04338DA5B45365E70F
23F0096A39009F6000D9F00A0D100AB6792C21A0004AF839FA630951840561FFC002E4690087808040D0625F918917C209CA602C02200572C00CBDB079ACE004
8E202B1E5033A7A0032D971BD7642C0E700DDDD90451500523B083C6927D22F506D0A09A05200D322003BD20730960006174098D57012E00068FE69C01001999
D04AE0900F5C981F1ED09D54D00C503066A890005DA002E7B109D4C40A060020405842027A2CB7A20CF4393D07400006B6091D2045B9D6184AE60F09300499D0
7EF1E002F2F90825002DB7902703B00B6C13067FE04D9036439C80007DE90FB9B006567038C60200DF761731D0096CDAA666E007C5B23050700567200B9D5003
CDE90F83B0057AC0A6DA10036E692CBB700528662DD4B00EDA60A76C7A0610FF000F99D62D4C0001DAD0A664B066D5F208DD30A99D4006807A2C78600764E0A6
10D034DDF20E1960069B6A0D2525A03510AA9D600610E00E0B832C1110038A4A067610A06CA007AEDAA6AF1A0337C0794F600FC5B6302370069DA00D4F903A09
60AB100008C6F2048A2A0B7A3036D5020BFA200B9AEAAB9D10039AF0ADE0AA09AD9006B36A48AD00AEE9102DA5B004E03A0BE4632CA6C02DD6520A6A70AEE1DA
0A883066DD8201B310AE9AA0A0D57200F6FAADADA0AFF1000EFEDA0AEF5A2D69B004E73A0BF5A0AF079008FDFAADB3C00BE56A2CC2A006E1DA0EC5CA0B89E0AF
E0DA0A18EB0FF8D0350B73021CAB09B3506C34F0052C5BB2F310AE8800B0C808120F152BB2DF1A10003B}}
\par\par \b \uc2 Alembic Pharmaceuticals\uc2  debuts in U.S. with Namenda generic\b0\par\par\uc2 114 \uc2 words\par \uc2 20 October 2015\par \uc2 Drug Store News\par \uc2 DRSN\par \uc2 English\par \uc2 \u169\'00\'A9 2015, Lebhar-Friedman, Inc. All Rights Reserved.   \par \par \uc2 GUJARAT, India \u8212\'20\'14 \uc2 Alembic Pharmaceuticals\uc2  has kicked off its operations in the United States with the \b \highlight22\uc2 launch\b0 \highlight\uc2  of its memantine hydrochloride tablets, a generic of Namenda. The drug, which is indicated to treat Alzheimer's diseases and dementia, will be available in 5- and 10-mg dosage strengths. \u8220\'20\'1CWe are very excited about the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Memantine tablets and the opportunity to provide patients an affordable therapeutic option\u8221\'20\'1D \uc2 Craig Salmon\uc2 , Alembic's president of U.S. operations said. \u8220\'20\'1CThis is an important step for Alembic and the first of many \b \highlight22\uc2 new products\b0 \highlight\uc2  to be \b \highlight22\uc2 launched\b0 \highlight\uc2  into the U.S. market in the immediate future.\u8221\'20\'1D {\field{\*\fldinst{HYPERLINK "http://www.drugstorenews.com/article/alembic-pharmaceuticals-debuts-us-namenda-generic?utm_term=DSN204811"}}{\fldrslt{\cf2 \uc2 Read more...}}}\par \par \uc2 Document DRSN000020151020ebak0005p\par }\page {\par\fs20\b \uc2 Medical, Healthcare; Rx Safes  \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Rights Acquisition\b0\par\par\uc2 482 \uc2 words\par \uc2 19 October 2015\par \uc2 Pharma Business Week\par \uc2 PHBW\par 129\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Pharma Business Week via NewsRx.com   \par \par \uc2 2015 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Rx Safes, Inc\uc2 . (OTC PINK: RXSF), the developer of autonomous fingerprint healthcare security products designed to combat drug abuse and diversion, announced that it has formed a partnership with MIKA MEDICAL and MK GLOBAL, a leading Korean innovative medical device and distribution company, to exclusively distribute their proprietary, reusable needleless injection system in the US market. The agreement calls for Rx Safes to further develop the product by integrating its autonomous fingerprint interface into the device, allowing only authorized patients and healthcare workers the ability to administer controlled substances including serious pain medications, through painless injection.\par \par \uc2  Rx Safes will own all of the new intellectual property rights developed as part of this initiative and MIKA, which is an ISO:13485 certified manufacturer, will manufacture the new fingerprint activated needleless device for Rx Safes.\par \par \uc2 "The MyDOSE product is a reusable needleless injection system that will feature the company's autonomous fingerprint technology, so only authorized patients and caregivers can inject medication for pain, once authenticated by the device. This is another innovative application of our company's technology into an existing medical device, and is consistent with our company mission to secure the storage and dispensing of potentially dangerous medications," noted Lorraine Yarde, CEO at \uc2 Rx Safes, Inc\uc2 .\par \par \uc2 The Injectable Drug Delivery Market exceeds $326 billion presently and is expected to grow to $574 billion by 2020. Through this new partnership, Rx Safes will be developing the world's first fingerprint activated needleless injection system, and will be well positioned to capture its share of this growing market. Needleless injection systems have been slowly gaining traction and the \uc2 FDA\uc2  has approved certification of these devices in the areas of flu vaccinations and insulin administration because they are designed to deliver medications efficiently and pain-free, without breaking or puncturing the skin. "There is a real need to ensure individuals are actually authorized to inject controlled medications as part of a pain management program whether recuperating from surgery or otherwise treating withdrawals from addiction," noted Rx Safes' Board Member, \uc2 Dr. Susan Kutzner\uc2 . "The company believes that this product will revolutionize pain free administration of controlled medications and will be adopted quickly by the healthcare community," Dr. Kutzner added.\par \par \uc2 To date the \uc2 FDA\uc2  has required needleless injection systems be paired with a pharmaceutical formulary in order to be awarded \uc2 FDA\uc2  510K certification. The company has started discussions with a high profile pharmaceutical company that concentrates on manufacturing pain medications. The company expects to file for certification with the \uc2 FDA\uc2  for this product once that relationship is finalized, possibly as soon as early next quarter.\par \par \uc2 Keywords for this news article include: Medical, Healthcare, Technology.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document PHBW000020151019ebaj00092\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E60000AC0000CF5B62E1979CCA4B54F9ECEBBA1121D46C74F4DADBB3000ABE212DF7E2E3D6737ACC525AB80D1EB60518EDC2C4C22D39CA
494DFDF9F9D1626CBB1424BB1923B10004E8B2B4B7071AC8454AEAB9BBE4A4AAB8131AD87B83BF2431BE1E2DDB858AE6A9ADC12935E7ADB1DE8C93FCF5F5B604
16BE2230F1D1D2FFFDFDC63D44C4353EC3313ABD1C29C53941BC1928F0CBCEC02633E29CA0B80A1CE9B5B9C43542DF9196F7E5E5B50214FBF1F1E3A1A4A40000
ECBDC0F3D5D5C3303DBB1520D2686DC9464CC12C36DC898EDA8085FEFBFAF1CED1C74046F8E9E7B60914C63D48C53946C84348F5E0DEB40010FDF8F6C63C43EE
C6C7B8091BEFC8CAF3D7D8F2D2D4C4373EC02833B80D1AB90F1FC8414DC73F4BBC1729B40510FBF3F1B20A0EBF262DF8E7E8CF6565D05F65BB1224BF2634F5DD
DFC230379D0000FAEEF0BB1626C4353CB70C16C3333CC4353ABD1B2CC12C33C84247FCF3F4DE8F91FAEFEDC12838C63748E7BBBBB7061BB80617FEFBFCD07071
C4343CBA1423BA1323FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A32323231316331352D643932322D343631632D623963372D3964323364383535393464662220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A46333841333939333343433131314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A46333841333939323343433131314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A32323231316331352D643932322D343631632D623963372D396432336438353539346466222073745265
663A646F63756D656E7449443D22786D702E6469643A32323231316331352D643932322D343631632D623963372D396432336438353539346466222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF80752F222D1F1F096A27576F8688653185866A651E86865C2209962D83961F6F2D84965C1F228C8789A68D6A1E8B
969365911F5C949E989A866F9D96A0A297A5A7095C09AA875C7E351E501F0D05140E2D4C2F59057D261E1914D40526422ADBDC2B50CD7E59182E2C33057E0D52
2A42EA7E330D471EEA7D180519CCCE182F71D3AA394870A4DC3A1357BE15586882858A6605CC5949B7AEDD913352D6CD3B12E35E462609D451F077448488170D
FC3C6B11E185143FD63C44A030C38F1F0742E2144859C0C18A230DB2943BB7225E83191733CACB924104069818284438F1F4D98B082D9E5A4B1084A64D844C76
FAE1C602A8D0021856145D67EE489B7CECFFE839B5F9344882AA0EAE1A3A217465043518FA583B11012D053F26443039DA871B9F38181AF4C992C785953CD58E
C63963A2DA8C2C41AE98804A614002137D46B27C91E7F0C008F8FA20BE1224CB8CC60D33CC9B9CC78A0B0C59FA34C0106745E73EF39A8E1E59C02EEA916AB03A
A0E4CCC18796516346F013959B10A03C7DAA003ED4C5DB2C524C3858E32132061C0D98C4C813346A840A4E54463DF2027803072704810502513920021452DCD6
931056988003355258618514423540CF5B9E65C184087990669703A9E5251D05943C731D60879910436181F504C16292F564C511C04D8601142B90C7DD196DE0
31525E7074E1801A5238A186690898604EFF0B7124D105170D38E141101674610707000891411726A8C14D1B6B74E6A50312E611DC7071B471DC671988A65F1F
119C16E2552F384041018F40F35776D71426C59D3881379678E4D9665E3E08D47080026628B001001DC87180171358804008328041010E3DDC904503600CA140
02001810050B16049103120418D082131A0C0180812E84A0000A0404F0438E15CD10070B6B6A18C368F85010C407265030129D76B273C21B8415EB070E574480
DE9D269C71C46E5998E0820A0E04670E142C38508D092F041042110CB401000D48B4B0C01F41EC00030A0800A042117F0400060044FC01041A43D001C00B7F6C
6081007FF80000018F5A11661A1B883000FF0342E483DC0C41005B0D85A12D671FB2CA8AC81A05F8B400411950F4E71A6D0548D1180610086ACEB714B23303B9
E6225700140088F187130058A0C0083B3CDCC1C38F42FA401421580000097F8400C00607EC60C01F5F2090000A633C2C40122A3831430A0BEC104A3CC971F6B1
3EC34215DD0776AAD6526B3165F0886D87E120420447615B9614928D0B45B8C221556E86418800E91F33E090401323000040130220A080D5008430C20517582E
83192840B08019907A0187151838D180E60FFCE0809245EC0140051ACF30430610E0F031531E106B5F0B76F6A1278ADA15F0C109EB202642068C1590C7192A10
5E9E0B66B2E3CEE2C8C5278209904A4081FF1508F03005004BFC01020053D060F90324108182D4215C10C504012800C0BC2AE40B40174E2040E8CC81851BA080
080C08CA3C82C019A8346758A9C1C0DCEA763C3EC9042DD4418C106AA3200794855B1850810BC2A5B38B7486260D0842DCF6F7870C14A0737F30C31F7420352A
840E0B48D88216908005005C400606E0C1E97610300478200424280316FE20000020260F0A28021542909E2C444008C779C9541C0095AB64A564278A0A625614
333F50428341081C5ADA50BDC285100AD93BCA11164713D07C4F252CFC00022C10850D6C8D0316B000151E95BF2F70800E6500401504E0042A68800716904109
10E0031430D1023778549458F00703ECC0FF04160A02048805B2E045303AC42B194B5034463F358612DD805E0759802071DD8875159A810A20602E9AE8C3035C
C44724E53003F0B52F097F5840D18C10050404A1041AA081C02C10CD1D8CE00F534040079E400604EC00091BD841181E35031640A0044B034E04EE880F3F7C68
4ED8419909AE232D15D5E64F0598C1093EC0025936C6016CAC913944781C398ED219A51419055A308412F404003CE8C10E348002CBC1600A3B004209E6008212
08C09A3CD84100B0B98305A4A00B16F8411186B00302C800005648000E24B03429F04E78523981C8BC181813ED2945D5BA165A62B0B215E473662B7041CED073
045EC9831E197B5B1080A99FE820C00029FFE80302108004A48DF40516A0C306D0C0031AA001005178C00E68A0811D9CE10F46405FBF00C080B9BAD46B08C842
1194E9860404332AC702915F5C46011310863B29DA207A66E6100FD823383D1187401D70840665263E584468012210BCAA46E0038F531218A8E0BE2478818666
08C10ECC30042754C0066100C0E79250012384215F0143C21F34B0C707FCA1092530000064D804F521002D7EF8AC60450418C198802B86715E1A67802D6D4921
011E604B5A70291C29B8C55C4F2DC95F9B2327E80481780D10410DAE930508B860060860C0029CD086B7D4A0B2D6898014CA1080363841085A885C0502400220
20C0750100C20416A004042C610E0B30C0FF00309087E8F85595F11C0C6CC418CBE879100AF3A0CE40CF50B4409A20032E905A17BA5901B4A8017C00004348B2
20B5166CA10B00480217A4E6821648AD681C00030EF200801D58000B2C2083142C90340EC4A00164E842925A5001CB0512003FF842898BD6020EEC60075FC842
1712A06527E4931555E2028E1330000A0432902C18001B8AD68E366C2B259430C70ACEF086010461004B0003F1DAC0001FE0600C0680809B3910803930000018
607310EAB1040678205144E85D1022B08501ECE103164802030CE02F2760C1024B008201AC60013208C7044100C21612200500B4A003208040A8D5B084054001
014A6000AD49BD84017800CB0CF0B3089CFFE08300306006CCF6B316B077A4C2884005F3184B19A8629952FDE1DB7FB8410BDEF5870774E1027FE801004E4007
7013610775FD430210C64400F4E00F13708204C09D8216200006E00E41BE4000EE267CC009E600C318BE1D801D2C1CDC4D5403BF26008003FCC1061C5000B8FF
30872468E1DBAADD40328BA6816F37017CF19E405620BBDF04480803DE4E010FC2F00719EC00DD550000C3722E03B8A2BB080EFEF6F2BE7D8304F000DF08D8B7
028C3005276C8D002348C11FB45000905BFCA51838420544F0ED2D20400E7F40816FFFC00030F00B08159FA1058CF087034CE1DB3EF0C3B715C0866B2E2D0954
F8F6138E3D00865BE04C336803044CF219FF6FCB8185EEBB664875506E2754E10F7BD8810208708591FEE1042700F711183681A4FF410C46BEDA1FEE70F3A943
E0DB0E57BB5B00E0826FD72003DF2671096A8E8534080C00792742DAD1FE6D0654BDF743F843077690803F4820077F88C00E22F0ED25584038598FE909EE0100
20FC81000020F8A38ECE030030BE0715F0ED0D4EB0030E24E0E1FB7437C302B0C4DB3B00003DFFC30076B0C787DBC07236E5830310D07AB2F7FD0F10000037F0
07446001B3170002A83E69B70006D82FBF277C01337C7DC70347E7490FA70516301C4D750DD9250FD9F70752F40754F00158E05BDDC7784D4057E0B600590000
FFC70531707D45300525D70160F0047F80FF7CCA6479F5B67551F06D55500115601C05C07FAE1783008800C807025F974C1C505CEB637117607D7FB005555702
255005E8265C73F0074360037F40022C347516401C7CD01967340F0CB57130906221506E3BD07328403404F76D36006FDF06051328723AE80460F76D3AD0433C
8802A4D2021AF76D47E0447D60016DF06D1020047908064BD88420B0765E686F1BE73EE953058CD76E4D147C0CB0705160011FF7074B00004C408478620F0DB0
250B970316D0017F000330E43ED2D4034486064120757F800576F06D8DF3073C106FFD8200FCE22A71300316800658F076F856643B40356A974F0860793E707A
7F30066CA07195887C6163711D60013477FF01968480D647053CC852D7148A6D0700A5680709B038635109292404DE867D0B47074EC07827085758300120C006
1EF06D6D5007DFF6066F208258607148C72FCA04002630012400061C307B0B500024F068D764040E52001C60050469907F700500A05B1D608CFDB203F726031C
2043404070BC953E699000F7D64998C88B4FE004E9D32F96A22C16420947C04BDE96063F0086611049BFD5056FF80008907761F36D57D0889797790AA094DFD6
79FC320408A047D2C40308508E1F970208302F464020FB3001DF5606C5277F72E785154000C28700B6777F96340141F0074F60447FA0070BF36D406001FBF600
E87679D808040D9000E8E1072E20024270FF177EE06DC6C72F175052DFB66F0A5872ABF2070AF0035488797F50026C60799D6799DFE60175250132F40735D07E
0A307BEBD3636CA7992F7006035804968976229702965903C325302DF06D33617C2DF07001F00120982F38380009096E95D38A22700835D10700300145600469
803962060720807C1240026A206822976E6390040310060A300B29D04C1550051230002D500507600604900376900436307B3960004E707E87C89256E06FBE05
030370066C20043F98024840045B550123A007D787763370012900022D70741769066170065DE05B5A500355630126204D6370040A500532440216500FD3915D
D0710405E0047940343F30005596057590FF0408B0026F902FBAF0036080162610A42C0007F981054E80002CE0023880030E800308A002245600370A00BF9263
75F098561003E6320F4E00071F80077B54006D802A33A06600B0020C8063CEE0042DA00246DA1918000742800758004094950066E6074EE00419C0024EA01E08
C0069C351A94800F736336D0B61A516102165001198022345601504006CDE0004EE010EA31193820046F8101C584037C0001F9C0A849D038C9B264491007E5E5
046CC004A9B42948D60E87810127E0A73860130EE0016EE01F4DBA022CF0201410A32E7006664301EDB09826902038E05D718327651018E7B55CABC42784115D
DD0038D4D5137C40236E8423E42147DC43FF2157243270E257A9812EEE593CCF35131CF63CD1932D474038DAE02D87634B2AE03134C1314270AB7D901119A053
369105CFA2068135ABD33AAB27E0422FC11D5A72146381010E9133F964054EF52950DA19ECB05977240FC62227DCD102E97A18D7C5AEB28101CF631B0FAB2D16
321652E002B5540E0D70AFE01514A274ABF2E04E3A251B33A00610700247F001ADB1132D90012E934F09A0B0633103EE5A13F90401E3711633C0072B602E0BD1
00C3DA190B910547E0261141013F0B223BF102446B273BF10161D12233100371E0B04D1BAF3C3103E2903D3B611E541B1141391A11E1072A3A160DD00225B104
6AF0066530B827E003A6100384EB0365F04B0183BB6D8ACBB889EB0127D0B865E00327E001838BB93E00B994200210C0B92700011020B8897BB889BBB88D5BB8
A81BB993DBB896DBBA9ACBB91E20023E40BADB26BAB65BB82DE0038100003B}}
\par\par \b \uc2 Raleigh drug developer announces 'short-term supply constraints' for  \highlight22\uc2 new drug \highlight\b0\par\par\uc2 Jason deBruyn   \par \uc2 234 \uc2 words\par \uc2 14 October 2015\par \uc2 Triangle Business Journal Online\par \uc2 RALBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2015 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Raleigh drug developer \uc2 BioDelivery Sciences International, Inc\uc2 . (\uc2 Nasdaq\uc2 : BDSI) {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/triangle/prnewswire/press_releases/North_Carolina/2015/10/14/CL27553"}}{\fldrslt{\cf2 \uc2  announced}}}\uc2 "short-term supply constraints" as it relates to its recently \b \highlight22\uc2 launched\b0 \highlight\uc2  pain drug Bunavail.\par \par \uc2 The announcement did not seem to bother investors. BioDelivery stock traded down early in the day Wednesday, but by mid-afternoon had rebounded and traded about 3 percent higher than Tuesday's close. Taking a broader view, BDSI stock still traded toward the low end of its 52-week range.\par \par \uc2 The delay affects four recently manufactured batches of Bunavail and is the result of a change made by a BioDelivery supplier. Before BioDelivery can release the batches to wholesalers, it must receive approval from the \uc2 U.S. Food and Drug Administration\uc2  on a requested change to a manufacturing specification. The \uc2 FDA\uc2  has told BDSI it will make a decision within days. A positive decision will allow release of these batches of Bunavail to wholesalers.\par \par {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/triangle/news/2015/08/10/biodelivery-sciences-international-raleigh-sales.html"}}{\fldrslt{\cf2 \uc2  Early sales of Bunavail recorded lower-than-expected revenue}}}\uc2 , helping to hold down the market value of the BioDelivery Sciences. For the first six months of this year, BDSI recorded $1.5 million in Bunavail sales, the only product that generates revenue for the company.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=triangle&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Triangle Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document RALBJO0020151014ebae0005o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw120\pich37\picscaley100\picscalex100\picwgoal1800\pichgoal555
47
494638396178002500E60000C12A35E0969BCE5A62F9ECEBBA1121AC0000F4DADBBE222DCD535BB3000AB80D1EB60518F7E2E3D67379CA494DC22D38D46C73ED
C2C3D1616CBB1424CA4B53B7071ABB1B23C8454ADB858BFDF9F9B10004BF2431BE1E2CE6A9AEEBBCBCF0CCCEE29BA1E8B2B4B9141CFEFDFCE4A4A9BE2230B604
17DE8D93C43542FBF1F1C53941C63D44B80A1CBC1928C3313AC4353EF3D4D6F1D1D2BD1C29D87B82BA1520C02733DF9196FCF5F5B50214D2676CE9B5B9C3303D
E7AEB0F1CFD1F7E5E5DC898DF2D2D4A40000B60914E3A1A4C84348C74046C9474CB8091BB40010C63C49DA8186C53946ECBEC1CC4E58F3D6D8C8414DC94752FE
FBFBC63C43C4383FC8404AB50511B90F1FFDF8F6EFC8C8BC1629FAF0EE9B0000B80D19F8E9E8C3343EFCF5F3D05F65F5DDDFD06466BF262EBF2633C23037BB12
24FAEFEFF6E0E0C3333CB3080DB70C16F7EAE5BD1B2CC73B45EFC6C9BB1626C84247FCF3F3C12837C63748E7BBBBEAB8B9B8061BFEFBFDCE7170C3343CC4343A
BE1F2FBA1423BA1323FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A33356336346461612D316638382D343331642D396633312D3163643537656637353533302220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A34373030323435323343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A34373030323435313343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A33356336346461612D316638382D343331642D396633312D316364353765663735353330222073745265
663A646F63756D656E7449443D22786D702E6469643A33356336346461612D316638382D343331642D396633312D316364353765663735353330222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000780025000007FF80732D00321C1C7C7025736D86886435858770351B8686590025963283967C6D32848D2D1C008C9225A68D701B8B
AB6464917C5994961C989A866D9D8DA0A287A4AA8759A9A7B37E281B521C0A04130B32442D56047D261B1713D40426002BDBDC2F52CD7E5615532E2C047E0A47
2B00EA7E2C0A451BEA7D150417CCCE152D71D3AA2D3850A4DC3A1335BE115868C2C58A6604CCA18BD7AE489923EBE615A9710F239103EA26F82B3207400B057E
9EC970D0E2881F6B1B1C4C60E1C7CF82077108A024B0E045110556CA5550F182220B8B18E559B900A0C2CB0A131C9470FAAC8503194EAD1DC846D30F42223AFD
7073F13328810A2F8AAE3357244D3E76F4FF9AD6746AE400D505560D9508AAD2019C0A7DAC957070768257004414B0E8C34D4F9C0A0AFA58593065CA826A8AE3
9431518DC5D21A269E4EA070C0441F912B5B2C303CD008BE3E5E6B5CB0B278EC85799229ABA860A58F820A715E70EE338F69689104EA9A1609E7EA02321B9C99
E0C0122A4C077EA07203F07367CF15BC854E71BB4E711100482AB0C8776103EF0A385A18816362C204242D885841C2E2088E0D467091000B137423857A132880
844FF3947344654704A5003DE411670511002C205A5D0B9C86977313405720757F1986106180F1F4406291F1344511BC495681142FE4431C0B449481437D5614
30060026C0C14202043840460247645105FF172CF5374F0D446820041D6B1400C0050B2460051C488C410464B955B6406FBFC591C6709E199712600EF0B1DC87
AA4D40002C0B70309F75D71076849C0B7037A158DF85479B0AE42915C7031A0000430C319C814001136820C01F36148042172F1460051A4F48A005101F0CA044
0102DCD0451760589000080CD0500006110C285E8DE5B110870B685E484668F84C600407F58964559CEC94D0C660BDFA81430D0E58B127376514819B1526A8B0
C298324AE1C26537626842024BFCD1000511FC815E013FFCC14301158C7042103F6460C5064B18E084000BCCF1C70F0974606E013AFCF128133D686085B334DA
C8020B17E05A4D844680B66654C0DA07E7FF6AF8C8F0001952B400954D351841C0118C55F04077E2AD10213B2C68CBAD67DEFA91001D7F8051400123548A8307
1F7CD0E3092968104108059810440C3A0451800D721450850C236010040F7F74B0340C039EA3C75BC56DF6B03EBB3E05C7AFC156901AC6D75C50430DB4198603
000E28266743451C119939524881AD79DB76B614902F6980C21F4D14A041172414D0C40739F8B044012E08DC83001AE0B0861620DC3C4418224C91C0002004A1
C3151FBC6A8006264891C6CB0C3F80C3C34B6DC02B5446C88031347EE11913011C94B0CE611728C6D80265A88C92392AA830263BEEF44D9C0231E38384187F3C
A141023E785005021F1C308000095810C2FF1F11AC81C406078491780101DC30060E48DC104010300CE181110DC050C0145E28ACC0059B794A7276759A0A34A7
627D29114C445601E81CE40146A0CDF0C832AD0AAC4079123A8AD766F23F89E1C30F0FA0C01F28A0010D30E0034180001A0A00031E58A00022FC41016A50040D
C4C06A0518C2191280832A7CE1040548010466400208C0E0000FB88C528CF080E1B8C40825D0103EAC82158B91E863271A991FA0731823C8ED2C69309E8C56A0
B70C16A16F33F9DB719CE280233C608405C0C11F48B0850E44600B3C40C3F50E40B82A108105053080D584E0813024003E03B0830680800100C4000406A0C1EB
6E748126BE2442ED598E0141F48C2B9A88FF0C7A620C744CF080E0D566012E904284B23585F02866054974863ADA234503FEAA0049F843129000801474200876
884200FE10830420810F7268C001CCA101030CA10A22605502B2E44BFA0DA100E50A81C1D26804C07D90431E1A169EEC942C8444F0592CD0840B4C39BC30C6C8
1C2B98C270CCD3446760527613FB5596C2858017B221733D6000084230000E68A00D23988106D4A1811E4440044B634301C2B7AF2018800441B0C11FB4491B2B
38C092BD82E21AA908984EE6CE44CC72969C1AF8801ABC8000B5418B0A56E6AC22D04A1EF478808D3062840D6888390EE0C06A1230B81C1440027F40010B08B7
050B08CC5284D340390AE0043BDC6C5228FF284003FE000516924003226482067813B1D9F94AA81E4A0D540A3498EC980882CE2A994336608FDEF0441CEF5C40
11E48919E8D573021871003E818AD6480DAE0B30F88312828054382029991A40C01F2847001CD000739AD2C030D9F0870018EE035840420106E08402B0C00100
C0C19AFCA0CF70E62E3026E003034D04002F12085A75E3437484F2825692E9086D51A2463224C00B94A68063B39D7D4C20830B74AA013528800C10900475B060
0714480301925082F5A4410F4BD8014690600108D8A009A863410E9E8084057841A9655DD3D8F8B09ABE786C0282710D16AF243C9EA4721E0E8467190C574213
5C40051A709A19C277163854E166630089FF15122C032AA8A10042C8C2F5DC20832078B8005CA0428F120C621798A10237F3D10A5820A52CE04006AE9A68020A
40033524200B04B899141E70332158A10A1CB83012600A87315C4F4905E000052255420DB8800255D2403BD2202D9440C71C2F28431B280005282C610C323081
1710B0031C8001020F889408047082C255800F5CAEC712103006A22AC1751780C2139A0001830A01011010C00190C0050D2C21070D988206CCE01B1318210754
28C111A43B030C204A0870584203DC90802420800F4708F41228B0011A3781CBE8D9810010C00224ECA0097A561E1CB84C006F34684E5351C1140A00813FF8FA
0F3E9001C0C85785F1E9EF0067F8F5629BFFE06B3EB4C0D79E4DAC049090815F8F400609F8C0AF3B30630CFC1A0D1C408239C600065F0B2008E5FE75E6E01085
3F18D500941201037EFD871308E109BEFE2509C465383BF81A0D0B509CAFC56081188D8C0C7CA80C8A7B3D020F74E10FA11B1F10D8F7878983E00F1F185F14C0
D5EC12F8DA070760C21F2490806A33A007A1EDF500A8563D02E41BDE99AB40112C00005F532101722066B904368676BFFB0F4368E81F0CF0065FEFC00FBE6600
17A836030C3BC1D7572835B3276B30DFB0200D0F00003C7AD4EBA66DD5AAFEF2401086403E2400E10F790802030650837497C0E3BE2EC230495E6D310421C1FB
AE4310C6F78437FE01DD40D7405B0AA002FF5FA3E002BE1EF00D20CE8501B89BAA8A0DE4E37D8D0097FBBA09E99A411038F0870CA480AB418082AF97A001DFC8
7C0A7CE86E350A90833F0CE055732C8007FEC0841CFE0106162817C883208203B89DF3BE56C23005C0055F1B35E0171F611012A0817457AA0047B88017BE5578
8189F00F3CF6816235B078011440FB18907C03B83F59CBFF61064A387F1098ED81D94300F0D593B2CC8543D78CC03E0A4F770207B850AEDA937D8592E56B0DD0
23D7D70235E07A518005B337036370057FF0790D402ABFE6593457741507071680029C9100D5870264E06B0F90009F870138272E2280067F107EF01602ADF707
54E07237700340303E117802FBA25140B4FF55F1071C7AC0195C340F16902EBFF6018AE62F111004171703A2E56DBE66034110806E1056FB0681F1F36B43D023
93E26B3D700049366F71570081930620E8776E3006235882182074329458BFA60305E006154776C9E659E98200E586051A806FBA540044201C0B011DC5510548
153433807105E02F6E18303010705B600423E06B5C40337FD04DB41780939500ED060115C6625BC00516280105E06136187830950059B8037E07066B808269F8
79A0086F0AA57D21100393C57A7F702FBFF603534338E5660005A0877470007D231695A0004CC46BAE5700E57606484076FE87715C900318B0061BE06B5EA02F
7FD0066D708B5C006F238789FC56341270FF026320028BD70004D0660540353D6002AF630553E06B6950737F105D0F3703E0786E890502221006EEE66D76C071
6770006C08012C446F578004E1427509601F1332071B500449848C6740031AE5031A70716850054698004F6733BE360762F8076FF7071BE92FDF586DFCC20109
10304C9000B42800F8360209B0551F7048FB80547F30077CE06B148074FB62018E878FC95629B4280146F007579000D588079A657C1A506D43E36B25E07739A0
007BE1122A501276E107C8D879ED160241A083D59682B2F7800FD72A2D58925FB006594877F4B601CC9601FE9854C5F7070CB078E1A70232A06D78D90265A07D
51509646B56F23509659E58F392003BE06FF0513D07932906E02C0791B57000E4801DBF86BEBF23F00700834D1074715053D70066800023F060018F079197002
7070001CB06FB708064200055D006E5930026F900070000419D004320004061006039002742004EDF3801080041C0006280871F0886D22F7011450066B000045
37025DA00409103E3CF0880360542C100251630122878E61E003655005E5F20483D3011A500501030645C00030E08F2720783EE540CC510404D05EA225024DE0
2A5630074290002FD00633B60B34300667B1003BE202E8E1075C800409E0022A800338E0A009B002034600045A00B7E23473E09553500397310F48F0001C7007
CC47005EB0070BD50217F6024DF060CEA0FF9C2B30A1AF530100F00077C00555D05E453068EB800448D03048600259B20682151AD0810F63136E0B83046A5520
1A4003175022134603526006CDB00048E0104A2A1938F0006EA11EEEA8073AC50D52D24DF57104521207C7751F6B4004CA350138C0052ED00E86510125E00248
A05A36B1017BC01B0AE0A02FE002386005CF80042A5006FC912047A0024072042C8003C0153673420680D15A09842725305B5E01415FB4007A00237733233562
46CE1321A8B5467D004E05D202BE591FD6C00732B15FEC845B76A30DD5524663E43033C1024CA45A7D8011175002A1510EC612A5AB911D3270277D5A0217A045
D9C15F3471160EB1323035053765050AC0F9A19CC10EC90138F2E02BC705AD14106686710407600422011B3C3A1BD95A01D1F227233305AA1414E0BA02C30814
C55A13342152B0C10270F0002550044225270AD05CF705535BA1453085AD62C1020F001E66C1025EF00297B1100AF0A89CB11056B011A1111113A0B01DA2132D
700171A2131C001629C2023510078A51B1276337152B0ECBA313E3D1B1112191251B14F5A0213A210324B10470D006B0400625B0038BB0B44D5B031C00B53B80
7054BB0125B0B464B00325B001B0B00135B0037CB0B41BD0A3530B0B55F9004A8BB63B600A544B0667CBB4553BB66C8BB55ACBB5590B1D614BB7D001003BB0B6
4CFB006A4BB532B0038100003B}}
\par\par \b \uc2 Local marketing company looking to double sales\b0\par\par\uc2 Joe Cogliano   \par \uc2 605 \uc2 words\par \uc2 14 October 2015\par \uc2 Dayton Business Journal Online\par \uc2 DAYBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2015 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 A local marketing company is poised for big growth in 2016.\par \par \uc2 Dayton-based Outta the Box Dispensers LLC is on track to hit $1.3 million in sales this year, which would be double what it posted in 2014. An influx of new clients, and the \b \highlight22\uc2 launch\b0 \highlight\uc2  of several \b \highlight22\uc2 new products\b0 \highlight\uc2 , will likely double revenue in 2016, company officials tell me.\par \par \uc2 Outta the Box sells coupon dispensers used by retailers like grocery stores and gas stations. It is affiliated with Boost Technologies \u8212\'20\'14 which has about 75 employees between its Boost Rewards and Shumsky divisions \u8212\'20\'14 and Shumsky Therapeutic Pillows. All four companies are located in the same facility and have the same ownership and management team.\par \par \uc2 Outta the Box itself employs just a handful of people, but will likely hire more as it grows. That growth also is good for suppliers as the printing and assembly of its products \u8212\'20\'14 except for the actual coupons \u8212\'20\'14 are all done in southwest Ohio.\par \par \uc2 Additionally, Outta the Box just began using Centerville-based Greenleaf Creative to help its online reach.\par \par \uc2 "The market is primed for more of this," said Michael Emoff, chairman of the companies. "We're investing for the first time in digital marketing, trying to get people who know they need to do something to be able to find us."\par \par \uc2 Outta the Box already supports a lot of big-name brands \u8212\'20\'14 such as \uc2 Pepsi\uc2  Cola and \uc2 Johnsonville Sausage\uc2  \u8212\'20\'14 and traditionally its products have been sold through marketing and point-of-purchase companies. However, the brands themselves have recently begun coming to Outta the Box to work directly on projects, Emoff said.\par \par \uc2 New products\par \par \uc2 In addition to getting more interest in its current line, Outta the Box has several new products that will hit the market soon:\par \par \uc2 * The Pumpsider, which was issued a patent last fall, is just starting to rollout. This goes on the side of gas pumps, which isn't as easy to design as it sounds. This display, which can have a coupon dispenser attached, is touted as weather resistant with an adhesive that makes it easy to remove. The idea is to drive gas customers into a convenience store as an inexpensive alternative to video screens, which cost a lot of money to install and effort to maintain the content.\par \par \uc2 * The Coolsider, for use on glass doors in cold sections of grocery stores, has a patent pending and will be released after the first of the year; and\par \par \uc2 * A teaching tool, similar to a dry erase board, that will allow pharmaceutical companies to market directly to patients through their doctors. For example, the board may have an anatomical view of nasal passages that a doctor can draw upon to illustrate a patient's problem. The board can be wiped clean after every use and contain a coupon for an antihistamine product made by the drug company. While this sounds simple enough, the board contains many complex elements to make it work. Emoff said the concept probably can't be patented, but some elements of it can. The pharma industry has lot of marketing dollars going into TV ads to drive consumers to certain drug, but this products would be a way to reach consumers directly and get a little more power into the doctor's hand.\par \par \uc2 Outta the Box began as a division of Shumsky 20 years ago, but has been a standalone company since the late 1990s.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=dayton&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Dayton Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document DAYBJO0020151014ebae0005p\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:07\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}